<SEC-DOCUMENT>0001144204-18-030045.txt : 20180521
<SEC-HEADER>0001144204-18-030045.hdr.sgml : 20180521
<ACCEPTANCE-DATETIME>20180521151648
ACCESSION NUMBER:		0001144204-18-030045
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20180331
FILED AS OF DATE:		20180521
DATE AS OF CHANGE:		20180521

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		18849346

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		4027385480

	MAIL ADDRESS:	
		STREET 1:		12325 EMMET STREET
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>tv492534_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 10-Q</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>(Mark One)</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0; padding-left: 0; font-size: 10pt"><FONT STYLE="font-family: Wingdings; font-size: 10pt">x</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0; padding-left: 0; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0; font-size: 10pt; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; font-size: 10pt"><B>For the quarterly period ended March 31, 2018</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>OR</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Wingdings; font-size: 10pt">o</FONT></TD>
    <TD STYLE="width: 94%; padding-right: 0; padding-left: 0"><FONT STYLE="font-size: 10pt"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0"><B>For the transition period from _____ to _____</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Commission File Number: 001-36439</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PRECIPIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Exact name of registrant as specified in
its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 49%; padding-right: 0; padding-left: 0; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 49%; padding-right: 0; padding-left: 0; text-align: center"><B>91-1789357</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0; padding-left: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(State or other jurisdiction of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>incorporation or organization)</B></P></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(I.R.S. Employer</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; text-align: center"><B>4 Science Park, New Haven, CT</B></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; text-align: center"><B>06511</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Address of principal executive offices)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0; text-align: center"><FONT STYLE="font-size: 10pt"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(203) 787-7888</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Registrant&rsquo;s telephone number, including
area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 35%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37pt">Indicate by check mark whether
the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has
been subject to such filing requirements for the past 90 days.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: right">Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%">No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 37pt">Indicate by check mark whether
the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files).</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: right">Yes&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%">No&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging
growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting
company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 24%; padding-right: 0; padding-left: 0">Large&nbsp;accelerated&nbsp;filer</TD>
    <TD STYLE="width: 1%; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="width: 45%; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="width: 24%; padding-right: 0; padding-left: 0">Accelerated&nbsp;filer</TD>
    <TD STYLE="width: 1%; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="width: 5%; padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0; padding-left: 0">Non-accelerated filer</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
    <TD STYLE="padding-right: 0; padding-left: 0">Smaller&nbsp;reporting&nbsp;company</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Wingdings">x</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 0; padding-left: 0">Emerging growth company</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act <FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Indicate by check mark
whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">o</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">As of May 18, 2018, the number of shares of common stock outstanding was 19,668,572.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PRECIPIO, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 11%; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="width: 78%; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: Black 1pt solid; padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Page&nbsp;No.</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_001"><B>PART&nbsp;I.</B></A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_001"><B>Financial Information</B></A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: right"><A HREF="#a_002"><B>Item&nbsp;1.</B></A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_002">Condensed Consolidated Financial Statements</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><A HREF="#a_002">3</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: right; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_003">Condensed Consolidated Balance Sheets at March 31, 2018 (unaudited) and December 31, 2017 </A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><A HREF="#a_003"><FONT STYLE="color: blue"></FONT>3</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0; text-align: right; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_004"> Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2018 and 2017  (unaudited)</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><A HREF="#a_004"><FONT STYLE="color: blue"></FONT>4</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: right; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_005">Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2018 and 2017  (unaudited)</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><FONT STYLE="color: blue"></FONT><A HREF="#a_005">5</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0; text-align: right; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_006">Notes to the  Condensed Consolidated Financial Statements  (unaudited)</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><A HREF="#a_006">6</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: right; padding-right: 0"><A HREF="#a_007"><B>Item 2.</B></A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_007">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><A HREF="#a_007">26</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0; text-align: right; padding-right: 0"><A HREF="#a_008"><B>Item 3.</B></A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_008">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><A HREF="#a_008">32</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: right; padding-right: 0"><A HREF="#a_009"><B>Item 4.</B></A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_009">Controls and Procedures</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><A HREF="#a_009">32</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_010"><B>PART II.</B></A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_010"><B>Other Information</B></A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom">&nbsp;<A HREF="#a_010"></A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: right; padding-right: 0"><A HREF="#a_011"><B>Item&nbsp;1.</B></A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_011">Legal Proceedings</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><FONT STYLE="color: blue"></FONT><A HREF="#a_011">32</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0; text-align: right; padding-right: 0"><A HREF="#a_012"><B>Item 1A.</B></A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="#a_012">Risk Factors</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: center; vertical-align: bottom"><A HREF="#a_012">32</A></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0; text-align: right; padding-right: 0"><A HREF="#a_013"><B>Item 6.</B></A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0"><A HREF="#a_013">Exhibits</A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0; text-align: center; vertical-align: bottom"><A HREF="#a_013">34</A></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0; padding-right: 0"><A HREF="#a_014"><B>Signatures</B></A></TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0; text-align: center; vertical-align: bottom"><A HREF="#a_014">35</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_001"></A>PART 1. FINANCIAL INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_002"></A><B>Item 1. Condensed Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_003"></A><B>PRECIPIO, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Dollars in thousands, except share data)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<BR>
2018<BR>
(unaudited)</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<BR>
 2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 0; padding-right: 0">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; padding-right: 0">CURRENT ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; padding-left: 0.125in; padding-right: 0">Cash</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">286</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">421</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Accounts receivable, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">552</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">730</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Inventories, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">161</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; padding-right: 0">Other current assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">209</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">430</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-right: 0">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,206</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,742</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; padding-right: 0">PROPERTY AND EQUIPMENT, NET</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">333</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">353</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; padding-right: 0">OTHER ASSETS:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; padding-right: 0">Goodwill</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,391</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,685</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Intangibles, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,138</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,458</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0.125in; padding-right: 0">Other assets</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">25</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">22</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 0.25in; padding-right: 0">Total assets</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">26,093</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,260</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-left: 0; padding-right: 0">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; padding-right: 0">CURRENT LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Current maturities of long-term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">676</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">587</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,956</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Current maturities of capital leases</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">51</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Accrued expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,529</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,248</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Deferred revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">189</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Other current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">1,350</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,982</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-right: 0">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,751</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,036</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; padding-right: 0">LONG TERM LIABILITIES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Long-term debt, less current maturities and discounts</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,829</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Common stock warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">124</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">841</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Capital leases, less current maturities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Deferred tax liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">349</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">349</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Other long-term liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">467</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">67</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-right: 0">Total liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12,685</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">14,235</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0; padding-right: 0">STOCKHOLDERS&rsquo; EQUITY:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Preferred stock - $0.01 par value, 15,000,000 shares authorized at March 31, 2018 and December 31, 2017, respectively, 47 and 4,935 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Common stock, $0.01 par value, 150,000,000 shares authorized at March 31, 2018 and December 31, 2017, 19,668,572 and 10,196,620 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">197</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47,192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">44,465</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Accumulated deficit</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(33,981</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(31,542</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.25in; padding-right: 0">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,408</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">13,025</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0; padding-right: 0">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">26,093</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">27,260</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See notes to unaudited condensed consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_004"></A>PRECIPIO, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Dollars in thousands, except per share data)<BR>
 (unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">SALES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; text-align: left; padding-left: 0.125in">Service revenue, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">791</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">303</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 0.125in">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Revenue, net of contractual allowances and adjustments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">796</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">303</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">less allowance for doubtful accounts</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(84</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(55</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Net sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">712</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">248</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1pt">COST OF SALES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">688</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">182</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">66</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING EXPENSES:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Operating expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,178</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">662</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Impairment of goodwill</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">294</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL OPERATING EXPENSES</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">2,472</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">662</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">OPERATING LOSS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,448</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(596</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">OTHER INCOME (EXPENSE):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Interest expense, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(8</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(162</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Warrant revaluation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">261</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Gain on settlement of liability, net</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">141</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; padding-right: 0">Loss on settlement of equity instruments</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(385</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(162</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">LOSS BEFORE INCOME TAXES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,439</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(758</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">INCOME TAX EXPENSE</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(2,439</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(758</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Deemed dividends related to beneficial conversion feature of preferred stock and fair value of consideration issued to induce conversion of preferred stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,514</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1pt">TOTAL DIVIDENDS</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(3,514</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(5,953</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(758</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">BASIC AND DILUTED LOSS PER COMMON SHARE</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(0.47</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(1.69</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">12,576,037</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">449,726</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See notes to unaudited condensed consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_005"></A>PRECIPIO, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Dollars in thousands)<BR>(unaudited)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left; padding-left: 0.25in">Net loss</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(2,439</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(758</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Adjustments to reconcile net loss to net cash flows used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Depreciation and amortization</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">352</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Amortization of deferred financing costs and debt discount</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Gain on settlement of liability, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(141</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Loss on settlement of equity instrument</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">385</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Stock-based compensation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">82</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.375in">Impairment of goodwill</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">294</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Provision for losses on doubtful accounts</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">84</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">55</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Warrant revaluation</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(261</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Accounts receivable, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">94</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(47</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Inventories, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(6</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Other assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">218</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(44</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">169</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.375in">Accrued expenses and other liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">228</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">227</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Net cash used in operating activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,145</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(326</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Purchase of property and equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(5</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.375in">Net cash used in investing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Principal payments on capital lease obligations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(12</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(11</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Issuance of common stock, net of issuance costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">618</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 0.25in">Proceeds from exercise of warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">225</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Proceeds from long-term debt</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">300</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">265</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Proceeds from convertible bridge notes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">100</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.25in">Principal payments on long-term debt</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(116</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(46</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0.5in">Net cash flows provided by financing activities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">308</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">NET CHANGE IN CASH</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(135</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(18</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">CASH AT BEGINNING OF PERIOD</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">421</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">51</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">CASH AT END OF PERIOD</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">286</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">33</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.25in">Cash paid during the period for interest</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">6</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">15</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Purchases of equipment financed through accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Deferred debt issuance cost financed through accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">31</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Other current liabilities canceled in exchange for common shares</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,897</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 0.125in">Warrant liability canceled due to settlement of equity instruments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">456</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">See notes to unaudited condensed consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_006"></A>PRECIPIO, INC. AND SUBSIDIARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTES TO UNAUDITED CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Three Months Ended March 31 2018
and 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>1. BUSINESS DESCRIPTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Business Description.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Precipio, Inc., and Subsidiary,
(&ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, the &ldquo;Company&rdquo; or &ldquo;Precipio&rdquo;) is a cancer diagnostics
company providing diagnostic products and services to the oncology market. We have built and continue to develop a platform designed
to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions
and delivering quality diagnostic information to physicians and their patients worldwide. We operate a cancer diagnostic laboratory
located in New Haven, Connecticut and have partnered with the Yale School of Medicine to capture the expertise, experience and
technologies developed within academia so that we can provide a better standard of cancer diagnostics and solve the growing problem
of cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which will focus on further development
of ICE-COLD-PCR (&ldquo;ICP&rdquo;), the patented technology which was exclusively licensed by us from Dana-Farber Cancer Institute,
Inc. (&ldquo;Dana-Farber&rdquo;) at Harvard University (&ldquo;Harvard&rdquo;). The research and development center will focus
on the development of this technology, which we believe will enable us to commercialize other technologies developed by our current
and future academic partners. Our platform connects patients, physicians and diagnostic experts residing within academic institutions.
Launched in 2017, the platform facilitates the following relationships:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Patients: patients may
search for physicians in their area and consult directly with academic experts that are on the platform. Patients may also have
access to new academic discoveries as they become commercially available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Physicians: physicians
can connect with academic experts to seek consultations on behalf of their patients and may also provide consultations for patients
in their area seeking medical expertise in that physician&rsquo;s relevant specialty. Physicians will also have access to new diagnostic
solutions to help improve diagnostic accuracy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Academic Experts: academic
experts on the platform can make themselves available for patients or physicians seeking access to their expertise. Additionally,
these experts have a platform available to commercialize their research discoveries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">We intend to continue
updating our platform to allow for patient-to-patient communications and allow individuals to share stories and provide support
for one another, to allow physicians to consult with their peers to discuss and share challenges and solutions, and to allow academic
experts to interact with others in academia on the platform to discuss their research and cross-collaborate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">ICP was developed at Harvard
and is licensed exclusively by us from Dana-Farber. The technology enables the detection of genetic mutations in liquid biopsies,
such as blood samples. The field of liquid biopsies is a rapidly growing market, aimed at solving the challenge of obtaining genetic
information on disease progression and changes from sources other than a tumor biopsy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Gene sequencing is performed
on tissue biopsies taken surgically from the tumor site in order to identify potential therapies that will be more effective in
treating the patient. There are several limitations to this process. First, surgical procedures have several limitations, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Cost: surgical procedures
are usually performed in a costly hospital environment. For example, according to a recent study the mean cost of lung biopsies
is greater than $14,000; surgery also involves hospitalization and recovery time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Surgical access: various
tumor sites are not always accessible (e.g. brain tumors), in which cases no biopsy is available for diagnosis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Risk: patient health may
not permit undergoing an invasive surgery; therefore a biopsy cannot be obtained at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Time: the process of scheduling
and coordinating a surgical procedure often takes time, delaying the start of patient treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Second, there are several
tumor-related limitations that provide a challenge to obtaining such genetic information from</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">a tumor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Tumors are heterogeneous
by nature: a tissue sample from one area of the tumor may not properly represent the tumor&rsquo;s entire genetic composition;
thus, the diagnostic results from a tumor may be incomplete and non-representative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Metastases: in order to
accurately test a patient with metastatic disease, ideally an individual biopsy sample should be taken from each site (if those
sites are even known). These biopsies are very difficult to obtain; therefore physicians often rely on biopsies taken from the
primary tumor site.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The advent of technologies
enabling liquid biopsies as an alternative to tumor biopsy and analysis is based on the fact that tumors (both primary and metastatic)
shed cells and fragments of DNA into the blood stream. These blood samples are called &ldquo;liquid biopsies&rdquo; that contain
circulating tumor DNA, or ctDNA, which hold the same genetic information found in the tumor(s). That tumor DNA is the target of
genetic analysis. However, since the quantity of tumor DNA is very small in proportion to the &ldquo;normal&rdquo; (or &ldquo;healthy&rdquo;)
DNA within the blood stream, there is a need to identify and separate the tumor DNA from the normal DNA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">ICP is an enrichment technology
that enables the laboratory to focus its analysis on the tumor DNA by enriching, and thereby &ldquo;multiplying&rdquo; the presence
of, tumor DNA, while maintaining the normal DNA at its same level. Once the enrichment process has been completed, the laboratory
genetic testing equipment is able to identify genetic abnormalities presented in the ctDNA, and an analysis can be conducted at
a higher level of sensitivity, to enable the detection of such genetic abnormalities. The technology is encapsulated into a chemical
that is provided in the form of a kit and sold to other laboratories who wish to conduct these tests in-house. The chemical within
the kit is added to the specimen preparation process, enriching the sample for the tumor DNA so that the analysis will detect those
genetic abnormalities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Merger Transaction</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">On June&nbsp;29, 2017,
the Company (then known as &ldquo;Transgenomic, Inc.&rdquo;, or &ldquo;Transgenomic&rdquo;), completed a reverse merger (the &ldquo;Merger&rdquo;)
with Precipio Diagnostics, LLC, a privately held Delaware limited liability company (&ldquo;Precipio Diagnostics&rdquo;) in accordance
with the terms of the Agreement and Plan of Merger (the &ldquo;Merger Agreement&rdquo;), dated October&nbsp;12, 2016, as amended
on February&nbsp;2, 2017 and June&nbsp;29, 2017, by and among Transgenomic, Precipio Diagnostics and New Haven Labs Inc. (&ldquo;Merger
Sub&rdquo;) a wholly-owned subsidiary of Transgenomic. Pursuant to the Merger Agreement, Merger Sub merged with and into Precipio
Diagnostics, with Precipio Diagnostics surviving the Merger as a wholly-owned subsidiary of the combined company. Upon the consummation
of the Merger, the historical financial statements of Precipio Diagnostics become the Company's historical financial statements.
Accordingly, the historical financial statements of Precipio Diagnostics are included in the comparative prior periods. As a result
of the Merger, historical preferred stock, common stock, restricted units, warrants and additional paid-in capital, including share
and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including the
effect of the Merger exchange ratio. Pursuant to the Merger Agreement, each outstanding unit of Precipio Diagnostics was exchanged
for 10.2502 pre-reverse stock split shares of Company Common Stock.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Going Concern.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">The condensed consolidated
financial statements have been prepared using accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;)
applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary
course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the
past few years. As of March 31, 2018, the Company had a net loss of $2.4 million, negative working capital of $7.5 million and
net cash used in operating activities of $1.1 million. The Company&rsquo;s ability to continue as a going concern over the next
twelve months from the date of issuance of this Form 10-Q is dependent upon a combination of achieving its business plan, including
generating additional revenue, and raising additional financing to meet its debt obligations and paying liabilities arising from
normal business operations when they come due.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">To meet its current and
future obligations the Company has taken the following steps to capitalize the business and successfully achieve its business plan:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>On April 13, 2018, the Company filed a Form S-1 General Registration Statement to register and offer for future sale shares
of our common stock,&nbsp;pursuant to entering into an Equity Purchase Agreement with Leviston Resources LLC (the &ldquo;Investor&rdquo;)
on February 8, 2018. &nbsp;See Note 8 &ndash; Stockholders&rsquo; Equity for further details.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD>On April 20, 2018, the Company&nbsp;entered into a securities purchase agreement (the &ldquo;Agreement&rdquo;) with certain
investors, pursuant to which the Company will issue up to approximately $3,296,703.30 in 8% Senior Secured Convertible Promissory
Notes with 100% common stock warrant coverage. See Note 12 &ndash; Subsequent Events for further details.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Notwithstanding the aforementioned
circumstances, there remains substantial doubt about the Company&rsquo;s ability to continue as a going concern over the next twelve
months from the date of issuance of the Form 10-Q. There can be no assurance that the Company will be able to successfully achieve
its initiatives summarized above in order to continue as a going concern over the next twelve months from the date of issuance
of the Form 10-Q. The accompanying financial statements have been prepared assuming the Company will continue as a going concern
and do not include any adjustments that might result should the Company be unable to continue as a going concern as a result of
the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I><U>Nasdaq Delisting
Notice </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">On March 26, 2018, Precipio, Inc. received
written notice (the &ldquo;Notice&rdquo;) from The Nasdaq Stock Market LLC (&ldquo;Nasdaq&rdquo;) indicating that, based on the
closing bid price of the Company&rsquo;s common stock for the preceding 30 consecutive business days, the Company is not in compliance
with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market (the &ldquo;Minimum Bid Price Requirement&rdquo;).
The Notice has no immediate effect on the listing of Precipio&rsquo;s common stock, and its common stock will continue to trade
on the Nasdaq Capital Market under the symbol &ldquo;PRPO&rdquo; at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
Precipio has a period of 180 calendar days, or until September 24, 2018 to regain compliance with the Minimum Bid Price Requirement.
The Company intends to monitor the closing bid price of its common stock and consider its available options to resolve its noncompliance
with the Minimum Bid Price Requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Basis of Presentation.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The accompanying condensed
consolidated financial statements are presented in conformity with GAAP. We have evaluated events occurring subsequent to March
31, 2018 for potential recognition or disclosure in the condensed consolidated financial statements and concluded that, other than
what is disclosed within the notes to unaudited condensed consolidated financial statements and in Note 12 - Subsequent Events,
there were no other subsequent events that required recognition or disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The condensed consolidated
balance sheet as of December&nbsp;31, 2017 was derived from our audited balance sheet as of that date. There has been no change
in the balance sheet from December 31, 2017. The accompanying condensed consolidated financial statements as of and for the three
months ended March&nbsp;31, 2018 and 2017 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments)
that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the
interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited
financial statements and notes thereto for the year ended December&nbsp;31, 2017 contained in our Annual Report Form 10-K, filed
with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on April 13, 2018. The results of operations for the interim
periods presented are not necessarily indicative of the results for fiscal year 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Recent Accounting Pronouncements. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">In May 2014, the Financial
Accounting Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) 2014-09, Revenue from Contracts
with Customers and has subsequently issued supplemental and/or clarifying ASUs (collectively &ldquo;ASC 606&rdquo;). ASC 606 outlines
a five-step framework that intends to clarify the principles for recognizing revenue and eliminate industry-specific guidance.
In addition, ASC 606 revises current disclosure requirements in an effort to help financial statement users better understand the
nature, amount, timing, and uncertainty of revenue that is recognized. ASC 606 may be applied either retrospectively to each prior
reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized
at the date of initial application. We adopted this new standard as of January 1, 2018, by using the modified-retrospective method.
An adjustment was not required and a change to the prior revenue recognition process and policy to adopt the new standard was not
necessary. See Note 11 &ndash; Sales Service Revenue, Net And Accounts Receivable for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In February 2016, the
FASB issued ASU No. 2016-02, <I>Leases</I>. The new standard amends the recognition of lease assets and lease liabilities by lessees
for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements.
The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018.
Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain
practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period
presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In January 2017, FASB
issued ASU No.&nbsp;2017-01, <I>Business Combinations</I> (Topic 805): Clarifying the Definition of a Business. ASU No. 2017-01
adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of
assets or businesses. The new guidance is effective for fiscal years beginning after December&nbsp;15, 2017, and interim periods
within those fiscal years. The adoption of ASU No. 2017-01 did not have a material effect on the Company&rsquo;s financial position
and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In May 2017, the FASB issued ASU 2017-09 &ldquo;<I>Compensation
&ndash; Stock Compensation (Topic 718): Scope of Modification Accounting&rdquo;, </I>which provides clarity and reduces both diversity
in practice and cost and complexity when applying guidance in Topic 718. This amendment provides guidance about which changes to
the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. &nbsp;The
amendments are effective for all entities for annual periods, and interim periods within those periods, beginning after December
15, 2017. The adoption of ASU No. 2017-09 did not have a material effect on the Company&rsquo;s financial position and results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Property and Equipment, net.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Depreciation expense was
less than $0.1 million for both the three months March&nbsp;31, 2018 and 2017. Depreciation expense during each year includes depreciation
related to equipment acquired under capital leases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Goodwill and Intangible Assets.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">As a result of the Merger,
the Company recorded goodwill and intangible assets as part of its allocation of the purchase consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><U>Goodwill</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Goodwill represents the
excess of the purchase price over the fair value of identifiable net assets of the business acquired. Goodwill is tested for impairment
annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may
indicate that the assets might be impaired. During the three months ended March 31, 2018, the Company experienced a decline in
its share price and a reduction in its market capitalization, as such the Company determined that an assessment of goodwill should
be performed using the qualitative approach. Based on the qualitative assessment, the Company concluded that it was more likely
than not that the fair value of the Company was less than its carry value. As part of its analysis, the Company considered triggering
events and compared its fair value with its carrying value. The analysis of the fair value of the Company involved using the discounted
cash flow model. Based on the analysis, the Company concluded that its carrying value exceeded its fair value and goodwill impairment
in the amount of $0.3 million was recorded for the three months ended March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><U>Intangibles</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Amortization expense for
intangible assets was $0.3 million and zero during the three months ended March&nbsp;31, 2018 and 2017, respectively. Amortization
expense for intangible assets is expected to be $1.2 million, $1.0 million, $1.0 million, $0.9 million and $0.9 million for each
of the years ending December 31, 2018, 2019, 2020, 2021 and 2022, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Revenue Recognition.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.3pt">Revenue recognition occurs when a customer
obtains control of the promised goods and service. Revenue assigned to the goods and services reflects the consideration which
the Company expects to receive in exchange for those goods and services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">The Company derives its
revenues from Diagnostic Testing - histology, flow cytometry, cytology and molecular testing; Clinical Research from bio-pharma
customers, state and federal grant programs; and from Biomarker Testing from bio-pharma customers. All sources of revenue are recorded
net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. Due to differences in the substance
of these revenue types, the transactions require, and the Company utilizes, different revenue recognition policies for each. See
more detailed information on revenue in Note 11 &ndash; Sales Service Revenue, Net And Accounts Receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">The Company recognizes
revenue utilizing the five-step framework of ASC 606. Control of the laboratory testing services is transferred to the customer
at a point in time. As such, the Company recognizes revenue for diagnostic testing at a point in time based on the delivery method
(web-portal access or fax) for a patient&rsquo;s laboratory report. Diagnostic testing service revenue is reported at the estimated
net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustment under
reimbursement agreements with third-party payors. Revenue under third-party payor agreements is subject to audit and retroactive
adjustment. Provisions for third-party payor settlements are provided in the period in which the related services are rendered
and adjusted in the future periods, as final settlements are determined. For clinical research and biomarker services, the Company
utilizes an &ldquo;effort based&rdquo; method of assessing performance and measures progress towards satisfaction of the performance
obligation based upon the delivery of results per the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">When we receive payment
in advance, we initially defer the revenue and recognize it when we deliver the service. Deferred net sales included in the balance
sheet as deferred revenue was $0.2 million and less than $0.1 million as of March 31, 2018 and December 31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Taxes collected from customers
and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income
statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Loss Per Share.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Basic loss per share is
calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes
shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices
below the market value of our common stock. Options, warrants and conversion rights pertaining to 9,506,515 and 2,753,814 shares
of our common stock have been excluded from the computation of diluted loss per share at March 31, 2018 and 2017, respectively,
because the effect is anti-dilutive due to the net loss.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The following table summarizes
the outstanding securities not included in the computation of diluted net loss per share:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>March 31,</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left">Stock options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">3,520,059</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">2,651</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,923,789</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,971,058</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Preferred stock</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">62,667</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">780,105</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Total</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,506,515</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,753,814</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>3. REVERSE MERGER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Unaudited pro forma information</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">The operating results
of Transgenomic have been included in the Company's consolidated financial statements for all periods after June 29, 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The following unaudited
pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1,
2017 and combines Transgenomic&rsquo;s unaudited condensed consolidated statement of operations for the three months ended March&nbsp;31,
2017 with Precipio&rsquo;s unaudited condensed statement of operations for the three months ended March&nbsp;31, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>Dollars in thousands, except per share amounts</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><B>&nbsp;</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><B>For the Three Months Ended March 31,</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><B>&nbsp;</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Net sales</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">712</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">907</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net loss available to common stockholders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5,953</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(2,778</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Loss per common share</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.47</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(0.42</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>4. LONG-TERM DEBT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Long-term debt consists of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Dollars&nbsp;in&nbsp;Thousands</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left">Department of Economic and Community Development (DECD)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">293</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">DECD debt issuance costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(30</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Secured debt obligations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,233</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,233</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Financed insurance loan</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">74</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">183</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total long-term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,570</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,416</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Current portion of long-term debt</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(676</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(587</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Long-term debt, net of current maturities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,894</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,829</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Department of Economic and Community Development.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">On January 8, 2018,
the Company received gross proceeds of $400,000 when it entered into an agreement with the Department of Economic and Community
Development (&ldquo;DECD&rdquo;) by which the Company received a grant of $100,000 and a loan of $300,000 secured by substantially
all of the Company&rsquo;s assets (the &ldquo;DECD 2018 Loan&rdquo;.) The grant is included in deferred revenue in the accompanying
condensed consolidated balance sheet.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Debt issuance costs associated
with the DECD 2018 Loan were approximately $31,000. Amortization of the debt issuance cost was approximately $1,000 for the three
months ended March 31, 2018. Net debt issuance costs were $30,000 at March 31, 2018 and are presented as a reduction of the related
debt in the accompanying condensed consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Secured Debt Obligations</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In 2017, the Company entered
into Debt Settlement Agreements (the &ldquo;Settlement Agreements&rdquo;) with certain of its accounts payable and accrued liability
vendors (the &ldquo;Creditors&rdquo;) pursuant to which the Creditors, who were owed $6.3 million (the &ldquo;Debt Obligations&rdquo;)
by the Company, agreed to reduce and exchange the Debt Obligations for a secured obligation in the amount of $3.2 million, $1.9
million in shares of the Company&rsquo;s common stock and 108,112 warrants to purchase shares of the Company&rsquo;s common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The Debt Obligations were
restructured as follows:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">The Company entered into a scheduled long-term debt repayment agreement of approximately $3.2 million,
which includes interest of approximately $0.6 million, to be paid in forty-eight equal monthly installments beginning in July 2018
(the &ldquo;Secured Debt Obligations&rdquo;).</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Debt Obligations of $1.9 million were canceled in exchange for 1,814,754 shares of the Company&rsquo;s
common stock with a weighted average price per share of $1.04 (the &ldquo;Settlement Common Shares&rdquo;). The stock was issued
in February 2018.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Warrants to purchase 108,112 shares of the Company&rsquo;s common stock at an exercise price of
$7.50 per share (the &ldquo;Creditor Warrants&rdquo;) were issued to certain Creditors. The Creditor Warrants were issued in February
2018.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Financed Insurance Loan.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">During 2017, the Company
financed certain of its insurance premiums (the &ldquo;Financed Insurance Loan&rdquo;). The original amount financed in July 2017
was $0.4 million with a 4.99 % interest rate. The Company will make monthly payments through May 2018. As of March 31, 2018 and
December 31, 2017, the Financed Insurance Loan outstanding balance of $0.1 million and $0.2 million, respectively, is included
in current maturities of long-term debt in the Company&rsquo;s condensed consolidated balance sheet. A corresponding prepaid asset
is included in other current assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>5. OTHER CURRENT LIABILITIES.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Other current liabilities
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 85%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="padding-right: 0; padding-left: 0; border-bottom: Black 1pt solid"><B>(dollars in thousands)</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; padding-right: 0; padding-left: 0"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; padding-right: 0; padding-left: 0"><B>March 31, 2018</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; padding-right: 0; padding-left: 0"><B>&nbsp;</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; padding-right: 0; padding-left: 0"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid; padding-right: 0; padding-left: 0"><B>December 31,<BR>
 2017</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; padding-right: 0; padding-left: 0"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: left; padding-left: 0; padding-right: 0">Obligation to issue common shares</TD><TD STYLE="width: 1%; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-right: 0; padding-left: 0">$</TD><TD STYLE="width: 14%; text-align: right; padding-right: 0; padding-left: 0">&mdash;</TD><TD STYLE="width: 1%; text-align: left; padding-right: 0; padding-left: 0">&nbsp;</TD><TD STYLE="width: 1%; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-right: 0; padding-left: 0">$</TD><TD STYLE="width: 14%; text-align: right; padding-right: 0; padding-left: 0">1,897</TD><TD STYLE="width: 1%; text-align: left; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 0; padding-right: 0">Liability for settlement of equity instrument</TD><TD STYLE="padding-bottom: 1pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; padding-right: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; padding-right: 0; padding-left: 0">1,350</TD><TD STYLE="padding-bottom: 1pt; text-align: left; padding-right: 0; padding-left: 0">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left; padding-right: 0; padding-left: 0">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right; padding-right: 0; padding-left: 0">1,085</TD><TD STYLE="padding-bottom: 1pt; text-align: left; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt; padding-left: 0; padding-right: 0">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; padding-right: 0; padding-left: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; padding-right: 0; padding-left: 0">1,350</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; padding-right: 0; padding-left: 0">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; padding-right: 0; padding-left: 0">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; padding-right: 0; padding-left: 0">2,982</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">As of December 31, 2017, the Company had recorded
a liability related to its obligation to issue shares of its common stock in the future. On February 12, 2018, the Company issued
1,814,754 Settlement Common Shares with a fair value of approximately $1.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">On February 20, 2018,
Crede Capital Group LLC (&ldquo;Crede&rdquo;) filed a lawsuit against the Company in the Supreme Court of the State of New York
for Summary Judgment in Lieu of Complaint requiring the Company to pay cash owed to Crede. Crede claimed that Precipio had breached
a Securities Purchase Agreement and Warrant that Crede entered into in connection with an investment in Transgenomic and that pursuant
to those agreements, Precipio owed Crede approximately $2.2 million. On March&nbsp;12, 2018, Precipio entered into a settlement
agreement (the &ldquo;Crede Agreement&rdquo;) with Crede pursuant to which Precipio agreed to pay Crede a total sum of $1.925 million
over a period of 16 months payable in cash, or at the Company&rsquo;s discretion, in stock, in accordance with terms contained
in the Crede Agreement. In accordance with the terms of the agreement and in addition to the agreement to pay, we have also executed
and delivered to Crede an affidavit of confession of judgment. As of December 31, 2017, the Company had recorded liabilities relating
to Crede of $1.1 million included in other current liabilities on the accompanying condensed consolidated balance sheets and $0.6
million included in common stock warrant liability on the accompanying condensed consolidated balance sheets related to warrants
classified as liabilities that Crede is the holder of.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt">As of the date of
the Crede Agreement, the fair value of the common stock warrant liability related to Crede was revalued to approximately $0.4 million,
resulting in a gain of $0.2 million included in warrant revaluation in the unaudited condensed consolidated statement of operations
during the three months ended March 31, 2018. See Note 9 &ndash; Fair Value for further discussion. During the three months ended
March 31, 2018, at the time of the Crede Agreement, the Company paid approximately $0.2 million to Crede and recorded $1.3 million
in other current liabilities and $0.4 million in other long-term liabilities, thus replacing its $1.1 million liability for settlement
of equity instrument and $0.4 million common stock warrant liability. This resulted in the Company recording an additional loss
of $0.4 million, which is included in loss on settlement of equity instruments in the unaudited condensed consolidated statement
of operations. The remaining amount due to Crede will be paid per the Crede Agreement payment schedule with the final installment
due in May 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><B>6. CONTINGENCIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The Company is involved
in legal proceedings related to matters, which are incidental to its business. The Company has also assumed a number of claims
as a result of the Merger. See below for a discussion on these matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The healthcare industry
is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are
not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirement,
reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to
investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Violations of these laws
and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines
and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is
in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material
regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation,
as well as regulatory actions unknown or unasserted at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The outcome of legal proceedings
and claims brought against us are subject to significant uncertainty. Therefore, although management considers the likelihood of
such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts
in excess of management&rsquo;s expectations, our financial statements for such reporting period could be materially adversely
affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could
be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>LITIGATIONS </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The Company is delinquent
on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal
action to collect such outstanding amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">On June 23, 2016, the
Icahn School of Medicine at Mount Sinai (&ldquo;Mount Sinai&rdquo;) filed a lawsuit against Transgenomic in the Supreme Court of
the State of New York, County of New York, alleging, among other things, breach of contract and, alternatively, unjust enrichment
and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai entered
into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and
our agreement to pay approximately $0.7 million to Mount Sinai in installments over a period of time. Effective as of October 31,
2017, we and Mount Sinai agreed to enter into a new settlement agreement to restructure these liabilities into a secured, long-term
debt obligation of $0.5 million which includes accrued interest at 10% with monthly principal and interest payments of $9,472 beginning
in July 2018 and continuing over 48 months and we issued warrants in the amount of 24,900 shares, that are exercisable for shares
of our common stock, on a 1-for-1 basis, with an exercise price of $7.50 per share, exercisable on the date of issuance with a
term of 5 years. We do not plan to apply to list the warrants on the NASDAQ Capital Market, any other national securities exchange
or any other nationally recognized trading system. A $0.5 million liability has been recorded and is reflected in long-term debt
within the accompanying condensed consolidated balance sheet at March 31, 2018 and December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">On February 21, 2017, XIFIN,
Inc. (&ldquo;XIFIN&rdquo;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach
of written contract and seeking recovery of approximately $0.27 million owed by us to XIFIN for damages arising from a breach of
our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated
on September 1, 2014. On April 5, 2017, the court clerk entered default against the Company. On May 5, 2017, XIFIN filed an application
for entry of default judgment against us. A liability of $0.1 million and $0.2 million is reflected in accounts payable within
the accompanying condensed consolidated balance sheet at March 31, 2018 and December 31, 2017, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">CPA Global provides us with
certain patent management services. On February 6, 2017, CPA Global claimed that we owe approximately $0.2 million for certain
patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. A liability
of approximately less than $0.1 million has been recorded and is reflected in accounts payable within the accompanying condensed
consolidated balance sheet at March 31, 2018 and December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">On February 17, 2017, Jesse
Campbell (&ldquo;Campbell&rdquo;) filed a lawsuit individually and on behalf of others similarly situated against us in the District
Court for the District of Nebraska alleging we had a materially incomplete and misleading proxy relating to a potential merger
and that the merger agreement&rsquo;s deal protection provisions deter superior offers.&nbsp; As a result, Campbell alleges that
we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&nbsp;The Company filed a motion
to dismiss all claims, which motion was fully briefed on November 27, 2017.&nbsp;The Court granted the Company&rsquo;s motion in
full on May 3, 2018 and dismissed the lawsuit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">On March 21, 2018, Bio-Rad
Laboratories filed a lawsuit against us in the Superior Court Judicial Branch of the State of Connecticut for Summary Judgment
in Lieu of Complaint requiring us to pay cash owed to Bio-Rad in the amount of $39,000. We are currently in discussions with Bio-Rad
to reach payment conditions. A liability of less than $0.1 million has been recorded in accounts payable within the accompanying
condensed consolidated balance sheet at March 31, 2018 and December 31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><B>7. INCOME TAXES </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">Income tax expense for the
three months ended March 31, 2018 and 2017 was zero as a result of recording a full valuation allowance against the deferred tax
asset generated during the periods, which are predominantly net operating losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">We had no material interest
or penalties during fiscal 2018 or fiscal 2017, and we do not anticipate any such items during the next twelve months. Our policy
is to record interest and penalties directly related to uncertain tax positions as income tax expense in the condensed consolidated
statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><B>8. STOCKHOLDERS&rsquo; EQUITY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Common Stock.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Pursuant to our Third
Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">shares of common stock authorized for issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">On February 8, 2018 the
Company entered into an equity purchase agreement (the &ldquo;2018 Purchase Agreement&rdquo;) with Leviston Resources LLC (&ldquo;Leviston&rdquo;)
for the purchase of up to $8,000,000 (the &ldquo;Aggregate Amount&rdquo;) of shares (the &ldquo;Shares&rdquo;) of the Company&rsquo;s
common stock from time to time, at the Company&rsquo;s option. Shares offered and sold prior to February 13, 2018 were issued pursuant
to the Company&rsquo;s shelf registration statement on Form S-3 (and the related prospectus) that the Company filed with the Securities
and Exchange Commission (the &ldquo;SEC&rdquo;) and which was declared effective by the SEC on February 13, 2015 (the &ldquo;Shelf
Registration Statement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Sales of the Company&rsquo;s common stock, if
any, may be made in sales deemed to be &ldquo;at-the-market&rdquo; equity offerings as defined in Rule 415 promulgated under the
Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), at a purchase price equal to 97.25% of the volume weighted
average sales price of the common stock reported on the date that Leviston receives a capital call from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Leviston purchased 721,153 shares (the &ldquo;Investor
Shares&rdquo;) of the Company&rsquo;s common stock following the close of business on February 9, 2018, subject to customary closing
conditions, at a price per share of $1.04. The shares were sold pursuant to the Shelf Registration Statement. The net proceeds
to the Company from this sale were approximately $744,000. In addition to the $6,000 fee (0.75% fee discussed below), the Company
incurred approximately $136,000 of additional costs, both of which have been treated as issuance costs within additional paid-in
capital in the accompanying unaudited condensed consolidated balance sheet.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In consideration of Leviston&rsquo;s agreement
to enter into the 2018 Purchase Agreement, the Company agreed to pay to Leviston a commitment fee in shares of the Company&rsquo;s
common stock equal in value to 5.25% of the total Aggregate Amount (the &ldquo;Commitment Shares&rdquo;), payable as follows: 1.75%
on or before February 12, 2018. This amount, of $140,000, was paid to Leviston through the issuance of 170,711 shares of the Company&rsquo;s
common stock on February 12, 2018; 1.75% on the third calendar day after the date on which the registration statement on Form S-1
filed on April 16, 2018 is declared effective by the SEC; and 1.75% on the thirtieth calendar day after the date on which such
registration statement on Form S-1 is declared effective by the SEC.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The Company agreed to pay to Leviston, on
each day that Leviston receives a capital call from the Company, all expenses associated with depositing, clearing, selling and
mailing of the stock certificates, a fee of 0.75% of any amount purchased by Leviston. Also, the Company paid $35,000 to Leviston
for a documentation fee for preparing the 2018 Purchase Agreement. This was recorded in additional paid-in-capital as an off-set
to the proceeds received. Leviston will refund the Company $15,000 if certain future conditions are met. Such conditions have not
been met as of the date of issuance of this Form 10-Q.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">Because the Company&rsquo;s existing registration
statement on Form S-3 expired on February 13, 2018 and, due to the timing of the filing of the Company&rsquo;s Quarterly Report
on Form 10-Q for the quarter ended June 30, 2017, the Company will not be eligible to file a new Form S-3 registration statement
until September 1, 2018, the Company agreed to prepare and file with the SEC a registration statement on Form S-1 the (&ldquo;S-1
Registration Statement&rdquo;), by April 15, 2018 and to use reasonable best efforts to cause the S-1 Registration Statement to
be declared effective by the SEC within ninety days thereafter. The Company filed the S-1 Registration Statement with the SEC on
April 16, 2018, which is yet to become effective and which was in a timely manner since the SEC was not open for filings on April
15, 2018. The Company is also required to pay liquidated damages of $100,000 on each event of default under the 2018 Purchase Agreement.
The Company has provided Leviston with customary indemnification rights under the 2018 Purchase Agreement.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">During the three months
ended March 31, 2018, the Company issued 3,120,000 shares of its common stock in connection with conversions of its Series B Preferred
Stock and 3,345,334 shares of its common stock in connection with conversions of its Series C Preferred Stock. Aside from 60,000
shares of common stock issued in connection with conversions of its Series C Preferred Stock, all of the shares of common stock
issued in the three months ended March 31, 2018 in connection with conversions of its Series B Preferred Stock and Series C Preferred
Stock (together the &ldquo;Preferred Stock&rdquo;) were issued after the Company induced the holders of its Preferred Stock to
convert their shares of Preferred Stock to shares of the company&rsquo;s common stock (see below - Preferred Stock induced conversions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">During the three months
ended March 31, 2018, the Company issued 300,000 shares of its common stock in connection with the exercise of 300,000 warrants.
The warrant exercise resulted in net cash proceeds to the Company of approximately $0.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Preferred Stock.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The Company&rsquo;s Board
of Directors is authorized to issue up to 15,000,000 shares of preferred stock in one or more series, from time to time, with such
designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution
or resolutions adopted by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Series B Preferred Stock.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">On August&nbsp;25, 2017,
the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series&nbsp;B Convertible Preferred Stock
(&ldquo;Series B Preferred Stock&rdquo;) with the State of Delaware which designates 6,900 shares of our preferred stock as Series&nbsp;B
Preferred Stock. The Series&nbsp;B Preferred Stock has a stated value of&thinsp;$1,000 per share and a par value of&thinsp;$0.01
per share. The Series B Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent
dividends are also paid on the common stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">On August&nbsp;28, 2017,
the Company completed the August 2017 Offering of 6,000 units consisting of one share of the Company&rsquo;s Series B Preferred
Stock, which was initially convertible into 400 shares of common stock, par value $0.01 per share, at a conversion price of $2.50
per share, and one warrant to purchase up to 400 shares of common stock (the &ldquo;August 2017 Offering Warrants&rdquo;) at a
combined public offering price of $1,000 per unit. The August 2017 Offering included the sale of 280,000 August 2017 Offering Warrants
pursuant to the over-allotment option exercised by Aegis Capital Corp. (&ldquo;Aegis&rdquo;) for $0.01 per share or $2,800.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">In November 2017, the
down round feature of the Series B Preferred Stock was triggered at the time of the Company&rsquo;s issuance of its Series C Preferred
Stock and, as a result, the conversion price of the Series B Preferred Stock was reduced from $2.50 per share to $1.40 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The 2018 Purchase Agreement
triggered the down round feature of the Series B Preferred Stock and, as a result, the conversion price of the Company&rsquo;s
Series B Convertible Preferred Stock was automatically adjusted from $1.40 per share to $1.04 per share. In connection with the
down round adjustment, the Company calculated an incremental beneficial conversion feature of approximately $1.4 million which
was recognized as a deemed dividend at time of the down round adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The 2018 Inducement Agreement,
discussed below, triggered the down round feature of the Series B Preferred Stock and, as a result, the conversion price of the
Company&rsquo;s Series B Convertible Preferred Stock was automatically adjusted from $1.04 per share to $0.75 per share. In connection
with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximately $40,000 which
was recognized as a deemed dividend at time of the down round adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">During the three months
ended March 31, 2018, 2,340 shares of Series B Preferred Stock that were outstanding at December 31, 2017 were converted into 3,120,000
shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">At March 31, 2018,
the Company had 6,900 shares of Series B designated and 47 shares of Series B issued and outstanding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Series C Preferred Stock</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">On November 6, 2017, the
Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series&nbsp;C Convertible Preferred Stock
(&ldquo;Series C Preferred Stock&rdquo;) with the State of Delaware which designates 2,748 shares of our preferred stock as Series&nbsp;C
Preferred Stock. The Series&nbsp;C Preferred Stock has a stated value of&thinsp;$1,000 per share and a par value of&thinsp;$0.01
per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">On November 2, 2017, the
Company entered into a Placement Agency Agreement (the &ldquo;Placement Agreement&rdquo;) with Aegis Capital Corp. for the sale
on a reasonable best efforts basis of 2,748 units, each consisting of one share of the Company&rsquo;s Series C Preferred Stock,
convertible into a number of shares of the Company&rsquo;s common stock equal to $1,000 divided by $1.40 and warrants to purchase
up to 1,962,857 shares of common stock with an exercise price of $1.63 per share (the &ldquo;Series C Warrants&rdquo;) at a combined
offering price of $1,000 per unit, in a registered direct offering (the &ldquo;Series C Preferred Offering&rdquo;). The Series
C Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid
on the common stock). The securities comprising the units are immediately separable and were issued separately.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The conversion price of
the Series C Preferred Stock contains a down round feature. The 2018 Purchase Agreement triggered the down round feature of the
Series C Preferred Stock and, as a result, the conversion price of the Company&rsquo;s Series B Convertible Preferred Stock was
automatically adjusted from $1.40 per share to $1.04 per share. In connection with the down round adjustment, the Company calculated
an incremental beneficial conversion feature of approximately $0.8 million which was recognized as a deemed dividend at time of
the down round adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">During the three months
ended March 31, 2018, 2,548 shares of Series C Preferred Stock that were outstanding at December 31, 2017 were converted into 3,345,334
shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">At March 31, 2018,
the Company had 2,748 shares of Series C designated and zero shares of Series C issued and outstanding.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Preferred Stock induced conversions </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">On March 21, 2018, the
Company entered into a Letter Agreement (the &ldquo;2018 Inducement Agreement&rdquo;) with certain holders (the &ldquo;Investors&rdquo;)
of shares of the Company&rsquo;s Series B Preferred Stock and Series C Preferred Stock (together the &ldquo;Preferred Stock&rdquo;),
and warrants (the &ldquo;Warrants&rdquo;) to purchase shares of the Company&rsquo;s common stock, par value $0.01 per share (&ldquo;Common
Stock&rdquo;), issued in the Company&rsquo;s public offering in August 2017 and registered direct offering in November 2017. Pursuant
to the 2018 Inducement Agreement, the Company and the Investors agreed that, as a result of the issuance of shares of Common Stock
pursuant to that Purchase Agreement, dated February 8, 2018, by and between the Company and the investor named therein, and effective
as of the time of execution of the 2018 Inducement Agreement, the exercise price of the Warrants was reduced to $0.75 per share
(the &ldquo;Exercise Price Reduction&rdquo;) and the conversion price of the Preferred Stock was reduced to $0.75 (the &ldquo;Conversion
Price Reduction&rdquo;). As consideration for the Company&rsquo;s agreement to the Exercise Price Reduction and the Conversion
Price Reduction, (i) each Investor agreed to convert the shares of Preferred Stock held by such Investor into shares of Common
Stock in increments of up to 4.99% of the shares of Common Stock outstanding as of the date of the 2018 Inducement Agreement and
(ii) one Investor agreed to exercise 666,666 Warrants and another Investor agreed to exercise 500,000 Warrants in increments of
up to 4.99% of the shares of Common Stock outstanding as of the date of the 2018 Inducement Agreement, in each case in accordance
with the beneficial ownership limitations set forth in the Company&rsquo;s Certificate of Designation of Preferences, Rights and
Limitations of Series B Convertible Preferred Stock, the Company&rsquo;s Certificate of Designation of Preferences, Rights and
Limitations of Series C Convertible Preferred Stock and the Warrants. As discussed above, as of March 31, 2018, all shares of Preferred
Stock, except 47 shares of Series B Preferred Stock, have been converted to shares of our common stock and 300,000 Warrants had
been exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">The 2018 Inducement Agreement
represented an inducement by the Company to convert shares of the Preferred Stock. The conversion price of the Preferred Stock
was reduced from $1.04 per share to $0.75 per share and the exercise price of the Warrants was reduced from $1.04 per share to
$0.75 per share. The Company calculated the fair value of the additional securities and consideration to be approximately $1.2
million. This amount was recorded as a charge to additional paid-in-capital and as a deemed dividend resulting in a reduction of
income available to common shareholders in our basic earnings per share calculation. The $1.2 million is comprised of two components:
1) $1.1 million related to the fair value of the additional common shares issued upon conversion of the Preferred Stock due to
the reduced conversion price and 2) $0.1 million in incremental fair value of the Warrants resulting from the reduction of the
exercise price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Common Stock Warrants.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The following represents
a summary of the warrants outstanding as of March 31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="text-align: left">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Issue&nbsp;Year</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Expiration</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Underlying<BR> Shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Exercise<BR> Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="5" STYLE="font-style: italic; text-decoration: underline; text-align: left">Warrants Assumed in Merger</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 6%; text-align: left">(1)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center">2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 26%; text-align: center">April 2020</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 20%; text-align: right">12,487</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">120.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">February 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,826</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">67.20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">December 2020</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,081</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">49.80</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">January 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,952</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">36.30</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-style: italic; text-decoration: underline; text-align: left">Warrants</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45,600</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2.75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">June 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">7.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">August 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,380,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">August 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.125</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(9)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">August 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">856,446</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10.00</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(10)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">August 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">359,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">(11)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">October 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">(12)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">May 2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,962,857</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.75</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">(13)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">2018</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">October 2022</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">108,112</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; text-align: right">7.50</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,923,789</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>These warrants were issued in connection with a private placement which was completed in October 2014.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>These warrants were issued in connection with an offering which was completed in February 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(3)</TD><TD>These warrants were issued in connection with an offering which was completed in July 2015.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(4)</TD><TD>These warrants were issued in connection with an offering which was completed in January 2016. Of the remaining outstanding
warrants as of March 31, 2018, 5,368 warrants are recorded as a liability, See Note 9 &ndash; Fair Value for further discussion,
and 3,584 are treated as equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD>These warrants were issued in connection with the Merger and are the 2017 New Bridge Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(6)</TD><TD>These warrants were issued in connection with the Merger and are considered Side Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(7)</TD><TD STYLE="text-align: justify">These warrants were issued in connection with the August 2017 Offering and are the August 2017
Offering Warrants discussed below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(8)</TD><TD STYLE="text-align: justify">These warrants were issued in connection with the August 2017 Offering and are considered Representative
Warrants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(9)</TD><TD STYLE="text-align: justify">These warrants were issued in connection with the conversion of our Series A Senior stock, at the
time of the closing of the August 2017 Offering, and are the Series A Conversion Warrants discussed above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(10)</TD><TD STYLE="text-align: justify">These warrants were issued in connection with the conversion of convertible bridge notes, at the
time of the closing of the August 2017 Offering, and are the Note Conversion Warrants discussed below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(11)</TD><TD STYLE="text-align: justify">These warrants were issued in connection with the waiver of default the Company received in the
fourth quarter of 2017 in connection with the Convertible Promissory Notes and are the Convertible Promissory Note Warrants discussed
below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(12)</TD><TD STYLE="text-align: justify">These warrants were issued in connection with the Series C Preferred Offering and are the Series
C Warrants discussed below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(13)</TD><TD STYLE="text-align: justify">These warrants were issued in connection with the Debt Obligation settlement agreements and are
the Creditor Warrants discussed below.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><U>Warrants Assumed in Merger</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">At the time of the Merger,
Transgenomic had a number of outstanding warrants related to various financing transactions that occurred between 2013-2016. Details
related to year issued, expiration date, amount of underlying common shares and exercise price are included in the table above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">During the three months
ended March 31, 2018, 23,055 of the warrants assumed in the Merger expired and are no longer outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><U>August 2017 Offering
Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">In connection with the August
2017 Offering, the Company issued 2,680,000 warrants at an exercise price of $3.00, which contain a down round provision. As a
result of the Series C Preferred Offering, the exercise price <FONT STYLE="background-color: white">of the August 2017 Offering
Warrants was adjusted to $1.40 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="background-color: white">During
the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the August 2017 Offering Warrants
was adjusted to $1.04. At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision
on the warrants to be approximately $62,000 and recorded this as a deemed dividend. In addition, as a result of the 2018 Inducement
Agreement, the exercise price of the August 2017 Offering Warrants was further adjusted to $0.75 as a result of the Exercise Price
Reduction discussed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="background-color: white">During
the three months ended March 31, 2018, 300,000 of the August 2017 Offering Warrants were exercised for $0.75 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><U>Note Conversion Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Upon the closing of the
August 2017 Offering, the Company issued 359,999 warrants to purchase the Company&rsquo;s common stock (the &ldquo;Note Conversion
Warrants&rdquo;). The Note Conversion Warrants have an exercise price of $3.00 per share and contain a down round provision. As
a result of the Series C Preferred Offering, the exercise price <FONT STYLE="background-color: white">of the Note Conversion Warrants
was adjusted to $1.40 per share. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="background-color: white">During
the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the Note Conversion Warrants
was adjusted to $1.04. At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision
on the warrants to be approximately $8,000 and recorded this as a deemed dividend. In addition, as a result of the 2018 Inducement
Agreement, the exercise price of the Note Conversion Warrants was further adjusted to $0.75. At the time the exercise price was
adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately $5,000 and recorded
this as a deemed dividend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><U>Convertible Promissory
Note Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The Convertible Promissory
Note Warrants had an original exercise price of $3.00 per share and contain a down round provision. As a result of the Series C
Preferred Offering, the exercise price <FONT STYLE="background-color: white">of the Convertible Promissory Note Warrants was adjusted
to $1.40 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="background-color: white">During
the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the Convertible Promissory
Note Warrants was adjusted to $1.04. At the time the exercise price was adjusted, the Company calculated the fair value of the
down round provision on the warrants to be less than $1,000 and recorded this as a deemed dividend. In addition, as a result of
the 2018 Inducement Agreement, the exercise price of the Convertible Promissory Note Warrants was further adjusted to $0.75. At
the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to
be less than $1,000 and recorded this as a deemed dividend.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><U>Series C Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">In connection with the Series
C Preferred Offering, the Company issued 1,962,857 warrants at an exercise price of $1.63, which contain a down round provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="background-color: white">During
the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the Series C Warrants was
adjusted to $1.04. At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision
on the warrants to be approximately $58,000 and recorded this as a deemed dividend. In addition, as a result of the 2018 Inducement
Agreement, the exercise price of the Series C Warrants was further adjusted to $0.75 as a result of the Exercise Price Reduction
discussed above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><U>Creditor Warrants</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">In the fourth quarter of
2017, the Company entered into Settlement Agreements with certain of its accounts payable and accrued liability vendors (the &ldquo;Creditors&rdquo;)
pursuant to which the Company agreed to issue, to certain of its Creditors, 108,112 warrants to purchase 108,112 shares of the
Company&rsquo;s common stock at an exercise price of $7.50 per share. The warrants were issued in February 2018. See Note 4 &ndash;
Long-Term Debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0"><B>9. FAIR VALUE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">FASB guidance on fair
value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair
value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair
value on a recurring basis in our condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">FASB guidance establishes
a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of
inputs used to measure fair value are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Level&nbsp;1&mdash;Unadjusted
quoted prices in active markets for identical assets or liabilities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Level&nbsp;2&mdash;Observable
inputs other than those included in Level&nbsp;1, such as quoted prices for similar assets and liabilities in active markets or
quoted prices for identical assets or liabilities in inactive markets;&nbsp;and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Level&nbsp;3&mdash;Unobservable
inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Common Stock Warrant Liabilities.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">Certain of our issued and outstanding warrants
to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><U>2016 Warrant Liability</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The Company assumed the
2016 Warrant Liability in the Merger and it represents the fair value of Transgenomic warrants issued in January 2016, of which,
5,368 warrants remain outstanding as of March 31, 2018. We are required to record these instruments at fair value at each reporting
date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other
income (expense) in our condensed consolidated statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">During the three months
ended March 31, 2018, a portion of the 2016 Warrant Liability was part of a settlement agreement pursuant to a lawsuit that was
filed against the Company by one of the warrant holders. As such, approximately $0.4 million of the warrant liability, representing
20,216 warrants, was canceled on the date of the settlement agreement and replaced by and amounts now recorded as other current
liabilities or other long-term liabilities. For further detail, see discussion of the Crede Agreement in Note 5 &ndash; Other Current Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The 2016 Warrant Liability
is considered a Level 3 financial instrument and was valued using the Monte Carlo methodology. As of March 31, 2018, assumptions
and inputs used in the valuation of the common stock warrants include: remaining life to maturity of 2.75 years; annual volatility
of 167%; and a risk-free interest rate of 2.39%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">During the three months
ended March 31, 2018, the change in the fair value of the liability measured using significant unobservable inputs (Level 3) were
comprised of the following: </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Dollars in Thousands</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">For the Three Months Ended</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">March 31, 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 83%; font: 10pt Times New Roman, Times, Serif; text-align: left">Beginning balance at January 1</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 14%; font: 10pt Times New Roman, Times, Serif; text-align: right">841</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total gains:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Recognized in earnings</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(261</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Deductions &ndash; warrant liability settlement</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(456</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Balance at March 31</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">124</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><B>10. EQUITY INCENTIVE PLAN</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The Company's 2006 Equity
Incentive Plan (the &quot;2006 Plan&quot;) was terminated as to future awards on July 12, 2016. The Company's 2017 Stock Option
and Incentive Plan (the &quot;2017 Plan&quot;) was adopted by the Company's stockholders on June 5, 2017 and there were 666,666
shares of common stock reserved for issuance under the 2017 Plan. The 2017 Plan will expire on June 5, 2027.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I><U>Amendment of the
2017 Stock Option and Incentive Plan </U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">On January 31, 2018, at
a special meeting of the stockholders of the Company, the stockholders approved an amendment and restatement of the Company&rsquo;s
2017 Stock Option and Incentive Plan (the &ldquo;2017 Plan&rdquo;) to:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increase the aggregate number of shares authorized for issuance under the 2017 Plan by 5,389,500
shares to 6,056,166 shares and cumulatively increased on January 1, 2019 and on each January 1 thereafter by the lesser of the
annual increase for such year or 500,000 shares;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">increase the maximum number of shares that may be granted in the form of stock options or stock
appreciation rights to any one individual in any one calendar year and the maximum number of shares underlying any award intended
to qualify as performance-based compensation to any one individual in any performance cycle, in each case to 1,000,000 shares of
Common Stock; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">add an &ldquo;evergreen&rdquo; provision, pursuant to which the aggregate number of shares authorized
for issuance under the 2017 Plan will be automatically increased each year beginning on January 1, 2019 by 5% of the number of
shares of Common Stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares determined
by the Company&rsquo;s Board of Directors or Compensation Committee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Stock Options.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left; text-indent: 22.5pt">During the three months ended March 31, 2018,
the Company granted stock options to employees and directors to purchase up to 3,286,528 shares of common stock at a weighted average
exercise price of $0.71. These awards have vesting periods of one to four years and had a weighted average grant date fair value
of $0.65. The fair value calculation of options granted during the three months ended March 31, 2018 used the follow assumptions:
risk free interest rate of 2.63% based on the U.S. Treasury yield in effect at the time of grant; expected life of six years; and
volatility of 135%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">The following table summarizes stock option
activity under our plans during the three months ended March 31, 2018:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number of</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Options</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Weighted-Average</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Exercise Price</B></P></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%">Outstanding at January&nbsp;1, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">236,484</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">7.12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,286,528</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.71</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 9pt">Forfeited</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(2,953</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">110.23</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2.5pt">Outstanding at March 31, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">3,520,059</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1.06</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 2.5pt">Exercisable at March 31, 2018</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">42,249</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">22.75</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">As of March 31, 2018,
there were 2,650,694 options that were vested or expected to vest with an aggregate intrinsic value of zero and a remaining weighted
average contractual life of 9.8 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">For the three months ended
March 31, 2018 and 2017, we recorded compensation expense for all stock awards of $0.1 million and zero, respectively, within operating
expense in the accompanying statements of operations. As of March 31, 2018, the unrecognized compensation expense related to unvested
stock awards was $2.4 million, which is expected to be recognized over a weighted-average period of 3.6 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><B>11. SALES SERVICE REVENUE, NET
AND ACCOUNTS RECEIVABLE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I><U>Adoption of ASC Topic 606, &ldquo;Revenue from contracts
with customers&rdquo;</U></I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">On January 1, 2018, the
Company adopted ASC 606 that amends the guidance for the recognition of revenue from contracts with customers to transfer goods
and services by using the modified-retrospective method applied to any contracts that were not completed as of January 1, 2018.
The Company performed a comprehensive review of its existing revenue arrangements following the five-step model:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">Step 1: Identification
of the contract with the customer. Sub-steps include determining the customer in a contract; Initial contract identification and
determine if multiple contracts should be combined and accounted for as a single transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">Step 2: Identify the performance
obligation in the contract. Sub-steps include identifying the promised goods and services in the contract and identifying which
performance obligations within the contract are distinct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">Step 3: Determine the
transaction price. Sub-steps include variable consideration, constraining estimates of variable consideration, the existence of
a significant financing component in the contract, noncash consideration and consideration payable to a customer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">Step 4: Allocate transaction
price. Sub-steps include assessing the amount of consideration to which the Company expects to be entitled in exchange for transferring
the promised goods or services to the customer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">Step 5: Satisfaction of
performance obligations. Sub-steps include ascertaining the point in time when an asset is transferred to the customer and the
customer obtains control of the asset upon which time the Company recognizes revenue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">Based on the Company's
analysis, there were no changes identified that impacted the amount or timing of revenues recognized under the new guidance as
compared to the previous guidance (ASC 605). Additionally, the Company's analysis indicated that there were no changes to how costs
to obtain and fulfill our customer contracts would be recognized under the new guidance as compared to the previous guidance. Accordingly,
the initial application of the new revenue standard did not result in the recognition of a cumulative effect adjustment to the
opening balance of accumulated deficit as of January 1, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.3pt"><I>Nature of Contracts and Customers</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.3pt">The Company&rsquo;s contracts and related
performance obligations are similar for its customers and the sales process for all customers start upon the receipt of requisition
forms from the customers for patient diagnostic testing and the execution of contracts for biomarker testing and clinical research.
Payment terms for the services provided are 30 days, unless separately negotiated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><I>Diagnostic testing</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">Control of the laboratory
testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for laboratory testing
services at a point in time based on the delivery method (web-portal access or fax) for the patient&rsquo;s laboratory report,
per the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.3pt"><I>Clinical research grants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">Control of the clinical
research services are transferred to the customer over time. The Company will recognize revenue utilizing the &ldquo;effort based&rdquo;
method, measuring its progress toward complete satisfaction of the performance obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.3pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.3pt"><I>Biomarker testing and clinical project
services</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Control of the biomarker testing and clinical project services
are transferred to the customer over time. The Company utilizes an &ldquo;effort based&rdquo; method of assessing performance and
measures progress towards satisfaction of the performance obligation based upon the delivery of results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">The Company generates
revenue from the provision of diagnostic testing provided to patients, biomarker testing provided to bio-pharma customers and clinical
research grants funded by both bio-pharma customers and government health programs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"><I></I></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Disaggregation of Revenues
by Transaction Type</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">We operate in one
business segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting,
consistent with internal management reporting. Revenues, net of contractual allowances and adjustments for the three months ended
March&nbsp;31, 2018 and 2017 were as follows (prior-period amounts are not adjusted under the modified-retrospective method of
adoption):</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><B>(dollars in thousands)</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Diagnostic Testing</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Biomarker Testing</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>Total</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 22%">Medicaid</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">12</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Medicare</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">134</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Self-pay</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Third party payers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">131</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">113</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Contract diagnostics</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">488</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">488</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Revenues, net of contractual allowances</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">303</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">303</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">488</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">791</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">303</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">Revenue from the Medicare
and Medicaid programs account for a portion of the Company&rsquo;s patient diagnostic service revenue. Laws and regulations governing
those programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that
recorded estimates will change by a material amount in the near term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Revenue Recognition</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">Revenue is recognized
when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects
to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company
estimates the amount of variable consideration that should be included in the transaction price using the expected value method
based on historical experience. The Company does not typically enter arrangements where multiple contracts can be combined as the
terms regarding services are generally found within a single agreement/requisition form. The Company derives its revenues from
three types of transactions: diagnostic testing, clinical research grants from state and federal research programs, and other revenues
from the Company&rsquo;s ICP technology and bio-pharma projects encompassing genetic diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Deferred revenue</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">Deferred revenue,
or&nbsp;unearned revenue, refers to advance payments for products or services that are to be delivered in the future. The Company
records such prepayment of unearned revenue as a liability, as revenue that has not yet been earned, but represents products or
services that are owed to a customer. As the product or service is delivered over time, the Company recognizes the appropriate
amount of revenue from deferred revenue. For the period ended March 31, 2018 and December 31, 2017, the deferred revenue was $189,000
and $66,000, respectively.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"><I></I></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><I>Contractual
Allowances and Adjustments</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">We are reimbursed
by payors for services we provide. Payments for services covered by payors average less than billed charges. We monitor revenue
and receivables from payors and record an estimated contractual allowance for certain revenue and receivable balances as of the
revenue recognition date to properly account for anticipated differences between amounts estimated in our billing system and amounts
ultimately reimbursed by payors. Accordingly, the total revenue and receivables reported in our financial statements are recorded
at the amounts expected to be received from these payors. For service revenue, the contractual allowance is estimated based on
several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement
terms and changes in customer base and payor/product mix. The billing functions for the remaining portion of our revenue are contracted
and fixed fees for specific services and are recorded without an allowance for contractual discounts. The following table presents
our revenues initially recognized for each associated payor class during the three months ended March 31, 2018 and 2017.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Gross Revenues</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Contractual Allowances and
    adjustments</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Revenues, net of Contractual
    Allowances and adjustments</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-size: 10pt">Medicaid</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">15</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">24</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">(3</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">(12</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">12</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">12</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Medicare</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">137</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">166</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(8</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">134</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">158</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Self-pay</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Third party payers</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">317</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">295</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(186</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(182</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">131</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">113</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Contract diagnostics</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">488</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">488</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">983</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">505</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(192</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(202</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">791</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">303</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">988</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">505</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(192</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(202</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">796</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">303</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><I>Allowance
for Doubtful Accounts</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">The Company provides
for a general allowance for collectability of services when recording net sales. The Company has adopted the policy of recognizing
net sales to the extent it expects to collect that amount. Reference FASB 954-605-45-5 and ASU 2011-07, Health Care Entities: Presentation
and Disclosure of Patient Service Revenue, Provision for Bad Debt, and the Allowance for Doubtful Accounts. The change in the allowance
for doubtful accounts is directly related to the increase in patient service revenues. The following table presents our reported
revenues net of the collection allowance and adjustments for the three months ended March 31, 2018 and 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><B>(dollars in thousands)</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><B>Revenues,
    net of <BR>Contractual Allowances and adjustments</B></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Allowances for doubtful accounts</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Total</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-size: 10pt; padding-left: 5.4pt">Medicaid</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">12</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">12</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">(11</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">(2</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">1</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">10</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 5.4pt">Medicare</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">134</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">158</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(20</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(30</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">114</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">128</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-left: 5.4pt">Self-pay</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">20</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">26</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">16</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 5.4pt">Third party payers</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">131</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">113</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(53</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(19</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">78</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">94</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Contract diagnostics</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">488</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">488</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">791</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">303</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(84</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(55</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">707</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">248</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt">Other</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">796</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">303</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(84</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(55</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">712</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">248</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.3pt"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>Costs to Obtain or Fulfill a Customer Contract</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.3pt; text-align: justify">Sales commissions are expensed when incurred
because the amortization period would have been one year or less. These costs are recorded in operating expenses in the condensed
consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify">Shipping and handling costs are comprised of
inbound and outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts
with customers as fulfillment costs which are included in cost of sales in the condensed consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I><U>Accounts Receivable</U></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt; text-align: justify">The Company has provided an allowance for potential
credit losses, which has been determined based on management&rsquo;s industry experience. The Company grants credit without collateral
to its patients, most of who are insured under third party payer agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">The following summarizes the mix of receivables:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 75%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,<BR>
2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<BR>
 2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-indent: -12pt; padding-left: 12pt">Medicaid</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">33</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">37</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">Medicare</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">611</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">256</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -12pt; padding-left: 12pt">Self-pay</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">102</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt">Third party payers</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">768</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,066</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -12pt; padding-left: 12pt">Contract diagnostic services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">246</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">445</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt; text-indent: -12pt; padding-left: 12pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left"></TD><TD STYLE="text-align: right">1,760</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,857</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Less allowance for doubtful accounts </TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,208</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,127</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Accounts receivable, net</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">552</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">730</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;The following table presents the roll-forward
of the allowance for doubtful accounts for the three months ended March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><B>(dollars in thousands)</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid"><B>Allowance for Doubtful Accounts</B></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; font-size: 10pt">Balance, January 1, 2018</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 14%; font-size: 10pt; text-align: right">(1,127</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Collection Allowance:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Medicaid</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(11</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Medicare</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(20</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Third party payers</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">(53</TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt; text-align: right"></TD><TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Service revenue, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(84</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"></TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Bad debt expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total charges</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left"></TD><TD STYLE="font-size: 10pt; text-align: right"></TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(81</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">Balance, March 31, 2018</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"></TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,208</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>12. SUBSEQUENT EVENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Issuance of Convertible Notes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">On April 20, 2018,
the Company entered into a securities purchase agreement with certain investors, pursuant to which the Company will issue up to
approximately $3,296,703 in 8% Senior Secured Convertible Promissory Notes with 25% common stock warrant coverage. The initial
closing provided the Company with $1,660,000 of gross proceeds for the issuance of Notes with an aggregate principal of $1,809,400.
The Note is payable by the Company on the earlier of (i) the one year anniversary after the initial closing date or (ii) upon the
closing of a qualified offering, namely the Company raising gross proceeds of at least $7,000,000. The obligations under the Note
are secured, subject to certain exceptions and other permitted payments by a perfected security interest on the assets of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_007"></A>Item 2. Management&rsquo;s Discussion and Analysis of Financial
Condition and Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Forward-Looking Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">This Quarterly Report on
Form 10-Q, including this Management&rsquo;s Discussion&nbsp;and Analysis, contains forward-looking statements. These statements
are based on management&rsquo;s current views, assumptions or beliefs of future events and financial performance and are subject
to uncertainty and changes in circumstances. Readers of this report should understand that these statements are not guarantees
of performance or results. Many factors could affect our actual financial results and cause them to vary materially from the expectations
contained in the forward-looking statements. These factors include, among other things: our expected revenue, income (loss), receivables,
operating expenses, supplier pricing, availability and prices of raw materials, insurance reimbursements, product pricing, sources
of funding operations and acquisitions, our ability to raise funds, sufficiency of available liquidity, future interest costs,
future economic circumstances, business strategy, industry conditions, our ability to execute our operating plans, the success
of our cost savings initiatives, competitive environment and related market conditions, expected financial and other benefits from
our organizational restructuring activities, actions of governments and regulatory factors affecting our business, retaining key
employees and other risks as described in our reports filed with the Securities and Exchange Commission. In some cases these statements
are identifiable through the use of words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;can,&rdquo; &ldquo;could,&rdquo;
&ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;will,&rdquo; &ldquo;would&rdquo; or the negative versions of these terms and other
similar expressions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">You are cautioned not to
place undue reliance on these forward-looking statements. The forward-looking statements we make are not guarantees of future performance
and are subject to various assumptions, risks and other factors that could cause actual results to differ materially from those
suggested by these forward-looking statements. Actual results may differ materially from those suggested by the forward-looking
statements that we make for a number of reasons, including those described in Part II, Item 1A, &ldquo;Risk Factors,&rdquo; of
this Quarterly Report on Form 10-Q and our prior filings with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">We expressly disclaim any
obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">The following discussion
should be read together with our financial statements and related notes contained in this Quarterly Report on Form 10-Q and with
the financial statements, related notes and Management&rsquo;s Discussion&nbsp;and Analysis included in our Annual Report on Form
10-K for the fiscal year ended December&nbsp;31, 2017, which we filed with the Securities and Exchange Commission on April 13,
2018. Results for the three months ended March 31, 2018 are not necessarily indicative of results that may be attained in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Precipio, Inc., and Subsidiary,
(&ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;, the &ldquo;Company&rdquo; or &ldquo;Precipio&rdquo;) is a cancer diagnostics
company providing diagnostic products and services to the oncology market. We have built and continue to develop a platform designed
to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions
and delivering quality diagnostic information to physicians and their patients worldwide. We operate a cancer diagnostic laboratory
located in New Haven, Connecticut and have partnered with the Yale School of Medicine to capture the expertise, experience and
technologies developed within academia so that we can provide a better standard of cancer diagnostics and solve the growing problem
of cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which will focus on further development
of ICE-COLD-PCR, or ICP, the patented technology which was exclusively licensed by us from Dana-Farber Cancer Institute, Inc.,
or Dana-Farber, at Harvard University. The research and development center will focus on the development of this technology, which
we believe will enable us to commercialize other technologies developed by our current and future academic partners. Our platform
connects patients, physicians and diagnostic experts residing within academic institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">During the first quarter
of 2018, we continued to further demonstrate the power of our value proposition. In a study conducted with Yale, preliminary results
showed a 4-fold superiority in arriving at accurate diagnostic results, compared with the diagnoses conducted by outside pathology
laboratories. Additionally, we partnered with the molecular laboratory at the University of Pennsylvania to conduct a parallel
study to demonstrate the efficacy of IV-Cell, a proprietary reagent developed and patented by Precipio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">As part of our ongoing
work to further develop our product line, we launched several new products and product-improvements related to our proprietary
liquid biopsy technology, ICE-COLD PCR (ICP). Among them, we launched our first lung cancer treatment resistance panel, both as
a kit, and in our laboratory. Additionally, we integrated a unique technology called High-Resolution Melt (HRM) into our ICP kits,
enabling a quick and cost-effective screen for the presence of mutations. HRM-enabled ICP kits further improve ICP&rsquo;s value
proposition by both rapidly improving the potential turnaround time for testing results, as well as substantially reducing the
costs of testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">These efforts drove further
expansion on the commercial side of the business. During the first quarter we established distribution partnerships with key local
players in the Japanese, Brazilian, and Indian markets. We believe these markets provide a tremendous opportunity for Precipio
to expand into the international markets where many patients pay out-of-pocket for their healthcare costs, thus rendering an effective,
low-cost technology for the monitoring of the tumor genetics. Additionally, we hired an experienced VP of Sales to lead the domestic
pathology sales team, and over the next several quarters we plan to double our sales force to expand into other regions in the
US.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">From a corporate and financial
perspective, this quarter saw us settle our final outstanding creditor claims that carried over from the Transgenomic merger in
mid-2017. We settled our claims with Crede Capital, which joins other creditors who will be receiving payments over time, to enable
us to manage cash outlays while growing our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">On March 26, 2018, we
received written notice (or the Notice) from The Nasdaq Stock Market LLC (or the Nasdaq) indicating that we are not in compliance
with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Notice has no immediate effect on
the listing of our common stock, and our common stock will continue to trade on the Nasdaq Capital Market under the symbol &ldquo;PRPO&rdquo;
at this time.&nbsp;&nbsp;In accordance with Nasdaq Listing rules, we have a period of 180 calendar days, or until September 24,
2018 to regain compliance. To regain compliance, the closing bid price of our common stock must meet or exceed $1.00 per share
for at least ten consecutive business days during this 180 calendar day period.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Going Concern</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">The condensed consolidated
financial statements have been prepared using accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;)
applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary
course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the
past several years. As of March 31, 2018, the Company had a net loss of $2.4 million, negative working capital of $7.5 million
and net cash used in operating activities of $1.1 million. The Company&rsquo;s ability to continue as a going concern over the
next twelve months from the date of issuance of this form 10-Q is dependent upon a combination of achieving its business plan, including
generating additional revenue, and raising additional financing to meet its debt obligations and paying liabilities arising from
normal business operations when they come due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">To meet its current and
future obligations the Company has taken the following steps to capitalize the business and successfully achieve its business plan:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>On April 16, 2018, we filed a Form S-1 General Registration Statement to register and offer for future sale shares of our common
stock,&nbsp;pursuant to entering into an Equity Purchase Agreement with Leviston Resources LLC on February 8, 2018. See Note 8
&ndash; Stockholders&rsquo; Equity of the notes to unaudited condensed consolidated financial statements.&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>On April 20, 2018, we&nbsp;entered into a securities purchase agreement with certain investors, pursuant to which we will issue
up to approximately $3,296,703.30 in 8% Senior Secured Convertible Promissory Notes with 100% common stock warrant coverage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Notwithstanding the aforementioned
circumstances, there remains substantial doubt about the Company&rsquo;s ability to continue as a going concern over the next twelve
months from this date of issuance of this form 10-Q. There can be no assurance that the Company will be able to successfully achieve
its initiatives summarized above in order to continue as a going concern over the next twelve months from the date of issuance
of this form 10-Q. The accompanying financial statements have been prepared assuming the Company will continue as a going concern
and do not include any adjustments that might result should the Company be unable to continue as a going concern as a result of
the outcome of this uncertainty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Results of Operations for the Three Months
Ended March 31, 2018 and 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>Net Sales. </I>Net sales
were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Dollars in Thousands</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center">Three Months Ended</TD><TD NOWRAP STYLE="font-weight: bold">&nbsp;</TD><TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP>&nbsp;</TD><TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">$</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">%</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left">Service revenue, net</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">707</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">248</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">459</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; text-align: right">185</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Net Sales</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">712</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">248</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">464</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">187</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Net sales for the three
months ended March 31, 2018 were $0.7 million, an increase of $0.5 million, or 185%, as compared to the same period in 2017. This
increase was a result of increased contract diagnostic service revenue as a result of the Merger. Contract diagnostic service revenue
was $0.5 million and zero for the three months ended March 31, 2018 and 2017, respectively. This increase was partially off-set
by a decrease of less than $0.1 million in patient diagnostic service revenue due to a decrease in cases processed during the three
months ended March 31, 2018 as compared to the same period in 2017. We processed 140 cases during the three months ended March
31, 2018 as compared to 199 cases during the same period in 2017, or a 30% decrease in cases. The decrease in volume is the result
of turnover of key sales personnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><I>Cost of Sales.</I>
Cost of sales includes material and supply costs for the patient tests performed and other direct costs (primarily personnel costs
and rent) associated with the operations of our laboratory and the costs of projects related to clinical research grants (personnel
costs and operating supplies). Cost of sales increased by $0.5 million for the three months ended March 31, 2018 as compared to
the same period in 2017. The increase is due to increased biomarker subcontracted processing fees, increased professional medical
fees involved with the processing of patient tests and increased operating supplies in our diagnostic laboratory.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I></I></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>Gross Profit.</I> Gross
profit and gross margins were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="14" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Dollars in Thousands</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-weight: bold"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center"><B>Three Months Ended</B></TD><TD NOWRAP STYLE="font-weight: bold"><B>&nbsp;</B></TD><TD NOWRAP><B>&nbsp;</B></TD>
    <TD COLSPAN="6" NOWRAP><B>&nbsp;</B></TD><TD NOWRAP><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>March 31,</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>Margin %</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2018</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid"><B>2017</B></TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 48%; text-align: left; padding-bottom: 2.5pt">Gross Profit</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">24</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">66</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">3</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">%</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; border-bottom: Black 2.5pt double; text-align: right">27</TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Gross margin was 3%
of total net sales, for the three months ended March 31, 2018, compared to 27% of total net sales for the same period in 2017.
The gross profit decreased by less than $0.1 million during the three months ended March 31, 2018 as compared to the same period
in 2017 and was due to the increased cost of professional medical fees and diagnostic operating supplies discussed above.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><I>Operating Expenses.</I>
Operating expenses primarily consist of personnel costs, professional fees, travel costs, facility costs and depreciation and amortization.
Our operating expenses increased by $1.8 million to $2.5 million for the three months ended March&nbsp;31, 2018 as compared to
the same period in 2017. The increase in operating expenses reflects increased compensation and other costs of $0.3 million associated
with increased headcount and additional facility costs of $0.1 million resulting from the Merger and increased expenses of $0.3
million related to operating as a public company which did not exist in the first quarter of 2017. Additional increases in our
general and administrative expenses resulted from increased amortization of $0.3 million related to acquired intangibles from the
Merger, increased stock compensation costs of $0.1 million and increased professional fees and other expenses of $0.4 million.
The increase during the three months ended March 31, 2018 also included a $0.3 million impairment of goodwill charge resulting
from impairment testing of goodwill during the quarter.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>Other Income (Expense).</I>
Other expense for the three months ended March&nbsp;31, 2018 and 2017 includes interest expense of less than $0.1 million and $0.2
million, respectively. During the three months ended March 31, 2018, we also had income from gains on settlements of certain vendor
liabilities of $0.1 million, income from warrant revaluation of $0.3 million and a loss on settlement of equity instruments of
$0.4 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Liquidity and Capital Resources</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">Our working capital positions were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Dollars in Thousands</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2018</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,<BR>
 2017</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Change</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; text-align: left">Current assets (including cash of $286 and $421 respectively)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,206</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">1,742</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">(536</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Current liabilities</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8,751</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">10,036</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(1,285</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Working capital</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(7,545</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">(8,294</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">749</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">During the first quarter
of 2018 we received gross proceeds of $400,000 when we entered into an agreement with the Connecticut Department of Economic and
Community Development by which we received a grant of $100,000 and a loan of $300,000 with a payment term of ten years and we entered
into an equity purchase agreement for the purchase of up to $8,000,000 of shares of our common stock from time to time, at our
option. The initial sale of 721,153 shares of our common stock resulted in net proceeds to us of approximately $709,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22pt">&nbsp;<B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Analysis of Cash Flows &ndash; Three Months Ended March 31, 2018
and 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>Net Change in Cash.</I>
Cash decreased by $0.1 million during the three months ended March 31, 2018, compared to a decrease of less than $0.1 million during
the three months ended March&nbsp;31, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><I>Cash Flows Used in
Operating Activities.</I> The cash flows used in operating activities of approximately $1.1 million during the three months ended
March 31, 2018 included a net loss of $2.4 million. These were partially offset by an increase in accrued expenses and other liabilities
of $0.2 million, a decrease accounts receivable of $0.2 million, a decrease in other assets of $0.2 million and non-cash adjustments
of $0.7 million. The cash flows used in operating activities in the three months ended March 31, 2017 included the net loss of
$0.8 million and an increase in accounts receivable of less than $0.1 million. These were partially offset by an increase in accounts
payable, accrued expenses and other liabilities of $0.4 million and non-cash adjustments of $0.1 million.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>Cash Flows Used In Investing
Activities.</I> Cash flows used in investing activities were less than $0.1 million and zero for the three months ended March 31,
2018 and 2017, respectively. The cash used of less than $0.1 million for the three months ended March 31, 2018 included purchases
of property and equipment of less than $0.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><I>Cash Flows Provided by
Financing Activities.</I> Cash flows provided by financing activities totaled $1.0 million for the three months ended March 31,
2018, which included proceeds of $0.6 million from the issuance of common stock, $0.3 million from the issuance of long-term debt,
and $0.2 million from the exercise of warrants. These proceeds were partially offset by payments on our long-term debt and capital
leases obligations of $0.1 million. Cash flows provided by financing activities during the three months ended March 31, 2017 included
proceeds of $0.4 million from the issuance of long-term debt and convertible notes partially offset by $0.1 million of payments
on our debt and capital lease obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Off-Balance Sheet Arrangements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">At each of March 31, 2018
and December&nbsp;31, 2017, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current
or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity,
capital expenditures or capital resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Contractual Obligations and Commitments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt">No significant changes
to contractual obligations and commitments occurred during the three months ended March 31, 2018, as compared to those disclosed
in our Annual Report on form 10-K for the fiscal year ended December 31, 2017, filed with the <FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
and Exchange Commission</FONT> on April 13, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Critical Accounting Policies and Estimates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Accounting policies used
in the preparation of our financial statements may involve the use of management judgments and estimates. Certain of our accounting
policies are considered critical as they are both important to the portrayal of our financial statements and require significant
or complex judgments on the part of management. Our judgments and estimates are based on experience and assumptions that we believe
are reasonable under the circumstances. Further, we evaluate our judgments and estimates from time to time as circumstances change.
Actual financial results based on judgments or estimates may vary under different assumptions or circumstances. O<FONT STYLE="font-family: Times New Roman, Times, Serif">ur
critical accounting policies are discussed in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2017,
filed with the Securities and Exchange Commission on April 13, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Recently Issued Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">See the accompanying unaudited
condensed consolidated financial statements and Note 2 - &ldquo;Summary of Significant Accounting Policies&rdquo; in the Notes
to unaudited condensed financial statements for additional information regarding recently issued accounting pronouncements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Impact of Inflation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">We do not believe that price
inflation or deflation had a material adverse effect on our financial condition or results of operations during the periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">&nbsp;</P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_008"></A>Item 3. Quantitative and Qualitative Disclosure
about Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">We are a smaller reporting
company, as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and are not required to provide the information
required under this item.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_009"></A>Item 4. Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><I>Evaluation of Disclosure Controls and
Procedures</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt; background-color: white; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"><FONT STYLE="color: #222222">As
of the end of the period covered by this Quarterly Report on Form 10-Q, management performed, with the participation of our Chief
Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of our disclosure controls and procedures as
defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;). Our
disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in the
reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified
in the rules and forms of the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), and that such information is accumulated
and communicated to management including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions
regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that
any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired
control objectives, and no evaluation of controls and procedures can provide absolute assurance that all control issues and instances
of fraud, if any, within a company have been detected. Management is required to apply its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. Based on the evaluation, the Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures were&nbsp;effective as of March 31, 2018</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Changes in Internal
Control over Financial Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.6in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.6in; background-color: white">We
have evaluated the changes in our internal control over financial reporting that occurred during the three months ended March 31,
2018 and concluded that there have not been any changes that have materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting. On January 1, 2018, we adopted ASC 606 by using the modified-retrospective method.
An adjustment was not required and a change to the prior revenue recognition process and policy to adopt the new standard was not
necessary.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_010"></A>PART II. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_011"></A>Item 1. Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">See the accompanying unaudited
condensed consolidated financial statements and Note 6 - &ldquo;Contingencies&rdquo; in the Notes to unaudited condensed consolidated
financial statements for additional information regarding legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><A NAME="a_012"></A>Item 1A. Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">As disclosed in &ldquo;Item 1A. Risk Factors&rdquo;
in our Annual Report on Form 10-K for the year ended December 31, 2017, there are a number of risks and uncertainties that may
have a material effect on the operating results of our business and our financial condition. The following information updates,
and should be read in conjunction with, the factors discussed in Part I, Item 1A, &ldquo;Risk Factors&rdquo; in our Annual Report
on Form 10-K for the year ended December 31, 2017, which could materially affect our business, financial condition or future results.
The risks described in this Quarterly Report and our Annual Report on Form 10-K are not the only risks we face. Additional risks
and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our
business, financial condition or operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We have incurred losses since our inception
and expect to incur losses for the foreseeable future. We cannot be certain that we will achieve or sustain profitability.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">We have incurred losses
since our inception and expect to incur losses in the future. As of March 31, 2018, we had a net loss of $2.4 million, negative
working capital of $7.5 million and net cash used in operating activities of $1.1 million. To date, we have experienced negative
cash flow from development of our diagnostic technology, as well as from the costs associated with establishing a laboratory and
building a sales force to market our products and services. We expect to incur substantial net losses for the foreseeable future
to further develop and commercialize our diagnostic technology. We also expect that our selling, general and administrative expenses
will continue to increase due to the additional costs associated with market development activities and expanding our staff to
sell and support our products. Our ability to achieve or, if achieved, sustain profitability is based on numerous factors, many
of which are beyond our control, including the market acceptance of our products, competitive product development and our market
penetration and margins. We may never be able to generate sufficient revenue to achieve or, if achieved, sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Because of the numerous
risks and uncertainties associated with further development and commercialization of our diagnostic technology and any future tests,
we are unable to predict the extent of any future losses or when we will become profitable, if ever. We may never become profitable
and you may never receive a return on an investment in our securities. An investor in our securities must carefully consider the
substantial challenges, risks and uncertainties inherent in the development and commercialization of tests in the medical diagnostic
industry. We may never successfully commercialize our diagnostic technology or any future tests, and our business may fail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We will need to raise substantial additional
capital to commercialize our diagnostic technology, and our failure to obtain funding when needed may force us to delay, reduce
or eliminate our product development programs or collaboration efforts or force us to restrict or cease operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">As of March 31, 2018,
our cash balance was $0.3 million and our working capital was approximately negative $7.5 million. Due to our recurring losses
from operations and the expectation that we will continue to incur losses in the future, we will be required to raise additional
capital to complete the development and commercialization of our current product candidates and to pay off our obligations. To
date, to fund our operations and develop and commercialize our products, we have relied primarily on equity and debt financings.
When we seek additional capital, we may seek to sell additional equity and/or debt securities or to obtain a credit facility, which
we may not be able to do on favorable terms, or at all. Our ability to obtain additional financing will be subject to a number
of factors, including market conditions, our operating performance and investor sentiment. If we are unable to raise additional
capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or
commercialization of one or more of our product candidates, restrict or cease our operations or obtain funds by entering into agreements
on unattractive terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 2. Unregistered Sales of Equity Securities
and Use of Proceeds </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><A NAME="a_013"></A>Item 6. Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B>&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; text-align: right; padding-right: 0; padding-left: 0; width: 10%">(a)</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 0; padding-left: 0; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: justify; width: 88%">Exhibits</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 10%; text-align: right; padding-right: 0; padding-left: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/1043961/000114420418006777/tv485376_ex10-1.htm" STYLE="-sec-extract: exhibit">10.1</A></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 88%; padding-right: 0; padding-left: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1043961/000114420418006777/tv485376_ex10-1.htm" STYLE="-sec-extract: exhibit">Equity Purchase Agreement between the Company and Leviston Resources LLC dated February 8, 2018 (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed on February 9, 2018).</A></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: right; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: right; padding-right: 0; padding-left: 0"><A HREF="http://www.sec.gov/Archives/edgar/data/1043961/000114420418016001/tv488973_ex10-1.htm" STYLE="-sec-extract: exhibit">10.2</A></TD>
    <TD STYLE="vertical-align: top; text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1043961/000114420418016001/tv488973_ex10-1.htm" STYLE="-sec-extract: exhibit">Agreement by and among the Company, Sabby Volatility Warrant Master Fund, Ltd., Lincoln Park Capital Fund, LLC, Alpha Capital and Osher Capital Partners, LLC dated as of March 21, 2018 (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Form 8-K filed on March 21, 2018).</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0"><A HREF="tv492534_ex31-1.htm" STYLE="-sec-extract: exhibit">31.1*</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="tv492534_ex31-1.htm" STYLE="-sec-extract: exhibit">Certification of Principal Executive Officer, pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002, as amended.</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0"><A HREF="tv492534_ex31-2.htm" STYLE="-sec-extract: exhibit">31.2**</A></TD>
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0"><A HREF="tv492534_ex31-2.htm" STYLE="-sec-extract: exhibit">Certification of Principal Financial Officer, pursuant to Section&nbsp;302 of the Sarbanes-Oxley Act of 2002, as amended.</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0"><A HREF="tv492534_ex32-1.htm" STYLE="-sec-extract: exhibit">32.1**</A></TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><A HREF="tv492534_ex32-1.htm" STYLE="-sec-extract: exhibit">Certification of Principal Executive Officer, pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, as amended.</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: right; padding-right: 0; padding-left: 0"><A HREF="tv492534_ex32-2.htm" STYLE="-sec-extract: exhibit">32.2**</A></TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify"><A HREF="tv492534_ex32-2.htm" STYLE="-sec-extract: exhibit">Certification of Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended.</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">101.INS</TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">XBRL Instance Document</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 0; text-align: right; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">101.SCH</TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 0; text-align: right; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">101.CAL</TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 0; text-align: right; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">101.DEF</TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 0; text-align: right; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">101.LAB</TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; padding-right: 0; text-align: right; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">101.PRE</TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">&nbsp;</TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">*</TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">Filed herewith</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; text-align: right; padding-left: 0">**</TD>
    <TD STYLE="text-align: justify; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-align: justify">Furnished herewith</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B></B></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a_014"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 43pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 0; padding-left: 0">PRECIPIO,&nbsp;INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 6%; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="width: 44%; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="width: 4%; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="width: 46%; padding-left: 0; padding-right: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">Date:</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">May 21, 2018</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">By:</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 0; padding-left: 0; text-align: center">/<FONT STYLE="font-size: 10pt">S</FONT>/ ILAN DANIELI</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Ilan Danieli</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 10pt"><I>Chief Executive Officer
        (Principal Executive<BR>
 Officer)</I></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">Date:</TD>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">May 21, 2018</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0">By:</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1pt solid; padding-right: 0; padding-left: 0; text-align: center">/<FONT STYLE="font-size: 10pt">S</FONT>/ CARL IBERGER</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-left: 0; padding-right: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Carl Iberger</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 10pt"><I>Chief Financial Officer
        (Principal Financial<BR>
 Officer)</I></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 35; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>tv492534_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Ilan Danieli, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD>I have reviewed this Quarterly Report on Form 10-Q of Precipio, Inc. (the Registrant);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD>The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
Registrant and we have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my
supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known
to me by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b)</TD><TD>Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed
under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c)</TD><TD>Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report my conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d)</TD><TD>Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the
Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD>The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors
and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: 0; padding-left: 0">/s/ ILAN DANIELI</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0">Ilan Danieli</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0"><I>Chief Executive Officer (Principal Executive
    Officer)</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: May&nbsp;21, 2018</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>tv492534_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Carl Iberger, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD>I have reviewed this Quarterly Report on Form 10-Q of Precipio, Inc. (the Registrant);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in
all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD>The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and we have:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a)</TD><TD>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiary, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b)</TD><TD>Designed such internal control over financial reporting, or caused internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">c)</TD><TD>Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">d)</TD><TD>Disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the
Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD>The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing
the equivalent function):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a)</TD><TD>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information;
and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b)</TD><TD>Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's
internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 55%; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: 0; padding-left: 0">/s/ CARL IBERGER</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0">Carl Iberger</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0"><I>Chief Financial Officer (Principal Financial
    Officer)</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: May 21, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>tv492534_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">In connection with the accompanying Quarterly
Report on Form 10-Q of Precipio, Inc. for the period ended March 31, 2018, I, Ilan Danieli, Chief Executive Officer of Precipio,
Inc., hereby certify pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act
of 2002, to my knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 31.5pt">(1)</TD><TD>Such Quarterly Report on Form 10-Q of Precipio, Inc. for the period ended March&nbsp;31, 2018, fully complies with the requirements
of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 31.5pt">(2)</TD><TD>The information contained in such Quarterly Report on Form 10-Q of Precipio, Inc. for the period ended March 31, 2018, fairly
presents, in all material respects, the financial condition and results of operations of Precipio, Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; padding-right: 0; padding-left: 0">/s/ ILAN DANIELI</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0">Ilan Danieli</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0"><I>Chief Executive Officer (Principal Executive
    Officer)</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: May 21, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">A signed original of the certification required
by Section&nbsp;906 has been provided to Precipio, Inc. and will be retained by Precipio, Inc. and furnished to the Securities
and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>tv492534_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO 18 U.S.C. SECTION 1350</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">In connection with the accompanying Quarterly
Report on Form 10-Q of Precipio, Inc. for the period ended March 31, 2018, I, Carl Iberger, Chief Financial Officer of Precipio,
Inc., hereby certify pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act
of 2002, to my knowledge, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 31.5pt">(1)</TD><TD>Such Quarterly Report on Form 10-Q of Precipio, Inc. for the period ended March 31, 2018, fully complies with the requirements
of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 22.5pt"></TD><TD STYLE="width: 31.5pt">(2)</TD><TD>The information contained in such Quarterly Report on Form 10-Q of Precipio, Inc. for the period ended March 31, 2018, fairly
presents, in all material respects, the financial condition and results of operations of Precipio, Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; padding-right: 0; padding-left: 0">/s/ CARL IBERGER</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0">Carl Iberger</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 0; padding-left: 0">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-right: 0; padding-left: 0"><I>Chief Financial Officer (Principal Financial
    Officer)</I></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: May 21, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24pt">A signed original of the certification required
by Section&nbsp;906 has been provided to Precipio, Inc. and will be retained by Precipio, Inc. and furnished to the Securities
and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>prpo-20180331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.18.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/21/2018 1:44:43 PM-->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:prpo="http://www.precipiodx.com/20180331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="prpo-20180331.xsd" />
  <!--Context Section-->
  <context id="As_Of_3_31_2018_us-gaap_DebtConversionByUniqueDescriptionAxis_prpo_WarrantsAfterConversionPriceReductionMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">prpo:WarrantsAfterConversionPriceReductionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_12_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CredeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-12</instant>
    </period>
  </context>
  <context id="Duration_2_1_2018_To_2_28_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prpo:SettlementAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <context id="Duration_3_20_2018_To_3_21_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_PreferredStockInducedConversionsSecondInvestorMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:PreferredStockInducedConversionsSecondInvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-20</startDate>
      <endDate>2018-03-21</endDate>
    </period>
  </context>
  <context id="As_Of_2_28_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prpo:SettlementAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-28</instant>
    </period>
  </context>
  <context id="As_Of_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:LevistonResourcesLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-09</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2017Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prpo:EquityIncentivePlan2017Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_1_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
    </entity>
    <period>
      <instant>2018-01-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2017Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prpo:EquityIncentivePlan2017Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CredeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:MountSinaiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicaidMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicaidMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:ContractDiagnosticServicesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:ContractDiagnosticServicesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicareMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicaidMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicaidMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:ContractDiagnosticServicesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:ContractDiagnosticServicesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:DiagnosticTestingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:ContractDiagnosticServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">prpo:BiomarkerTestingAndClinicalProjectServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_11_1_2017_To_11_2_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PlacementAgreementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:PlacementAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-11-01</startDate>
      <endDate>2017-11-02</endDate>
    </period>
  </context>
  <context id="Duration_8_1_2017_To_8_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PublicStockOfferingMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:PublicStockOfferingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-08-01</startDate>
      <endDate>2017-08-31</endDate>
    </period>
  </context>
  <context id="Duration_4_19_2018_To_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorSecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-19</startDate>
      <endDate>2018-04-20</endDate>
    </period>
  </context>
  <context id="Duration_1_7_2018_To_1_8_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:DepartmentofEconomicandCommunityDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-07</startDate>
      <endDate>2018-01-08</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_11_6_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-06</instant>
    </period>
  </context>
  <context id="As_Of_8_25_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-08-25</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CredeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_LitigationCaseAxis_prpo_XIFINInc.Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:XIFINInc.Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_LitigationCaseAxis_prpo_CPAGlobalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CPAGlobalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2016_To_12_31_2016_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:MountSinaiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_XIFINInc.Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:XIFINInc.Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CPAGlobalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CPAGlobalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_BioRadLaboratoriesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:BioRadLaboratoriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_XIFINInc.Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:XIFINInc.Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_CPAGlobalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CPAGlobalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_BioRadLaboratoriesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:BioRadLaboratoriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Duration_3_20_2018_To_3_21_2018_us-gaap_LitigationCaseAxis_prpo_BioRadLaboratoriesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:BioRadLaboratoriesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-20</startDate>
      <endDate>2018-03-21</endDate>
    </period>
  </context>
  <context id="Duration_3_12_2018_To_3_12_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CredeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-12</startDate>
      <endDate>2018-03-12</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CredeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">prpo:A2016WarrantLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prpo:SettlementAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:DepartmentofEconomicandCommunityDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_1_8_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:DepartmentofEconomicandCommunityDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-01-08</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_FinancedInsuranceLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:FinancedInsuranceLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorSecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-04-20</instant>
    </period>
  </context>
  <context id="As_Of_7_31_2017_us-gaap_DebtInstrumentAxis_prpo_FinancedInsuranceLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:FinancedInsuranceLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-07-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prpo:SettlementAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_4_19_2018_To_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorSecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-04-19</startDate>
      <endDate>2018-04-20</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PurchaseAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PurchaseAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_7_1_2017_To_7_31_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-07-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_FinancedInsuranceLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:FinancedInsuranceLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:DepartmentofEconomicandCommunityDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prpo:SettlementAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prpo:SettlementAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_DebtInstrumentAxis_prpo_FinancedInsuranceLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:FinancedInsuranceLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">prpo:A2016WarrantLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_InducementAgreement2018Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_SeriesCWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SeriesCWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_InducementAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsNotAssumedInMergerExpiringOctober2022Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringMay2023Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsNotAssumedInMergerExpiringMay2023Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsNotAssumedInMergerExpiringJune2022GroupMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsNotAssumedInMergerExpiringJune2022GroupBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsNotAssumedInMergerExpiringAugust2022GroupMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsAssumedInMergerExpiringJanuary2021GroupBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringFebruary2020Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsAssumedInMergerExpiringFebruary2020Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringDecember2020Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsAssumedInMergerExpiringDecember2020Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringApril2020Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:WarrantsAssumedInMergerExpiringApril2020Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_OfferingWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:OfferingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_21_2018_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-21</instant>
    </period>
  </context>
  <context id="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_CreditorWarrantsRelatingToSecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:CreditorWarrantsRelatingToSecuredDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">prpo:SettlementAgreementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-28</instant>
    </period>
  </context>
  <context id="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_CreditorWarrantsRelatingToSecuredDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:CreditorWarrantsRelatingToSecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-28</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:MountSinaiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_11_30_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_SeriesCWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SeriesCWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-30</instant>
    </period>
  </context>
  <context id="As_Of_11_30_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_OfferingWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:OfferingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-30</instant>
    </period>
  </context>
  <context id="As_Of_8_31_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-08-31</instant>
    </period>
  </context>
  <context id="As_Of_8_31_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_OfferingWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:OfferingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-08-31</instant>
    </period>
  </context>
  <context id="As_Of_8_31_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-08-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2016">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:DepartmentofEconomicandCommunityDevelopmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:TermLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_2_8_2018_To_2_9_2018_us-gaap_ShortTermDebtTypeAxis_prpo_LevistonResourcesLlcMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">prpo:LevistonResourcesLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-08</startDate>
      <endDate>2018-02-09</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_ShortTermDebtTypeAxis_prpo_LevistonResourcesLlcMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">prpo:LevistonResourcesLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicaidMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:ContractDiagnosticServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicaidMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:ContractDiagnosticServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="Duration_3_20_2018_To_3_21_2018_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-20</startDate>
      <endDate>2018-03-21</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">prpo:A2016WarrantLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_1_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ServicesRevenueNetMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:ServicesRevenueNetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_OtherPartyMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:OtherPartyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicaidMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:ContractDiagnosticServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:ThirdPartyPayorMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">us-gaap:SelfPayMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ServicesRevenueNetMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:ServicesRevenueNetMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicareMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:HealthCareOrganizationRevenueSourcesAxis">prpo:MedicaidMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">prpo:SeniorSecuredConvertiblePromissoryNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-04-20</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CredeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="As_Of_12_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_CredeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CredeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_2_12_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:CredeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-12</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_3_31_2017">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_7_2018_To_1_8_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:DepartmentofEconomicandCommunityDevelopmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-07</startDate>
      <endDate>2018-01-08</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_SeriesCWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:SeriesCWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_InducementAgreement2018Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_InducementAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:ConvertiblePromissoryNoteWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_OfferingWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:OfferingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PurchaseAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PurchaseAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PurchaseAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:PurchaseAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:InducementAgreement2018Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="As_Of_11_30_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-30</instant>
    </period>
  </context>
  <context id="As_Of_10_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-10-31</instant>
    </period>
  </context>
  <context id="As_Of_8_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredClassBMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-08-31</instant>
    </period>
  </context>
  <context id="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">prpo:LevistonResourcesLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-08</startDate>
      <endDate>2018-02-09</endDate>
    </period>
  </context>
  <context id="Duration_3_20_2018_To_3_21_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_PreferredStockInducedConversionsFirstInvestorMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:PreferredStockInducedConversionsFirstInvestorMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-03-20</startDate>
      <endDate>2018-03-21</endDate>
    </period>
  </context>
  <context id="As_Of_11_30_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-30</instant>
    </period>
  </context>
  <context id="As_Of_8_31_2017_dei_LegalEntityAxis_prpo_AegisCapitalCorpMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:AegisCapitalCorpMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-08-31</instant>
    </period>
  </context>
  <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">prpo:MountSinaiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="Duration_8_1_2017_To_8_31_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_OfferingWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prpo:OfferingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-08-01</startDate>
      <endDate>2017-08-31</endDate>
    </period>
  </context>
  <context id="Duration_8_1_2017_To_8_31_2017_dei_LegalEntityAxis_prpo_AegisCapitalCorpMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prpo:AegisCapitalCorpMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-08-01</startDate>
      <endDate>2017-08-31</endDate>
    </period>
  </context>
  <context id="Duration_6_28_2017_To_6_29_2017_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prpo:TransgenomicsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-06-28</startDate>
      <endDate>2017-06-29</endDate>
    </period>
  </context>
  <context id="As_Of_3_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="As_Of_5_18_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
    </entity>
    <period>
      <instant>2018-05-18</instant>
    </period>
  </context>
  <context id="Duration_1_1_2018_To_3_31_2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001043961</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-03-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="Unit14">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Unit13">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="Unit12">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Unit1">
    <measure>xbrli:shares</measure>
  </unit>
  <!--Tuple Section-->
  <!--Element Section-->
  <dei:AmendmentFlag contextRef="Duration_1_1_2018_To_3_31_2018">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Duration_1_1_2018_To_3_31_2018">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Duration_1_1_2018_To_3_31_2018">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Duration_1_1_2018_To_3_31_2018">2018</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Duration_1_1_2018_To_3_31_2018">2018-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Duration_1_1_2018_To_3_31_2018">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Duration_1_1_2018_To_3_31_2018">0001043961</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_5_18_2018" unitRef="Unit1" decimals="INF">19668572</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory contextRef="Duration_1_1_2018_To_3_31_2018">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="Duration_1_1_2018_To_3_31_2018">Precipio, Inc.</dei:EntityRegistrantName>
  <prpo:AccumulatedNetIncomeLoss contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-5">-2400000</prpo:AccumulatedNetIncomeLoss>
  <prpo:BusinessCombinationStockExchangeRatio contextRef="Duration_6_28_2017_To_6_29_2017_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" unitRef="Unit13" decimals="INF">10.2502</prpo:BusinessCombinationStockExchangeRatio>
  <prpo:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="Duration_8_1_2017_To_8_31_2017_dei_LegalEntityAxis_prpo_AegisCapitalCorpMember" unitRef="Unit1" decimals="INF">280000</prpo:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
  <prpo:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights contextRef="Duration_8_1_2017_To_8_31_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_OfferingWarrantsMember" unitRef="Unit1" decimals="INF">2680000</prpo:ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights>
  <prpo:ClassOfWarrantOrRightTerm contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember">P5Y</prpo:ClassOfWarrantOrRightTerm>
  <prpo:ClassofWarrantorRightUnitValueofWarrantsorRights contextRef="As_Of_8_31_2017_dei_LegalEntityAxis_prpo_AegisCapitalCorpMember" unitRef="Unit12" decimals="0">2800</prpo:ClassofWarrantorRightUnitValueofWarrantsorRights>
  <prpo:ClassofWarrantorRightUnitValueofWarrantsorRights contextRef="As_Of_11_30_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit12" decimals="0">1000</prpo:ClassofWarrantorRightUnitValueofWarrantsorRights>
  <prpo:ClassOfWarrantOrRightWarrantsOrRightsExcercised contextRef="Duration_3_20_2018_To_3_21_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_PreferredStockInducedConversionsFirstInvestorMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit1" decimals="INF">666666</prpo:ClassOfWarrantOrRightWarrantsOrRightsExcercised>
  <prpo:CommonStockPurchaseFee contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit13" decimals="4">0.0075</prpo:CommonStockPurchaseFee>
  <prpo:CompanyStockPercentageOfMarketRate contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit13" decimals="4">0.9725</prpo:CompanyStockPercentageOfMarketRate>
  <prpo:ConversionofStockPerShareConversionPrice contextRef="As_Of_8_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit14" decimals="2">2.50</prpo:ConversionofStockPerShareConversionPrice>
  <prpo:ConversionofStockPerShareConversionPrice contextRef="As_Of_10_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit14" decimals="INF">2.50</prpo:ConversionofStockPerShareConversionPrice>
  <prpo:ConversionofStockPerShareConversionPrice contextRef="As_Of_11_30_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit14" decimals="2">1.40</prpo:ConversionofStockPerShareConversionPrice>
  <prpo:ConversionofStockPerShareConversionPrice contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member" unitRef="Unit14" decimals="2">1.04</prpo:ConversionofStockPerShareConversionPrice>
  <prpo:ConversionofStockPerShareConversionPrice contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PurchaseAgreement2018Member" unitRef="Unit14" decimals="2">1.40</prpo:ConversionofStockPerShareConversionPrice>
  <prpo:ConversionofStockPerShareConversionPrice contextRef="As_Of_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member" unitRef="Unit14" decimals="2">1.04</prpo:ConversionofStockPerShareConversionPrice>
  <prpo:ConversionofStockPerShareConversionPrice contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member" unitRef="Unit14" decimals="2">0.75</prpo:ConversionofStockPerShareConversionPrice>
  <prpo:ConversionofStockPerShareConversionPrice contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PurchaseAgreement2018Member" unitRef="Unit14" decimals="INF">1.04</prpo:ConversionofStockPerShareConversionPrice>
  <prpo:ConversionofStockPerShareConversionPrice contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member" unitRef="Unit14" decimals="2">0.75</prpo:ConversionofStockPerShareConversionPrice>
  <prpo:ConversionofStockPerShareConversionPrice contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PurchaseAgreement2018Member" unitRef="Unit14" decimals="2">1.04</prpo:ConversionofStockPerShareConversionPrice>
  <prpo:DebtRestructured contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" unitRef="Unit12" decimals="-5">6300000</prpo:DebtRestructured>
  <prpo:DeemedDividend contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_OfferingWarrantsMember" unitRef="Unit12" decimals="-3">62000</prpo:DeemedDividend>
  <prpo:DeemedDividend contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_InducementAgreement2018Member" unitRef="Unit12" decimals="0">1000</prpo:DeemedDividend>
  <prpo:DeemedDividend contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member" unitRef="Unit12" decimals="0">1000</prpo:DeemedDividend>
  <prpo:DeemedDividend contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_InducementAgreement2018Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" unitRef="Unit12" decimals="0">5000</prpo:DeemedDividend>
  <prpo:DeemedDividend contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember" unitRef="Unit12" decimals="0">8000</prpo:DeemedDividend>
  <prpo:DeemedDividend contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_SeriesCWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member" unitRef="Unit12" decimals="0">58000</prpo:DeemedDividend>
  <prpo:EquityPurchaseAgreement contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit12" decimals="0">8000000</prpo:EquityPurchaseAgreement>
  <prpo:EquityPurchaseAgreementCommitmentFeeInstallmentPercentage contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit13" decimals="4">0.0175</prpo:EquityPurchaseAgreementCommitmentFeeInstallmentPercentage>
  <prpo:EquityPurchaseAgreementCommitmentFeePercentage contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit13" decimals="4">0.0525</prpo:EquityPurchaseAgreementCommitmentFeePercentage>
  <prpo:EquityPurchaseAgreementFee contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit12" decimals="0">35000</prpo:EquityPurchaseAgreementFee>
  <prpo:EquityPurchaseAgreementFeeContingentDiscount contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit12" decimals="0">15000</prpo:EquityPurchaseAgreementFeeContingentDiscount>
  <prpo:GainLossOnStockWarrantsRevaluation contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">261000</prpo:GainLossOnStockWarrantsRevaluation>
  <prpo:GrossProceedsFromGrantReceivedAndLoan contextRef="Duration_1_7_2018_To_1_8_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember" unitRef="Unit12" decimals="0">400000</prpo:GrossProceedsFromGrantReceivedAndLoan>
  <prpo:GrossRevenueIncludingOtherAdjustments contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">505000</prpo:GrossRevenueIncludingOtherAdjustments>
  <prpo:GrossRevenueIncludingOtherAdjustments contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">988000</prpo:GrossRevenueIncludingOtherAdjustments>
  <prpo:InterestIncomeAndExpenseNet contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">-162000</prpo:InterestIncomeAndExpenseNet>
  <prpo:InterestIncomeAndExpenseNet contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-8000</prpo:InterestIncomeAndExpenseNet>
  <prpo:LiabilityForSettlementCommonSharesIssued contextRef="As_Of_2_12_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember" unitRef="Unit1" decimals="0">1814754</prpo:LiabilityForSettlementCommonSharesIssued>
  <prpo:LiabilityForSettlementFairValueOfCommonSharesIssued contextRef="As_Of_2_12_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember" unitRef="Unit12" decimals="-5">1900000</prpo:LiabilityForSettlementFairValueOfCommonSharesIssued>
  <prpo:LiabilityForSettlementOfCommonStockWarrantLiability contextRef="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_CredeMember" unitRef="Unit12" decimals="-5">600000</prpo:LiabilityForSettlementOfCommonStockWarrantLiability>
  <prpo:LiabilityForSettlementOfEquityInstrument contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">1085000</prpo:LiabilityForSettlementOfEquityInstrument>
  <prpo:LiabilityForSettlementOfEquityInstrument contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">1350000</prpo:LiabilityForSettlementOfEquityInstrument>
  <prpo:LiabilityForSettlementPaymentPeriod contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">P16M</prpo:LiabilityForSettlementPaymentPeriod>
  <prpo:MaximumProceedsRaisedBeforeNotePayableBecomesDue contextRef="As_Of_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="0">7000000</prpo:MaximumProceedsRaisedBeforeNotePayableBecomesDue>
  <prpo:NetSalesServiceRevenueAndAccountsReceivableTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;1&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;1&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;.&amp;nbsp; &lt;/font&gt;&lt;a name="_Hlk510532097"&gt;&lt;/a&gt;&lt;font style="display: inline;font-weight:bold;"&gt;SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;text-decoration:underline;"&gt;Adoption of ASC Topic 606, &amp;#x201C;Revenue from contracts with customers&amp;#x201D;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;text-decoration:underline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;On January 1, 2018, the Company adopted ASC 606 that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services by using the modified-retrospective method applied to any contracts that were not completed as of January 1, 2018. The Company performed a comprehensive review of its existing revenue arrangements following the five-step model:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:EYInterstate;color:#000000;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Step 1: Identification of the contract with the customer.&amp;nbsp;&amp;nbsp;Sub-steps include determining the customer in a contract; Initial contract identification and determine if multiple contracts should be combined and accounted for as a single transaction.&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:EYInterstate;color:#000000;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Step 2: Identify the performance obligation in the contract.&amp;nbsp;&amp;nbsp;Sub-steps include identifying the promised goods and services in the contract and identifying which performance obligations within the contract are distinct.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:EYInterstate;color:#000000;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Step 3: Determine the transaction price.&amp;nbsp;&amp;nbsp;Sub-steps include variable consideration, constraining estimates of variable consideration, the existence of a significant financing component in the contract, noncash consideration and consideration payable to a customer.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 6pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:EYInterstate;color:#000000;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;"&gt;Step 4: Allocate transaction price.&amp;nbsp;&amp;nbsp;Sub-steps include assessing the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to the customer. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Step 5: Satisfaction of performance obligations.&amp;nbsp;&amp;nbsp;Sub-steps include ascertaining the point in time when an asset is transferred to the customer and the customer obtains control of the asset upon which time the Company recognizes revenue.&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt; Based on the Company's analysis, there were no changes identified that impacted the amount or timing of revenues recognized under the new guidance as compared to the previous guidance (ASC 605). Additionally, the Company's analysis indicated that there were no changes to how costs to obtain and fulfill our customer contracts would be recognized under the new guidance as compared to the previous guidance. Accordingly, the initial application of the new revenue standard did not result in the recognition of a cumulative effect adjustment to the opening balance of accumulated deficit as of January 1, 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Nature of Contracts and Customers&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;T&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;he Company&amp;#x2019;s contracts and related performance obligations are similar for its customers and the sales process for all customers start upon the receipt of requisition forms from the customers for patient diagnostic testing and the execution of contracts for biomarker testing and clinical research.&amp;nbsp; &lt;/font&gt;&lt;font style="display: inline;"&gt;Payment terms for the services provided are 30 days, unless separately negotiated.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Diagnostic testing&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for laboratory testing services at a point in time based on the delivery method (web-portal access or fax) for the patient&amp;#x2019;s laboratory report, per the contract. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Clinical research grants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Control of the clinical research services are transferred to the customer over time.&amp;nbsp;&amp;nbsp;The Company will recognize revenue utilizing the &amp;#x201C;effort based&amp;#x201D; method, measuring its progress toward complete satisfaction of the performance obligation.&amp;nbsp;&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Biomarker testing and clinical project services&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Control of the biomarker testing and clinical project services are transferred to the customer over time.&amp;nbsp;&amp;nbsp;The Company utilizes an &amp;#x201C;effort based&amp;#x201D; method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company generates revenue from the provision of diagnostic testing provided to patients, biomarker testing provided to bio-pharma customers and clinical research grants funded by both bio-pharma customers and government health programs.&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Disaggregation of Revenues by Transaction Type&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;We operate in one business segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. &lt;/font&gt;&lt;font style="display: inline;"&gt;Revenues, net of contractual allowances and adjustments for the three months ended March&amp;nbsp;31, 2018 and 2017 were as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:521.35pt;margin-left:5.4pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:112.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Diagnostic Testing&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:94.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Biomarker Testing&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:94.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicaid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicare&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;134&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;158&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;134&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;158&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Self-pay&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Third party payers&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;131&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;113&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;131&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;113&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Contract diagnostics&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Revenues, net of contractual allowances&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;791&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Revenue from the Medicare and Medicaid programs account for a portion of the Company&amp;#x2019;s patient diagnostic service revenue. Laws and regulations governing those programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Revenue Recognition&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. &lt;/font&gt;&lt;font style="display: inline;"&gt;The Company does not typically enter arrangements where multiple contracts can be combined as the terms regarding services are generally found within a single agreement/requisition form. &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;The Company derives its revenues from three types of transactions: diagnostic testing, clinical research grants from state and federal research programs, and other revenues from the Company&amp;#x2019;s ICP technology and bio-pharma projects encompassing genetic diagnostics.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt; Deferred revenue&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; Deferred revenue, or&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;text-decoration:none;"&gt;unearned revenue&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;, refers to advance payments for products or services that are to be delivered in the future. The Company records such prepayment of unearned revenue as a liability, as revenue that has not yet been earned, but represents products or services that are owed to a customer.&amp;nbsp;&amp;nbsp;As the product or service is delivered over time, the Company recognizes&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; the&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;appropriate amount of&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;text-decoration:none;"&gt;revenue&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;text-decoration:none;"&gt; from deferred revenue&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;. For the period ended March 31, 2018 and December 31, 2017, the deferred revenue was &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$189,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$66,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;, respectively&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;font-size:10pt;"&gt;Contractual Allowances and Adjustments&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;We are reimbursed by payors for services we provide. Payments for services covered by payors average less than billed charges. We monitor revenue and receivables from payors and record an estimated contractual allowance for certain revenue and receivable balances as of the revenue recognition date to properly account for anticipated differences between amounts estimated in our billing system and amounts ultimately reimbursed by payors. Accordingly, the total revenue and receivables reported in our financial statements are recorded at the amounts expected to be received from these payors. For service revenue, the contractual allowance is estimated based on several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payor/product mix. The billing functions for the remaining portion of our revenue are contracted and fixed fees for specific services and are recorded without an allowance for contractual discounts&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;. &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The following table presents our revenues initially recognized for each associated payor class during the three months ended March 31, 2018 and 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:521.40pt;margin-left:5.4pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:114.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Gross Revenues&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:137.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Contractual Allowances and adjustments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:128.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Revenues, net of Contractual Allowances and adjustments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.20pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicaid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;15&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;24&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(3)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(12)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicare&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;137&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;166&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(3)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(8)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;134&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;158&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Self-pay&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Third party payers&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;317&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;295&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(186)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(182)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;131&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;113&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Contract diagnostics&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;983&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;505&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(192)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(202)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;791&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;988&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;505&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(192)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(202)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;796&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.20pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Allowance for Doubtful Accounts&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The Company provides for a general allowance for collectability of services when recording &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;n&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;et &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;sales.&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; &amp;nbsp;The Company has adopted the policy of recognizing net &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;sales&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; to the extent it expects to collect that amount.&amp;nbsp;&amp;nbsp;Reference FASB 954-605-45-5 and ASU 2011-07, Health Care Entities: Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debt, and the Allowance for Doubtful Accounts.&amp;nbsp;&amp;nbsp;The change in the allowance for doubtful accounts is directly related to the increase in &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;p&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;atient service revenues.&amp;nbsp; &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The following table presents our reported revenues net of the collection allowance and adjustments for the three months ended March 31, 2018 and 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:527.40pt;margin-left:5.4pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:112.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Revenues, net of &lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Contractual Allowances and adjustments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:144.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Allowances for doubtful accounts&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:128.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.75pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicaid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(11)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(2)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;10&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicare&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;134&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;158&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(20)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(30)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;114&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;128&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Self-pay&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(4)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;16&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Third party payers&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;131&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;113&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(53)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(19)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;78&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;94&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Contract diagnostics&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;791&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(84)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(55)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;707&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;248&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;796&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(84)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(55)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;712&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;248&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.75pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Costs to Obtain or Fulfill a Customer Contract&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in operating expenses in the condensed consolidated statements of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Shipping and handling costs are comprised of inbound and outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in cost of sales in the condensed consolidated statements of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;text-decoration:underline;"&gt;Accounts Receivable&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company has provided an allowance for potential credit losses, which has been determined based on management&amp;#x2019;s industry experience. The Company grants credit without collateral to its patients, most of who are insured under third party payer agreements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following summarizes the mix of receivables: &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 76.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:67.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:67.82%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:10.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:00.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.32%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:10.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:00.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Medicaid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;37
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Medicare&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;611
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;256
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Self-pay&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;102
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;53
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Third party payers&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;768
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,066
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Contract diagnostic services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;background-color: #CCECFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;246
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCECFF;height:11.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;445
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,760
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,857
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.82%;background-color: #auto;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Less allowance for doubtful accounts &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #auto;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,208
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #auto;height:11.50pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #auto;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;background-color: #auto;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,127
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Accounts receivable, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;552
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;730
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;background-color:lime;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following table presents the roll-forward of the allowance for doubtful accounts for the three months ended March 31, 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 60.00%;margin-left:0pt;font-family:Calibri;font-size:11pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:114.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden"&gt;
						&amp;nbsp;&lt;/p&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:24.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:14.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:19.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:110.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:14.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;"&gt;
						&amp;nbsp;&lt;/p&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;border-bottom:1pt solid #000000 ;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Allowance for Doubtful Accounts&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:110.90pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,127
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.85pt;background-color: #CCEEFF;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Collection Allowance:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Medicaid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(11
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Medicare&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(20
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Third party payers&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(53
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Service revenue, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;border-top:1pt solid #000000 ;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(84
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Bad debt expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Total charges&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;border-top:1pt solid #000000 ;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;border-bottom:1pt solid #000000 ;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(81
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Balance, March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:110.90pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:28.80pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,208
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:28.80pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:110.90pt;border-top:2pt double #000000 ;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</prpo:NetSalesServiceRevenueAndAccountsReceivableTextBlock>
  <prpo:ObigationToIssueCommonShares contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">1897000</prpo:ObigationToIssueCommonShares>
  <prpo:OtherIncomeExpense contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">-162000</prpo:OtherIncomeExpense>
  <prpo:OtherIncomeExpense contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">9000</prpo:OtherIncomeExpense>
  <prpo:OtherSalesRevenueGross contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">5000</prpo:OtherSalesRevenueGross>
  <prpo:PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit12" decimals="0">100000</prpo:PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">303000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">12000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">158000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ServicesRevenueNetMember" unitRef="Unit12" decimals="-3">303000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">20000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">113000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">796000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember" unitRef="Unit12" decimals="-3">488000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">12000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">134000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_OtherPartyMember" unitRef="Unit12" decimals="-3">5000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ServicesRevenueNetMember" unitRef="Unit12" decimals="-3">791000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">26000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:RevenueNetOfAllowanceAndAdjustments contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">131000</prpo:RevenueNetOfAllowanceAndAdjustments>
  <prpo:ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following table presents the roll-forward of the allowance for doubtful accounts for the three months ended March 31, 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 60.00%;margin-left:0pt;font-family:Calibri;font-size:11pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:114.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden"&gt;
						&amp;nbsp;&lt;/p&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:24.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:14.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:19.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:110.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:14.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;"&gt;
						&amp;nbsp;&lt;/p&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;border-bottom:1pt solid #000000 ;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Allowance for Doubtful Accounts&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:36.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Balance, January 1, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:110.90pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,127
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.85pt;background-color: #CCEEFF;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Collection Allowance:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Medicaid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(11
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Medicare&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(20
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Third party payers&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(53
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Service revenue, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;border-top:1pt solid #000000 ;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(84
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Bad debt expense&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Total charges&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;border-top:1pt solid #000000 ;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;border-bottom:1pt solid #000000 ;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(81
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Balance, March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:110.90pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:28.80pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,208
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:28.80pt;"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:110.90pt;border-top:2pt double #000000 ;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</prpo:ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock>
  <prpo:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The following table presents our revenues initially recognized for each associated payor class during the three months ended March 31, 2018 and 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:521.40pt;margin-left:5.4pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:114.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Gross Revenues&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:137.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Contractual Allowances and adjustments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:128.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Revenues, net of Contractual Allowances and adjustments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.20pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicaid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;15&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;24&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(3)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(12)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicare&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;137&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;166&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(3)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(8)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;134&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;158&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Self-pay&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Third party payers&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;317&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;295&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(186)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(182)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;131&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;113&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Contract diagnostics&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;983&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;505&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(192)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(202)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;791&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;988&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;505&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(192)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(202)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;796&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.20pt;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.20pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</prpo:ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock>
  <prpo:ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The following table presents our reported revenues net of the collection allowance and adjustments for the three months ended March 31, 2018 and 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:527.40pt;margin-left:5.4pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:112.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Revenues, net of &lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Contractual Allowances and adjustments&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:144.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Allowances for doubtful accounts&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:128.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.75pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicaid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(11)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(2)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;10&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicare&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;134&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;158&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(20)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(30)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;114&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;128&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Self-pay&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(4)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;16&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Third party payers&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;131&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;113&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(53)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(19)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;78&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;94&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Contract diagnostics&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;791&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(84)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(55)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;707&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;248&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;796&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(84)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(55)
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;712&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:23.75pt;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:46.65pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;248&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:23.75pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</prpo:ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok>
  <prpo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized contextRef="Duration_1_1_2018_To_1_31_2018" unitRef="Unit1" decimals="INF">500000</prpo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized>
  <prpo:StockNotIssuedShares contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" unitRef="Unit1" decimals="0">47</prpo:StockNotIssuedShares>
  <prpo:StockNotIssuedShares contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit1" decimals="0">60000</prpo:StockNotIssuedShares>
  <prpo:WarrantsCanceledInSettlementAgreement contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" unitRef="Unit1" decimals="0">20216</prpo:WarrantsCanceledInSettlementAgreement>
  <prpo:WarrantsExercised contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit1" decimals="0">300000</prpo:WarrantsExercised>
  <prpo:WarrantsExpiredInPeriod contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit1" decimals="0">23055</prpo:WarrantsExpiredInPeriod>
  <prpo:WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock contextRef="Duration_3_20_2018_To_3_21_2018_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit13" decimals="INF">0.0499</prpo:WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock>
  <prpo:WorkingCapitalDeficiency contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-5">7500000</prpo:WorkingCapitalDeficiency>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">5103000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">4956000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">1857000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_12_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember" unitRef="Unit12" decimals="-3">445000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_12_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">37000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_12_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">256000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_12_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">53000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_12_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">1066000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">1760000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember" unitRef="Unit12" decimals="-3">246000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">33000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">611000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">102000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableGross contextRef="As_Of_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">768000</us-gaap:AccountsReceivableGross>
  <us-gaap:AccountsReceivableNet contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">730000</us-gaap:AccountsReceivableNet>
  <us-gaap:AccountsReceivableNet contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">552000</us-gaap:AccountsReceivableNet>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">730000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">552000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">1248000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">1529000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">44465000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">47192000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_ShortTermDebtTypeAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit12" decimals="0">136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_ShortTermDebtTypeAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit12" decimals="0">6000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-5">100000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">1127000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">1208000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
  <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">81000</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
  <us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">3000</us-gaap:AllowanceForDoubtfulAccountsReceivableRecoveries>
  <us-gaap:AmortizationOfFinancingCosts contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" unitRef="Unit12" decimals="0">1000</us-gaap:AmortizationOfFinancingCosts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">6000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">1000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfIntangibleAssets contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-5">300000</us-gaap:AmortizationOfIntangibleAssets>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit1" decimals="0">2753814</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0">2651</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember" unitRef="Unit1" decimals="0">780105</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="0">1971058</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit1" decimals="INF">2753814</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit1" decimals="0">9506515</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="0">3520059</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_PreferredStockMember" unitRef="Unit1" decimals="0">62667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember" unitRef="Unit1" decimals="0">5923789</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">27260000</us-gaap:Assets>
  <us-gaap:Assets contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">26093000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">1742000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">1206000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Basis of Presentation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The accompanying condensed consolidated financial statements are presented in conformity with GAAP. We have evaluated events occurring subsequent to March 31, 2018 for potential recognition or disclosure in the condensed consolidated financial statements and concluded that, other than what is disclosed within the notes to unaudited condensed consolidated financial statements and in Note 12 - Subsequent Events, there were no other subsequent events that required recognition or disclosure.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The condensed consolidated balance sheet as of December&amp;nbsp;31, 2017 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2017. The accompanying condensed consolidated financial statements as of and for the three months ended March&amp;nbsp;31, 2018 and 2017 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December&amp;nbsp;31, 2017 contained in our Annual Report Form 10-K, filed with the Securities and Exchange Commission (the &amp;#x201C;SEC&amp;#x201D;) on April 13, 2018. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1 contextRef="Duration_6_28_2017_To_6_29_2017_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember">2016-10-12</us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1>
  <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1 contextRef="Duration_6_28_2017_To_6_29_2017_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember">2017-06-29</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
  <us-gaap:BusinessAcquisitionNameOfAcquiredEntity contextRef="Duration_6_28_2017_To_6_29_2017_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember">Precipio Diagnostics, LLC, a privately held Delaware limited liability company</us-gaap:BusinessAcquisitionNameOfAcquiredEntity>
  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" unitRef="Unit14" decimals="2">-0.42</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit14" decimals="2">-0.42</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit14" decimals="2">-0.47</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
  <us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" unitRef="Unit14" decimals="2">-0.47</us-gaap:BusinessAcquisitionProFormaEarningsPerShareBasic>
  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2017 and combines Transgenomic&amp;#x2019;s unaudited condensed consolidated statement of operations for the three months ended March&amp;nbsp;31, 2017 with Precipio&amp;#x2019;s unaudited condensed statement of operations for the three months ended March&amp;nbsp;31, 2017:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:405.00pt;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Dollars in thousands, except per share amounts&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="7" valign="bottom" style="width:210.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;For the Three Months Ended March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;border-top:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Net sales&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;712
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;907
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Net loss available to common stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(5,953
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(2,778
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Loss per common share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.47
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" unitRef="Unit12" decimals="-3">-2778000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit12" decimals="-3">-2778000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-5953000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" unitRef="Unit12" decimals="-3">-5953000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" unitRef="Unit12" decimals="-3">907000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit12" decimals="-3">907000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">712000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_BusinessAcquisitionAxis_prpo_TransgenomicsMember" unitRef="Unit12" decimals="-3">712000</us-gaap:BusinessAcquisitionsProFormaRevenue>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;3.&amp;nbsp;&amp;nbsp;REVERSE MERGER&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Unaudited pro forma information&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The operating results of Transgenomic &lt;/font&gt;&lt;font style="display: inline;"&gt;have b&lt;/font&gt;&lt;font style="display: inline;"&gt;een included in the Company's consolidated financial statements for &lt;/font&gt;&lt;font style="display: inline;"&gt;all &lt;/font&gt;&lt;font style="display: inline;"&gt;period&lt;/font&gt;&lt;font style="display: inline;"&gt;s&lt;/font&gt;&lt;font style="display: inline;"&gt; after &lt;/font&gt;&lt;font style="display: inline;"&gt;June 29, 2017&lt;/font&gt;&lt;font style="display: inline;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2017 and combines Transgenomic&amp;#x2019;s unaudited condensed consolidated statement of operations for the three months ended March&amp;nbsp;31, 2017 with Precipio&amp;#x2019;s unaudited condensed statement of operations for the three months ended March&amp;nbsp;31, 2017:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:405.00pt;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Dollars in thousands, except per share amounts&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="7" valign="bottom" style="width:210.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;For the Three Months Ended March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;border-top:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Net sales&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;712
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;907
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Net loss available to common stockholders&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(5,953
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(2,778
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Loss per common share&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.47
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(0.42
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:195.00pt;background-color: #auto;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;1. BUSINESS DESCRIPTION&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Business Description.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Precipio, Inc., and Subsidiary, (&amp;#x201C;we&amp;#x201D;, &amp;#x201C;us&amp;#x201D;, &amp;#x201C;our&amp;#x201D;, the &amp;#x201C;Company&amp;#x201D; or &amp;#x201C;Precipio&amp;#x201D;) is a cancer diagnostics company providing diagnostic products and services to the oncology market. We have built and continue to develop a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. We operate a cancer diagnostic laboratory located in New Haven, Connecticut and have partnered with the Yale School of Medicine to capture the expertise, experience and technologies developed within academia so that we can provide a better standard of cancer diagnostics and solve the growing problem of cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which will focus on further development of ICE-COLD-PCR (&amp;#x201C;ICP&amp;#x201D;), the patented technology which was exclusively licensed by us from Dana-Farber Cancer Institute, Inc. (&amp;#x201C;Dana-Farber&amp;#x201D;) at Harvard University (&amp;#x201C;Harvard&amp;#x201D;). The research and development center will focus on the development of this technology, which we believe will enable us to commercialize other technologies developed by our current and future academic partners. Our platform connects patients, physicians and diagnostic experts residing within academic institutions. Launched in 2017, the platform facilitates the following relationships:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Patients: patients may search for physicians in their area and consult directly with academic experts that are on the platform. Patients may also have access to new academic discoveries as they become commercially available.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Physicians: physicians can connect with academic experts to seek consultations on behalf of their patients and may also provide consultations for patients in their area seeking medical expertise in that physician&amp;#x2019;s relevant specialty. Physicians will also have access to new diagnostic solutions to help improve diagnostic accuracy.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Academic Experts: academic experts on the platform can make themselves available for patients or physicians seeking access to their expertise. Additionally, these experts have a platform available to commercialize their research discoveries.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;We intend to continue updating our platform to allow for patient-to-patient communications and allow individuals to share stories and provide support for one another, to allow physicians to consult with their peers to discuss and share challenges and solutions, and to allow academic experts to interact with others in academia on the platform to discuss their research and cross-collaborate.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;ICP was developed at Harvard and is licensed exclusively by us from Dana-Farber. The technology enables the detection of genetic mutations in liquid biopsies, such as blood samples. The field of liquid biopsies is a rapidly growing market, aimed at solving the challenge of obtaining genetic information on disease progression and changes from sources other than a tumor biopsy.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Gene sequencing is performed on tissue biopsies taken surgically from the tumor site in order to identify potential therapies that will be more effective in treating the patient. There are several limitations to this process. First, surgical procedures have several limitations, including:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Cost: surgical procedures are usually performed in a costly hospital environment. For example, according to a recent study the mean cost of lung biopsies is greater than &lt;/font&gt;&lt;font style="display: inline;"&gt;$14,000&lt;/font&gt;&lt;font style="display: inline;"&gt;; surgery also involves hospitalization and recovery time.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Surgical access: various tumor sites are not always accessible (e.g. brain tumors), in which cases no biopsy is available for diagnosis.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Risk: patient health may not permit undergoing an invasive surgery; therefore a biopsy cannot be obtained at all.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Time: the process of scheduling and coordinating a surgical procedure often takes time, delaying the start of patient treatment.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Second, there are several tumor-related limitations that provide a challenge to obtaining such genetic information from&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;a tumor:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Tumors are heterogeneous by nature: a tissue sample from one area of the tumor may not properly represent the tumor&amp;#x2019;s entire genetic composition; thus, the diagnostic results from a tumor may be incomplete and non-representative.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Metastases: in order to accurately test a patient with metastatic disease, ideally an individual biopsy sample should be taken from each site (if those sites are even known). These biopsies are very difficult to obtain; therefore physicians often rely on biopsies taken from the primary tumor site.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The advent of technologies enabling liquid biopsies as an alternative to tumor biopsy and analysis is based on the fact that tumors (both primary and metastatic) shed cells and fragments of DNA into the blood stream. These blood samples are called &amp;#x201C;liquid biopsies&amp;#x201D; that contain circulating tumor DNA, or ctDNA, which hold the same genetic information found in the tumor(s). That tumor DNA is the target of genetic analysis. However, since the quantity of tumor DNA is very small in proportion to the &amp;#x201C;normal&amp;#x201D; (or &amp;#x201C;healthy&amp;#x201D;) DNA within the blood stream, there is a need to identify and separate the tumor DNA from the normal DNA.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;ICP is an enrichment technology that enables the laboratory to focus its analysis on the tumor DNA by enriching, and thereby &amp;#x201C;multiplying&amp;#x201D; the presence of, tumor DNA, while maintaining the normal DNA at its same level. Once the enrichment process has been completed, the laboratory genetic testing equipment is able to identify genetic abnormalities presented in the ctDNA, and an analysis can be conducted at a higher level of sensitivity, to enable the detection of such genetic abnormalities. The technology is encapsulated into a chemical that is provided in the form of a kit and sold to other laboratories who wish to conduct these tests in-house. The chemical within the kit is added to the specimen preparation process, enriching the sample for the tumor DNA so that the analysis will detect those genetic abnormalities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Merger Transaction&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On &lt;/font&gt;&lt;font style="display: inline;"&gt;June&amp;nbsp;29, 2017&lt;/font&gt;&lt;font style="display: inline;"&gt;, the Company (then known as &amp;#x201C;Transgenomic, Inc.&amp;#x201D;, or &amp;#x201C;Transgenomic&amp;#x201D;), completed a reverse merger (the &amp;#x201C;Merger&amp;#x201D;) with &lt;/font&gt;&lt;font style="display: inline;"&gt;Precipio Diagnostics, LLC, a privately held Delaware limited liability company&lt;/font&gt;&lt;font style="display: inline;"&gt; (&amp;#x201C;Precipio Diagnostics&amp;#x201D;) in accordance with the terms of the Agreement and Plan of Merger (the &amp;#x201C;Merger Agreement&amp;#x201D;), dated &lt;/font&gt;&lt;font style="display: inline;"&gt;October&amp;nbsp;12, 2016&lt;/font&gt;&lt;font style="display: inline;"&gt;, as amended on February&amp;nbsp;2, 2017 and June&amp;nbsp;29, 2017, by and among Transgenomic, Precipio Diagnostics and New Haven Labs Inc. (&amp;#x201C;Merger Sub&amp;#x201D;) a wholly-owned subsidiary of Transgenomic. Pursuant to the Merger Agreement, Merger Sub merged with and into Precipio Diagnostics, with Precipio Diagnostics surviving the Merger as a wholly-owned subsidiary of the combined company. Upon the consummation of the Merger, the historical financial statements of Precipio Diagnostics become the Company's historical financial statements. Accordingly, the historical financial statements of Precipio Diagnostics are included in the comparative prior periods.&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;As a result of the Merger, historical preferred stock, common stock, restricted units, warrants and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including the effect of the Merger exchange ratio. Pursuant to the Merger Agreement, each outstanding unit of Precipio Diagnostics was exchanged for &lt;/font&gt;&lt;font style="display: inline;"&gt;10.2502&lt;/font&gt;&lt;font style="display: inline;"&gt; pre-reverse stock split shares of Company Common Stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Going Concern.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The &lt;/font&gt;&lt;font style="display: inline;"&gt;condensed &lt;/font&gt;&lt;font style="display: inline;"&gt;consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (&amp;#x201C;GAAP&amp;#x201D;) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the past &lt;/font&gt;&lt;font style="display: inline;"&gt;few&lt;/font&gt;&lt;font style="display: inline;"&gt; years. As of &lt;/font&gt;&lt;font style="display: inline;"&gt;March&lt;/font&gt;&lt;font style="display: inline;"&gt; 31, 201&lt;/font&gt;&lt;font style="display: inline;"&gt;8&lt;/font&gt;&lt;font style="display: inline;"&gt;, the Company had a net loss of &lt;/font&gt;&lt;font style="display: inline;"&gt;$2.4&lt;/font&gt;&lt;font style="display: inline;"&gt; million, negative working capital of &lt;/font&gt;&lt;font style="display: inline;"&gt;$7.5&lt;/font&gt;&lt;font style="display: inline;"&gt; million and net cash used in operating activities of &lt;/font&gt;&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;font style="display: inline;"&gt;1.1&lt;/font&gt;&lt;font style="display: inline;"&gt; million. The Company&amp;#x2019;s ability to continue as a going concern &lt;/font&gt;&lt;font style="display: inline;"&gt;over the next twelve months from the date of issuance of this Form 10-Q &lt;/font&gt;&lt;font style="display: inline;"&gt;is dependent upon a combination of achieving its business plan, including generating additional revenue, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due.&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;To meet its current and future obligations the Company has taken the following steps to capitalize the business and successfully achieve its business plan:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;font-size:11pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;On April 13, 2018, the Company filed a Form S-1 General Registration Statement to register and offer for future sale shares of our common stock,&amp;nbsp;pursuant to entering into an &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Equity Purchase Agreement with Leviston Resources LLC (the &amp;#x201C;Investor&amp;#x201D;) on February 8, 2018. &amp;nbsp;See Note 8 &amp;#x2013; Stockholders&amp;#x2019; Equity for further details.&lt;/font&gt;&lt;font style="display: inline;font-size:11pt;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;On April 20, 2018, the Company&amp;nbsp;entered into a securities purchase agreement (the &amp;#x201C;Agreement&amp;#x201D;) with certain investors, pursuant to which the Company will issue up to approximately &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$3,296,703.30&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; in &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;8%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; Senior Secured Convertible Promissory Notes with &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;100%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; common stock warrant coverage. &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;See Note 12 &amp;#x2013; Subsequent Events for further details.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"&gt;
			&lt;font style="display: inline;font-size:11pt;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company&amp;#x2019;s ability to continue as a going concern&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; over the next twelve months from the date of issuance of the Form 10-Q&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;. There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; over the next twelve months from the date of issuance of the Form 10-Q&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;. The accompanying financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result should the Company be unable to continue as a going concern as a result of the outcome of this uncertainty.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;text-decoration:underline;color:#000000;"&gt;Nasdaq Delisting Notice &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;text-decoration:underline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;On March 26, 2018, Precipio, Inc. received written notice (the &amp;#x201C;Notice&amp;#x201D;) from The Nasdaq Stock Market LLC (&amp;#x201C;Nasdaq&amp;#x201D;) indicating that, based on the closing bid price of the Company&amp;#x2019;s common stock for the preceding 30 consecutive business days&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market (the &amp;#x201C;Minimum Bid Price Requirement&amp;#x201D;). The Notice has no immediate effect on the listing of Precipio&amp;#x2019;s common stock, and its common stock will continue to trade on the Nasdaq Capital Market under the symbol &amp;#x201C;PRPO&amp;#x201D; at this time.&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Precipio has a period of 180 calendar days, or until September 24, 2018 to regain compliance with the Minimum Bid Price Requirement.&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;The Company intends to monitor the closing bid price of its common stock and consider its available options to resolve its noncompliance with the Minimum Bid Price Requirement. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">7000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">50000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsCurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">51000</us-gaap:CapitalLeaseObligationsCurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">113000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">100000</us-gaap:CapitalLeaseObligationsNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2016" unitRef="Unit12" decimals="-3">51000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2017" unitRef="Unit12" decimals="-3">33000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">421000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">286000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">-18000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-135000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_8_31_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember" unitRef="Unit14" decimals="2">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_8_31_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_OfferingWarrantsMember" unitRef="Unit14" decimals="2">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_8_31_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="2">3.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_11_30_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_OfferingWarrantsMember" unitRef="Unit14" decimals="2">1.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_11_30_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_SeriesCWarrantsMember" unitRef="Unit14" decimals="2">1.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_11_30_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit14" decimals="2">1.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember" unitRef="Unit14" decimals="INF">1.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" unitRef="Unit14" decimals="INF">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_12_31_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="2">1.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_CreditorWarrantsRelatingToSecuredDebtMember" unitRef="Unit14" decimals="2">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_CreditorWarrantsRelatingToSecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember" unitRef="Unit14" decimals="2">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_21_2018_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit14" decimals="INF">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018" unitRef="Unit14" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_OfferingWarrantsMember" unitRef="Unit14" decimals="2">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringApril2020Member" unitRef="Unit14" decimals="2">120.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringDecember2020Member" unitRef="Unit14" decimals="2">49.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringFebruary2020Member" unitRef="Unit14" decimals="2">67.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" unitRef="Unit14" decimals="2">36.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" unitRef="Unit14" decimals="INF">3.125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" unitRef="Unit14" decimals="2">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" unitRef="Unit14" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" unitRef="Unit14" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" unitRef="Unit14" decimals="2">7.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember" unitRef="Unit14" decimals="2">2.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringMay2023Member" unitRef="Unit14" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" unitRef="Unit14" decimals="2">7.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member" unitRef="Unit14" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_InducementAgreement2018Member" unitRef="Unit14" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_ConvertiblePromissoryNoteWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member" unitRef="Unit14" decimals="2">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_SeriesCWarrantsMember_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member" unitRef="Unit14" decimals="2">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_InducementAgreement2018Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="2">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_PurchaseAgreement2018Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit14" decimals="2">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="As_Of_8_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit1" decimals="INF">400</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_11_30_2017_us-gaap_ClassOfWarrantOrRightAxis_prpo_SeriesCWarrantsMember" unitRef="Unit1" decimals="INF">1962857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_CreditorWarrantsRelatingToSecuredDebtMember" unitRef="Unit1" decimals="0">108112</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_CreditorWarrantsRelatingToSecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember" unitRef="Unit1" decimals="0">108112</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018" unitRef="Unit1" decimals="INF">5923789</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringApril2020Member" unitRef="Unit1" decimals="0">12487</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringDecember2020Member" unitRef="Unit1" decimals="0">4081</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringFebruary2020Member" unitRef="Unit1" decimals="0">23826</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" unitRef="Unit1" decimals="0">8952</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" unitRef="Unit1" decimals="0">60000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" unitRef="Unit1" decimals="0">856446</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" unitRef="Unit1" decimals="0">359999</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" unitRef="Unit1" decimals="0">2380000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" unitRef="Unit1" decimals="0">91429</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember" unitRef="Unit1" decimals="0">45600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringMay2023Member" unitRef="Unit1" decimals="0">1962857</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" unitRef="Unit1" decimals="0">108112</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_3_31_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member" unitRef="Unit1" decimals="0">10000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_11_30_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit1" decimals="INF">1962857</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" unitRef="Unit1" decimals="INF">24900</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="As_Of_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" unitRef="Unit1" decimals="0">5368</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;6&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;.&amp;nbsp;&amp;nbsp;CONTINGENCIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company is involved in legal proceedings related to matters, which are incidental to its business. The Company has also assumed a number of claims as a result of the Merger. See below for a discussion on these matters.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The healthcare industry is subject to numerous laws and regulations of federal, state and local governments.&amp;nbsp;&amp;nbsp;These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed.&amp;nbsp;&amp;nbsp;Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations.&amp;nbsp;&amp;nbsp;While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The outcome of legal proceedings and claims brought against us are subject to significant uncertainty.&amp;nbsp;&amp;nbsp;Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management&amp;#x2019;s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:18pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;L&lt;/font&gt;&lt;font style="display: inline;font-style:italic;"&gt;ITIGATIONS&lt;/font&gt;&lt;font style="display: inline;font-style:italic;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&amp;#x201C;Mount Sinai&amp;#x201D;) filed a lawsuit against Transgenomic in the Supreme Court of the State of New York, County of New York, &lt;/font&gt;&lt;font style="display: inline;"&gt;alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.7&lt;/font&gt;&lt;font style="display: inline;"&gt; million to Mount Sinai in installments over a period of time.&amp;nbsp;&amp;nbsp;Effective as of October 31, 2017, we and Mount Sinai agreed to enter into a new settlement agreement to restructure these liabilities into a secured, long-term debt obligation of &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.5&lt;/font&gt;&lt;font style="display: inline;"&gt; million which includes accrued interest at &lt;/font&gt;&lt;font style="display: inline;"&gt;10%&lt;/font&gt;&lt;font style="display: inline;"&gt; with monthly principal and interest payments of &lt;/font&gt;&lt;font style="display: inline;"&gt;$9,472&lt;/font&gt;&lt;font style="display: inline;"&gt; beginning in July 2018 and con&lt;/font&gt;&lt;font style="display: inline;"&gt;tinuing over 48 months and we issued warrants in the amount &lt;/font&gt;&lt;font style="display: inline;"&gt;of &lt;/font&gt;&lt;font style="display: inline;"&gt;24,900&lt;/font&gt;&lt;font style="display: inline;"&gt; shares, that are exercisable for shares of our common stock, on a 1-for-1 basis, with an exercise price of &lt;/font&gt;&lt;font style="display: inline;"&gt;$7.50&lt;/font&gt;&lt;font style="display: inline;"&gt; per share, exercisable&lt;/font&gt;&lt;font style="display: inline;"&gt; on the date of issuance with a term of &lt;/font&gt;&lt;font style="display: inline;"&gt;5&lt;/font&gt;&lt;font style="display: inline;"&gt; years. We do not plan to apply to list the warrants on the NASDAQ Capital Market, any other national securities exchange or any other nationally recognized trading system.&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;A &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;$0.5&lt;/font&gt;&lt;font style="display: inline;"&gt; million liability has been recorded and is reflected in long-term debt&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;within the accompanying condensed consolidated balance sheet at March 31, 2018 and December 31, 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On February 21, 2017, XIFIN, Inc. (&amp;#x201C;XIFIN&amp;#x201D;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of &lt;/font&gt;&lt;font style="display: inline;"&gt;approximately &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.27&lt;/font&gt;&lt;font style="display: inline;"&gt; million owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against the Company. On May 5, 2017, XIFIN filed an application for entry of default judgment against us.&lt;/font&gt;&lt;font style="display: inline;"&gt; &amp;nbsp; &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;A liability of &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.1&lt;/font&gt;&lt;font style="display: inline;"&gt; million and &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.2&lt;/font&gt;&lt;font style="display: inline;"&gt; million is reflected in accounts payable within the accompanying condensed consolidated bal&lt;/font&gt;&lt;font style="display: inline;"&gt;ance sheet at &lt;/font&gt;&lt;font style="display: inline;"&gt;March 31, 2018 and &lt;/font&gt;&lt;font style="display: inline;"&gt;December 31,&lt;/font&gt;&lt;font style="display: inline;"&gt; 2017, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owe approximately &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.2&lt;/font&gt;&lt;font style="display: inline;"&gt; million for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. &lt;/font&gt;&lt;font style="display: inline;"&gt;A&lt;/font&gt;&lt;font style="display: inline;"&gt; liability of approximately less than &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.1&lt;/font&gt;&lt;font style="display: inline;"&gt; million has been recorded and is reflected in accounts payable within the accompanying &lt;/font&gt;&lt;font style="display: inline;"&gt;condensed &lt;/font&gt;&lt;font style="display: inline;"&gt;consolidated balance sheet at &lt;/font&gt;&lt;font style="display: inline;"&gt;March 31, 2018 and &lt;/font&gt;&lt;font style="display: inline;"&gt;December&lt;/font&gt;&lt;font style="display: inline;"&gt; 31, 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On February 17, 2017, Jesse Campbell (&amp;#x201C;Campbell&amp;#x201D;) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we had a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement&amp;#x2019;s deal protection provisions deter superior offers.&amp;nbsp; As a result, Campbell alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;The Company filed a motion to dismiss all claims, which motion was fully briefed on November 27, 2017.&amp;nbsp;The Court granted the Company&amp;#x2019;s motion in full on May 3, 2018 and dismissed the lawsuit&lt;/font&gt;&lt;font style="display: inline;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On March 21, 2018, Bio-Rad Laboratories filed a lawsuit against&lt;/font&gt;&lt;font style="display: inline;"&gt; us in the Superior Court Judicial Branch of the State of Connecticut for Summary Judgment in Lieu of Complaint requiring us to pay cash owed to Bio-Rad in the &lt;/font&gt;&lt;font style="display: inline;"&gt;amount of &lt;/font&gt;&lt;font style="display: inline;"&gt;$39,000&lt;/font&gt;&lt;font style="display: inline;"&gt;. We are currently in discussions with Bio-Rad to reach payment conditions. A liability of less than &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.1&lt;/font&gt;&lt;font style="display: inline;"&gt; million has been&lt;/font&gt;&lt;font style="display: inline;"&gt; recorded in accounts payable &lt;/font&gt;&lt;font style="display: inline;"&gt;within the accompanying condensed consolidated balance sheet &lt;/font&gt;&lt;font style="display: inline;"&gt;at &lt;/font&gt;&lt;font style="display: inline;"&gt;March 31, 2018 and &lt;/font&gt;&lt;font style="display: inline;"&gt;December 31, 2017.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_12_31_2017" unitRef="Unit14" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_3_31_2018" unitRef="Unit14" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_3_31_2018" unitRef="Unit1" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="INF">10196620</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="As_Of_3_31_2018" unitRef="Unit1" decimals="INF">19668572</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="INF">10196620</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_3_31_2018" unitRef="Unit1" decimals="INF">19668572</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">102000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">197000</us-gaap:CommonStockValue>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member" unitRef="Unit12" decimals="-5">1100000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit1" decimals="0">2340</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit1" decimals="0">2548</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">182000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:CostOfGoodsAndServicesSold contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">688000</us-gaap:CostOfGoodsAndServicesSold>
  <us-gaap:DebtAndCapitalLeaseObligations contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">3416000</us-gaap:DebtAndCapitalLeaseObligations>
  <us-gaap:DebtAndCapitalLeaseObligations contextRef="As_Of_12_31_2017_us-gaap_DebtInstrumentAxis_prpo_FinancedInsuranceLoanMember" unitRef="Unit12" decimals="-3">183000</us-gaap:DebtAndCapitalLeaseObligations>
  <us-gaap:DebtAndCapitalLeaseObligations contextRef="As_Of_12_31_2017_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember" unitRef="Unit12" decimals="-5">3200000</us-gaap:DebtAndCapitalLeaseObligations>
  <us-gaap:DebtAndCapitalLeaseObligations contextRef="As_Of_12_31_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" unitRef="Unit12" decimals="-3">3233000</us-gaap:DebtAndCapitalLeaseObligations>
  <us-gaap:DebtAndCapitalLeaseObligations contextRef="As_Of_12_31_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember" unitRef="Unit12" decimals="-5">3200000</us-gaap:DebtAndCapitalLeaseObligations>
  <us-gaap:DebtAndCapitalLeaseObligations contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">3570000</us-gaap:DebtAndCapitalLeaseObligations>
  <us-gaap:DebtAndCapitalLeaseObligations contextRef="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember" unitRef="Unit12" decimals="-3">293000</us-gaap:DebtAndCapitalLeaseObligations>
  <us-gaap:DebtAndCapitalLeaseObligations contextRef="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_FinancedInsuranceLoanMember" unitRef="Unit12" decimals="-3">74000</us-gaap:DebtAndCapitalLeaseObligations>
  <us-gaap:DebtAndCapitalLeaseObligations contextRef="As_Of_3_31_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" unitRef="Unit12" decimals="-3">3233000</us-gaap:DebtAndCapitalLeaseObligations>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">1897000</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Duration_7_1_2017_To_7_31_2017_us-gaap_ShortTermDebtTypeAxis_us-gaap_BridgeLoanMember_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="INF">359999</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" unitRef="Unit1" decimals="0">300000</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">456000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:DebtDisclosureTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;4&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;. LONG-TERM DEBT&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Long-term debt consists of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:510.00pt;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="7" valign="bottom" style="width:204.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;"&gt;Dollars&amp;nbsp;in&amp;nbsp;Thousands&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;"&gt;March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;"&gt;December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Department of Economic and Community Development (DECD)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;293
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;DECD debt issuance costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(30
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;background-color: #auto;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Secured debt obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;background-color: #auto;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,233
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;background-color: #auto;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,233
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Financed insurance loan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;74
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;183
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Total long-term debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;border-top:1pt solid #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,570
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;border-top:1pt solid #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,416
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(676
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(587
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Long-term debt, net of current maturities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-bottom:2pt double #000000 ;height:16.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,894
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-bottom:2pt double #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,829
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Department of Economic and Community Development.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On January 8, 2018, the Company received gross proceeds of &lt;/font&gt;&lt;font style="display: inline;"&gt;$400,000&lt;/font&gt;&lt;font style="display: inline;"&gt; when it entered into an agreement with the &lt;/font&gt;&lt;font style="display: inline;"&gt;Department of Economic and Community Development (&amp;#x201C;DECD&amp;#x201D;)&lt;/font&gt;&lt;font style="display: inline;"&gt; by which the Company received a grant of &lt;/font&gt;&lt;font style="display: inline;"&gt;$100,000&lt;/font&gt;&lt;font style="display: inline;"&gt; and a loan of &lt;/font&gt;&lt;font style="display: inline;"&gt;$300,000&lt;/font&gt;&lt;font style="display: inline;"&gt; secured by substantially all of the Company&amp;#x2019;s assets (the &amp;#x201C;DECD 2018 Loan&amp;#x201D;.) The grant is included in deferred revenue in the accompanying condensed consolidated balance sheet. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Debt issuance costs associated with the DECD 2018 Loan were approximately &lt;/font&gt;&lt;font style="display: inline;"&gt;$31,000&lt;/font&gt;&lt;font style="display: inline;"&gt;. Amortization of the debt issuance cost was approximately &lt;/font&gt;&lt;font style="display: inline;"&gt;$1,000&lt;/font&gt;&lt;font style="display: inline;"&gt; for the three months ended March 31, 2018.&amp;nbsp;&amp;nbsp;Net debt issuance costs were &lt;/font&gt;&lt;font style="display: inline;"&gt;$30,000&lt;/font&gt;&lt;font style="display: inline;"&gt; at March 31, 2018 and are presented as a reduction of the related debt in the accompanying condensed consolidated balance sheet.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Secured Debt Obligations&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;In 2017, the Company entered into Debt Settlement Agreements (the &amp;#x201C;Settlement Agreements&amp;#x201D;) with certain of its accounts payable and accrued liability vendors (the &lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;#x201C;Creditors&amp;#x201D;) pursuant to which the Creditors&lt;/font&gt;&lt;font style="display: inline;"&gt;, who were owed &lt;/font&gt;&lt;font style="display: inline;"&gt;$6.3&lt;/font&gt;&lt;font style="display: inline;"&gt; million (the &amp;#x201C;Debt Obligations&amp;#x201D;)&lt;/font&gt;&lt;font style="display: inline;"&gt; by the Company, agreed to reduce and exchange the Debt Obligations for a secured obligation in the amount of &lt;/font&gt;&lt;font style="display: inline;"&gt;$3.2&lt;/font&gt;&lt;font style="display: inline;"&gt; million, &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.9&lt;/font&gt;&lt;font style="display: inline;"&gt; million in shares of the Company&amp;#x2019;s common stock and &lt;/font&gt;&lt;font style="display: inline;"&gt;108,112&lt;/font&gt;&lt;font style="display: inline;"&gt; warrants to purchase shares of the Company&amp;#x2019;s common stock. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Debt Obligations were restructured as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:40pt;"&gt;&lt;p style="width:40pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company entered into a scheduled long-term debt repayment agreement of approximately &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$3.2&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; million, which includes interest of approximately &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$0.6&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; million, to be paid in &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;forty-eight&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; equal monthly installments beginning in &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;July 2018&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; (the &amp;#x201C;Secured Debt Obligations&amp;#x201D;).&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:40pt;"&gt;&lt;p style="width:40pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Debt &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Obligations of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$1.9&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; million&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; were canceled in exchange for &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;1,814,754&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; shares of the Company&amp;#x2019;s common stock with a weighted average price per &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;share of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; (the &amp;#x201C;Settlement&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; Common Shares&amp;#x201D;). The stock was issued in February 2018.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:40pt;"&gt;&lt;p style="width:40pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Warrants to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;purchase &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;108,112&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; shares of the Company&amp;#x2019;s common stock at an exercise price of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$7.50&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per share (the &amp;#x201C;Creditor Warrants&amp;#x201D;) were issued to certain Creditors. The Creditor Warrants were issued in February 2018&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;. &amp;nbsp;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Financed Insurance Loan&lt;/font&gt;&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;During 2017, t&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;he Company financed&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; certain of its insurance premiums &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;(the &amp;#x201C;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Financed Insurance Loan&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;#x201D;)&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;. The original amount financed in July 2017 was &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$0.4&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; million with a &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;4.99&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; % interest rate. The Company will make monthly payments through May 2018. As of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;March 31, 2018&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; and December 31, 2017, the Financed Insurance Loan outstanding balance of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$0.1&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; million and &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$0.2&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; million, respectively, is included in current maturities of long-term debt in the Company&amp;#x2019;s condensed consolidated balance sheet. A corresponding prepaid asset is included in other current assets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member" unitRef="Unit12" decimals="-3">40000000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PurchaseAgreement2018Member" unitRef="Unit12" decimals="-5">1400000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PurchaseAgreement2018Member" unitRef="Unit12" decimals="-5">800000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="Duration_4_19_2018_To_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit13" decimals="0">1</us-gaap:DebtInstrumentConvertibleConversionRatio1>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember">2018-07-01</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_7_31_2017_us-gaap_DebtInstrumentAxis_prpo_FinancedInsuranceLoanMember" unitRef="Unit12" decimals="INF">400000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="INF">3296703.30</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="As_Of_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="INF">1809400</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_7_31_2017_us-gaap_DebtInstrumentAxis_prpo_FinancedInsuranceLoanMember" unitRef="Unit13" decimals="INF">0.0499</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" unitRef="Unit13" decimals="INF">0.1</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="As_Of_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit13" decimals="INF">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentMaturityDate contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_FinancedInsuranceLoanMember">2018-03-31</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">2019-05-01</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentPeriodicPayment contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" unitRef="Unit12" decimals="0">9472</us-gaap:DebtInstrumentPeriodicPayment>
  <us-gaap:DebtInstrumentTerm contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember">P48M</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentTerm contextRef="Duration_4_19_2018_To_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">31000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
  <us-gaap:DeferredFinanceCostsNet contextRef="As_Of_1_8_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" unitRef="Unit12" decimals="0">31000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DeferredFinanceCostsNet contextRef="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" unitRef="Unit12" decimals="0">30000</us-gaap:DeferredFinanceCostsNet>
  <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="As_Of_3_31_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember" unitRef="Unit12" decimals="-3">30000</us-gaap:DeferredFinanceCostsNoncurrentNet>
  <us-gaap:DeferredRevenueCurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">66000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">189000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">349000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">349000</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:Depreciation contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-5">100000</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-5">100000</us-gaap:Depreciation>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">24000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">352000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DerivativeLiabilities contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">841000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">124000</us-gaap:DerivativeLiabilities>
  <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Revenues, net of contractual allowances and adjustments for the three months ended March&amp;nbsp;31, 2018 and 2017 were as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption):&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:521.35pt;margin-left:5.4pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:112.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Diagnostic Testing&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:94.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Biomarker Testing&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:94.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicaid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Medicare&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;134&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;158&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;134&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;158&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Self-pay&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;26&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;20&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Third party payers&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;131&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;113&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;131&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;113&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Contract diagnostics&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Revenues, net of contractual allowances&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;488&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;791&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;303&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;color:#000000;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;10.&amp;nbsp;&amp;nbsp;EQUITY INCENTIVE PLAN&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 9pt"&gt;
			&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;&lt;font style="display: inline;font-size:10pt;"&gt;The Company's 2006 Equity Incentive Plan (the "2006 Plan") was terminated as to future awards on July 12, 2016. The Company's 2017 Stock Option and Incentive Plan (the "2017 Plan") was adopted by the Company's stockholders on June 5, 2017 and&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; &amp;nbsp;t&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;here &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;were&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;666,666&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; shares of common stock reserved for&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; issuance&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; under the 2017 Plan&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;The 2017 Plan &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;will expire on &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;June 5, 2027&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;text-decoration:underline;"&gt;Amendment of the 2017 Stock Option and Incentive Plan &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;text-decoration:underline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On January 31, 2018, at a special meeting of the stockholders of the Company, the stockholders approved an amendment and restatement of the Company&amp;#x2019;s 2017 Stock Option and Incentive Plan (the &amp;#x201C;2017 Plan&amp;#x201D;) to:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:40pt;"&gt;&lt;p style="width:40pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;increase the aggregate number of shares authorized for issuance under the 2017 Plan by &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;5,389,500&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; shares to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;6,056,166&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; shares and cumulatively increased on January 1, 2019 and on each January 1 thereafter by the lesser of the annual increase for such year or &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;500,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; shares;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:40pt;"&gt;&lt;p style="width:40pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;increase the maximum number of shares that may be granted in the form of stock options or stock appreciation rights to any one individual in any one calendar year and the maximum number of shares underlying any award intended to qualify as performance-based compensation to any one individual in any performance cycle, in each case to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;1,000,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; shares of Common Stock; and&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:40pt;"&gt;&lt;p style="width:40pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
				&lt;font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:10pt;;"&gt; &amp;#xB7;&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;add an &amp;#x201C;evergreen&amp;#x201D; provision, pursuant to which the aggregate number of shares authorized for issuance under the 2017 Plan will be automatically increased each year beginning on January 1, 2019 by &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;5%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares determined by the Company&amp;#x2019;s Board of Directors or Compensation Committee.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;Stock Options.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;During the three months ended March 31, 2018, the Company granted stock options to employees and directors to purchase up to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;3,286,528&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; shares of common stock at a weighted average exercise price of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$0.71&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;. These awards have vesting periods of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;four&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; years and had a weighted average grant date fair value of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$0.65&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;. The fair value calculation of options granted during the three months ended March 31, 2018 used the follow assumptions: risk free interest rate of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2.63%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; based on the U.S. Treasury yield in effect at the time of grant; expected life of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;six&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; years; and volatility of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;135%&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 7pt;line-height:120%;text-indent:22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The following table summarizes stock option activity under our plans during the three months ended March 31, 2018:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:512.00pt;margin-left:2.5pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:61.15pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:00.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Weighted-Average&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;"&gt;Exercise Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Outstanding at January&amp;nbsp;1, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;236,484
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.65pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;7.12
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;padding:0pt 2.4pt 0pt 25.2pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,286,528
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:71.15pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;0.71
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 25.2pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(2,953
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:71.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;110.23
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:17.85pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Outstanding at March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:17.85pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,520,059
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:17.85pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:17.85pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.06
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:17.89pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Exercisable at March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:17.89pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;42,249
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:17.89pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.65pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:17.89pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;22.75
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:3pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;March 31&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;, 201&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;8&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;, there were &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2,650,694&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; options that were vested or expected to vest with an aggregate intrinsic value of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; and a remaining weighted average contractual life of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;9.8&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; years. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;For the three months &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;ended &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;March 31&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;, 201&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;8&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; and 201&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;7&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;, we recorded compensation expense for all stock awards of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$0.1&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; million&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;, respectively, &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;within operating expense&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; in the accompanying statements of operations&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;.&amp;nbsp;&amp;nbsp;As of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;March &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;31, 201&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;8&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;, the unrecognized compensation expense related to unvested stock awards was &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$2.4&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; million, which is expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;3.6&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; years.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 7pt;line-height:120%;text-indent:22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following table summarizes stock option activity under our plans during the three months ended March 31, 2018:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:512.00pt;margin-left:2.5pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:61.15pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Number of&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:00.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Weighted-Average&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Exercise Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Outstanding at January&amp;nbsp;1, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;236,484
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.65pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;7.12
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;padding:0pt 2.4pt 0pt 25.2pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Granted&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,286,528
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:71.15pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;0.71
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 25.2pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Forfeited&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(2,953
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:71.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;110.23
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:17.85pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Outstanding at March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:17.85pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,520,059
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:17.85pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:17.85pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1.06
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:17.89pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Exercisable at March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:61.15pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:17.89pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;42,249
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:17.89pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.65pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:17.89pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;22.75
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit14" decimals="2">-1.69</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit14" decimals="2">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Loss Per Share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.&amp;nbsp;&amp;nbsp;Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to &lt;/font&gt;&lt;font style="display: inline;"&gt;9,506,515&lt;/font&gt;&lt;font style="display: inline;"&gt; and &lt;/font&gt;&lt;font style="display: inline;"&gt;2,753,814&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of our common stock have been excluded from the computation of diluted loss per share at March 31, 2018 and 2017, respectively, because the effect is anti-dilutive due to the net loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;font-family:Calibri;font-size:11pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:61.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:124.35pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,520,059&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,651&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,923,789&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,971,058&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;62,667&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;780,105&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,506,515&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,753,814&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-5">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:ExtinguishmentOfDebtAmount contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember" unitRef="Unit12" decimals="-5">1900000</us-gaap:ExtinguishmentOfDebtAmount>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-261000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember">P2Y9M</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" unitRef="Unit13" decimals="2">1.67</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" unitRef="Unit13" decimals="4">0.0239</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;During the three months ended March 31, 2018, the change in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:&amp;nbsp; &lt;/font&gt;&lt;font style="display: inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:7pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:374.00pt;margin-left:2.5pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:86.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:08.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:18.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Dollars in Thousands&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 0pt;height:18.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:101.00pt;padding:0pt 0pt 0pt 3.6pt;height:18.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:101.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:101.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Beginning balance at January 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:91.00pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;841
				&lt;/td&gt;
				&lt;td valign="top" style="width:04.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 25.2pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Total gains:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:101.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 46.8pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Recognized in earnings&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:96.50pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(261
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.50pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 46.8pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Deductions &amp;#x2013; warrant liability settlement&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:96.50pt;border-bottom:1pt solid #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(456
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.50pt;border-bottom:1pt solid #000000 ;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Balance at March 31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:91.00pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;124
				&lt;/td&gt;
				&lt;td valign="top" style="width:04.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" unitRef="Unit12" decimals="-3">261000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" unitRef="Unit12" decimals="-3">456000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="As_Of_12_31_2017_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" unitRef="Unit12" decimals="-3">841000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="As_Of_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" unitRef="Unit12" decimals="-3">124000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -18pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;9&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;.&amp;nbsp;&amp;nbsp;FAIR VALUE&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 9pt"&gt;
			&lt;font style="display: inline;font-size:9pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our &lt;/font&gt;&lt;font style="display: inline;"&gt;condensed &lt;/font&gt;&lt;font style="display: inline;"&gt;consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Level&amp;nbsp;1&amp;#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Level&amp;nbsp;2&amp;#x2014;Observable inputs other than those included in Level&amp;nbsp;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&amp;nbsp;and&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Level&amp;nbsp;3&amp;#x2014;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Common Stock Warrant Liabilities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;2016 Warrant Liability&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company assumed the 2016 Warrant Liability in the Merger and it represents the fair value of Transgenomic warrants issued in January 2016, of which, &lt;/font&gt;&lt;font style="display: inline;"&gt;5,368&lt;/font&gt;&lt;font style="display: inline;"&gt; warrants remain outstanding as of &lt;/font&gt;&lt;font style="display: inline;"&gt;March &lt;/font&gt;&lt;font style="display: inline;"&gt;31, 201&lt;/font&gt;&lt;font style="display: inline;"&gt;8&lt;/font&gt;&lt;font style="display: inline;"&gt;. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our &lt;/font&gt;&lt;font style="display: inline;"&gt;condensed &lt;/font&gt;&lt;font style="display: inline;"&gt;consolidated &lt;/font&gt;&lt;font style="display: inline;"&gt;s&lt;/font&gt;&lt;font style="display: inline;"&gt;tatement of &lt;/font&gt;&lt;font style="display: inline;"&gt;o&lt;/font&gt;&lt;font style="display: inline;"&gt;perations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;During the three months ended March 31, 2018, a portion of the 2016 Warrant Liability was part of a settlement agreement pursuant to a lawsuit that was filed against the Company by one of the warrant holders. As such, approximately &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.4&lt;/font&gt;&lt;font style="display: inline;"&gt; million of the warrant liability, representing &lt;/font&gt;&lt;font style="display: inline;"&gt;20,216&lt;/font&gt;&lt;font style="display: inline;"&gt; warrants, was canceled on the date of the settlement agreement and replaced by and amounts now recorded as other current liabilities or other long-term liabilities. For further detail, see discussion of the Crede &lt;/font&gt;&lt;font style="display: inline;"&gt;Agreement in Note &lt;/font&gt;&lt;font style="display: inline;"&gt;5&lt;/font&gt;&lt;font style="display: inline;"&gt; &amp;#x2013; &lt;/font&gt;&lt;font style="display: inline;"&gt;Other Current Liabilities.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The 2016 Warrant Liability is considered a Level 3 financial instrument and was valued using the Monte Carlo methodology. &lt;/font&gt;&lt;font style="display: inline;"&gt; As of March 31, 2018, a&lt;/font&gt;&lt;font style="display: inline;"&gt;ssumptions and inputs used in the valuation of the common stock warrants include: remaining life to maturity of &lt;/font&gt;&lt;font style="display: inline;"&gt;2.75&lt;/font&gt;&lt;font style="display: inline;"&gt; years; annual volatility of &lt;/font&gt;&lt;font style="display: inline;"&gt;167%&lt;/font&gt;&lt;font style="display: inline;"&gt;; and a risk-free interest rate of &lt;/font&gt;&lt;font style="display: inline;"&gt;2.39%&lt;/font&gt;&lt;font style="display: inline;"&gt;. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt; &amp;nbsp; &lt;/font&gt;&lt;font style="display: inline;"&gt;During the three months ended March 31, 2018, the change in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:&amp;nbsp; &lt;/font&gt;&lt;font style="display: inline;"&gt;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:7pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:374.00pt;margin-left:2.5pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:86.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:08.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:18.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Dollars in Thousands&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 0pt;height:18.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:101.00pt;padding:0pt 0pt 0pt 3.6pt;height:18.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:101.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;For the Three Months Ended&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:101.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Beginning balance at January 1&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:91.00pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;841
				&lt;/td&gt;
				&lt;td valign="top" style="width:04.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 25.2pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Total gains:&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="4" valign="bottom" style="width:101.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 46.8pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Recognized in earnings&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:96.50pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(261
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.50pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 46.8pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Deductions &amp;#x2013; warrant liability settlement&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:96.50pt;border-bottom:1pt solid #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(456
				&lt;/td&gt;
				&lt;td valign="middle" style="width:04.50pt;border-bottom:1pt solid #000000 ;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Balance at March 31&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:91.00pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;124
				&lt;/td&gt;
				&lt;td valign="top" style="width:04.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt"&gt;
			&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-5">1200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-5">900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-5">900000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-5">1000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
  <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-5">1000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
  <us-gaap:GainLossOnNonRecourseDebt contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-385000</us-gaap:GainLossOnNonRecourseDebt>
  <us-gaap:GainLossOnSaleOfEquityInvestments contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-385000</us-gaap:GainLossOnSaleOfEquityInvestments>
  <us-gaap:GainLossRelatedToLitigationSettlement contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">141000</us-gaap:GainLossRelatedToLitigationSettlement>
  <us-gaap:GainLossRelatedToLitigationSettlement contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember" unitRef="Unit12" decimals="-5">-400000</us-gaap:GainLossRelatedToLitigationSettlement>
  <us-gaap:Goodwill contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">4685000</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">4391000</us-gaap:Goodwill>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Goodwill and Intangible Assets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;As a result of the Merger, the Company recorded goodwill and intangible assets as part of its allocation of the purchase consideration.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;Goodwill&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Goodwill represents the excess of the purchase price over the fair value of identifiable net assets of the business acquired. Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may indicate that the assets might be impaired. During the three months ended March 31, 2018, the Company experienced a decline in its share price and a reduction in its market capitalization, as such the Company determined that an assessment of goodwill should be performed using the qualitative approach. Based on the qualitative assessment, the Company concluded that it was more likely than not that the fair value of the Company was less than its carry value. As part of its analysis, the Company considered triggering events and compared its fair value with its carrying value. The analysis of the fair value of the Company involved using the discounted cash flow model. Based on the analysis, the Company concluded that its carrying value exceeded its fair value and goodwill impairment in the amount of &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.3&lt;/font&gt;&lt;font style="display: inline;"&gt; million was recorded for the three months ended March 31, 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;Intangibles&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Amortization expense for intangible assets was &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.3&lt;/font&gt;&lt;font style="display: inline;"&gt; million and zero during the three months ended March&amp;nbsp;31, 2018 and 2017, respectively. Amortization expense for intangible assets is expected to be &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.2&lt;/font&gt;&lt;font style="display: inline;"&gt; million, &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.0&lt;/font&gt;&lt;font style="display: inline;"&gt; million, &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.0&lt;/font&gt;&lt;font style="display: inline;"&gt; million, &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.9&lt;/font&gt;&lt;font style="display: inline;"&gt; million and &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.9&lt;/font&gt;&lt;font style="display: inline;"&gt; million for each of the years ending December 31, 2018, 2019, 2020, 2021 and 2022, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <us-gaap:GoodwillImpairmentLoss contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">294000</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:GrossProfit contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">66000</us-gaap:GrossProfit>
  <us-gaap:GrossProfit contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">24000</us-gaap:GrossProfit>
  <us-gaap:IncomeLossFromContinuingOperations contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">-758000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperations contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-2439000</us-gaap:IncomeLossFromContinuingOperations>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">-758000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-2439000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;7&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;.&amp;nbsp;&amp;nbsp;INCOME TAXES &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Income tax expense for the three months ended March 31, 2018 and 2017 was &lt;/font&gt;&lt;font style="display: inline;"&gt;zero&lt;/font&gt;&lt;font style="display: inline;"&gt; as a result of recording a full valuation allowance against the deferred tax asset generated during the periods, which are predominantly net operating losses. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;We had &lt;/font&gt;&lt;font style="display: inline;"&gt;no&lt;/font&gt;&lt;font style="display: inline;"&gt; material interest or penalties during fiscal 2018 or fiscal 2017, and we do not anticipate any such items during the next twelve months. Our policy is to record interest and penalties directly related to uncertain tax positions as income tax expense in the condensed consolidated statements of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="Duration_1_1_2017_To_12_31_2017" unitRef="Unit12" decimals="-3">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
  <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">169000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-44000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">47000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-94000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">6000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInInventories contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-2000</us-gaap:IncreaseDecreaseInInventories>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">227000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">228000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">-4000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-218000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit1" decimals="0">3120000</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember" unitRef="Unit1" decimals="0">3120000</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
  <us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit1" decimals="0">3345334</us-gaap:IncrementalCommonSharesAttributableToConversionOfPreferredStock>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">20458000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">20138000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InterestPaidNet contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">15000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">6000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="As_Of_12_31_2017_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember" unitRef="Unit12" decimals="-5">600000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:InventoryNet contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">161000</us-gaap:InventoryNet>
  <us-gaap:InventoryNet contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">159000</us-gaap:InventoryNet>
  <us-gaap:Liabilities contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">14235000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">12685000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">27260000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">26093000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">10036000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">8751000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="Duration_3_12_2018_To_3_12_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="Unit12" decimals="-3">1925000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
  <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="Duration_3_20_2018_To_3_21_2018_us-gaap_LitigationCaseAxis_prpo_BioRadLaboratoriesMember" unitRef="Unit12" decimals="-3">39000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
  <us-gaap:LongTermDebtCurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">587000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtCurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">676000</us-gaap:LongTermDebtCurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">2829000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LongTermDebtNoncurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">2894000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_BioRadLaboratoriesMember" unitRef="Unit12" decimals="-5">100000</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_CPAGlobalMember" unitRef="Unit12" decimals="-5">100000</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_XIFINInc.Member" unitRef="Unit12" decimals="-5">200000</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_BioRadLaboratoriesMember" unitRef="Unit12" decimals="-5">100000</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CPAGlobalMember" unitRef="Unit12" decimals="-5">100000</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_XIFINInc.Member" unitRef="Unit12" decimals="-5">100000</us-gaap:LossContingencyAccrualAtCarryingValue>
  <us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_FairValueByLiabilityClassAxis_prpo_A2016WarrantLiabilityMember" unitRef="Unit12" decimals="-5">-400000</us-gaap:LossContingencyAccrualCarryingValuePeriodIncreaseDecrease>
  <us-gaap:LossContingencyDamagesPaidValue contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="Unit12" decimals="-5">200000</us-gaap:LossContingencyDamagesPaidValue>
  <us-gaap:LossContingencyDamagesSoughtValue contextRef="Duration_1_1_2016_To_12_31_2016_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" unitRef="Unit12" decimals="-5">700000</us-gaap:LossContingencyDamagesSoughtValue>
  <us-gaap:LossContingencyDamagesSoughtValue contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_LitigationCaseAxis_prpo_CPAGlobalMember" unitRef="Unit12" decimals="-5">200000</us-gaap:LossContingencyDamagesSoughtValue>
  <us-gaap:LossContingencyDamagesSoughtValue contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_LitigationCaseAxis_prpo_XIFINInc.Member" unitRef="Unit12" decimals="-4">270000</us-gaap:LossContingencyDamagesSoughtValue>
  <us-gaap:LossContingencyDamagesSoughtValue contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember" unitRef="Unit12" decimals="-5">2200000</us-gaap:LossContingencyDamagesSoughtValue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">308000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">1015000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-5000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">-326000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-1145000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">-758000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-2439000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">-758000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-5953000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:12pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Recent Accounting Pronouncements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) 2014-09, Revenue from Contracts with Customers and has subsequently issued supplemental and/or clarifying ASUs (collectively &amp;#x201C;ASC 606&amp;#x201D;). ASC 606 outlines a five-step framework that intends to clarify the principles for recognizing revenue and eliminate industry-specific guidance. In addition, ASC 606 revises current disclosure requirements in an effort to help financial statement users better understand the nature, amount, timing, and uncertainty of revenue that is recognized. ASC 606 may be applied either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We adopted this new standard as of January 1, 2018, by using the modified-retrospective method. An adjustment was not required and a change to the prior revenue recognition process and policy to adopt the new standard was not necessary. See Note 11 &amp;#x2013; Sales Service Revenue, Net And Accounts Receivable for further details.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="display: inline;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="display: inline;"&gt;. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;In January 2017, FASB issued ASU No.&amp;nbsp;2017-01, &lt;/font&gt;&lt;font style="display: inline;font-style:italic;"&gt;Business Combinations&lt;/font&gt;&lt;font style="display: inline;"&gt; (Topic 805): Clarifying the Definition of a Business.&amp;nbsp;&amp;nbsp;ASU No. 2017-01 adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&amp;nbsp;15, 2017, and interim periods within those fiscal years. The adoption of ASU No. 2017-01 did not have a material effect on the Company&amp;#x2019;s financial position and results of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;In May 2017, the FASB issued ASU 2017-09 &amp;#x201C;&lt;/font&gt;&lt;font style="display: inline;font-style:italic;"&gt;Compensation &amp;#x2013; Stock Compensation (Topic 718): Scope of Modification Accounting&amp;#x201D;, &lt;/font&gt;&lt;font style="display: inline;"&gt;which provides clarity and reduces both diversity in practice and cost and complexity when applying guidance in Topic 718. This amendment provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. &amp;nbsp;The amendments are effective for all entities for annual periods, and interim periods within those periods, beginning after December 15, 2017. The adoption of ASU No. 2017-09 did not have a material effect on the Company&amp;#x2019;s financial position and results of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">662000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">2472000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">-596000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">-2448000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="Unit12" decimals="-5">400000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
  <us-gaap:OtherAssetsCurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">430000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">209000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">22000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">25000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Other current liabilities are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:387.00pt;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:206.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:1pt;"&gt;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:72.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:69.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:206.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:82.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:27.20pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:79.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:27.20pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:206.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Obligation to issue common shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:72.65pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:69.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,897&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:206.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Liability for settlement of equity instrument&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:78.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:75.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,085&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:206.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:72.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:69.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,982&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
  <us-gaap:OtherLiabilitiesCurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">2982000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">1350000</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;5&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;.&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt; &amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;OTHER CURRENT LIABILITIES&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Other current liabilities are as follows:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:387.00pt;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:206.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-size:1pt;"&gt;0&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:72.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:69.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:206.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;(dollars in thousands)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:82.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:27.20pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:79.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:27.20pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:206.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Obligation to issue common shares&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:72.65pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:69.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,897&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:206.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Liability for settlement of equity instrument&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:78.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:75.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,085&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:206.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:72.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,350&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:69.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,982&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;As of December 31, 2017, t&lt;/font&gt;&lt;font style="display: inline;"&gt;he Company &lt;/font&gt;&lt;font style="display: inline;"&gt;had recorded a liability related to its obligation to issue shares of its common stock in the future.&amp;nbsp;&amp;nbsp;On February 12, 2018, the Company issued &lt;/font&gt;&lt;font style="display: inline;"&gt;1,814,754&lt;/font&gt;&lt;font style="display: inline;"&gt; Settlement Common Shares with a fair value of approximately &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.9&lt;/font&gt;&lt;font style="display: inline;"&gt; million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;On February 20, 2018, Crede Capital Group LLC (&amp;#x201C;Crede&amp;#x201D;) filed a lawsuit against the Company in the Supreme Court of the State of New York for Summary Judgment in Lieu of Complaint requiring the Company to pay cash owed to Crede. Crede claimed that Precipio had breached a Securities Purchase Agreement and Warrant that Crede entered into in connection with an investment in Transgenomic and that pursuant to those agreements, Precipio owed Crede approximately &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$2.2&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million. On March&amp;nbsp;12, 2018, Precipio entered into a settlement agreement (the &amp;#x201C;Crede Agreement&amp;#x201D;) with Crede pursuant to which Precipio agreed to pay Crede a total sum of &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$1.925&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million over a period of &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;16&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; months payable in cash, or at the Company&amp;#x2019;s discretion, in stock, in accordance with terms contained in the Crede Agreement. &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;In accordance with the terms of the agreement and in addition to the agreement to pay, we have also executed and delivered to Crede an affidavit of confession of judgment.&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;As of December 31, 2017, the Compan&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;y had recorded liabilities relating to Crede of &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$1.1&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million included in other current liabilities on the accompanying condensed consolidated balance sheets and &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$0.6&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million included in common stock warrant liability on the accompanying condensed consolidated balance sheets related to warrants classified as liabilities that Crede is the holder of. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:5pt 0pt 0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;As of the date of the Crede Agreement, the fair value of the common stock warrant liability related to Crede was&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; revalued to&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; approximately &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$0.4&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;, resulting in &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;a gain of &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$0.2&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;included in w&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;arrant revaluation&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;in the unaudited condensed consolidated statement of operations&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; during the three months ended March 31, 2018. See Note 9 &amp;#x2013; Fair Value for further discussion. During the three months ended March 31, 2018, at the time of the Crede Agreement, the Company paid approximately &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$0.2&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million to Crede and recorded &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$1.3&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million in other current liabilities and &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$0.4&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million in &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;other long-term liabilities, thus replacing its &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$1.1&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million liability for settlement of equity instrument and &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$0.4&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million common stock warrant liability. This resulted in the Company recording a&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;n additional&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; loss&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; of&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$0.4&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; million&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;, which is&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;included in loss &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;on settlement of equity instruments &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;in the unaudited condensed consolidated statement of operations&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;. The remaining amount due to Crede will be paid per the Crede Agreement payment schedule with the final installment&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; due in &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;May 2019&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">67000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">467000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonrecurringIncome contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-5">200000</us-gaap:OtherNonrecurringIncome>
  <us-gaap:OtherPreferredStockDividendsAndAdjustments contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">3514000</us-gaap:OtherPreferredStockDividendsAndAdjustments>
  <us-gaap:OtherSalesRevenueNet contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">5000</us-gaap:OtherSalesRevenueNet>
  <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="Duration_1_7_2018_To_1_8_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember" unitRef="Unit12" decimals="0">100000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">5000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">3514000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
  <us-gaap:PreferredStockLiquidationPreference contextRef="As_Of_8_25_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit14" decimals="INF">1000</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:PreferredStockLiquidationPreference contextRef="As_Of_11_6_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit14" decimals="INF">1000</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_8_25_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit14" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_8_31_2017_dei_LegalEntityAxis_prpo_AegisCapitalCorpMember" unitRef="Unit14" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_11_6_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit14" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_12_31_2017" unitRef="Unit14" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="As_Of_3_31_2018" unitRef="Unit14" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_8_25_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit1" decimals="INF">6900</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_11_6_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit1" decimals="INF">2748</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="INF">15000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_3_31_2018" unitRef="Unit1" decimals="INF">15000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit1" decimals="INF">6900</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit1" decimals="INF">2748</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="INF">4935</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_3_31_2018" unitRef="Unit1" decimals="INF">47</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit1" decimals="0">47</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_12_31_2017" unitRef="Unit1" decimals="INF">4935</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_3_31_2018" unitRef="Unit1" decimals="INF">47</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember" unitRef="Unit1" decimals="INF">47</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" unitRef="Unit1" decimals="0">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_12_31_2017" unitRef="Unit12" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="As_Of_3_31_2018" unitRef="Unit12" />
  <us-gaap:ProceedsFromConvertibleDebt contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">100000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">618000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">265000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="Duration_1_7_2018_To_1_8_2018_us-gaap_DebtInstrumentAxis_prpo_DepartmentofEconomicandCommunityDevelopmentMember_us-gaap_LongtermDebtTypeAxis_prpo_TermLoanMember" unitRef="Unit12" decimals="0">300000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="Duration_4_19_2018_To_4_20_2018_us-gaap_DebtInstrumentAxis_prpo_SecuritiesPurchaseAgreementMember_us-gaap_DebtInstrumentRedemptionPeriodAxis_us-gaap_DebtInstrumentRedemptionPeriodOneMember_us-gaap_LongtermDebtTypeAxis_prpo_SeniorSecuredConvertiblePromissoryNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Unit12" decimals="0">1660000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit12" decimals="0">744000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromWarrantExercises contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">225000</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">353000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">333000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Property and Equipment, net.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Depreciation expense was less than &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.1&lt;/font&gt;&lt;font style="display: inline;"&gt; million for both the three months March&amp;nbsp;31, 2018 and 2017. Depreciation expense during each year includes depreciation related to equipment acquired under capital leases.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">55000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:ProvisionForDoubtfulAccounts contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">84000</us-gaap:ProvisionForDoubtfulAccounts>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">11000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">12000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
  <us-gaap:RepaymentsOfNotesPayable contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">46000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:RepaymentsOfNotesPayable contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">116000</us-gaap:RepaymentsOfNotesPayable>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">-31542000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">-33981000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Revenue Recognition.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Revenue recognition occurs when a customer obtains control of the promised goods and service. Revenue assigned to the goods and services reflects the consideration which the Company expects to receive in exchange for those goods and services.&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company derives its revenues from Diagnostic Testing - histology, flow cytometry, cytology and molecular testing; Clinical Research from bio-pharma customers, state and federal grant programs; and from Biomarker Testing from bio-pharma customers. All sources of revenue are recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. Due to differences in the substance of these revenue types, the transactions require, and the Company utilizes, different revenue recognition policies for each. See more detailed information on revenue in Note 11 &amp;#x2013; Sales Service Revenue, Net And Accounts Receivable.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company recognizes revenue utilizing the five-step framework of ASC 606. Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for diagnostic testing at a point in time based on the delivery method (web-portal access or fax) for a patient&amp;#x2019;s laboratory report. Diagnostic testing service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payors. Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions for third-party payor settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined. For clinical research and biomarker services, the Company utilizes an &amp;#x201C;effort based&amp;#x201D; method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results per the contract.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
			&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. Deferred net sales included in the balance sheet as deferred revenue was &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.2 million and less than $0.1 million&lt;/font&gt;&lt;font style="display: inline;"&gt; as of March 31, 2018 and December 31, 2017, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:Revenues contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">248000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">10000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">128000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ServicesRevenueNetMember" unitRef="Unit12" decimals="-3">248000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">16000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">94000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">712000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember" unitRef="Unit12" decimals="-3">488000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">1000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">114000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_OtherPartyMember" unitRef="Unit12" decimals="-3">5000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ServicesRevenueNetMember" unitRef="Unit12" decimals="-3">707000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">26000</us-gaap:Revenues>
  <us-gaap:Revenues contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">78000</us-gaap:Revenues>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Duration_8_1_2017_To_8_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredClassBMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PublicStockOfferingMember" unitRef="Unit1" decimals="INF">6000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Duration_11_1_2017_To_11_2_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_PlacementAgreementMember" unitRef="Unit1" decimals="0">2748</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">55000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">2000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">30000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ServicesRevenueNetMember" unitRef="Unit12" decimals="-3">55000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">4000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">19000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">84000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">11000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">20000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ServicesRevenueNetMember" unitRef="Unit12" decimals="-3">84000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesAllowancesServices contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">53000</us-gaap:SalesAllowancesServices>
  <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">202000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
  <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">12000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
  <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">8000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
  <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">182000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
  <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">192000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
  <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">3000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
  <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">3000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
  <us-gaap:SalesDiscountsReturnsAndAllowancesGoods contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">186000</us-gaap:SalesDiscountsReturnsAndAllowancesGoods>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">505000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">24000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">166000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">20000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">295000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">983000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember" unitRef="Unit12" decimals="-3">488000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">15000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">137000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">26000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueGoodsGross contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">317000</us-gaap:SalesRevenueGoodsGross>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">303000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" decimals="-3">303000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">12000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">158000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">20000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">113000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" decimals="-3">12000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" decimals="-3">158000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" decimals="-3">20000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2017_To_3_31_2017_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" decimals="-3">113000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">791000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" decimals="-3">488000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember" unitRef="Unit12" decimals="-3">488000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" decimals="-3">303000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember" unitRef="Unit12" decimals="-3">12000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember" unitRef="Unit12" decimals="-3">134000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember" unitRef="Unit12" decimals="-3">26000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember" unitRef="Unit12" decimals="-3">131000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" decimals="-3">488000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_ContractDiagnosticServicesMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicaidMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" decimals="-3">12000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_prpo_MedicareMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" decimals="-3">134000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_SelfPayMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" decimals="-3">26000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:SalesRevenueServicesNet xsi:nil="true" contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember_us-gaap_ProductOrServiceAxis_prpo_BiomarkerTestingAndClinicalProjectServicesMember" unitRef="Unit12" />
  <us-gaap:SalesRevenueServicesNet contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_HealthCareOrganizationRevenueSourcesAxis_us-gaap_ThirdPartyPayorMember_us-gaap_ProductOrServiceAxis_prpo_DiagnosticTestingMember" unitRef="Unit12" decimals="-3">131000</us-gaap:SalesRevenueServicesNet>
  <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following summarizes the mix of receivables: &lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 76.00%;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:67.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:67.82%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 11pt"&gt;
						&lt;font style="display: inline;font-size:11pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:01.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:10.28%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:00.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:02.32%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:10.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="middle" style="width:00.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"&gt;
					&lt;p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Medicaid&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;33
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;37
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Medicare&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;611
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;256
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Self-pay&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;102
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;53
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Third party payers&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;768
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,066
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Contract diagnostic services&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;background-color: #CCECFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;246
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;background-color: #CCECFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;background-color: #CCECFF;height:11.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;445
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Other&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,760
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,857
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.82%;background-color: #auto;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Less allowance for doubtful accounts &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #auto;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,208
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #auto;height:11.50pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #auto;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;background-color: #auto;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(1,127
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Accounts receivable, net&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.28%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;552
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:02.32%;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:10.86%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;730
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;font-family:Calibri;font-size:11pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:61.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:124.35pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,520,059&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,651&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,923,789&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,971,058&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;62,667&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;780,105&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,506,515&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,753,814&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDebtTableTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Long-term debt consists of the following:&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:510.00pt;margin-left:0pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="7" valign="bottom" style="width:204.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;"&gt;Dollars&amp;nbsp;in&amp;nbsp;Thousands&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;"&gt;March 31, 2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;"&gt;December 31, 2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Department of Economic and Community Development (DECD)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;293
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;DECD debt issuance costs&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(30
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#x2014;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;background-color: #auto;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Secured debt obligations&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;background-color: #auto;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,233
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;background-color: #auto;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,233
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Financed insurance loan&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;74
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;183
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Total long-term debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;border-top:1pt solid #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,570
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;border-top:1pt solid #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,416
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Current portion of long-term debt&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(676
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="width:96.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;(587
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:03.85pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Long-term debt, net of current maturities&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-bottom:2pt double #000000 ;height:16.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,894
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:90.65pt;border-bottom:2pt double #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,829
				&lt;/td&gt;
				&lt;td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:9pt 0pt 7pt;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following represents a summary of the warrants outstanding as of March 31, 2018:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:318.00pt;margin-left:2.5pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:89.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Issue&amp;nbsp;Year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 0pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:89.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Underlying&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="8" valign="bottom" style="width:318.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-style:italic;color:#000000;text-decoration:underline;"&gt;Warrants Assumed in Merger&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;April 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12,487&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$120.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;February 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;23,826&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$67.20&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;December 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,081&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$49.80&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(4)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;January 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,952&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$36.30&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="8" valign="bottom" style="width:318.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-style:italic;color:#000000;text-decoration:underline;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(5)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;June 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;45,600&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$2.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(6)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;June 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;91,429&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$7.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(7)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;August 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,380,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$0.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(8)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;August 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;60,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$3.125&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(9)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;August 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;856,446&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$10.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(10)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;August 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;359,999&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$0.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #auto;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(11)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;October 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #auto;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;10,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$0.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(12)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;May 2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,962,857&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$0.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(13)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;October 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;108,112&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$7.50&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-top:1pt solid #000000 ;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,923,789&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (1)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with a private placement which was completed in October 2014.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (2)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with an offering which was completed in February 2015.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (3)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with an offering which was completed in July 2015.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (4)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with an offering which was completed in January 2016. Of the remaining outstanding warrants as of March 31, 2018, 5,368 warrants are recorded as a liability, See Note 9 &amp;#x2013; Fair Value for further discussion, and 3,584 are treated as equity.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (5)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the Merger and are the 2017 New Bridge Warrants.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (6)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the Merger and are considered Side Warrants.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (7)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the August 2017 Offering and are the August 2017 Offering Warrants discussed below.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (8)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the August 2017 Offering and are considered Representative Warrants.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (9)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the conversion of our Series A Senior stock, at the time of the closing of the August 2017 Offering, and are the Series A Conversion Warrants discussed above.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (10)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the conversion of convertible bridge notes, at the time of the closing of the August 2017 Offering, and are the Note Conversion Warrants discussed below.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (11)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the waiver of default the Company received in the fourth quarter of 2017 in connection with the Convertible Promissory Notes and are the Convertible Promissory Note Warrants discussed below.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (12)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the Series C Preferred Offering and are the Series C Warrants discussed below.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (13)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the Debt Obligation settlement agreements and are the Creditor Warrants discussed below.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:SecuredDebt contextRef="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" unitRef="Unit12" decimals="-5">500000</us-gaap:SecuredDebt>
  <us-gaap:SecuredDebt contextRef="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_MountSinaiMember" unitRef="Unit12" decimals="-5">500000</us-gaap:SecuredDebt>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit12" decimals="-3">662000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">2178000</us-gaap:SellingGeneralAndAdministrativeExpense>
  <us-gaap:SettlementLiabilitiesCurrent contextRef="As_Of_12_31_2017_us-gaap_LitigationCaseAxis_prpo_CredeMember" unitRef="Unit12" decimals="-5">1100000</us-gaap:SettlementLiabilitiesCurrent>
  <us-gaap:SettlementLiabilitiesCurrent contextRef="As_Of_3_31_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember" unitRef="Unit12" decimals="-5">1300000</us-gaap:SettlementLiabilitiesCurrent>
  <us-gaap:ShareBasedCompensation contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit12" decimals="-3">82000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RangeAxis_us-gaap_MaximumMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RangeAxis_us-gaap_MinimumMember">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="Duration_1_1_2018_To_3_31_2018">P3Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2017Member">2027-06-05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="2">1.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit13" decimals="4">0.0263</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee contextRef="Duration_1_1_2018_To_1_31_2018" unitRef="Unit1" decimals="INF">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="Duration_1_1_2018_To_1_31_2018" unitRef="Unit1" decimals="INF">5389500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="As_Of_1_31_2018" unitRef="Unit1" decimals="INF">6056166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="As_Of_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF">42249</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="As_Of_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit14" decimals="2">22.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF">2953</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF">3286528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit14" decimals="INF">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF">236484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="As_Of_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF">3520059</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_12_31_2017_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit14" decimals="2">7.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="As_Of_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit14" decimals="2">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="As_Of_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit12" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="As_Of_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit1" decimals="INF">2650694</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">P9Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="Duration_1_1_2018_To_1_31_2018" unitRef="Unit13" decimals="INF">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit14" decimals="2">110.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="Unit14" decimals="2">0.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="Duration_1_1_2018_To_3_31_2018_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_prpo_EquityIncentivePlan2017Member" unitRef="Unit1" decimals="0">666666</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
  <us-gaap:SharePrice contextRef="As_Of_8_31_2017_dei_LegalEntityAxis_prpo_AegisCapitalCorpMember" unitRef="Unit14" decimals="0">1000</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="As_Of_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit14" decimals="2">1.04</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="As_Of_2_28_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember" unitRef="Unit14" decimals="2">1.04</us-gaap:SharePrice>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;2.&amp;nbsp;&amp;nbsp;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Basis of Presentation.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The accompanying condensed consolidated financial statements are presented in conformity with GAAP. We have evaluated events occurring subsequent to March 31, 2018 for potential recognition or disclosure in the condensed consolidated financial statements and concluded that, other than what is disclosed within the notes to unaudited condensed consolidated financial statements and in Note 12 - Subsequent Events, there were no other subsequent events that required recognition or disclosure.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The condensed consolidated balance sheet as of December&amp;nbsp;31, 2017 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2017. The accompanying condensed consolidated financial statements as of and for the three months ended March&amp;nbsp;31, 2018 and 2017 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December&amp;nbsp;31, 2017 contained in our Annual Report Form 10-K, filed with the Securities and Exchange Commission (the &amp;#x201C;SEC&amp;#x201D;) on April 13, 2018. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Recent Accounting Pronouncements. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update (&amp;#x201C;ASU&amp;#x201D;) 2014-09, Revenue from Contracts with Customers and has subsequently issued supplemental and/or clarifying ASUs (collectively &amp;#x201C;ASC 606&amp;#x201D;). ASC 606 outlines a five-step framework that intends to clarify the principles for recognizing revenue and eliminate industry-specific guidance. In addition, ASC 606 revises current disclosure requirements in an effort to help financial statement users better understand the nature, amount, timing, and uncertainty of revenue that is recognized. ASC 606 may be applied either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We adopted this new standard as of January 1, 2018, by using the modified-retrospective method. An adjustment was not required and a change to the prior revenue recognition process and policy to adopt the new standard was not necessary. See Note 11 &amp;#x2013; Sales Service Revenue, Net And Accounts Receivable for further details.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:12pt 0pt 0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="display: inline;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="display: inline;"&gt;. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;In January 2017, FASB issued ASU No.&amp;nbsp;2017-01, &lt;/font&gt;&lt;font style="display: inline;font-style:italic;"&gt;Business Combinations&lt;/font&gt;&lt;font style="display: inline;"&gt; (Topic 805): Clarifying the Definition of a Business.&amp;nbsp;&amp;nbsp;ASU No. 2017-01 adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&amp;nbsp;15, 2017, and interim periods within those fiscal years. The adoption of ASU No. 2017-01 did not have a material effect on the Company&amp;#x2019;s financial position and results of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;In May 2017, the FASB issued ASU 2017-09 &amp;#x201C;&lt;/font&gt;&lt;font style="display: inline;font-style:italic;"&gt;Compensation &amp;#x2013; Stock Compensation (Topic 718): Scope of Modification Accounting&amp;#x201D;, &lt;/font&gt;&lt;font style="display: inline;"&gt;which provides clarity and reduces both diversity in practice and cost and complexity when applying guidance in Topic 718. This amendment provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. &amp;nbsp;The amendments are effective for all entities for annual periods, and interim periods within those periods, beginning after December 15, 2017. The adoption of ASU No. 2017-09 did not have a material effect on the Company&amp;#x2019;s financial position and results of operations.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
			&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Property and Equipment, net.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Depreciation expense was less than &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.1&lt;/font&gt;&lt;font style="display: inline;"&gt; million for both the three months March&amp;nbsp;31, 2018 and 2017. Depreciation expense during each year includes depreciation related to equipment acquired under capital leases.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Goodwill and Intangible Assets.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;As a result of the Merger, the Company recorded goodwill and intangible assets as part of its allocation of the purchase consideration.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;Goodwill&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Goodwill represents the excess of the purchase price over the fair value of identifiable net assets of the business acquired. Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may indicate that the assets might be impaired. During the three months ended March 31, 2018, the Company experienced a decline in its share price and a reduction in its market capitalization, as such the Company determined that an assessment of goodwill should be performed using the qualitative approach. Based on the qualitative assessment, the Company concluded that it was more likely than not that the fair value of the Company was less than its carry value. As part of its analysis, the Company considered triggering events and compared its fair value with its carrying value. The analysis of the fair value of the Company involved using the discounted cash flow model. Based on the analysis, the Company concluded that its carrying value exceeded its fair value and goodwill impairment in the amount of &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.3&lt;/font&gt;&lt;font style="display: inline;"&gt; million was recorded for the three months ended March 31, 2018.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;Intangibles&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Amortization expense for intangible assets was &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.3&lt;/font&gt;&lt;font style="display: inline;"&gt; million and zero during the three months ended March&amp;nbsp;31, 2018 and 2017, respectively. Amortization expense for intangible assets is expected to be &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.2&lt;/font&gt;&lt;font style="display: inline;"&gt; million, &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.0&lt;/font&gt;&lt;font style="display: inline;"&gt; million, &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.0&lt;/font&gt;&lt;font style="display: inline;"&gt; million, &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.9&lt;/font&gt;&lt;font style="display: inline;"&gt; million and &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.9&lt;/font&gt;&lt;font style="display: inline;"&gt; million for each of the years ending December 31, 2018, 2019, 2020, 2021 and 2022, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Revenue Recognition.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Revenue recognition occurs when a customer obtains control of the promised goods and service. Revenue assigned to the goods and services reflects the consideration which the Company expects to receive in exchange for those goods and services.&amp;nbsp; &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company derives its revenues from Diagnostic Testing - histology, flow cytometry, cytology and molecular testing; Clinical Research from bio-pharma customers, state and federal grant programs; and from Biomarker Testing from bio-pharma customers. All sources of revenue are recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. Due to differences in the substance of these revenue types, the transactions require, and the Company utilizes, different revenue recognition policies for each. See more detailed information on revenue in Note 11 &amp;#x2013; Sales Service Revenue, Net And Accounts Receivable.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The Company recognizes revenue utilizing the five-step framework of ASC 606. Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for diagnostic testing at a point in time based on the delivery method (web-portal access or fax) for a patient&amp;#x2019;s laboratory report. Diagnostic testing service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payors. Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions for third-party payor settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined. For clinical research and biomarker services, the Company utilizes an &amp;#x201C;effort based&amp;#x201D; method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results per the contract.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt"&gt;
			&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. Deferred net sales included in the balance sheet as deferred revenue was &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.2 million and less than $0.1 million&lt;/font&gt;&lt;font style="display: inline;"&gt; as of March 31, 2018 and December 31, 2017, respectively.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Loss Per Share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.&amp;nbsp;&amp;nbsp;Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to &lt;/font&gt;&lt;font style="display: inline;"&gt;9,506,515&lt;/font&gt;&lt;font style="display: inline;"&gt; and &lt;/font&gt;&lt;font style="display: inline;"&gt;2,753,814&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of our common stock have been excluded from the computation of diluted loss per share at March 31, 2018 and 2017, respectively, because the effect is anti-dilutive due to the net loss.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;font-family:Calibri;font-size:11pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:81.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="width:61.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="5" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:124.35pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;March 31,&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;3,520,059&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,651&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,923,789&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,971,058&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;font-family:Times New Roman;font-size:10pt;"&gt;Preferred stock&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;62,667&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;780,105&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;"&gt;Total&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;9,506,515&amp;nbsp;
				&lt;/td&gt;
				&lt;td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt"&gt;
					&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,753,814&amp;nbsp;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit12" decimals="INF">721153</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants contextRef="Duration_3_20_2018_To_3_21_2018_us-gaap_ClassOfWarrantOrRightAxis_prpo_PreferredStockInducedConversionsSecondInvestorMember_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" unitRef="Unit12" decimals="INF">500000</us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants>
  <us-gaap:StockholdersEquity contextRef="As_Of_12_31_2017" unitRef="Unit12" decimals="-3">13025000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="As_Of_3_31_2018" unitRef="Unit12" decimals="-3">13408000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt 0pt 0pt 27pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;8&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;.&amp;nbsp;&amp;nbsp;STOCKHOLDERS&amp;#x2019; EQUITY&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 27pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 27pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Common Stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt 0pt 0pt 27pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have &lt;/font&gt;&lt;font style="display: inline;"&gt;150,000,000&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;shares of common stock authorized for issuance.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On February 8, 2018 the Company entered into an equity purchase agreement (the &amp;#x201C;&lt;/font&gt;&lt;font style="display: inline;"&gt;2018 &lt;/font&gt;&lt;font style="display: inline;"&gt;Purchase &lt;/font&gt;&lt;font style="display: inline;"&gt;A&lt;/font&gt;&lt;font style="display: inline;"&gt;greement&amp;#x201D;) with Leviston Resources LLC (&amp;#x201C;Leviston&amp;#x201D;) for the purchase of up to &lt;/font&gt;&lt;font style="display: inline;"&gt;$8,000,000&lt;/font&gt;&lt;font style="display: inline;"&gt; (the &amp;#x201C;Aggregate Amount&amp;#x201D;) of shares (the &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;#x201C;&lt;/font&gt;&lt;font style="display: inline;"&gt;Shares&amp;#x201D;) of the Company&amp;#x2019;s common stock from time to time, at the Company&amp;#x2019;s option. &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Shares offered and sold prior to February 13, 2018 were issued pursuant to the Company&amp;#x2019;s shelf registration statement on Form S-3 (and the related prospectus) that the Company filed with the Securities and Exchange Commission (the &amp;#x201C;SEC&amp;#x201D;) and which was declared effective by the SEC on February 13, 2015 (the &amp;#x201C;Shelf Registration Statement&amp;#x201D;). &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;Sales of the Company&amp;#x2019;s common stock, if any, may be made in sales deemed to be &amp;#x201C;at-the-market&amp;#x201D; equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the &amp;#x201C;Securities Act&amp;#x201D;), at a purchase price equal to &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;97.25%&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; of the volume weighted average sales price of the common stock reported on the date that Leviston receives a capital call from the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;Leviston purchased &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;721,153&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; shares (the &amp;#x201C;Investor Shares&amp;#x201D;) of the Company&amp;#x2019;s common stock following the close of business on February 9, 2018, subject to customary closing conditions, at a price per share of &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;. The shares were sold pursuant to the Shelf Registration Statement. The net proceeds to the Company from this sale were approximately &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$744,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;. In addition to the &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$6,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; fee (&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;0.75%&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; fee discussed below), the Company incurred approximately &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$136,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; of additional costs, both of which have been treated as issuance costs within additional paid-in capital in the accompanying unaudited condensed consolidated balance sheet&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;In consideration of Leviston&amp;#x2019;s agreement to enter into the &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;2018 &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;Purchase Agreement, the Company agreed to pay to Leviston a commitment fee in shares of the Company&amp;#x2019;s common stock equal in value to &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;5.25%&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; of the total Aggregate Amount (the &amp;#x201C;Commitment Shares&amp;#x201D;), payable as follows: &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;1.75%&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; on or before February 12, 2018. This amount, of &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$140,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;, was paid to Leviston through the issuance of &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;170,711&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; shares of the Company&amp;#x2019;s common stock on February 12, 2018; 1.75% on the third calendar day after the date on which the registration statement on Form S-1 file&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;d&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;on April 16, 2018 &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;is declared effective by the SEC; and 1.75% on the thirtieth calendar day after the date on which such registration statement on Form S-1 is declared effective by the SEC.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The Company agreed to pay to Leviston, on each day that Leviston receives a capital call from the Company, all expenses associated with depositing, clearing, selling and mailing of the stock certificates, a fee of &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;0.75%&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; of any amount purchased by Leviston. Also, the Company paid &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$35,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; to Leviston for a documentation fee for preparing the &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;2018 &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;Purchase Agreement.&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; This was recorded in additional paid-in-capital as an off-set to the proceeds received. &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;Leviston will refund the Company &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$15,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; if certain future conditions are met&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;. Such conditions have not been met as of the date of issuance of this Form 10-Q&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;Because the Company&amp;#x2019;s existing registration statement on Form S-3 expired on February 13, 2018 and, due to the timing of the filing of the Company&amp;#x2019;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, the Company will not be eligible to file a new Form S-3 registration statement until September 1, 2018, the Company agreed to prepare and file with the SEC a registration statement on Form S-1 the (&amp;#x201C;S-1 Registration Statement&amp;#x201D;), by April 15, 2018 and to use reasonable best efforts to cause the S-1 Registration Statement to be declared effective by the SEC within ninety days thereafter.&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; The Company filed the S-1 Registration Statement with the SEC on April 16, 2018, which is yet to become effective and which was in a timely manner since the SEC was not open for filings on April 15, 2018. &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;The Company is also required to pay liquidated damages of &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;$100,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt; on each event of default under the &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;2018 &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;Purchase Agreement. The Company has provided Leviston with customary indemnification rights under the &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;2018 &lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:10pt;"&gt;Purchase Agreement.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;During the three months ended March 31, 2018, the Company issued &lt;/font&gt;&lt;font style="display: inline;"&gt;3,120,000&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;shares of its common stock in connection with conversions of its Series B Preferred Stock&lt;/font&gt;&lt;font style="display: inline;"&gt; and &lt;/font&gt;&lt;font style="display: inline;"&gt;3,345,334&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;shares of its common stock in connection with conversions of its Series &lt;/font&gt;&lt;font style="display: inline;"&gt;C&lt;/font&gt;&lt;font style="display: inline;"&gt; Preferred Stock&lt;/font&gt;&lt;font style="display: inline;"&gt;. Aside from &lt;/font&gt;&lt;font style="display: inline;"&gt;60,000&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of common stock issued in connection&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;with conversions of its Series &lt;/font&gt;&lt;font style="display: inline;"&gt;C&lt;/font&gt;&lt;font style="display: inline;"&gt; Preferred Stock&lt;/font&gt;&lt;font style="display: inline;"&gt;, all of the &lt;/font&gt;&lt;font style="display: inline;"&gt;shares of common stock &lt;/font&gt;&lt;font style="display: inline;"&gt;issued in the three months ended March 31, 2018 &lt;/font&gt;&lt;font style="display: inline;"&gt;in connection with conversions of its Series B Preferred Stock&lt;/font&gt;&lt;font style="display: inline;"&gt; and Series C Preferred Stock &lt;/font&gt;&lt;font style="display: inline;"&gt;(together the &amp;#x201C;Preferred Stock&amp;#x201D;)&lt;/font&gt;&lt;font style="display: inline;"&gt; were issued after the Company induced the holders &lt;/font&gt;&lt;font style="display: inline;"&gt;of &lt;/font&gt;&lt;font style="display: inline;"&gt;its &lt;/font&gt;&lt;font style="display: inline;"&gt;Preferred Stock &lt;/font&gt;&lt;font style="display: inline;"&gt;to convert their shares of Preferred Stock to shares of the company&amp;#x2019;s common stock (see below - Preferred Stock induced conversions). &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;During the three months ended March 31, 2018, the Company issued &lt;/font&gt;&lt;font style="display: inline;"&gt;300,000&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;shares of its common stock &lt;/font&gt;&lt;font style="display: inline;"&gt;in connection with the exercise of &lt;/font&gt;&lt;font style="display: inline;"&gt;300,000&lt;/font&gt;&lt;font style="display: inline;"&gt; warrants. The warrant exercise resulted in &lt;/font&gt;&lt;font style="display: inline;"&gt;net cash proceeds to the Company&lt;/font&gt;&lt;font style="display: inline;"&gt; of approximately &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.2&lt;/font&gt;&lt;font style="display: inline;"&gt; million.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Preferred Stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The Company&amp;#x2019;s Board of Directors is authorized to issue up to &lt;/font&gt;&lt;font style="display: inline;"&gt;15,000,000&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Series B Preferred Stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On August&amp;nbsp;25, 2017, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series&amp;nbsp;B Convertible Preferred Stock (&amp;#x201C;Series B Preferred Stock&amp;#x201D;) with the State of Delaware which designates &lt;/font&gt;&lt;font style="display: inline;"&gt;6,900&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of our preferred stock as Series&amp;nbsp;B Preferred Stock. The Series&amp;nbsp;B Preferred Stock has a stated value of&amp;#x2009;&lt;/font&gt;&lt;font style="display: inline;"&gt;$1,000&lt;/font&gt;&lt;font style="display: inline;"&gt; per share and a par value of&amp;#x2009;&lt;/font&gt;&lt;font style="display: inline;"&gt;$0.01&lt;/font&gt;&lt;font style="display: inline;"&gt; per share. The Series B Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock).&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On August&amp;nbsp;28, 2017, the Company completed the August 2017 Offering of &lt;/font&gt;&lt;font style="display: inline;"&gt;6,000&lt;/font&gt;&lt;font style="display: inline;"&gt; units consisting of one share of the Company&amp;#x2019;s Series B Preferred Stock, which &lt;/font&gt;&lt;font style="display: inline;"&gt;was initially&lt;/font&gt;&lt;font style="display: inline;"&gt; convertible into &lt;/font&gt;&lt;font style="display: inline;"&gt;400&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of common stock, par value $0.01 per share, at a conversion price of &lt;/font&gt;&lt;font style="display: inline;"&gt;$2.50&lt;/font&gt;&lt;font style="display: inline;"&gt; per share, and one warrant to purchase up to 400 shares of common stock (the &amp;#x201C;August 2017 Offering Warrants&amp;#x201D;) at a combined public offering price of &lt;/font&gt;&lt;font style="display: inline;"&gt;$1,000&lt;/font&gt;&lt;font style="display: inline;"&gt; per unit. The August 2017 Offering included the sale of &lt;/font&gt;&lt;font style="display: inline;"&gt;280,000&lt;/font&gt;&lt;font style="display: inline;"&gt; August 2017 Offering Warrants pursuant to the over-allotment option exercised by Aegis Capital Corp. (&amp;#x201C;Aegis&amp;#x201D;) for &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.01&lt;/font&gt;&lt;font style="display: inline;"&gt; per share or &lt;/font&gt;&lt;font style="display: inline;"&gt;$2,800&lt;/font&gt;&lt;font style="display: inline;"&gt;. &amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;In November 2017, the down round feature of the Series B Preferred Stock was triggered at the time of the Company&amp;#x2019;s issuance of its Series C Preferred Stock and, as a result, the conversion price of the Series B Preferred Stock was reduced from &lt;/font&gt;&lt;font style="display: inline;"&gt;$2.50&lt;/font&gt;&lt;font style="display: inline;"&gt; per share to &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.40&lt;/font&gt;&lt;font style="display: inline;"&gt; per share. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;T&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;he &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2018 Purchase Agreement&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;triggered &lt;/font&gt;&lt;font style="display: inline;"&gt;the down round feature of the Series B Preferred Stock&lt;/font&gt;&lt;font style="display: inline;"&gt; and&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; as a result,&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; the conversion price of the Company&amp;#x2019;s Series B Convertible Preferred Stock was automatically adjusted from &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$1.40&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per share to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;share.&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximatel&lt;/font&gt;&lt;font style="display: inline;"&gt;y &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;$1.4&lt;/font&gt;&lt;font style="display: inline;"&gt; million&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;which was recognized as a deemed dividend at time of the down round adjustment&lt;/font&gt;&lt;font style="display: inline;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;T&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;he &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2018 Inducement Agreement, discussed below, &lt;/font&gt;&lt;font style="display: inline;"&gt;triggered &lt;/font&gt;&lt;font style="display: inline;"&gt;the down round feature of the Series B Preferred Stock&lt;/font&gt;&lt;font style="display: inline;"&gt; and&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; as a result,&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; the conversion price of the Company&amp;#x2019;s Series B Convertible Preferred Stock was automatically adjusted from &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per share to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$0.75&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;share.&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximatel&lt;/font&gt;&lt;font style="display: inline;"&gt;y &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;$40,000&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;which was recognized as a deemed dividend at time of the down round adjustment&lt;/font&gt;&lt;font style="display: inline;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;During the three months ended March 31, 2018, &lt;/font&gt;&lt;font style="display: inline;"&gt;2,340&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;shares of Series B Preferred Stock &lt;/font&gt;&lt;font style="display: inline;"&gt;that were outstanding at December 31, 2017 &lt;/font&gt;&lt;font style="display: inline;"&gt;were converted&lt;/font&gt;&lt;font style="display: inline;"&gt; into &lt;/font&gt;&lt;font style="display: inline;"&gt;3,120,000&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of our common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;At &lt;/font&gt;&lt;font style="display: inline;"&gt;March 31&lt;/font&gt;&lt;font style="display: inline;"&gt;, 201&lt;/font&gt;&lt;font style="display: inline;"&gt;8&lt;/font&gt;&lt;font style="display: inline;"&gt;, the Company had &lt;/font&gt;&lt;font style="display: inline;"&gt;6,900&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of Series B designated and &lt;/font&gt;&lt;font style="display: inline;"&gt;47&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;shares of Series B&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;issued&lt;/font&gt;&lt;font style="display: inline;"&gt; and outstanding&lt;/font&gt;&lt;font style="display: inline;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Series C Preferred Stock&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On November 6, 2017, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series&amp;nbsp;C Convertible Preferred Stock (&amp;#x201C;Series C Preferred Stock&amp;#x201D;) with the State of Delaware which designates &lt;/font&gt;&lt;font style="display: inline;"&gt;2,748&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of our preferred stock as Series&amp;nbsp;C Preferred Stock. The Series&amp;nbsp;C Preferred Stock has a stated value &lt;/font&gt;&lt;font style="display: inline;"&gt;of&amp;#x2009;&lt;/font&gt;&lt;font style="display: inline;"&gt;$1,000&lt;/font&gt;&lt;font style="display: inline;"&gt; per share and a par value &lt;/font&gt;&lt;font style="display: inline;"&gt;of&amp;#x2009;&lt;/font&gt;&lt;font style="display: inline;"&gt;$0.01&lt;/font&gt;&lt;font style="display: inline;"&gt; per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On November 2, 2017, the Company entered into a Placement Agency Agreement (the &amp;#x201C;Placement Agreement&amp;#x201D;) with Aegis Capital Corp. for the sale on a reasonable best efforts basis of &lt;/font&gt;&lt;font style="display: inline;"&gt;2,748&lt;/font&gt;&lt;font style="display: inline;"&gt; units, each consisting of one share of the Company&amp;#x2019;s Series C Preferred Stock, convertible into a number of shares of the Company&amp;#x2019;s common stock equal to &lt;/font&gt;&lt;font style="display: inline;"&gt;$1,000&lt;/font&gt;&lt;font style="display: inline;"&gt; divided by $1.40 and warrants to purchase up to &lt;/font&gt;&lt;font style="display: inline;"&gt;1,962,857&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of common stock with an exercise price of &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.63&lt;/font&gt;&lt;font style="display: inline;"&gt; per share (the &amp;#x201C;Series C Warrants&amp;#x201D;) at a combined offering price of &lt;/font&gt;&lt;font style="display: inline;"&gt;$1,000&lt;/font&gt;&lt;font style="display: inline;"&gt; per unit, in a registered direct offering (the &amp;#x201C;Series C Preferred Offering&amp;#x201D;). The Series C Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock). The securities comprising the units are immediately separable and were issued separately.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;The conversion price of the Series C Preferred Stock contains a down round feature. T&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;he &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2018 Purchase Agreement&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;triggered &lt;/font&gt;&lt;font style="display: inline;"&gt;the down round feature of the Series &lt;/font&gt;&lt;font style="display: inline;"&gt;C&lt;/font&gt;&lt;font style="display: inline;"&gt; Preferred Stock&lt;/font&gt;&lt;font style="display: inline;"&gt; and&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; as a result,&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; the conversion price of the Company&amp;#x2019;s Series B Convertible Preferred Stock was automatically adjusted from &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$1.40&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per share to &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;share.&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximatel&lt;/font&gt;&lt;font style="display: inline;"&gt;y &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;$0.8&lt;/font&gt;&lt;font style="display: inline;"&gt; million&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;which was recognized as a deemed dividend at time of the down round adjustment&lt;/font&gt;&lt;font style="display: inline;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;During the three months ended March 31, 2018, &lt;/font&gt;&lt;font style="display: inline;"&gt;2,548&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;shares of Series &lt;/font&gt;&lt;font style="display: inline;"&gt;C&lt;/font&gt;&lt;font style="display: inline;"&gt; Preferred Stock &lt;/font&gt;&lt;font style="display: inline;"&gt;that &lt;/font&gt;&lt;font style="display: inline;"&gt;were&lt;/font&gt;&lt;font style="display: inline;"&gt; outstanding at December 31, 2017 were&lt;/font&gt;&lt;font style="display: inline;"&gt; converted&lt;/font&gt;&lt;font style="display: inline;"&gt; into &lt;/font&gt;&lt;font style="display: inline;"&gt;3,345,334&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of our common stock.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;At &lt;/font&gt;&lt;font style="display: inline;"&gt;March &lt;/font&gt;&lt;font style="display: inline;"&gt;31, 201&lt;/font&gt;&lt;font style="display: inline;"&gt;8&lt;/font&gt;&lt;font style="display: inline;"&gt;, the Company had &lt;/font&gt;&lt;font style="display: inline;"&gt;2,748&lt;/font&gt;&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;"&gt;shares of Series C&lt;/font&gt;&lt;font style="display: inline;"&gt; designated &lt;/font&gt;&lt;font style="display: inline;"&gt;and &lt;/font&gt;&lt;font style="display: inline;"&gt;zero&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of Series C &lt;/font&gt;&lt;font style="display: inline;"&gt;issued&lt;/font&gt;&lt;font style="display: inline;"&gt; and outstanding.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Preferred Stock induced conversions &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;text-decoration:underline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;On March 21, 2018, the Company entered into a Letter Agreement (the &amp;#x201C;&lt;/font&gt;&lt;font style="display: inline;"&gt;2018 Inducement &lt;/font&gt;&lt;font style="display: inline;"&gt;Agreement&amp;#x201D;) with certain holders (the &amp;#x201C;Investors&amp;#x201D;) of shares of the Company&amp;#x2019;s Series B Preferred Stock and Series C &lt;/font&gt;&lt;font style="display: inline;"&gt;Preferred Stock (together the &amp;#x201C;Preferred Stock&amp;#x201D;), and warrants (the &amp;#x201C;Warrants&amp;#x201D;) to purchase shares of the Company&amp;#x2019;s common stock, par value $0.01 per share (&amp;#x201C;Common Stock&amp;#x201D;), issued in the Company&amp;#x2019;s public offering in August 2017 and registered direct offering in November 2017. Pursuant to the &lt;/font&gt;&lt;font style="display: inline;"&gt;2018 Inducement &lt;/font&gt;&lt;font style="display: inline;"&gt;Agreement, the Company and the Investors agreed that, as a result of the issuance of shares of Common Stock pursuant to that Purchase Agreement, dated February 8, 2018, by and between the Company and the investor named therein, and effective as of the time of execution of the &lt;/font&gt;&lt;font style="display: inline;"&gt;2018 Inducement &lt;/font&gt;&lt;font style="display: inline;"&gt;Agreement, the exercise price of the Warrants was reduced to $0.75 per share (the &amp;#x201C;Exercise Price Reduction&amp;#x201D;) and the conversion price of the Preferred Stock was reduced to &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.75&lt;/font&gt;&lt;font style="display: inline;"&gt; (the &amp;#x201C;Conversion Price Reduction&amp;#x201D;). As consideration for the Company&amp;#x2019;s agreement to the Exercise Price Reduction and the Conversion Price Reduction, (i) each Investor agreed to convert the shares of Preferred Stock held by such Investor into shares of Common Stock in increments of up to &lt;/font&gt;&lt;font style="display: inline;"&gt;4.99%&lt;/font&gt;&lt;font style="display: inline;"&gt; of the shares of Common Stock outstanding as of the date of the &lt;/font&gt;&lt;font style="display: inline;"&gt;2018 Inducement &lt;/font&gt;&lt;font style="display: inline;"&gt;Agreement &lt;/font&gt;&lt;font style="display: inline;"&gt;and (ii) one Investor agreed to exercise &lt;/font&gt;&lt;font style="display: inline;"&gt;666,666&lt;/font&gt;&lt;font style="display: inline;"&gt; Warrants and another Investor agreed to exercise &lt;/font&gt;&lt;font style="display: inline;"&gt;500,000&lt;/font&gt;&lt;font style="display: inline;"&gt; Warrants in increments of&lt;/font&gt;&lt;font style="display: inline;"&gt; up to 4.99% of the shares of Common Stock outstanding as of the date of the &lt;/font&gt;&lt;font style="display: inline;"&gt;2018 Inducement &lt;/font&gt;&lt;font style="display: inline;"&gt;Agreement, in each case in accordance with the beneficial ownership limitations set forth in the Company&amp;#x2019;s Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, the Company&amp;#x2019;s Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible &lt;/font&gt;&lt;font style="display: inline;"&gt;Preferred Stock and the Warrants. &lt;/font&gt;&lt;font style="display: inline;"&gt;As discussed above, as of March 31, 2018, all shares of Preferred Stock, except &lt;/font&gt;&lt;font style="display: inline;"&gt;47&lt;/font&gt;&lt;font style="display: inline;"&gt; shares of Series B Preferred Stock, have been converted to shares of our common stock and &lt;/font&gt;&lt;font style="display: inline;"&gt;300,000&lt;/font&gt;&lt;font style="display: inline;"&gt; Warrants had been exercised.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The 2018 Inducement Agreement represented an inducement by the Company to convert shares of the Preferred Stock. The conversion price of the Preferred Stock was reduced from &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;"&gt; per share to &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.75&lt;/font&gt;&lt;font style="display: inline;"&gt; per share and the exercise price of the Warrants was reduced from &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;"&gt; per share to &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.75&lt;/font&gt;&lt;font style="display: inline;"&gt; per share. The Company calculated the fair value of the additional securities and consideration to be approximately &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.2&lt;/font&gt;&lt;font style="display: inline;"&gt; million. This amount was recorded as a charge to additional paid-in-capital and as a deemed dividend resulting in &lt;/font&gt;&lt;font style="display: inline;"&gt;a reduction of income available to common shareholders in our basic earnings per share calculation.&lt;/font&gt;&lt;font style="display: inline;"&gt; The $1.2 million is comprised of two components: 1) &lt;/font&gt;&lt;font style="display: inline;"&gt;$1.1&lt;/font&gt;&lt;font style="display: inline;"&gt; million related to the fair value of the additional common shares issued upon conversion of the Preferred Stock due to the reduced conversion price and 2) &lt;/font&gt;&lt;font style="display: inline;"&gt;$0.1&lt;/font&gt;&lt;font style="display: inline;"&gt; million in incremental fair value of the Warrants resulting from the reduction of the exercise price.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Common Stock Warrants.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 7pt;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;The following represents a summary of the warrants outstanding as of March 31, 2018:&lt;/font&gt;
		&lt;/p&gt;
		&lt;div style="width:100%"&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:318.00pt;margin-left:2.5pt;"&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt"&gt;
						&lt;font style="display: inline;font-size:1pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:89.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt"&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="bottom" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Issue&amp;nbsp;Year&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 0pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:89.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;"&gt;Expiration&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Underlying&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Shares &lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt"&gt;
					&lt;p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Exercise&lt;/font&gt;&lt;/p&gt;
					&lt;p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-weight:bold;font-size:8pt;"&gt;Price&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="8" valign="bottom" style="width:318.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-style:italic;color:#000000;text-decoration:underline;"&gt;Warrants Assumed in Merger&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(1)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2014&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;April 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;12,487&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$120.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(2)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;February 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;23,826&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$67.20&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(3)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2015&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;December 2020&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;4,081&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$49.80&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(4)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2016&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;January 2021&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;8,952&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$36.30&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td colspan="8" valign="bottom" style="width:318.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;font-style:italic;color:#000000;text-decoration:underline;"&gt;Warrants&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(5)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;June 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;45,600&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$2.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(6)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;June 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;91,429&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$7.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(7)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;August 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;2,380,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$0.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(8)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;August 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;60,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$3.125&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(9)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;August 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;856,446&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$10.00&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(10)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;August 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;359,999&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$0.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #auto;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(11)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;October 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #auto;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;10,000&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$0.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(12)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2017&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;May 2023&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;1,962,857&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$0.75&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt"&gt;
						&lt;font style="display: inline;font-size:8pt;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;font style="display: inline;color:#000000;font-size:8pt;"&gt;(13)&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;2018&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;October 2022&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;108,112&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;color:#000000;"&gt;$7.50&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
			&lt;tr&gt;
				&lt;td valign="top" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt"&gt;
						&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:65.00pt;border-top:1pt solid #000000 ;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap"&gt;5,923,789&amp;nbsp;
				&lt;/td&gt;
				&lt;td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
				&lt;td valign="top" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt"&gt;
					&lt;p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;"&gt;
						&amp;nbsp;&lt;/p&gt;
				&lt;/td&gt;
			&lt;/tr&gt;
		&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (1)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with a private placement which was completed in October 2014.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (2)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with an offering which was completed in February 2015.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (3)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with an offering which was completed in July 2015.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (4)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with an offering which was completed in January 2016. Of the remaining outstanding warrants as of March 31, 2018, 5,368 warrants are recorded as a liability, See Note 9 &amp;#x2013; Fair Value for further discussion, and 3,584 are treated as equity.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (5)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the Merger and are the 2017 New Bridge Warrants.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"&gt; (6)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the Merger and are considered Side Warrants.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (7)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the August 2017 Offering and are the August 2017 Offering Warrants discussed below.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (8)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the August 2017 Offering and are considered Representative Warrants.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (9)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the conversion of our Series A Senior stock, at the time of the closing of the August 2017 Offering, and are the Series A Conversion Warrants discussed above.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (10)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the conversion of convertible bridge notes, at the time of the closing of the August 2017 Offering, and are the Note Conversion Warrants discussed below.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (11)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the waiver of default the Company received in the fourth quarter of 2017 in connection with the Convertible Promissory Notes and are the Convertible Promissory Note Warrants discussed below.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (12)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the Series C Preferred Offering and are the Series C Warrants discussed below.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;div style="width:100%"&gt;&lt;table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"&gt;&lt;tr&gt;&lt;td style="width:0pt;"&gt;&lt;p style="width:0pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td valign="top" align="left" style="width: 18.00pt;"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
				&lt;font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"&gt; (13)&lt;/font&gt;
			&lt;/p&gt;
		&lt;/td&gt;&lt;td style="width:18pt;"&gt;&lt;p style="width:18pt;width:18pt;font-size:0pt;"&gt;&lt;/p&gt;&lt;/td&gt;&lt;td align="left" valign="top"&gt;
			&lt;p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;"&gt;
			&lt;font style="display: inline;font-size:8pt;color:#000000;"&gt;These warrants were issued in connection with the Debt Obligation settlement agreements and are the Creditor Warrants discussed below.&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;Warrants Assumed in Merger&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;At the time of the Merger, Transgenomic had a number of outstanding warrants related to various financing transactions that occurred between 2013-2016. Details related to year issued, expiration date, amount of underlying common shares and exercise price are included in the table &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;above&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;During the three months ended March 31, 2018, &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;23,055&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; of the warrants assumed in the Merger expired and are no longer outstanding. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;August 2017 Offering Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In connection with the August 2017 Offering, the Company issued &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;2,680,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; warrants at an exercise price of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;, which contain a down round provision. As a result of the Series C Preferred Offering, the exercise price&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; of the August 2017 Offering Warrants was adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$1.40&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;During the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the August 2017 Offering Warrants was adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;.&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$62,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; and recorded this as a deemed dividend.&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;In addition, as a result of the 2018 Inducement Agreement, the exercise price of the August 2017 Offering Warrants was further adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$0.75&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; as a result of the Exercise Price Reduction discussed above.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;During the three months ended March 31, 2018, &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;300,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; of the August 2017 Offering Warrants were exercised for &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$0.75&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;Note Conversion Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;Upon the closing of the August 2017 Offering, the Company&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; issued&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;359,999&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;warrants to purchase the Company&amp;#x2019;s common stock (the &amp;#x201C;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Note Conversion Warrants&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;&amp;#x201D;)&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;. The Note Conversion Warrants have an exercise price of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per share and contain a down round provision. As a result of the Series C Preferred Offering, the exercise price&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; of the Note Conversion Warrants was adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$1.40&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; per share. &lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;During the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the Note Conversion Warrants was adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;.&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$8,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; and recorded this as a deemed dividend. In addition, as a result of the 2018 Inducement Agreement, the exercise price of the Note Conversion Warrants was further adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$0.75&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;.&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$5,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; and recorded this as a deemed dividend.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;Convertible Promissory Note Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;T&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;he Convertible Promissory Note Warrants ha&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;d &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;an&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; original&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; exercise price of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$3.00&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per share&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; and&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; contain a down round provision&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;. &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;As a result of the Series C Preferred Offering, the exercise price&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; of the Convertible Promissory Note Warrants was adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$1.40&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; per share.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;During the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the Convertible Promissory Note Warrants was adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;.&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;less than &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$1,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; and recorded this as a deemed dividend. In addition, as a result of the 2018 Inducement Agreement, the exercise price of the Convertible Promissory Note Warrants was further adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$0.75&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;.&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;less than &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$1,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; and recorded this as a deemed dividend.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;Series C Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In connection with the Series C Preferred Offering, the Company issued &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;1,962,857&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; warrants at an exercise price of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$1.63&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;, which contain a down round provision.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;During the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the Series C Warrants was adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$1.04&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;.&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$58,000&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; and recorded this as a deemed dividend. In addition, as a result of the 2018 Inducement Agreement, the exercise price of the Series C Warrants was further adjusted to &lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt;$0.75&lt;/font&gt;&lt;font style="display: inline;color:#000000;background-color: #FFFFFF;"&gt; as a result of the Exercise Price Reduction discussed above.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;Creditor &lt;/font&gt;&lt;font style="display: inline;color:#000000;text-decoration:underline;"&gt;Warrants&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;In the fourth quarter of 2017, the Company entered into Settlement Agreements with certain of its accounts payable and accrued liability vendors (the &amp;#x201C;Creditors&amp;#x201D;) pursuant to which the Company agreed to issue, to certain of its Creditors, &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;108,112&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; warrants to purchase &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;108,112&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; shares of the Company&amp;#x2019;s common stock at an exercise price of &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;$7.50&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; per share. The warrants &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;were issued in February 2018. See &lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;Note 4 &amp;#x2013;&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt; Long&lt;/font&gt;&lt;font style="display: inline;color:#000000;"&gt;-Term Debt.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:6pt 0pt 0pt;line-height:120%;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;color:#000000;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit1" decimals="INF">170711</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Duration_2_1_2018_To_2_28_2018_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember" unitRef="Unit1" decimals="0">1814754</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="Duration_2_8_2018_To_2_9_2018_us-gaap_SubsidiarySaleOfStockAxis_prpo_LevistonResourcesLlcMember" unitRef="Unit12" decimals="0">140000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:SubsequentEventsTextBlock contextRef="Duration_1_1_2018_To_3_31_2018">&lt;div&gt; &lt;div style="margin-left:0pt;margin-right:0pt;"&gt;
		&lt;p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;"&gt;1&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;2&lt;/font&gt;&lt;font style="display: inline;font-weight:bold;"&gt;.&amp;nbsp;&amp;nbsp;SUBSEQUENT EVENTS&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-weight:bold;font-style:italic;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;"&gt;Issuance of Convertible Notes&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-style:italic;text-decoration:underline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;background-color: #FFFFFF;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;font-size:10pt;"&gt;On April 20&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;, 2018, the Company entered into a securities purchase agreement with certain investors, pursuant to which the Company will issue up to approximately &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$3,296,703&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;8%&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; Senior Secured Convertible Promissory Notes with &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; common stock warrant&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; coverage&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;. The initial closing provided the Company with &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$1,660,000&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; of gross proceeds for the issuance of Notes with an aggregate principal of &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$1,809,400&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;.&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;&amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;The Note is payable by the Company on the earlier of (i) the &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt; year anniversary after the initial closing date or (ii) upon the closing of a qualified offering, namely the Company raising gross proceeds of at least &lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;$7,000,000&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;. &amp;nbsp;&lt;/font&gt;&lt;font style="display: inline;font-size:10pt;"&gt;The obligations under the Note are secured, subject to certain exceptions and other permitted payments by a perfected security interest on the assets of the Company.&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;background-color: #FFFFFF;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;nbsp;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt"&gt;
			&lt;font style="display: inline;"&gt;&amp;#xFEFF;&lt;/font&gt;
		&lt;/p&gt;
		&lt;p&gt;&lt;font size="1"&gt; &lt;/font&gt;&lt;/p&gt;
	&lt;/div&gt; &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="As_Of_12_31_2017_us-gaap_TypeOfArrangementAxis_prpo_SettlementAgreementsMember" unitRef="Unit12" decimals="-5">1900000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="As_Of_3_12_2018_us-gaap_LitigationCaseAxis_prpo_CredeMember" unitRef="Unit12" decimals="-5">400000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="As_Of_3_31_2018_us-gaap_DebtConversionByUniqueDescriptionAxis_prpo_WarrantsAfterConversionPriceReductionMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member" unitRef="Unit12" decimals="-5">100000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="As_Of_3_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_prpo_InducementAgreement2018Member" unitRef="Unit12" decimals="-5">1200000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2017_To_3_31_2017" unitRef="Unit1" decimals="0">449726</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Duration_1_1_2018_To_3_31_2018" unitRef="Unit1" decimals="0">12576037</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <!--Extensible List Section-->
  <!--Footnote Section-->
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>prpo-20180331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.18.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/21/2018 1:44:54 PM-->
<!--Modified on: 5/21/2018 1:44:54 PM-->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.precipiodx.com/20180331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:prpo="http://www.precipiodx.com/20180331">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" id="StatementUnauditedCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails" id="DisclosureLongTermDebtScheduleOfDebtDetails">
        <link:definition>40401 - Disclosure - LONG-TERM DEBT (Schedule of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesOtherCurrentLiabilitiesDetails" id="DisclosureOtherCurrentLiabilitiesOtherCurrentLiabilitiesDetails">
        <link:definition>40503 - Disclosure - OTHER CURRENT LIABILITIES (Other Current Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" id="DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails">
        <link:definition>41104 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails" id="DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails">
        <link:definition>41106 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails" id="DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails">
        <link:definition>41107 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivable" id="DisclosureNetSalesServiceRevenueAndAccountsReceivable">
        <link:definition>11101 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableTables" id="DisclosureNetSalesServiceRevenueAndAccountsReceivableTables">
        <link:definition>31103 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails" id="DisclosureBusinessDescriptionNarrativeDetails">
        <link:definition>40101 - Disclosure - BUSINESS DESCRIPTION (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesNotIncludedInComputationOfDilutedNetLossDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesNotIncludedInComputationOfDilutedNetLossDetails">
        <link:definition>40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities not Included in the Computation of Diluted Net Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureReverseMergerProFormaDisclosuresDetails" id="DisclosureReverseMergerProFormaDisclosuresDetails">
        <link:definition>40306 - Disclosure - REVERSE MERGER (Pro-forma Disclosures) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtDepartmentOfEconomicAndCommunityDevelopmentDetails" id="DisclosureLongTermDebtDepartmentOfEconomicAndCommunityDevelopmentDetails">
        <link:definition>40404 - Disclosure - LONG-TERM DEBT (Department of Economic and Community Development) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtSecuredDebtObligationsDetails" id="DisclosureLongTermDebtSecuredDebtObligationsDetails">
        <link:definition>40406 - Disclosure - LONG-TERM DEBT (Secured Debt Obligations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtFinancedInsuranceLoanDetails" id="DisclosureLongTermDebtFinancedInsuranceLoanDetails">
        <link:definition>40408 - Disclosure - LONG-TERM DEBT (Financed Insurance Loan ) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesNarrativeDetails" id="DisclosureOtherCurrentLiabilitiesNarrativeDetails">
        <link:definition>40501 - Disclosure - OTHER CURRENT LIABILITIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureContingenciesNarrativeDetails" id="DisclosureContingenciesNarrativeDetails">
        <link:definition>40601 - Disclosure - CONTINGENCIES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureIncomeTaxesNarrativeDetails" id="DisclosureIncomeTaxesNarrativeDetails">
        <link:definition>40701 - Disclosure - INCOME TAXES (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails" id="DisclosureStockholdersEquityCommonStockDetails">
        <link:definition>40801 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesAndSeriesBPreferredStockDetails" id="DisclosureStockholdersEquitySeriesAndSeriesBPreferredStockDetails">
        <link:definition>40802 - Disclosure - STOCKHOLDERS' EQUITY (Series A and Series B Preferred Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockInducedConversionsDetails" id="DisclosureStockholdersEquityPreferredStockInducedConversionsDetails">
        <link:definition>40804 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Induced Conversions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" id="DisclosureStockholdersEquitySeriesBPreferredStockDetails">
        <link:definition>40805 - Disclosure - STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCPreferredStockDetails" id="DisclosureStockholdersEquitySeriesCPreferredStockDetails">
        <link:definition>40806 - Disclosure - STOCKHOLDERS' EQUITY (Series C Preferred Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails" id="DisclosureStockholdersEquityCommonStockWarrantsDetails">
        <link:definition>40807 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityOfferingWarrantsDetails" id="DisclosureStockholdersEquityOfferingWarrantsDetails">
        <link:definition>40810 - Disclosure - STOCKHOLDERS' EQUITY (Offering Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityNoteConversionWarrantsDetails" id="DisclosureStockholdersEquityNoteConversionWarrantsDetails">
        <link:definition>40814 - Disclosure - STOCKHOLDERS' EQUITY (Note Conversion Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityConvertiblePromissoryNoteWarrantsDetails" id="DisclosureStockholdersEquityConvertiblePromissoryNoteWarrantsDetails">
        <link:definition>40815 - Disclosure - STOCKHOLDERS' EQUITY (Convertible Promissory Note Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCWarrantsDetails" id="DisclosureStockholdersEquitySeriesCWarrantsDetails">
        <link:definition>40816 - Disclosure - STOCKHOLDERS' EQUITY (Series C Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityCreditorWarrantsDetails" id="DisclosureStockholdersEquityCreditorWarrantsDetails">
        <link:definition>40817 - Disclosure - STOCKHOLDERS' EQUITY (Creditor Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails" id="DisclosureStockholdersEquityScheduleOfWarrantsDetails">
        <link:definition>40818 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails" id="DisclosureFairValueNarrativesDetails">
        <link:definition>40901 - Disclosure - FAIR VALUE (Narratives) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureFairValueScheduleOfChangesInFairValueOfLiabilityDetails" id="DisclosureFairValueScheduleOfChangesInFairValueOfLiabilityDetails">
        <link:definition>40902 - Disclosure - FAIR VALUE (Schedule of Changes in Fair Value of Liability) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails" id="DisclosureEquityIncentivePlanNarrativeDetails">
        <link:definition>41001 - Disclosure - EQUITY INCENTIVE PLAN (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" id="DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails">
        <link:definition>41001 - Disclosure - EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableNarrativeDetails" id="DisclosureNetSalesServiceRevenueAndAccountsReceivableNarrativeDetails">
        <link:definition>41101 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfNetRevenuesDetails" id="DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfNetRevenuesDetails">
        <link:definition>41103 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails" id="DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails">
        <link:definition>41105 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41201 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00050 - Document - DOCUMENT AND ENTITY INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureBusinessDescription" id="DisclosureBusinessDescription">
        <link:definition>10101 - Disclosure - BUSINESS DESCRIPTION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureReverseMerger" id="DisclosureReverseMerger">
        <link:definition>10301 - Disclosure - REVERSE MERGER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebt" id="DisclosureLongTermDebt">
        <link:definition>10401 - Disclosure - LONG-TERM DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilities" id="DisclosureOtherCurrentLiabilities">
        <link:definition>10501 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureContingencies" id="DisclosureContingencies">
        <link:definition>10601 - Disclosure - CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10701 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10801 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureFairValue" id="DisclosureFairValue">
        <link:definition>10901 - Disclosure - FAIR VALUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlan" id="DisclosureEquityIncentivePlan">
        <link:definition>11001 - Disclosure - EQUITY INCENTIVE PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11201 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicy">
        <link:definition>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureReverseMergerTables" id="DisclosureReverseMergerTables">
        <link:definition>30303 - Disclosure - REVERSE MERGER (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtTables" id="DisclosureLongTermDebtTables">
        <link:definition>30403 - Disclosure - LONG-TERM DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesTables" id="DisclosureOtherCurrentLiabilitiesTables">
        <link:definition>30503 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>30803 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureFairValueTables" id="DisclosureFairValueTables">
        <link:definition>30903 - Disclosure - FAIR VALUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables" id="DisclosureEquityIncentivePlanTables">
        <link:definition>31003 - Disclosure - EQUITY INCENTIVE PLAN (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockDetails" id="DisclosureStockholdersEquityPreferredStockDetails">
        <link:definition>40803 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prpo-20180331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prpo-20180331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prpo-20180331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prpo-20180331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="prpo_A2016WarrantLiabilityMember" name="A2016WarrantLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_AegisCapitalCorpMember" name="AegisCapitalCorpMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_CPAGlobalMember" name="CPAGlobalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" name="ClassofWarrantorRightUnitValueofWarrantsorRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="prpo_ConversionofStockPerShareConversionPrice" name="ConversionofStockPerShareConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <element id="prpo_DeemedDividend" name="DeemedDividend" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <xsd:element abstract="true" id="prpo_DepartmentofEconomicandCommunityDevelopmentMember" name="DepartmentofEconomicandCommunityDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_GainLossOnStockWarrantsRevaluation" name="GainLossOnStockWarrantsRevaluation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="prpo_InterestIncomeAndExpenseNet" name="InterestIncomeAndExpenseNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_MountSinaiMember" name="MountSinaiMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_OfferingWarrantsMember" name="OfferingWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_OtherIncomeExpense" name="OtherIncomeExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_PublicStockOfferingMember" name="PublicStockOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_TermLoanMember" name="TermLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_TotalGainsOrLossesAbstract" name="TotalGainsOrLossesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="prpo_TransgenomicsMember" name="TransgenomicsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="prpo_WorkingCapitalDeficiency" name="WorkingCapitalDeficiency" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="prpo_XIFINInc.Member" name="XIFINInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <element id="prpo_AccumulatedNetIncomeLoss" name="AccumulatedNetIncomeLoss" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_FinancedInsuranceLoanMember" name="FinancedInsuranceLoanMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_ConvertiblePromissoryNoteWarrantsMember" name="ConvertiblePromissoryNoteWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_CreditorWarrantsRelatingToSecuredDebtMember" name="CreditorWarrantsRelatingToSecuredDebtMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_ClassOfWarrantOrRightTerm" name="ClassOfWarrantOrRightTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_DebtRestructured" name="DebtRestructured" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_LiabilityForSettlementOfEquityInstrument" name="LiabilityForSettlementOfEquityInstrument" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_ObigationToIssueCommonShares" name="ObigationToIssueCommonShares" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_CredeMember" name="CredeMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_LiabilityForSettlementCommonSharesIssued" name="LiabilityForSettlementCommonSharesIssued" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_LiabilityForSettlementFairValueOfCommonSharesIssued" name="LiabilityForSettlementFairValueOfCommonSharesIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_LiabilityForSettlementPaymentPeriod" name="LiabilityForSettlementPaymentPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_LiabilityForSettlementOfCommonStockWarrantLiability" name="LiabilityForSettlementOfCommonStockWarrantLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_SeriesCWarrantsMember" name="SeriesCWarrantsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsAssumedInMergerMember" name="WarrantsAssumedInMergerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsAssumedInMergerExpiringApril2020Member" name="WarrantsAssumedInMergerExpiringApril2020Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member" name="WarrantsAssumedInMergerExpiringFebruary2020Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsAssumedInMergerExpiringDecember2020Member" name="WarrantsAssumedInMergerExpiringDecember2020Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" name="WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsNotAssumedInMergerMember" name="WarrantsNotAssumedInMergerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember" name="WarrantsNotAssumedInMergerExpiringJune2022GroupMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" name="WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" name="WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" name="WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" name="WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" name="WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member" name="WarrantsNotAssumedInMergerExpiringOctober2022Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member" name="WarrantsNotAssumedInMergerExpiringMay2023Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_RevenueNetOfAllowanceAndAdjustments" name="RevenueNetOfAllowanceAndAdjustments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" name="NetSalesServiceRevenueAndAccountsReceivableAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock" name="NetSalesServiceRevenueAndAccountsReceivableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_MedicaidMember" name="MedicaidMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_MedicareMember" name="MedicareMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_ContractDiagnosticServicesMember" name="ContractDiagnosticServicesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_OtherPartyMember" name="OtherPartyMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_EquityPurchaseAgreement" name="EquityPurchaseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_LevistonResourcesLlcMember" name="LevistonResourcesLlcMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_EquityPurchaseAgreementCommitmentFeePercentage" name="EquityPurchaseAgreementCommitmentFeePercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage" name="EquityPurchaseAgreementCommitmentFeeInstallmentPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_EquityPurchaseAgreementFee" name="EquityPurchaseAgreementFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_EquityPurchaseAgreementFeeContingentDiscount" name="EquityPurchaseAgreementFeeContingentDiscount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_CompanyStockPercentageOfMarketRate" name="CompanyStockPercentageOfMarketRate" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement" name="PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_PreferredStockInducedConversionsFirstInvestorMember" name="PreferredStockInducedConversionsFirstInvestorMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock" name="WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised" name="ClassOfWarrantOrRightWarrantsOrRightsExcercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_PreferredStockInducedConversionsSecondInvestorMember" name="PreferredStockInducedConversionsSecondInvestorMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_BioRadLaboratoriesMember" name="BioRadLaboratoriesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_CommonStockPurchaseFee" name="CommonStockPurchaseFee" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_EquityIncentivePlan2017Member" name="EquityIncentivePlan2017Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_BusinessCombinationStockExchangeRatio" name="BusinessCombinationStockExchangeRatio" nillable="true" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_SettlementAgreementsMember" name="SettlementAgreementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_PlacementAgreementMember" name="PlacementAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_StockNotIssuedShares" name="StockNotIssuedShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_SeniorSecuredConvertiblePromissoryNotesMember" name="SeniorSecuredConvertiblePromissoryNotesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_GrossProceedsFromGrantReceivedAndLoan" name="GrossProceedsFromGrantReceivedAndLoan" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsExercised" name="WarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsAfterConversionPriceReductionMember" name="WarrantsAfterConversionPriceReductionMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_PurchaseAgreement2018Member" name="PurchaseAgreement2018Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_InducementAgreement2018Member" name="InducementAgreement2018Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" name="WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsExpiredInPeriod" name="WarrantsExpiredInPeriod" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" name="ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_DiagnosticTestingMember" name="DiagnosticTestingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_BiomarkerTestingAndClinicalProjectServicesMember" name="BiomarkerTestingAndClinicalProjectServicesMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue" name="MaximumProceedsRaisedBeforeNotePayableBecomesDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_WarrantsCanceledInSettlementAgreement" name="WarrantsCanceledInSettlementAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_OtherSalesRevenueGross" name="OtherSalesRevenueGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_GrossRevenueIncludingOtherAdjustments" name="GrossRevenueIncludingOtherAdjustments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_ServicesRevenueNetMember" name="ServicesRevenueNetMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock" name="ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
  <element id="prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok" name="ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xmlns="http://www.w3.org/2001/XMLSchema" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>prpo-20180331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.18.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/21/2018 1:44:54 PM-->
<!--Modified on: 5/21/2018 1:44:54 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.precipiodx.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.precipiodx.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtScheduleOfDebtDetails" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureOtherCurrentLiabilitiesOtherCurrentLiabilitiesDetails" roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="us-gaap_Goodwill_636625070913010534" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_636625070913010534" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="us-gaap_OtherAssetsNoncurrent_636625070913010534" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636625070913010534" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="us-gaap_AssetsCurrent_636625070913010534" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636625070913010534" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636625070913010534" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636625070913010534" xlink:to="us-gaap_AccountsReceivableNetCurrent_636625070913010534" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636625070913010534" xlink:to="us-gaap_InventoryNet_636625070913010534" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_636625070913010534" xlink:to="us-gaap_OtherAssetsCurrent_636625070913010534" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="us-gaap_StockholdersEquity_636625070913010534" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636625070913010534" xlink:to="us-gaap_PreferredStockValue_636625070913010534" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636625070913010534" xlink:to="us-gaap_CommonStockValue_636625070913010534" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636625070913010534" xlink:to="us-gaap_AdditionalPaidInCapital_636625070913010534" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_636625070913010534" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636625070913010534" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="us-gaap_Liabilities_636625070913010534" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636625070913010534" xlink:to="us-gaap_LongTermDebtNoncurrent_636625070913010534" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636625070913010534" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_636625070913010534" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636625070913010534" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_636625070913010534" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636625070913010534" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636625070913010534" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636625070913010534" xlink:to="us-gaap_LiabilitiesCurrent_636625070913010534" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636625070913010534" xlink:to="us-gaap_LongTermDebtCurrent_636625070913010534" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636625070913010534" xlink:to="us-gaap_AccountsPayableCurrent_636625070913010534" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636625070913010534" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_636625070913010534" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636625070913010534" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636625070913010534" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636625070913010534" xlink:to="us-gaap_DeferredRevenueCurrent_636625070913010534" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_636625070913010534" xlink:to="us-gaap_OtherLiabilitiesCurrent_636625070913010534" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636625070913010534" xlink:to="us-gaap_DerivativeLiabilities_636625070913010534" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementOfCommonStockWarrantLiability" xlink:label="prpo_LiabilityForSettlementOfCommonStockWarrantLiability_636625070913010534" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_636625070913010534" xlink:to="prpo_LiabilityForSettlementOfCommonStockWarrantLiability_636625070913010534" order="7" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.precipiodx.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:to="us-gaap_NetIncomeLoss_636625070913088649" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636625070913088649" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636625070913088649" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_636625070913088649" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636625070913088649" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_636625070913088649" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments_636625070913088649" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_636625070913088649" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="us-gaap_OperatingExpenses_636625070913088649" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636625070913088649" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_636625070913088649" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_636625070913088649" xlink:to="us-gaap_GoodwillImpairmentLoss_636625070913088649" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="us-gaap_GrossProfit_636625070913088649" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_636625070913088649" xlink:to="us-gaap_Revenues_636625070913088649" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_RevenueNetOfAllowanceAndAdjustments" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_636625070913088649" xlink:to="prpo_RevenueNetOfAllowanceAndAdjustments_636625070913088649" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="prpo_RevenueNetOfAllowanceAndAdjustments_636625070913088649" xlink:to="us-gaap_SalesRevenueServicesNet_636625070913088649" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="us-gaap_OtherSalesRevenueNet_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="prpo_RevenueNetOfAllowanceAndAdjustments_636625070913088649" xlink:to="us-gaap_OtherSalesRevenueNet_636625070913088649" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="us-gaap_SalesAllowancesServices_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues_636625070913088649" xlink:to="us-gaap_SalesAllowancesServices_636625070913088649" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_636625070913088649" xlink:to="us-gaap_CostOfGoodsAndServicesSold_636625070913088649" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherIncomeExpense" xlink:label="loc_prpo_OtherIncomeExpense_bcfdb149-aff4-b569-caad-5ea1f55634dd" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InterestIncomeAndExpenseNet" xlink:label="prpo_InterestIncomeAndExpenseNet_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prpo_OtherIncomeExpense_bcfdb149-aff4-b569-caad-5ea1f55634dd" xlink:to="prpo_InterestIncomeAndExpenseNet_636625070913088649" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_GainLossOnStockWarrantsRevaluation" xlink:label="prpo_GainLossOnStockWarrantsRevaluation_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prpo_OtherIncomeExpense_bcfdb149-aff4-b569-caad-5ea1f55634dd" xlink:to="prpo_GainLossOnStockWarrantsRevaluation_636625070913088649" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prpo_OtherIncomeExpense_bcfdb149-aff4-b569-caad-5ea1f55634dd" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_636625070913088649" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnNonRecourseDebt" xlink:label="us-gaap_GainLossOnNonRecourseDebt_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prpo_OtherIncomeExpense_bcfdb149-aff4-b569-caad-5ea1f55634dd" xlink:to="us-gaap_GainLossOnNonRecourseDebt_636625070913088649" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.precipiodx.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_636625070913088649" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636625070913088649" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_636625070913088649" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636625070913088649" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636625070913088649" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636625070913088649" xlink:to="us-gaap_ProceedsFromWarrantExercises_636625070913088649" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636625070913088649" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_636625070913088649" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636625070913088649" xlink:to="us-gaap_RepaymentsOfNotesPayable_636625070913088649" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_636625070913088649" xlink:to="us-gaap_ProceedsFromConvertibleDebt_636625070913088649" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_636625070913088649" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_636625070913088649" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636625070913088649" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_GoodwillImpairmentLoss_636625070913088649" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_636625070913088649" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_IncomeLossFromContinuingOperations_636625070913088649" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_DepreciationDepletionAndAmortization_636625070913088649" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_636625070913088649" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_ShareBasedCompensation_636625070913088649" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_636625070913088649" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_636625070913088649" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_636625070913088649" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_IncreaseDecreaseInInventories_636625070913088649" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_636625070913088649" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_636625070913088649" order="12" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_636625070913088649" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913088649" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments_636625070913088649" order="14" use="optional" weight="-1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails" xlink:type="extended" xlink:title="40401 - Disclosure - LONG-TERM DEBT (Schedule of Debt) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_c63917e8-031d-3018-e68e-e4b72c6d04b8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_c63917e8-031d-3018-e68e-e4b72c6d04b8" xlink:to="us-gaap_LongTermDebtCurrent_636625070913088649" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations_c63917e8-031d-3018-e68e-e4b72c6d04b8" xlink:to="us-gaap_LongTermDebtNoncurrent_636625070913088649" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40503 - Disclosure - OTHER CURRENT LIABILITIES (Other Current Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementOfEquityInstrument" xlink:label="prpo_LiabilityForSettlementOfEquityInstrument_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="prpo_LiabilityForSettlementOfEquityInstrument_636625070913088649" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ObigationToIssueCommonShares" xlink:label="prpo_ObigationToIssueCommonShares_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="prpo_ObigationToIssueCommonShares_636625070913088649" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" xlink:type="extended" xlink:title="41104 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_GrossRevenueIncludingOtherAdjustments" xlink:label="prpo_GrossRevenueIncludingOtherAdjustments" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherSalesRevenueGross" xlink:label="prpo_OtherSalesRevenueGross_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="prpo_GrossRevenueIncludingOtherAdjustments" xlink:to="prpo_OtherSalesRevenueGross_636625070913088649" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsGross" xlink:label="us-gaap_SalesRevenueGoodsGross_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="prpo_GrossRevenueIncludingOtherAdjustments" xlink:to="us-gaap_SalesRevenueGoodsGross_636625070913088649" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails" xlink:type="extended" xlink:title="41106 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableGross_636625070913088649" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_636625070913088649" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails" xlink:type="extended" xlink:title="41107 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_636625070913088649" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="us-gaap_SalesAllowancesServices_636625070913088649" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="us-gaap_SalesAllowancesServices_636625070913088649" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>prpo-20180331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.18.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/21/2018 1:44:54 PM-->
<!--Modified on: 5/21/2018 1:44:54 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureBusinessDescriptionNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesNotIncludedInComputationOfDilutedNetLossDetails" roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesNotIncludedInComputationOfDilutedNetLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureReverseMergerProFormaDisclosuresDetails" roleURI="http://www.precipiodx.com/role/DisclosureReverseMergerProFormaDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtScheduleOfDebtDetails" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtDepartmentOfEconomicAndCommunityDevelopmentDetails" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtSecuredDebtObligationsDetails" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtSecuredDebtObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtFinancedInsuranceLoanDetails" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtFinancedInsuranceLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureOtherCurrentLiabilitiesNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureContingenciesNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityCommonStockDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityPreferredStockInducedConversionsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockInducedConversionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquitySeriesBPreferredStockDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquitySeriesCPreferredStockDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityOfferingWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityOfferingWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityNoteConversionWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityNoteConversionWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityConvertiblePromissoryNoteWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityConvertiblePromissoryNoteWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquitySeriesCWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityCreditorWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityCreditorWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityScheduleOfWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureFairValueNarrativesDetails" roleURI="http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureFairValueScheduleOfChangesInFairValueOfLiabilityDetails" roleURI="http://www.precipiodx.com/role/DisclosureFairValueScheduleOfChangesInFairValueOfLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureEquityIncentivePlanNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfNetRevenuesDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfNetRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.precipiodx.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilities" xlink:href="prpo-20180331.xsd#DisclosureOtherCurrentLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesTables" xlink:href="prpo-20180331.xsd#DisclosureOtherCurrentLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureBusinessDescription" xlink:href="prpo-20180331.xsd#DisclosureBusinessDescription" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheets" xlink:href="prpo-20180331.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="prpo-20180331.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureContingencies" xlink:href="prpo-20180331.xsd#DisclosureContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation" xlink:href="prpo-20180331.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureFairValue" xlink:href="prpo-20180331.xsd#DisclosureFairValue" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureFairValueTables" xlink:href="prpo-20180331.xsd#DisclosureFairValueTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureIncomeTaxes" xlink:href="prpo-20180331.xsd#DisclosureIncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebt" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebt" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtTables" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureReverseMerger" xlink:href="prpo-20180331.xsd#DisclosureReverseMerger" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureReverseMergerTables" xlink:href="prpo-20180331.xsd#DisclosureReverseMergerTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlan" xlink:href="prpo-20180331.xsd#DisclosureEquityIncentivePlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables" xlink:href="prpo-20180331.xsd#DisclosureEquityIncentivePlanTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquity" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockDetails" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityTables" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureSubsequentEvents" xlink:href="prpo-20180331.xsd#DisclosureSubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="prpo-20180331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" xlink:href="prpo-20180331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicy" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureBusinessDescription" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureFairValue" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureFairValueTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureIncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebt" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureReverseMerger" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureReverseMergerTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureEquityIncentivePlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureSubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" xlink:type="extended" />
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - BUSINESS DESCRIPTION (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636625070913088649" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636625070913088649" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LevistonResourcesLlcMember" xlink:label="prpo_LevistonResourcesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prpo_LevistonResourcesLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636625070913088649" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636625070913088649" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TransgenomicsMember" xlink:label="prpo_TransgenomicsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="prpo_TransgenomicsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636625070913088649" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_636625070913088649" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SecuritiesPurchaseAgreementMember" xlink:label="prpo_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_SecuritiesPurchaseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636625070913088649" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_636625070913088649" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain_636625070913088649" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain_636625070913088649" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CredeMember" xlink:label="prpo_CredeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="prpo_CredeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_636625070913088649" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_636625070913088649" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SeniorSecuredConvertiblePromissoryNotesMember" xlink:label="prpo_SeniorSecuredConvertiblePromissoryNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="prpo_SeniorSecuredConvertiblePromissoryNotesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_BusinessCombinationStockExchangeRatio" xlink:label="prpo_BusinessCombinationStockExchangeRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="prpo_BusinessCombinationStockExchangeRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_AccumulatedNetIncomeLoss" xlink:label="prpo_AccumulatedNetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="prpo_AccumulatedNetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WorkingCapitalDeficiency" xlink:label="prpo_WorkingCapitalDeficiency" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="prpo_WorkingCapitalDeficiency" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SecuredDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreement" xlink:label="prpo_EquityPurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="prpo_EquityPurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CompanyStockPercentageOfMarketRate" xlink:label="prpo_CompanyStockPercentageOfMarketRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="prpo_CompanyStockPercentageOfMarketRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636625070913166764" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_636625070913166764" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesNotIncludedInComputationOfDilutedNetLossDetails" xlink:type="extended" xlink:title="40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities not Included in the Computation of Diluted Net Loss) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636625070913166764" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636625070913166764" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureReverseMergerProFormaDisclosuresDetails" xlink:type="extended" xlink:title="40306 - Disclosure - REVERSE MERGER (Pro-forma Disclosures) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TransgenomicsMember" xlink:label="prpo_TransgenomicsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="prpo_TransgenomicsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails" xlink:type="extended" xlink:title="40401 - Disclosure - LONG-TERM DEBT (Schedule of Debt) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:label="prpo_DepartmentofEconomicandCommunityDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_DepartmentofEconomicandCommunityDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_FinancedInsuranceLoanMember" xlink:label="prpo_FinancedInsuranceLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_FinancedInsuranceLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtAndCapitalLeaseObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:type="extended" xlink:title="40404 - Disclosure - LONG-TERM DEBT (Department of Economic and Community Development) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TermLoanMember" xlink:label="prpo_TermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="prpo_TermLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:label="prpo_DepartmentofEconomicandCommunityDevelopmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_DepartmentofEconomicandCommunityDevelopmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_GrossProceedsFromGrantReceivedAndLoan" xlink:label="prpo_GrossProceedsFromGrantReceivedAndLoan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="prpo_GrossProceedsFromGrantReceivedAndLoan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtAndCapitalLeaseObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtSecuredDebtObligationsDetails" xlink:type="extended" xlink:title="40406 - Disclosure - LONG-TERM DEBT (Secured Debt Obligations) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SecuredDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636625070913166764" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636625070913166764" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CreditorWarrantsRelatingToSecuredDebtMember" xlink:label="prpo_CreditorWarrantsRelatingToSecuredDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_CreditorWarrantsRelatingToSecuredDebtMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636625070913166764" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636625070913166764" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SettlementAgreementsMember" xlink:label="prpo_SettlementAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="prpo_SettlementAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtAndCapitalLeaseObligations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="prpo_ClassOfWarrantOrRightTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DebtRestructured" xlink:label="prpo_DebtRestructured" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="prpo_DebtRestructured" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtFinancedInsuranceLoanDetails" xlink:type="extended" xlink:title="40408 - Disclosure - LONG-TERM DEBT (Financed Insurance Loan ) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_FinancedInsuranceLoanMember" xlink:label="prpo_FinancedInsuranceLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_FinancedInsuranceLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtAndCapitalLeaseObligations" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER CURRENT LIABILITIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070913244879" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070913244879" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="prpo_A2016WarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="prpo_A2016WarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_636625070913244879" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain_636625070913244879" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_SettledLitigationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CredeMember" xlink:label="prpo_CredeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="prpo_CredeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementCommonSharesIssued" xlink:label="prpo_LiabilityForSettlementCommonSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="prpo_LiabilityForSettlementCommonSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementFairValueOfCommonSharesIssued" xlink:label="prpo_LiabilityForSettlementFairValueOfCommonSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="prpo_LiabilityForSettlementFairValueOfCommonSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementPaymentPeriod" xlink:label="prpo_LiabilityForSettlementPaymentPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="prpo_LiabilityForSettlementPaymentPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="us-gaap_SettlementLiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SettlementLiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementOfCommonStockWarrantLiability" xlink:label="prpo_LiabilityForSettlementOfCommonStockWarrantLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="prpo_LiabilityForSettlementOfCommonStockWarrantLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyDamagesPaidValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:label="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="us-gaap_OtherNonrecurringIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonrecurringIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureContingenciesNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - CONTINGENCIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LitigationCaseAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MountSinaiMember" xlink:label="prpo_MountSinaiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="prpo_MountSinaiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_XIFINInc.Member" xlink:label="prpo_XIFINInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="prpo_XIFINInc.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CPAGlobalMember" xlink:label="prpo_CPAGlobalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="prpo_CPAGlobalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_BioRadLaboratoriesMember" xlink:label="prpo_BioRadLaboratoriesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="prpo_BioRadLaboratoriesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyDamagesSoughtValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_SecuredDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="prpo_ClassOfWarrantOrRightTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails" xlink:type="extended" xlink:title="40801 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636625070913322994" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_636625070913322994" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_636625070913322994" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_636625070913322994" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_BridgeLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LevistonResourcesLlcMember" xlink:label="prpo_LevistonResourcesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="prpo_LevistonResourcesLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="prpo_ConversionofStockPerShareConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ConversionofStockPerShareConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_StockNotIssuedShares" xlink:label="prpo_StockNotIssuedShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_StockNotIssuedShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockInducedConversionsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Induced Conversions) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prpo_InducementAgreement2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_636625070913322994" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain_636625070913322994" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAfterConversionPriceReductionMember" xlink:label="prpo_WarrantsAfterConversionPriceReductionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="prpo_WarrantsAfterConversionPriceReductionMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="prpo_ConversionofStockPerShareConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ConversionofStockPerShareConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_StockNotIssuedShares" xlink:label="prpo_StockNotIssuedShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_StockNotIssuedShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_DeemedDividend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsExercised" xlink:label="prpo_WarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_WarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" xlink:type="extended" xlink:title="40805 - Disclosure - STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PublicStockOfferingMember" xlink:label="prpo_PublicStockOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prpo_PublicStockOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prpo_PurchaseAgreement2018Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prpo_InducementAgreement2018Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OfferingWarrantsMember" xlink:label="prpo_OfferingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_OfferingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_636625070913479224" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_636625070913479224" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_AegisCapitalCorpMember" xlink:label="prpo_AegisCapitalCorpMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="prpo_AegisCapitalCorpMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="prpo_ConversionofStockPerShareConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ConversionofStockPerShareConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" xlink:label="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCPreferredStockDetails" xlink:type="extended" xlink:title="40806 - Disclosure - STOCKHOLDERS' EQUITY (Series C Preferred Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PublicStockOfferingMember" xlink:label="prpo_PublicStockOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prpo_PublicStockOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PlacementAgreementMember" xlink:label="prpo_PlacementAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prpo_PlacementAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prpo_PurchaseAgreement2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OfferingWarrantsMember" xlink:label="prpo_OfferingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_OfferingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="prpo_ConversionofStockPerShareConversionPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ConversionofStockPerShareConversionPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" xlink:label="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityOfferingWarrantsDetails" xlink:type="extended" xlink:title="40810 - Disclosure - STOCKHOLDERS' EQUITY (Offering Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OfferingWarrantsMember" xlink:label="prpo_OfferingWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_OfferingWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ClassOfWarrantOrRightTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_DeemedDividend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsExercised" xlink:label="prpo_WarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_WarrantsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityNoteConversionWarrantsDetails" xlink:type="extended" xlink:title="40814 - Disclosure - STOCKHOLDERS' EQUITY (Note Conversion Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_BridgeLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_InducementAgreement2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_PurchaseAgreement2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ClassOfWarrantOrRightTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_DeemedDividend" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityConvertiblePromissoryNoteWarrantsDetails" xlink:type="extended" xlink:title="40815 - Disclosure - STOCKHOLDERS' EQUITY (Convertible Promissory Note Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_InducementAgreement2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_PurchaseAgreement2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConvertiblePromissoryNoteWarrantsMember" xlink:label="prpo_ConvertiblePromissoryNoteWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_ConvertiblePromissoryNoteWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ClassOfWarrantOrRightTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_DeemedDividend" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCWarrantsDetails" xlink:type="extended" xlink:title="40816 - Disclosure - STOCKHOLDERS' EQUITY (Series C Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_InducementAgreement2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_PurchaseAgreement2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SeriesCWarrantsMember" xlink:label="prpo_SeriesCWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_SeriesCWarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_ClassOfWarrantOrRightTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="prpo_DeemedDividend" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityCreditorWarrantsDetails" xlink:type="extended" xlink:title="40817 - Disclosure - STOCKHOLDERS' EQUITY (Creditor Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CreditorWarrantsRelatingToSecuredDebtMember" xlink:label="prpo_CreditorWarrantsRelatingToSecuredDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_CreditorWarrantsRelatingToSecuredDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails" xlink:type="extended" xlink:title="40818 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerMember" xlink:label="prpo_WarrantsAssumedInMergerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_WarrantsAssumedInMergerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringApril2020Member" xlink:label="prpo_WarrantsAssumedInMergerExpiringApril2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="prpo_WarrantsAssumedInMergerMember" xlink:to="prpo_WarrantsAssumedInMergerExpiringApril2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringFebruary2020Member" xlink:label="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="prpo_WarrantsAssumedInMergerMember" xlink:to="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringDecember2020Member" xlink:label="prpo_WarrantsAssumedInMergerExpiringDecember2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="prpo_WarrantsAssumedInMergerMember" xlink:to="prpo_WarrantsAssumedInMergerExpiringDecember2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" xlink:label="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="prpo_WarrantsAssumedInMergerMember" xlink:to="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerMember" xlink:label="prpo_WarrantsNotAssumedInMergerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_WarrantsNotAssumedInMergerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="prpo_WarrantsNotAssumedInMergerMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="prpo_WarrantsNotAssumedInMergerMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="prpo_WarrantsNotAssumedInMergerMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="prpo_WarrantsNotAssumedInMergerMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="prpo_WarrantsNotAssumedInMergerMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="prpo_WarrantsNotAssumedInMergerMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="prpo_WarrantsNotAssumedInMergerMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringMay2023Member" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="prpo_WarrantsNotAssumedInMergerMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="prpo_WarrantsNotAssumedInMergerMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - FAIR VALUE (Narratives) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="prpo_A2016WarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="prpo_A2016WarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:label="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsCanceledInSettlementAgreement" xlink:label="prpo_WarrantsCanceledInSettlementAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="prpo_WarrantsCanceledInSettlementAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureFairValueScheduleOfChangesInFairValueOfLiabilityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - FAIR VALUE (Schedule of Changes in Fair Value of Liability) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="prpo_A2016WarrantLiabilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="prpo_A2016WarrantLiabilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TotalGainsOrLossesAbstract" xlink:label="prpo_TotalGainsOrLossesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="prpo_TotalGainsOrLossesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="prpo_TotalGainsOrLossesAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="prpo_TotalGainsOrLossesAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - EQUITY INCENTIVE PLAN (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636625070913635454" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_636625070913635454" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityIncentivePlan2017Member" xlink:label="prpo_EquityIncentivePlan2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="prpo_EquityIncentivePlan2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636625070913635454" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636625070913635454" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" xlink:label="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="41001 - Disclosure - EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfNetRevenuesDetails" xlink:type="extended" xlink:title="41103 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070913635454" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070913635454" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_MedicaidMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_MedicareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ContractDiagnosticServicesMember" xlink:label="prpo_ContractDiagnosticServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_ContractDiagnosticServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_636625070913635454" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain_636625070913635454" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DiagnosticTestingMember" xlink:label="prpo_DiagnosticTestingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="prpo_DiagnosticTestingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_BiomarkerTestingAndClinicalProjectServicesMember" xlink:label="prpo_BiomarkerTestingAndClinicalProjectServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="prpo_BiomarkerTestingAndClinicalProjectServicesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_SalesRevenueServicesNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" xlink:type="extended" xlink:title="41104 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_MedicaidMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_MedicareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ContractDiagnosticServicesMember" xlink:label="prpo_ContractDiagnosticServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_ContractDiagnosticServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherPartyMember" xlink:label="prpo_OtherPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_OtherPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsGross" xlink:label="us-gaap_SalesRevenueGoodsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_SalesRevenueGoodsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherSalesRevenueGross" xlink:label="prpo_OtherSalesRevenueGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="prpo_OtherSalesRevenueGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_GrossRevenueIncludingOtherAdjustments" xlink:label="prpo_GrossRevenueIncludingOtherAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="prpo_GrossRevenueIncludingOtherAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="us-gaap_SalesDiscountsReturnsAndAllowancesGoods" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_SalesDiscountsReturnsAndAllowancesGoods" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_SalesRevenueServicesNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="us-gaap_OtherSalesRevenueNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_OtherSalesRevenueNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_RevenueNetOfAllowanceAndAdjustments" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="prpo_RevenueNetOfAllowanceAndAdjustments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails" xlink:type="extended" xlink:title="41105 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_MedicaidMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_MedicareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ContractDiagnosticServicesMember" xlink:label="prpo_ContractDiagnosticServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_ContractDiagnosticServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ServicesRevenueNetMember" xlink:label="prpo_ServicesRevenueNetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_ServicesRevenueNetMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherPartyMember" xlink:label="prpo_OtherPartyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_OtherPartyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_RevenueNetOfAllowanceAndAdjustments" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="prpo_RevenueNetOfAllowanceAndAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="us-gaap_SalesAllowancesServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_SalesAllowancesServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails" xlink:type="extended" xlink:title="41106 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_MedicaidMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_MedicareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ContractDiagnosticServicesMember" xlink:label="prpo_ContractDiagnosticServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_ContractDiagnosticServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails" xlink:type="extended" xlink:title="41107 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_MedicaidMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="prpo_MedicareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_SelfPayMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_ThirdPartyPayorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="us-gaap_SalesAllowancesServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesAllowancesServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.precipiodx.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SeniorSecuredConvertiblePromissoryNotesMember" xlink:label="prpo_SeniorSecuredConvertiblePromissoryNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="prpo_SeniorSecuredConvertiblePromissoryNotesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SecuritiesPurchaseAgreementMember" xlink:label="prpo_SecuritiesPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="prpo_SecuritiesPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PreferredStockInducedConversionsSecondInvestorMember" xlink:label="prpo_PreferredStockInducedConversionsSecondInvestorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_PreferredStockInducedConversionsSecondInvestorMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PreferredStockInducedConversionsFirstInvestorMember" xlink:label="prpo_PreferredStockInducedConversionsFirstInvestorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="prpo_PreferredStockInducedConversionsFirstInvestorMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LevistonResourcesLlcMember" xlink:label="prpo_LevistonResourcesLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="prpo_LevistonResourcesLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_636625070913713569" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_636625070913713569" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue" xlink:label="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_ClassOfWarrantOrRightTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SecuredDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" xlink:label="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreement" xlink:label="prpo_EquityPurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_EquityPurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementCommitmentFeePercentage" xlink:label="prpo_EquityPurchaseAgreementCommitmentFeePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_EquityPurchaseAgreementCommitmentFeePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage" xlink:label="prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementFee" xlink:label="prpo_EquityPurchaseAgreementFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_EquityPurchaseAgreementFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementFeeContingentDiscount" xlink:label="prpo_EquityPurchaseAgreementFeeContingentDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_EquityPurchaseAgreementFeeContingentDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CompanyStockPercentageOfMarketRate" xlink:label="prpo_CompanyStockPercentageOfMarketRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_CompanyStockPercentageOfMarketRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement" xlink:label="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised" xlink:label="prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock" xlink:label="prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CommonStockPurchaseFee" xlink:label="prpo_CommonStockPurchaseFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="prpo_CommonStockPurchaseFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>prpo-20180331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.18.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/21/2018 1:44:54 PM-->
<!--Modified on: 5/21/2018 1:44:54 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DocumentAndEntityInformationAbstract" xlink:label="prpo_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_DocumentAndEntityInformationAbstract" xlink:to="prpo_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Financial Position [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY AND EQUIPMENT, NET</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Net (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangibles, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current maturities of long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Lease Obligations, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current maturities of capital leases</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred revenue</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current, Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, less current maturities and discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term debt, net of current maturities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant liability</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementOfCommonStockWarrantLiability" xlink:label="prpo_LiabilityForSettlementOfCommonStockWarrantLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_LiabilityForSettlementOfCommonStockWarrantLiability" xlink:to="prpo_LiabilityForSettlementOfCommonStockWarrantLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_LiabilityForSettlementOfCommonStockWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability For Settlement Of Common Stock Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_LiabilityForSettlementOfCommonStockWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability For Settlement Of Common Stock Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_LiabilityForSettlementOfCommonStockWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Lease Obligations, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital leases, less current maturities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock - $0.01 par value, 15,000,000 shares authorized at March 31, 2018 and December 31, 2017, respectively, 47 and 4,935 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock issued, value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.01 par value, 150,000,000 and 150,000,000 shares authorized at March 31, 2018 and December 31, 2017, respectively, 19,668,572 and 10,196,620 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueServicesNet" xlink:to="us-gaap_SalesRevenueServicesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueServicesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Revenue, Services, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueServicesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service revenue, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueServicesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues, net of contractual allowances and adjustments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="us-gaap_OtherSalesRevenueNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSalesRevenueNet" xlink:to="us-gaap_OtherSalesRevenueNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSalesRevenueNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Revenue, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherSalesRevenueNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherSalesRevenueNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other, net</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_RevenueNetOfAllowanceAndAdjustments" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_RevenueNetOfAllowanceAndAdjustments" xlink:to="prpo_RevenueNetOfAllowanceAndAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue net of allowance and adjustments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Net of Allowance And Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, net of contractual allowances and adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue, net of contractual allowances and adjustments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="us-gaap_SalesAllowancesServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAllowancesServices" xlink:to="us-gaap_SalesAllowancesServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesAllowancesServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Allowances, Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SalesAllowancesServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowances for dubtful accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_SalesAllowancesServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">less allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING EXPENSES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill, Impairment Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of goodwill</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL OPERATING EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER INCOME (EXPENSE):</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InterestIncomeAndExpenseNet" xlink:label="prpo_InterestIncomeAndExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_InterestIncomeAndExpenseNet" xlink:to="prpo_InterestIncomeAndExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_InterestIncomeAndExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income and (expense), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_InterestIncomeAndExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income and (expense), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_InterestIncomeAndExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense, net</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_GainLossOnStockWarrantsRevaluation" xlink:label="prpo_GainLossOnStockWarrantsRevaluation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_GainLossOnStockWarrantsRevaluation" xlink:to="prpo_GainLossOnStockWarrantsRevaluation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_GainLossOnStockWarrantsRevaluation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase"></label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_GainLossOnStockWarrantsRevaluation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) On Stock Warrants Revaluation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_GainLossOnStockWarrantsRevaluation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant revaluation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) Related to Litigation Settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on settlement of liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain on settlement liability, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (loss) on settlement of equity instrments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnNonRecourseDebt" xlink:label="us-gaap_GainLossOnNonRecourseDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnNonRecourseDebt" xlink:to="us-gaap_GainLossOnNonRecourseDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnNonRecourseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Non-Recourse Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnNonRecourseDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on settlement of equity instrument</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherIncomeExpense" xlink:label="prpo_OtherIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_OtherIncomeExpense" xlink:to="prpo_OtherIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_OtherIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_OtherIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="prpo_OtherIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LOSS BEFORE INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAX EXPENSE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Preferred Stock Dividends and Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">DEEMED DIVIDENDS ON ISSUANCE OR EXCHANGE OF PREFERRED UNITS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Dividends and Other Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL DIVIDENDS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS USED IN OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash flows used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of deferred financing costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfEquityInvestments" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Sale of Equity Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on settlement of equity instrument</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation and change in liability of stock appreciation rights</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for losses on doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant revaluation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS PROVIDED BY INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Long-term Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal payments on capital lease obligations</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from convertible bridge notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal payments on long-term debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flows provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET CHANGE IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUPPLEMENTAL CASH FLOW INFORMATION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid during the period for interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred unit dividend financed through exchange agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares converted, value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of equipment financed through accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred debt issuance cost financed through accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities canceled in exchange for common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt converted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Original Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability canceled due to settlement of equity instruments</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BUSINESS DESCRIPTION [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Description and Basis of Presentation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BUSINESS DESCRIPTION</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REVERSE MERGER [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Combination Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">REVERSE MERGER</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LONG-TERM DEBT [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LONG-TERM DEBT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER CURRENT LIABILITIES [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONTINGENCIES [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FAIR VALUE</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EQUITY INCENTIVE PLAN [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EQUITY INCENTIVE PLAN</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:to="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sales Service Revenue and Accounts Receivable [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sales Service Revenue and Accounts Receivable [Abstract]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock" xlink:to="prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sales Service Revenue and Accounts Receivable [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sales Service Revenue and Accounts Receivable [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Sales Service Revenue and Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Securities not Included in the Computation of Diluted Net Loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Pro Forma Information [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Pro Forma Information</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stockholders' equity, including warrants and rights</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Changes in Fair Value of Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Net Revenues</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:label="prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:to="prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Gross to Net Sales Adjustments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Gross to Net Sales Adjustments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Gross to Net Sales Adjustments</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok" xlink:label="prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok" xlink:to="prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Reported Revenues Net of Collection Allowance [Table Text Blcok]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Reported Revenues Net of Collection Allowance [Table Text Blcok]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Reported Revenues Net of Collection Allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Receivables</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock" xlink:label="prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock" xlink:to="prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Allowance for Doubtful Accounts [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Allowance for Doubtful Accounts [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Allowance for Doubtful Accounts</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Business Acquisitions, by Acquisition [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LevistonResourcesLlcMember" xlink:label="prpo_LevistonResourcesLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_LevistonResourcesLlcMember" xlink:to="prpo_LevistonResourcesLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_LevistonResourcesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leviston Resources LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_LevistonResourcesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leviston Resources Llc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_LevistonResourcesLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leviston Resources LLC [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TransgenomicsMember" xlink:label="prpo_TransgenomicsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_TransgenomicsMember" xlink:to="prpo_TransgenomicsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_TransgenomicsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transgenomics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_TransgenomicsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transgenomics [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_TransgenomicsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transgenomics</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SecuritiesPurchaseAgreementMember" xlink:label="prpo_SecuritiesPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_SecuritiesPurchaseAgreementMember" xlink:to="prpo_SecuritiesPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationCaseAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="us-gaap_LitigationCaseTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationCaseTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationCaseTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Case [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CredeMember" xlink:label="prpo_CredeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_CredeMember" xlink:to="prpo_CredeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_CredeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Crede [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_CredeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Crede [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_CredeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Crede [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Effective Date of Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger transaction, effective date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Date of Acquisition Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger transaction, agrement date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Name of Acquired Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger transaction, name of acquired entity</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_BusinessCombinationStockExchangeRatio" xlink:label="prpo_BusinessCombinationStockExchangeRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_BusinessCombinationStockExchangeRatio" xlink:to="prpo_BusinessCombinationStockExchangeRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_BusinessCombinationStockExchangeRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination stock exchange ratio.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_BusinessCombinationStockExchangeRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combination stock exchange ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_BusinessCombinationStockExchangeRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Merger transaction, pre-reverse stock split exchange ratio</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_AccumulatedNetIncomeLoss" xlink:label="prpo_AccumulatedNetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_AccumulatedNetIncomeLoss" xlink:to="prpo_AccumulatedNetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_AccumulatedNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_AccumulatedNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Net Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WorkingCapitalDeficiency" xlink:label="prpo_WorkingCapitalDeficiency" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WorkingCapitalDeficiency" xlink:to="prpo_WorkingCapitalDeficiency_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WorkingCapitalDeficiency_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working Capital (Deficiency)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WorkingCapitalDeficiency_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working Capital (Deficiency)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="prpo_WorkingCapitalDeficiency_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working deficiency</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument, term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Settlement, Amount Awarded to Other Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation settlement in favor of other party, amount</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreement" xlink:label="prpo_EquityPurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_EquityPurchaseAgreement" xlink:to="prpo_EquityPurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_EquityPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_EquityPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_EquityPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity purchase agreement</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CompanyStockPercentageOfMarketRate" xlink:label="prpo_CompanyStockPercentageOfMarketRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_CompanyStockPercentageOfMarketRate" xlink:to="prpo_CompanyStockPercentageOfMarketRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_CompanyStockPercentageOfMarketRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company stock percentage of market rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_CompanyStockPercentageOfMarketRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company Stock Percentage Of Market Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_CompanyStockPercentageOfMarketRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company stock percentage of market rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument, face amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrant coverage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense for intangible assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense, next twelve months</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense, 2019</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense, 2020</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense, 2021</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization expense, 2022</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options, unvested options, vesting period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Option</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities not included in the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Pro Forma Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net sales</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Pro Forma Net Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss available to common stockholders</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:to="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Acquisition, Pro Forma Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per common share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Longterm Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secured Debt [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:label="prpo_DepartmentofEconomicandCommunityDevelopmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:to="prpo_DepartmentofEconomicandCommunityDevelopmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_DepartmentofEconomicandCommunityDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Department of Economic and Community Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_DepartmentofEconomicandCommunityDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Departmentof Economicand Community Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_DepartmentofEconomicandCommunityDevelopmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Department of Economic and Community Development (DECD)</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_FinancedInsuranceLoanMember" xlink:label="prpo_FinancedInsuranceLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_FinancedInsuranceLoanMember" xlink:to="prpo_FinancedInsuranceLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_FinancedInsuranceLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financed Insurance Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_FinancedInsuranceLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financed Insurance Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_FinancedInsuranceLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financed Insurance Loan [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtAndCapitalLeaseObligations" xlink:to="us-gaap_DebtAndCapitalLeaseObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt and Capital Lease Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Noncurrent, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance cost</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TermLoanMember" xlink:label="prpo_TermLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_TermLoanMember" xlink:to="prpo_TermLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_TermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_TermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_TermLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term loan</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_GrossProceedsFromGrantReceivedAndLoan" xlink:label="prpo_GrossProceedsFromGrantReceivedAndLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_GrossProceedsFromGrantReceivedAndLoan" xlink:to="prpo_GrossProceedsFromGrantReceivedAndLoan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_GrossProceedsFromGrantReceivedAndLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from grant received and loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_GrossProceedsFromGrantReceivedAndLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from grant received and loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_GrossProceedsFromGrantReceivedAndLoan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from grant received and loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from grant</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt instrument, maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt issuance costs, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of debt issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SettlementAgreementsMember" xlink:label="prpo_SettlementAgreementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_SettlementAgreementsMember" xlink:to="prpo_SettlementAgreementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_SettlementAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_SettlementAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_SettlementAgreementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Warrant Or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CreditorWarrantsRelatingToSecuredDebtMember" xlink:label="prpo_CreditorWarrantsRelatingToSecuredDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_CreditorWarrantsRelatingToSecuredDebtMember" xlink:to="prpo_CreditorWarrantsRelatingToSecuredDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_CreditorWarrantsRelatingToSecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Creditor Warrants Relating to Secured Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_CreditorWarrantsRelatingToSecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Creditor Warrants Relating To Secured Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_CreditorWarrantsRelatingToSecuredDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Creditor Warrants Relating to Secured Debt [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underlying shares (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant, number of securities called by warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, exercise price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and rights outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Date of First Required Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Date of first required payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extinguishment of Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extinguishment of debt, amount</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ClassOfWarrantOrRightTerm" xlink:to="prpo_ClassOfWarrantOrRightTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ClassOfWarrantOrRightTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ClassOfWarrantOrRightTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_ClassOfWarrantOrRightTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of warrant or right, term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Periodic Payment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DebtRestructured" xlink:label="prpo_DebtRestructured" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_DebtRestructured" xlink:to="prpo_DebtRestructured_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_DebtRestructured_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Restructured</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_DebtRestructured_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Restructured</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value by Liability Class [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="prpo_A2016WarrantLiabilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_A2016WarrantLiabilityMember" xlink:to="prpo_A2016WarrantLiabilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_A2016WarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_A2016WarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">A2016 Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_A2016WarrantLiabilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2016 Warrant Liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Status [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Litigation Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettledLitigationMember" xlink:to="us-gaap_SettledLitigationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettledLitigationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settled Litigation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SettledLitigationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settled Litigation [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementCommonSharesIssued" xlink:label="prpo_LiabilityForSettlementCommonSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_LiabilityForSettlementCommonSharesIssued" xlink:to="prpo_LiabilityForSettlementCommonSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_LiabilityForSettlementCommonSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability For Settlement Common Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_LiabilityForSettlementCommonSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability For Settlement Common Shares Issued</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementFairValueOfCommonSharesIssued" xlink:label="prpo_LiabilityForSettlementFairValueOfCommonSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_LiabilityForSettlementFairValueOfCommonSharesIssued" xlink:to="prpo_LiabilityForSettlementFairValueOfCommonSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_LiabilityForSettlementFairValueOfCommonSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability For Settlement Fair Value Of Common Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_LiabilityForSettlementFairValueOfCommonSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability For Settlement Fair Value Of Common Shares Issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Damages Sought, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss contingency, damages sought</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementPaymentPeriod" xlink:label="prpo_LiabilityForSettlementPaymentPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_LiabilityForSettlementPaymentPeriod" xlink:to="prpo_LiabilityForSettlementPaymentPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_LiabilityForSettlementPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability For Settlement Payment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_LiabilityForSettlementPaymentPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability For Settlement Payment Period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="us-gaap_SettlementLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementLiabilitiesCurrent" xlink:to="us-gaap_SettlementLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SettlementLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement liablity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, fair value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesPaidValue" xlink:to="us-gaap_LossContingencyDamagesPaidValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Damages Paid, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyDamagesPaidValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Damages paid</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Accrued Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:label="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:to="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency Accrual, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) in warrant liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="us-gaap_OtherNonrecurringIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonrecurringIncome" xlink:to="us-gaap_OtherNonrecurringIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonrecurringIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonrecurring Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonrecurringIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain in warrant revaluation</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ObigationToIssueCommonShares" xlink:label="prpo_ObigationToIssueCommonShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ObigationToIssueCommonShares" xlink:to="prpo_ObigationToIssueCommonShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ObigationToIssueCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obigation To Issue Common Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ObigationToIssueCommonShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Obigation To Issue Common Shares</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementOfEquityInstrument" xlink:label="prpo_LiabilityForSettlementOfEquityInstrument" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_LiabilityForSettlementOfEquityInstrument" xlink:to="prpo_LiabilityForSettlementOfEquityInstrument_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_LiabilityForSettlementOfEquityInstrument_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability For Settlement Of Equity Instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_LiabilityForSettlementOfEquityInstrument_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liability For Settlement Of Equity Instrument</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Table]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MountSinaiMember" xlink:label="prpo_MountSinaiMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_MountSinaiMember" xlink:to="prpo_MountSinaiMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_MountSinaiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mount Sinai [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_MountSinaiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mount Sinai [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_MountSinaiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mount Sinai</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_XIFINInc.Member" xlink:label="prpo_XIFINInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_XIFINInc.Member" xlink:to="prpo_XIFINInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_XIFINInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">XIFIN, Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_XIFINInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">X I F I N Inc. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_XIFINInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">XIFIN, Inc.</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CPAGlobalMember" xlink:label="prpo_CPAGlobalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_CPAGlobalMember" xlink:to="prpo_CPAGlobalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_CPAGlobalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CPA Global [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_CPAGlobalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">C P A Global [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_CPAGlobalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CPA Global</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_BioRadLaboratoriesMember" xlink:label="prpo_BioRadLaboratoriesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_BioRadLaboratoriesMember" xlink:to="prpo_BioRadLaboratoriesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_BioRadLaboratoriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bio-Rad Laboratories [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_BioRadLaboratoriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bio Rad Laboratories [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_BioRadLaboratoriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bio-Rad Laboratories [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingencies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency Accrual</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss contingency accrual</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax, interest and penalites</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short Term Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BridgeLoanMember" xlink:to="us-gaap_BridgeLoanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BridgeLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bridge Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BridgeLoanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bridge Loan</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="prpo_ConversionofStockPerShareConversionPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ConversionofStockPerShareConversionPrice" xlink:to="prpo_ConversionofStockPerShareConversionPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ConversionofStockPerShareConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Per Share Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ConversionofStockPerShareConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Per Share Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_ConversionofStockPerShareConversionPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock issued on conversion of preferred shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from sale of stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares converted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock for consulting services in connection with the merger (in shares)</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_StockNotIssuedShares" xlink:label="prpo_StockNotIssuedShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_StockNotIssuedShares" xlink:to="prpo_StockNotIssuedShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_StockNotIssuedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Not Issued, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_StockNotIssuedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Not Issued, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_StockNotIssuedShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares not converted</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Converted Instrument, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares converted from debt instrument (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of debt into stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_DeemedDividend" xlink:to="prpo_DeemedDividend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_DeemedDividend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed Dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_DeemedDividend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed Dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_DeemedDividend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deemed dividend</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:to="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Issued Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Issued Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock rights issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsExercised" xlink:label="prpo_WarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsExercised" xlink:to="prpo_WarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercised</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PublicStockOfferingMember" xlink:label="prpo_PublicStockOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_PublicStockOfferingMember" xlink:to="prpo_PublicStockOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_PublicStockOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Stock Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_PublicStockOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Stock Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_PublicStockOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Stock Offering</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_PurchaseAgreement2018Member" xlink:to="prpo_PurchaseAgreement2018Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_PurchaseAgreement2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement 2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_PurchaseAgreement2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_PurchaseAgreement2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Agreement 2018 [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_InducementAgreement2018Member" xlink:to="prpo_InducementAgreement2018Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_InducementAgreement2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Agreement 2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_InducementAgreement2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Agreement2018 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_InducementAgreement2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inducement Agreement 2018 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredClassBMember" xlink:to="us-gaap_PreferredClassBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredClassBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Class B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredClassBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Class B</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OfferingWarrantsMember" xlink:label="prpo_OfferingWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_OfferingWarrantsMember" xlink:to="prpo_OfferingWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_OfferingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_OfferingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_OfferingWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering Warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_AegisCapitalCorpMember" xlink:label="prpo_AegisCapitalCorpMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_AegisCapitalCorpMember" xlink:to="prpo_AegisCapitalCorpMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_AegisCapitalCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aegis Capital Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_AegisCapitalCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aegis Capital Corp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_AegisCapitalCorpMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aegis</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Shares Issued in Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares sold in offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares callable by warrant (in shares)</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" xlink:label="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" xlink:to="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Unit Value of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Unit Value of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant unit value (per unit)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Liquidation Preference Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, liquidation preference per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beneficial conversion feature</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PlacementAgreementMember" xlink:label="prpo_PlacementAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_PlacementAgreementMember" xlink:to="prpo_PlacementAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_PlacementAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agreement [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_PlacementAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_PlacementAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsExpiredInPeriod" xlink:label="prpo_WarrantsExpiredInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsExpiredInPeriod" xlink:to="prpo_WarrantsExpiredInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsExpiredInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants expired in period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsExpiredInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants expired in period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsExpiredInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants expired in period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConvertiblePromissoryNoteWarrantsMember" xlink:label="prpo_ConvertiblePromissoryNoteWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ConvertiblePromissoryNoteWarrantsMember" xlink:to="prpo_ConvertiblePromissoryNoteWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ConvertiblePromissoryNoteWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Promissory Note Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ConvertiblePromissoryNoteWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Promissory Note Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_ConvertiblePromissoryNoteWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Promissory Note Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SeriesCWarrantsMember" xlink:label="prpo_SeriesCWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_SeriesCWarrantsMember" xlink:to="prpo_SeriesCWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_SeriesCWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_SeriesCWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_SeriesCWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerMember" xlink:label="prpo_WarrantsAssumedInMergerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsAssumedInMergerMember" xlink:to="prpo_WarrantsAssumedInMergerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsAssumedInMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed in Merger [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsAssumedInMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed In Merger [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsAssumedInMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed in Merger [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringApril2020Member" xlink:label="prpo_WarrantsAssumedInMergerExpiringApril2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsAssumedInMergerExpiringApril2020Member" xlink:to="prpo_WarrantsAssumedInMergerExpiringApril2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsAssumedInMergerExpiringApril2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed in Merger, Expiring April 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsAssumedInMergerExpiringApril2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed In Merger Expiring April2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsAssumedInMergerExpiringApril2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed in Merger, Expiring April 2020 [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringFebruary2020Member" xlink:label="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member" xlink:to="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed in Merger, Expiring February 2020[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed In Merger Expiring February2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed in Merger, Expiring February 2020[Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringDecember2020Member" xlink:label="prpo_WarrantsAssumedInMergerExpiringDecember2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsAssumedInMergerExpiringDecember2020Member" xlink:to="prpo_WarrantsAssumedInMergerExpiringDecember2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsAssumedInMergerExpiringDecember2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed in Merger, Expiring December 2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsAssumedInMergerExpiringDecember2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed In Merger Expiring December2020 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsAssumedInMergerExpiringDecember2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed in Merger, Expiring December 2020 [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" xlink:label="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" xlink:to="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed in Merger, Expiring January 2021, Group B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed In Merger Expiring January2021 Group B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Assumed in Merger, Expiring January 2021, Group B [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerMember" xlink:label="prpo_WarrantsNotAssumedInMergerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsNotAssumedInMergerMember" xlink:to="prpo_WarrantsNotAssumedInMergerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsNotAssumedInMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsNotAssumedInMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed In Merger [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsNotAssumedInMergerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring June 2022, Group A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed In Merger Expiring June2022 Group [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring June 2022, Group A [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring June 2022, Group B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed In Merger Expiring June2022 Group B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring June 2022, Group B [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring August 2022, Group A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed In Merger Expiring August2022 Group [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring August 2022, Group A [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring August 2022, Group B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed In Merger Expiring August2022 Group B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring August 2022, Group B [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring August 2022, Group C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed In Merger Expiring August2022 Group C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring August 2022, Group C [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring August 2022, Group D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed In Merger Expiring August2022 Group D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring August 2022, Group D [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring October 2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed In Merger Expiring October2022 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring October 2022 Group A [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringMay2023Member" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring May 2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed In Merger Expiring May2023 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring May 2023 [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring October 2022 Group B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed In Merger Expiring October2022 Group B [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Not Assumed in Merger, Expiring October 2022 Group B [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsCanceledInSettlementAgreement" xlink:label="prpo_WarrantsCanceledInSettlementAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsCanceledInSettlementAgreement" xlink:to="prpo_WarrantsCanceledInSettlementAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsCanceledInSettlementAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants canceled in settlement agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsCanceledInSettlementAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants canceled in settlement agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsCanceledInSettlementAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants canceled in settlement agreement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deductions - warrant liability settlement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt settlment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TotalGainsOrLossesAbstract" xlink:label="prpo_TotalGainsOrLossesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_TotalGainsOrLossesAbstract" xlink:to="prpo_TotalGainsOrLossesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_TotalGainsOrLossesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total gains or losses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_TotalGainsOrLossesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total gains or losses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_TotalGainsOrLossesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total (gains) or losses:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized in earnings</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityIncentivePlan2017Member" xlink:label="prpo_EquityIncentivePlan2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_EquityIncentivePlan2017Member" xlink:to="prpo_EquityIncentivePlan2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_EquityIncentivePlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2017 [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_EquityIncentivePlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan2017 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_EquityIncentivePlan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2017 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan expiration date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" xlink:label="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" xlink:to="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Annual Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Annual Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional annual shares authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of shares per employee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award plan, percentage of outstanding stock maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to unvested stock awards</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested stock options, unrecognized compensation expense weighted average recognition period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options, expected to vest, outstanding (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options, expected to vest, outstanding, aggregate intrinsic value</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options, expected to vest remaining contractual term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Goods and Nonemployee Services Transaction, Shares Approved for Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for issuance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of period (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of period (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disaggregation of Revenue [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsGross" xlink:label="us-gaap_SalesRevenueGoodsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueGoodsGross" xlink:to="us-gaap_SalesRevenueGoodsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueGoodsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Revenue, Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueGoodsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross revenue</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherSalesRevenueGross" xlink:label="prpo_OtherSalesRevenueGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_OtherSalesRevenueGross" xlink:to="prpo_OtherSalesRevenueGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_OtherSalesRevenueGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Sales Revenue, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_OtherSalesRevenueGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Sales Revenue, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_OtherSalesRevenueGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other, gross</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_GrossRevenueIncludingOtherAdjustments" xlink:label="prpo_GrossRevenueIncludingOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_GrossRevenueIncludingOtherAdjustments" xlink:to="prpo_GrossRevenueIncludingOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_GrossRevenueIncludingOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross revenue including other adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_GrossRevenueIncludingOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross revenue including other adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="prpo_GrossRevenueIncludingOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross revenue including other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:to="us-gaap_SalesDiscountsReturnsAndAllowancesGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesDiscountsReturnsAndAllowancesGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Discounts, Returns and Allowances, Goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_SalesDiscountsReturnsAndAllowancesGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual allowance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, gross</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Doubtful Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less allowance for doubtful accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for doubtful accounts, Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for doubtful accounts, Beginning balance</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Doubtful Accounts Receivable, Recoveries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bad debt expense</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for Doubtful Accounts Receivable, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total charges</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PreferredStockInducedConversionsSecondInvestorMember" xlink:label="prpo_PreferredStockInducedConversionsSecondInvestorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_PreferredStockInducedConversionsSecondInvestorMember" xlink:to="prpo_PreferredStockInducedConversionsSecondInvestorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_PreferredStockInducedConversionsSecondInvestorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Induced Conversions, Second Investor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_PreferredStockInducedConversionsSecondInvestorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Induced Conversions Second Investor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_PreferredStockInducedConversionsSecondInvestorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Induced Conversions, Second Investor [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PreferredStockInducedConversionsFirstInvestorMember" xlink:label="prpo_PreferredStockInducedConversionsFirstInvestorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_PreferredStockInducedConversionsFirstInvestorMember" xlink:to="prpo_PreferredStockInducedConversionsFirstInvestorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_PreferredStockInducedConversionsFirstInvestorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Induced Conversions, First Investor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_PreferredStockInducedConversionsFirstInvestorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Induced Conversions First Investor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_PreferredStockInducedConversionsFirstInvestorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Induced Conversions, First Investor [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue" xlink:label="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue" xlink:to="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum proceeds raised before note payable becomes due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum proceeds raised before note payable becomes due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum proceeds raised before note payable becomes due</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementCommitmentFeePercentage" xlink:label="prpo_EquityPurchaseAgreementCommitmentFeePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_EquityPurchaseAgreementCommitmentFeePercentage" xlink:to="prpo_EquityPurchaseAgreementCommitmentFeePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_EquityPurchaseAgreementCommitmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Purchase Agreement, Commitment Fee Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_EquityPurchaseAgreementCommitmentFeePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Purchase Agreement, Commitment Fee Percentage</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage" xlink:label="prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage" xlink:to="prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Purchase Agreement, Commitment Fee Installment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Purchase Agreement, Commitment Fee Installment Percentage</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementFee" xlink:label="prpo_EquityPurchaseAgreementFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_EquityPurchaseAgreementFee" xlink:to="prpo_EquityPurchaseAgreementFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_EquityPurchaseAgreementFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Purchase Agreement, Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_EquityPurchaseAgreementFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Purchase Agreement, Fee</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementFeeContingentDiscount" xlink:label="prpo_EquityPurchaseAgreementFeeContingentDiscount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_EquityPurchaseAgreementFeeContingentDiscount" xlink:to="prpo_EquityPurchaseAgreementFeeContingentDiscount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_EquityPurchaseAgreementFeeContingentDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Purchase Agreement, Fee, Contingent Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_EquityPurchaseAgreementFeeContingentDiscount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Purchase Agreement, Fee, Contingent Discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Issued for Services</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement" xlink:label="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement" xlink:to="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential liquidation damage amount to each occurrence of default related to the purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential Liquidation Damage Amount To Each Occurrence of Default Related to the Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Potential liquidation damage amount to each occurrence of default related to the purchase agreement</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised" xlink:label="prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised" xlink:to="prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Warrants or Rights Excercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Warrants or Rights Excercised</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock" xlink:label="prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock" xlink:to="prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued During Period, Maximum Allowed Percentage of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Issued During Period, Maximum Allowed Percentage of Common Stock</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CommonStockPurchaseFee" xlink:label="prpo_CommonStockPurchaseFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_CommonStockPurchaseFee" xlink:to="prpo_CommonStockPurchaseFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_CommonStockPurchaseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock purchase fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_CommonStockPurchaseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_CommonStockPurchaseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock purchase fee</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Debt [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SeniorSecuredConvertiblePromissoryNotesMember" xlink:label="prpo_SeniorSecuredConvertiblePromissoryNotesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_SeniorSecuredConvertiblePromissoryNotesMember" xlink:to="prpo_SeniorSecuredConvertiblePromissoryNotesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_SeniorSecuredConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Secured Convertible Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_SeniorSecuredConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Secured Convertible Promissory Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_SeniorSecuredConvertiblePromissoryNotesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Senior Secured Convertible Promissory Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion Description [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Conversion, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAfterConversionPriceReductionMember" xlink:label="prpo_WarrantsAfterConversionPriceReductionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_WarrantsAfterConversionPriceReductionMember" xlink:to="prpo_WarrantsAfterConversionPriceReductionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_WarrantsAfterConversionPriceReductionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants After Conversion Price Reduction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_WarrantsAfterConversionPriceReductionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants After Conversion Price Reduction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_WarrantsAfterConversionPriceReductionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants After Conversion Price Reduction [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Health Care Organization, Revenue Sources [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Health Care Organization Revenue Sources [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Health Care Organization, Revenue Sources [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_MedicaidMember" xlink:to="prpo_MedicaidMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_MedicaidMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medicaid [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_MedicaidMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medicaid [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_MedicaidMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medicaid [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_MedicareMember" xlink:to="prpo_MedicareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_MedicareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medicare [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_MedicareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medicare [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_MedicareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Medicare [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SelfPayMember" xlink:to="us-gaap_SelfPayMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SelfPayMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Self Pay [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SelfPayMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Self-Pay [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ThirdPartyPayorMember" xlink:to="us-gaap_ThirdPartyPayorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Party Payor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ThirdPartyPayorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third-Party Payor [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ContractDiagnosticServicesMember" xlink:label="prpo_ContractDiagnosticServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ContractDiagnosticServicesMember" xlink:to="prpo_ContractDiagnosticServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ContractDiagnosticServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract diagnostic services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ContractDiagnosticServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Diagnostic Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_ContractDiagnosticServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract Diagnostic Services [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and Services [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and Services [Domain]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DiagnosticTestingMember" xlink:label="prpo_DiagnosticTestingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_DiagnosticTestingMember" xlink:to="prpo_DiagnosticTestingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_DiagnosticTestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diagnostic Testing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_DiagnosticTestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diagnostic Testing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_DiagnosticTestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diagnostic Testing [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_BiomarkerTestingAndClinicalProjectServicesMember" xlink:label="prpo_BiomarkerTestingAndClinicalProjectServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_BiomarkerTestingAndClinicalProjectServicesMember" xlink:to="prpo_BiomarkerTestingAndClinicalProjectServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_BiomarkerTestingAndClinicalProjectServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biomarker Testing and Clinical Project Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_BiomarkerTestingAndClinicalProjectServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biomarker Testing And Clinical Project Services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_BiomarkerTestingAndClinicalProjectServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Biomarker Testing and Clinical Project Services [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherPartyMember" xlink:label="prpo_OtherPartyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_OtherPartyMember" xlink:to="prpo_OtherPartyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_OtherPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_OtherPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Party [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_OtherPartyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other [Member]</label>
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ServicesRevenueNetMember" xlink:label="prpo_ServicesRevenueNetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="prpo_ServicesRevenueNetMember" xlink:to="prpo_ServicesRevenueNetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="prpo_ServicesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Services Revenue, Net [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="prpo_ServicesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Services Revenue Net [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="prpo_ServicesRevenueNetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Services Revenue, Net [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Redemption Period [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument Redemption Period One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Redemption, Period Within 180 Days [Member]</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>prpo-20180331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created by Certent Disclosure Management 6.18.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/21/2018 1:44:54 PM-->
<!--Modified on: 5/21/2018 1:44:54 PM-->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.precipiodx.com/role/StatementConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.precipiodx.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureBusinessDescription" roleURI="http://www.precipiodx.com/role/DisclosureBusinessDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureReverseMerger" roleURI="http://www.precipiodx.com/role/DisclosureReverseMerger" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebt" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureOtherCurrentLiabilities" roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureContingencies" roleURI="http://www.precipiodx.com/role/DisclosureContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureIncomeTaxes" roleURI="http://www.precipiodx.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquity" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureFairValue" roleURI="http://www.precipiodx.com/role/DisclosureFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureEquityIncentivePlan" roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivable" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureSubsequentEvents" roleURI="http://www.precipiodx.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicy" roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureReverseMergerTables" roleURI="http://www.precipiodx.com/role/DisclosureReverseMergerTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtTables" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureOtherCurrentLiabilitiesTables" roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureFairValueTables" roleURI="http://www.precipiodx.com/role/DisclosureFairValueTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureEquityIncentivePlanTables" roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableTables" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureBusinessDescriptionNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesNotIncludedInComputationOfDilutedNetLossDetails" roleURI="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesNotIncludedInComputationOfDilutedNetLossDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureReverseMergerProFormaDisclosuresDetails" roleURI="http://www.precipiodx.com/role/DisclosureReverseMergerProFormaDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtScheduleOfDebtDetails" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtDepartmentOfEconomicAndCommunityDevelopmentDetails" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtSecuredDebtObligationsDetails" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtSecuredDebtObligationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureLongTermDebtFinancedInsuranceLoanDetails" roleURI="http://www.precipiodx.com/role/DisclosureLongTermDebtFinancedInsuranceLoanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureOtherCurrentLiabilitiesNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureOtherCurrentLiabilitiesOtherCurrentLiabilitiesDetails" roleURI="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureContingenciesNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureContingenciesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureIncomeTaxesNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureIncomeTaxesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityCommonStockDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquitySeriesAndSeriesBPreferredStockDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesAndSeriesBPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityPreferredStockDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityPreferredStockInducedConversionsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockInducedConversionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquitySeriesBPreferredStockDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquitySeriesCPreferredStockDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCPreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityCommonStockWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityOfferingWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityOfferingWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityNoteConversionWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityNoteConversionWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityConvertiblePromissoryNoteWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityConvertiblePromissoryNoteWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquitySeriesCWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityCreditorWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityCreditorWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureStockholdersEquityScheduleOfWarrantsDetails" roleURI="http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureFairValueNarrativesDetails" roleURI="http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureFairValueScheduleOfChangesInFairValueOfLiabilityDetails" roleURI="http://www.precipiodx.com/role/DisclosureFairValueScheduleOfChangesInFairValueOfLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureEquityIncentivePlanNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" roleURI="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableNarrativeDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfNetRevenuesDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfNetRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails" roleURI="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="prpo-20180331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.precipiodx.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <presentationLink xlink:role="http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00050 - Document - DOCUMENT AND ENTITY INFORMATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DocumentAndEntityInformationAbstract" xlink:label="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" xlink:to="dei_EntityRegistrantName_636625070913869799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" xlink:to="dei_EntityCentralIndexKey_636625070913869799" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" xlink:to="dei_CurrentFiscalYearEndDate_636625070913869799" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" xlink:to="dei_EntityFilerCategory_636625070913869799" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" xlink:to="dei_DocumentType_636625070913869799" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" xlink:to="dei_DocumentPeriodEndDate_636625070913869799" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" xlink:to="dei_DocumentFiscalYearFocus_636625070913869799" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" xlink:to="dei_DocumentFiscalPeriodFocus_636625070913869799" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" xlink:to="dei_AmendmentFlag_636625070913869799" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prpo_DocumentAndEntityInformationAbstract_E01E3772E42A513CEF5C5EA220666F0B" xlink:to="dei_EntityCommonStockSharesOutstanding_636625070913869799" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_92C9CC28E5D32BA3C30DC07561CD607C" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_92C9CC28E5D32BA3C30DC07561CD607C" xlink:to="us-gaap_AssetsAbstract_636625070913869799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636625070913869799" xlink:to="us-gaap_AssetsCurrentAbstract_636625070913869799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636625070913869799" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636625070913869799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636625070913869799" xlink:to="us-gaap_AccountsReceivableNetCurrent_636625070913869799" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636625070913869799" xlink:to="us-gaap_InventoryNet_636625070913869799" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636625070913869799" xlink:to="us-gaap_OtherAssetsCurrent_636625070913869799" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_636625070913869799" xlink:to="us-gaap_AssetsCurrent_636625070913869799" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636625070913869799" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_636625070913869799" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636625070913869799" xlink:to="us-gaap_AssetsNoncurrentAbstract_636625070913869799" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_636625070913869799" xlink:to="us-gaap_Goodwill_636625070913869799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_636625070913869799" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_636625070913869799" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_636625070913869799" xlink:to="us-gaap_OtherAssetsNoncurrent_636625070913869799" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_636625070913869799" xlink:to="us-gaap_Assets_636625070913869799" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_92C9CC28E5D32BA3C30DC07561CD607C" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636625070913869799" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636625070913869799" xlink:to="us-gaap_LiabilitiesCurrentAbstract_636625070913869799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636625070913869799" xlink:to="us-gaap_LongTermDebtCurrent_636625070913869799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636625070913869799" xlink:to="us-gaap_AccountsPayableCurrent_636625070913869799" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636625070913869799" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_636625070913869799" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636625070913869799" xlink:to="us-gaap_AccruedLiabilitiesCurrent_636625070913869799" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636625070913869799" xlink:to="us-gaap_DeferredRevenueCurrent_636625070913869799" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636625070913869799" xlink:to="us-gaap_OtherLiabilitiesCurrent_636625070913869799" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_636625070913869799" xlink:to="us-gaap_LiabilitiesCurrent_636625070913869799" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636625070913869799" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_636625070913869799" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_636625070913869799" xlink:to="us-gaap_LongTermDebtNoncurrent_636625070913869799" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_636625070913869799" xlink:to="us-gaap_DerivativeLiabilities_636625070913869799" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementOfCommonStockWarrantLiability" xlink:label="prpo_LiabilityForSettlementOfCommonStockWarrantLiability_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_636625070913869799" xlink:to="prpo_LiabilityForSettlementOfCommonStockWarrantLiability_636625070913869799" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_636625070913869799" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_636625070913869799" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_636625070913869799" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_636625070913869799" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_636625070913869799" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_636625070913947914" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636625070913869799" xlink:to="us-gaap_Liabilities_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636625070913869799" xlink:to="us-gaap_StockholdersEquityAbstract_636625070913947914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636625070913947914" xlink:to="us-gaap_PreferredStockValue_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636625070913947914" xlink:to="us-gaap_CommonStockValue_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636625070913947914" xlink:to="us-gaap_AdditionalPaidInCapital_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636625070913947914" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_636625070913947914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_636625070913947914" xlink:to="us-gaap_StockholdersEquity_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_636625070913869799" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_E2CB957A15C14D2DAAFF5EA2212FC0CD" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E2CB957A15C14D2DAAFF5EA2212FC0CD" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E2CB957A15C14D2DAAFF5EA2212FC0CD" xlink:to="us-gaap_PreferredStockSharesAuthorized_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E2CB957A15C14D2DAAFF5EA2212FC0CD" xlink:to="us-gaap_PreferredStockSharesIssued_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E2CB957A15C14D2DAAFF5EA2212FC0CD" xlink:to="us-gaap_PreferredStockSharesOutstanding_636625070913947914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E2CB957A15C14D2DAAFF5EA2212FC0CD" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E2CB957A15C14D2DAAFF5EA2212FC0CD" xlink:to="us-gaap_CommonStockSharesAuthorized_636625070913947914" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E2CB957A15C14D2DAAFF5EA2212FC0CD" xlink:to="us-gaap_CommonStockSharesIssued_636625070913947914" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_E2CB957A15C14D2DAAFF5EA2212FC0CD" xlink:to="us-gaap_CommonStockSharesOutstanding_636625070913947914" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_SalesRevenueServicesNet_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="us-gaap_OtherSalesRevenueNet_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_OtherSalesRevenueNet_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_RevenueNetOfAllowanceAndAdjustments" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="prpo_RevenueNetOfAllowanceAndAdjustments_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="us-gaap_SalesAllowancesServices_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_SalesAllowancesServices_636625070913947914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_Revenues_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_CostOfGoodsAndServicesSold_636625070913947914" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_GrossProfit_636625070913947914" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_OperatingExpensesAbstract_636625070913947914" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636625070913947914" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636625070913947914" xlink:to="us-gaap_GoodwillImpairmentLoss_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_636625070913947914" xlink:to="us-gaap_OperatingExpenses_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_OperatingIncomeLoss_636625070913947914" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_636625070913947914" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InterestIncomeAndExpenseNet" xlink:label="prpo_InterestIncomeAndExpenseNet_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_636625070913947914" xlink:to="prpo_InterestIncomeAndExpenseNet_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_GainLossOnStockWarrantsRevaluation" xlink:label="prpo_GainLossOnStockWarrantsRevaluation_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_636625070913947914" xlink:to="prpo_GainLossOnStockWarrantsRevaluation_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_636625070913947914" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnNonRecourseDebt" xlink:label="us-gaap_GainLossOnNonRecourseDebt_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_636625070913947914" xlink:to="us-gaap_GainLossOnNonRecourseDebt_636625070913947914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherIncomeExpense" xlink:label="prpo_OtherIncomeExpense_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_636625070913947914" xlink:to="prpo_OtherIncomeExpense_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_636625070913947914" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636625070913947914" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_NetIncomeLoss_636625070913947914" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_636625070913947914" order="14" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_636625070913947914" order="15" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_636625070913947914" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_636625070913947914" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_BC458E267EF116B7DED1CF6863B398E4" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_636625070913947914" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_3334C21976D573E9976CD973D9BB0521" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3334C21976D573E9976CD973D9BB0521" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_IncomeLossFromContinuingOperations_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_DepreciationDepletionAndAmortization_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfEquityInvestments" xlink:label="us-gaap_GainLossOnSaleOfEquityInvestments_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_GainLossOnSaleOfEquityInvestments_636625070913947914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_ShareBasedCompensation_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_GoodwillImpairmentLoss_636625070913947914" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_636625070913947914" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_636625070913947914" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636625070913947914" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636625070913947914" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636625070913947914" xlink:to="us-gaap_IncreaseDecreaseInInventories_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636625070913947914" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636625070913947914" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_636625070913947914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_636625070913947914" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3334C21976D573E9976CD973D9BB0521" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3334C21976D573E9976CD973D9BB0521" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_ProceedsFromWarrantExercises_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_636625070913947914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_ProceedsFromConvertibleDebt_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_RepaymentsOfNotesPayable_636625070913947914" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_636625070913947914" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_636625070913947914" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3334C21976D573E9976CD973D9BB0521" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_636625070913947914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3334C21976D573E9976CD973D9BB0521" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6366250709139479141" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3334C21976D573E9976CD973D9BB0521" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6366250709139479141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3334C21976D573E9976CD973D9BB0521" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_636625070913947914" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_636625070913947914" xlink:to="us-gaap_InterestPaidNet_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_3334C21976D573E9976CD973D9BB0521" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636625070913947914" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636625070913947914" xlink:to="us-gaap_ConversionOfStockAmountConverted1_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636625070913947914" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_636625070913947914" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636625070913947914" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_636625070913947914" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636625070913947914" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_636625070913947914" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_636625070913947914" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_636625070913947914" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureBusinessDescription" xlink:type="extended" xlink:title="10101 - Disclosure - BUSINESS DESCRIPTION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9B2D4EF99976CD885FAF5EA2206C2DBE" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9B2D4EF99976CD885FAF5EA2206C2DBE" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_773EA8260C21A73218755EA22059FE66" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_773EA8260C21A73218755EA22059FE66" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureReverseMerger" xlink:type="extended" xlink:title="10301 - Disclosure - REVERSE MERGER" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_BAEB563A8376AA6CC03E5EA2206285AA" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_BAEB563A8376AA6CC03E5EA2206285AA" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebt" xlink:type="extended" xlink:title="10401 - Disclosure - LONG-TERM DEBT" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_DAD9F2DF8CE7D1E6E848C5F8F6ECBC84" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_DAD9F2DF8CE7D1E6E848C5F8F6ECBC84" xlink:to="us-gaap_DebtDisclosureTextBlock_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilities" xlink:type="extended" xlink:title="10501 - Disclosure - OTHER CURRENT LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureContingencies" xlink:type="extended" xlink:title="10601 - Disclosure - CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_341D279C85D0327D022F5EA2206A8FC8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_341D279C85D0327D022F5EA2206A8FC8" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10701 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_80D8B8ACB36EF70B60929D84248E5BC1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_80D8B8ACB36EF70B60929D84248E5BC1" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10801 - Disclosure - STOCKHOLDERS' EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_6269D8C903E2B8A493795EA2219560B7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_6269D8C903E2B8A493795EA2219560B7" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureFairValue" xlink:type="extended" xlink:title="10901 - Disclosure - FAIR VALUE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_52DB4C29CCC59AA150925EA22061E5EB" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_52DB4C29CCC59AA150925EA22061E5EB" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureEquityIncentivePlan" xlink:type="extended" xlink:title="11001 - Disclosure - EQUITY INCENTIVE PLAN" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10FE20BFC9809D6899BD5EA22057B802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_636625070913947914" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_10FE20BFC9809D6899BD5EA22057B802" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_636625070913947914" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivable" xlink:type="extended" xlink:title="11101 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:to="prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11201 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5B2A7EF685D5DADDAB17D99230788B39" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5B2A7EF685D5DADDAB17D99230788B39" xlink:to="us-gaap_SubsequentEventsTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy" xlink:type="extended" xlink:title="20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_037296B8957B3C2ED096CF6B4F95F2EA" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_037296B8957B3C2ED096CF6B4F95F2EA" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_037296B8957B3C2ED096CF6B4F95F2EA" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_037296B8957B3C2ED096CF6B4F95F2EA" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_636625070914026029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_037296B8957B3C2ED096CF6B4F95F2EA" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_636625070914026029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_037296B8957B3C2ED096CF6B4F95F2EA" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_636625070914026029" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_037296B8957B3C2ED096CF6B4F95F2EA" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_636625070914026029" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureReverseMergerTables" xlink:type="extended" xlink:title="30303 - Disclosure - REVERSE MERGER (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_DFDF30FD2627DF511D7C5EA221341C94" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_DFDF30FD2627DF511D7C5EA221341C94" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtTables" xlink:type="extended" xlink:title="30403 - Disclosure - LONG-TERM DEBT (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D26C10E4C3954A539D58C5F8F6EC3D5B" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D26C10E4C3954A539D58C5F8F6EC3D5B" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30503 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="30803 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_ECD505BFAE5CB7874D285EA221297423" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_ECD505BFAE5CB7874D285EA221297423" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureFairValueTables" xlink:type="extended" xlink:title="30903 - Disclosure - FAIR VALUE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_22CB4F6CE9E017158C065EA220F973B9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_22CB4F6CE9E017158C065EA220F973B9" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables" xlink:type="extended" xlink:title="31003 - Disclosure - EQUITY INCENTIVE PLAN (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_20FFDCF5E8F2A2AF0F265EA221000856" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_20FFDCF5E8F2A2AF0F265EA221000856" xlink:to="us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableTables" xlink:type="extended" xlink:title="31103 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636583686348636935" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636583686348636935" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock" xlink:label="prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636583686348636935" xlink:to="prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok" xlink:label="prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636583686348636935" xlink:to="prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok_636625070914026029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636583686348636935" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_636625070914026029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock" xlink:label="prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636583686348636935" xlink:to="prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock_636625070914026029" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails" xlink:type="extended" xlink:title="40101 - Disclosure - BUSINESS DESCRIPTION (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9E422E1E827F712E4206DA3EA75618F8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9E422E1E827F712E4206DA3EA75618F8" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636625070914026029" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636625070914026029" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LevistonResourcesLlcMember" xlink:label="prpo_LevistonResourcesLlcMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914026029" xlink:to="prpo_LevistonResourcesLlcMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionAxis_636625070914026029" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TransgenomicsMember" xlink:label="prpo_TransgenomicsMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636625070914026029" xlink:to="prpo_TransgenomicsMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" xlink:to="us-gaap_DebtInstrumentAxis_636625070914026029" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636625070914026029" xlink:to="us-gaap_DebtInstrumentNameDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SecuritiesPurchaseAgreementMember" xlink:label="prpo_SecuritiesPurchaseAgreementMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914026029" xlink:to="prpo_SecuritiesPurchaseAgreementMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" xlink:to="us-gaap_SubsequentEventTypeAxis_636625070914026029" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_636625070914026029" xlink:to="us-gaap_SubsequentEventTypeDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_636625070914026029" xlink:to="us-gaap_SubsequentEventMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" xlink:to="us-gaap_LitigationCaseAxis_636625070914026029" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis_636625070914026029" xlink:to="us-gaap_LitigationCaseTypeDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CredeMember" xlink:label="prpo_CredeMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain_636625070914026029" xlink:to="prpo_CredeMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" xlink:to="us-gaap_LongtermDebtTypeAxis_636625070914026029" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_636625070914026029" xlink:to="us-gaap_LongtermDebtTypeDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_636625070914026029" xlink:to="us-gaap_ConvertibleDebtMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SeniorSecuredConvertiblePromissoryNotesMember" xlink:label="prpo_SeniorSecuredConvertiblePromissoryNotesMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleDebtMember_636625070914026029" xlink:to="prpo_SeniorSecuredConvertiblePromissoryNotesMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionLineItems_636625070914026029" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionNameOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionNameOfAcquiredEntity_636625070914026029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_BusinessCombinationStockExchangeRatio" xlink:label="prpo_BusinessCombinationStockExchangeRatio_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="prpo_BusinessCombinationStockExchangeRatio_636625070914026029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_AccumulatedNetIncomeLoss" xlink:label="prpo_AccumulatedNetIncomeLoss_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="prpo_AccumulatedNetIncomeLoss_636625070914026029" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WorkingCapitalDeficiency" xlink:label="prpo_WorkingCapitalDeficiency_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="prpo_WorkingCapitalDeficiency_636625070914026029" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_636625070914026029" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_SecuredDebt_636625070914026029" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_DebtInstrumentTerm_636625070914026029" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_636625070914026029" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636625070914026029" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_636625070914026029" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreement" xlink:label="prpo_EquityPurchaseAgreement_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="prpo_EquityPurchaseAgreement_636625070914026029" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CompanyStockPercentageOfMarketRate" xlink:label="prpo_CompanyStockPercentageOfMarketRate_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="prpo_CompanyStockPercentageOfMarketRate_636625070914026029" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_DebtInstrumentFaceAmount_636625070914026029" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914026029" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_636625070914026029" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_19AE6E578232E357D5D3DA3EA74AAF9A" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_19AE6E578232E357D5D3DA3EA74AAF9A" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_636625070914026029" xlink:to="us-gaap_RangeAxis_636625070914026029" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636625070914026029" xlink:to="us-gaap_RangeMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636625070914026029" xlink:to="us-gaap_MinimumMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636625070914026029" xlink:to="us-gaap_MaximumMember_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_636625070914026029" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_GoodwillImpairmentLoss_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_OtherAssetsCurrent_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_Depreciation_636625070914026029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_AmortizationOfIntangibleAssets_636625070914026029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_636625070914026029" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_636625070914026029" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_636625070914026029" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_636625070914026029" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_636625070914026029" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636625070914026029" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_636625070914026029" xlink:to="us-gaap_DeferredRevenueCurrent_636625070914026029" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesNotIncludedInComputationOfDilutedNetLossDetails" xlink:type="extended" xlink:title="40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities not Included in the Computation of Diluted Net Loss) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636625070914026029" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636625070914026029" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636625070914026029" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_636625070914026029" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636625070914026029" xlink:to="us-gaap_EmployeeStockOptionMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636625070914026029" xlink:to="us-gaap_WarrantMember_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_636625070914026029" xlink:to="us-gaap_PreferredStockMember_636625070914026029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_636625070914026029" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636625070914026029" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_636625070914026029" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureReverseMergerProFormaDisclosuresDetails" xlink:type="extended" xlink:title="40306 - Disclosure - REVERSE MERGER (Pro-forma Disclosures) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_A9609DC1EB54FF3F5EEDC55E072DBE7E" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_A9609DC1EB54FF3F5EEDC55E072DBE7E" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionAxis_636625070914026029" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TransgenomicsMember" xlink:label="prpo_TransgenomicsMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_636625070914026029" xlink:to="prpo_TransgenomicsMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionLineItems_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic" xlink:label="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems_636625070914026029" xlink:to="us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic_636625070914026029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails" xlink:type="extended" xlink:title="40401 - Disclosure - LONG-TERM DEBT (Schedule of Debt) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3B5AD3F25ADED4FA51F2C5F8F6EC470D" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3B5AD3F25ADED4FA51F2C5F8F6EC470D" xlink:to="us-gaap_DebtInstrumentTable_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914026029" xlink:to="us-gaap_LongtermDebtTypeAxis_636625070914026029" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_636625070914026029" xlink:to="us-gaap_LongtermDebtTypeDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_636625070914026029" xlink:to="us-gaap_SecuredDebtMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914026029" xlink:to="us-gaap_DebtInstrumentAxis_636625070914026029" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636625070914026029" xlink:to="us-gaap_DebtInstrumentNameDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:label="prpo_DepartmentofEconomicandCommunityDevelopmentMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914026029" xlink:to="prpo_DepartmentofEconomicandCommunityDevelopmentMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_FinancedInsuranceLoanMember" xlink:label="prpo_FinancedInsuranceLoanMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914026029" xlink:to="prpo_FinancedInsuranceLoanMember_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914026029" xlink:to="us-gaap_DebtInstrumentLineItems_636625070914026029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_DebtAndCapitalLeaseObligations_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_636625070914026029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_LongTermDebtCurrent_636625070914026029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_LongTermDebtNoncurrent_636625070914026029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtDepartmentOfEconomicAndCommunityDevelopmentDetails" xlink:type="extended" xlink:title="40404 - Disclosure - LONG-TERM DEBT (Department of Economic and Community Development) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_A5385C3DB9686A9FD189C5F8F6DC9DCC" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_A5385C3DB9686A9FD189C5F8F6DC9DCC" xlink:to="us-gaap_DebtInstrumentTable_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914026029" xlink:to="us-gaap_LongtermDebtTypeAxis_636625070914026029" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_636625070914026029" xlink:to="us-gaap_LongtermDebtTypeDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TermLoanMember" xlink:label="prpo_TermLoanMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_636625070914026029" xlink:to="prpo_TermLoanMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914026029" xlink:to="us-gaap_DebtInstrumentAxis_636625070914026029" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636625070914026029" xlink:to="us-gaap_DebtInstrumentNameDomain_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DepartmentofEconomicandCommunityDevelopmentMember" xlink:label="prpo_DepartmentofEconomicandCommunityDevelopmentMember_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914026029" xlink:to="prpo_DepartmentofEconomicandCommunityDevelopmentMember_636625070914026029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_636625070914026029" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914026029" xlink:to="us-gaap_DebtInstrumentLineItems_636625070914026029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_DebtInstrumentTerm_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_GrossProceedsFromGrantReceivedAndLoan" xlink:label="prpo_GrossProceedsFromGrantReceivedAndLoan_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="prpo_GrossProceedsFromGrantReceivedAndLoan_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_636625070914104144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_636625070914104144" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_DebtInstrumentFaceAmount_636625070914104144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_DebtInstrumentMaturityDate_636625070914104144" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914104144" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_DebtAndCapitalLeaseObligations_636625070914104144" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_DeferredFinanceCostsNet_636625070914104144" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914026029" xlink:to="us-gaap_AmortizationOfFinancingCosts_636625070914104144" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtSecuredDebtObligationsDetails" xlink:type="extended" xlink:title="40406 - Disclosure - LONG-TERM DEBT (Secured Debt Obligations) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_636572555730895368" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_636572555730895368" xlink:to="us-gaap_DebtInstrumentTable_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914104144" xlink:to="us-gaap_LongtermDebtTypeAxis_636625070914104144" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_636625070914104144" xlink:to="us-gaap_LongtermDebtTypeDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_636625070914104144" xlink:to="us-gaap_SecuredDebtMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914104144" xlink:to="us-gaap_SubsequentEventTypeAxis_636625070914104144" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_636625070914104144" xlink:to="us-gaap_SubsequentEventTypeDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_636625070914104144" xlink:to="us-gaap_SubsequentEventMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914104144" xlink:to="us-gaap_TypeOfArrangementAxis_636625070914104144" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_636625070914104144" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SettlementAgreementsMember" xlink:label="prpo_SettlementAgreementsMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_636625070914104144" xlink:to="prpo_SettlementAgreementsMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914104144" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636625070914104144" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636625070914104144" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CreditorWarrantsRelatingToSecuredDebtMember" xlink:label="prpo_CreditorWarrantsRelatingToSecuredDebtMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914104144" xlink:to="prpo_CreditorWarrantsRelatingToSecuredDebtMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914104144" xlink:to="us-gaap_DebtInstrumentLineItems_636625070914104144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentFaceAmount_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtAndCapitalLeaseObligations_636625070914104144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_636625070914104144" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636625070914104144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914104144" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_WarrantsAndRightsOutstanding_636625070914104144" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentTerm_636625070914104144" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_636625070914104144" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_ExtinguishmentOfDebtAmount_636625070914104144" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="prpo_ClassOfWarrantOrRightTerm_636625070914104144" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_636625070914104144" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636625070914104144" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_636625070914104144" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_SharePrice_636625070914104144" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DebtRestructured" xlink:label="prpo_DebtRestructured_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="prpo_DebtRestructured_636625070914104144" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureLongTermDebtFinancedInsuranceLoanDetails" xlink:type="extended" xlink:title="40408 - Disclosure - LONG-TERM DEBT (Financed Insurance Loan ) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7A8648D3BDFA31B870A3C5F8F6CC7E33" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7A8648D3BDFA31B870A3C5F8F6CC7E33" xlink:to="us-gaap_DebtInstrumentTable_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914104144" xlink:to="us-gaap_DebtInstrumentAxis_636625070914104144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636625070914104144" xlink:to="us-gaap_DebtInstrumentNameDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_FinancedInsuranceLoanMember" xlink:label="prpo_FinancedInsuranceLoanMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914104144" xlink:to="prpo_FinancedInsuranceLoanMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_636625070914104144" xlink:to="us-gaap_DebtInstrumentLineItems_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentTerm_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentFaceAmount_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914104144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentMaturityDate_636625070914104144" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtAndCapitalLeaseObligations" xlink:label="us-gaap_DebtAndCapitalLeaseObligations_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_636625070914104144" xlink:to="us-gaap_DebtAndCapitalLeaseObligations_636625070914104144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER CURRENT LIABILITIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_StatementTable_636625070914104144" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636625070914104144" xlink:to="us-gaap_FairValueByLiabilityClassAxis_636625070914104144" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_636625070914104144" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="prpo_A2016WarrantLiabilityMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070914104144" xlink:to="prpo_A2016WarrantLiabilityMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636625070914104144" xlink:to="us-gaap_LitigationStatusAxis_636625070914104144" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis_636625070914104144" xlink:to="us-gaap_LitigationStatusDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusDomain_636625070914104144" xlink:to="us-gaap_SettledLitigationMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636625070914104144" xlink:to="us-gaap_LitigationCaseAxis_636625070914104144" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis_636625070914104144" xlink:to="us-gaap_LitigationCaseTypeDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CredeMember" xlink:label="prpo_CredeMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain_636625070914104144" xlink:to="prpo_CredeMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636625070914104144" xlink:to="us-gaap_StatementLineItems_636625070914104144" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementCommonSharesIssued" xlink:label="prpo_LiabilityForSettlementCommonSharesIssued_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="prpo_LiabilityForSettlementCommonSharesIssued_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementFairValueOfCommonSharesIssued" xlink:label="prpo_LiabilityForSettlementFairValueOfCommonSharesIssued_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="prpo_LiabilityForSettlementFairValueOfCommonSharesIssued_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_636625070914104144" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_636625070914104144" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementPaymentPeriod" xlink:label="prpo_LiabilityForSettlementPaymentPeriod_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="prpo_LiabilityForSettlementPaymentPeriod_636625070914104144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent" xlink:label="us-gaap_SettlementLiabilitiesCurrent_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="us-gaap_SettlementLiabilitiesCurrent_636625070914104144" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914104144" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementOfCommonStockWarrantLiability" xlink:label="prpo_LiabilityForSettlementOfCommonStockWarrantLiability_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="prpo_LiabilityForSettlementOfCommonStockWarrantLiability_636625070914104144" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesPaidValue" xlink:label="us-gaap_LossContingencyDamagesPaidValue_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="us-gaap_LossContingencyDamagesPaidValue_636625070914104144" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_636625070914104144" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:label="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_636625070914104144" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonrecurringIncome" xlink:label="us-gaap_OtherNonrecurringIncome_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="us-gaap_OtherNonrecurringIncome_636625070914104144" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement_636625070914104144" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentMaturityDate_636625070914104144" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40503 - Disclosure - OTHER CURRENT LIABILITIES (Other Current Liabilities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ObigationToIssueCommonShares" xlink:label="prpo_ObigationToIssueCommonShares_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="prpo_ObigationToIssueCommonShares_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LiabilityForSettlementOfEquityInstrument" xlink:label="prpo_LiabilityForSettlementOfEquityInstrument_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="prpo_LiabilityForSettlementOfEquityInstrument_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent_636625070914104144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureContingenciesNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - CONTINGENCIES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55D05FB491EFE64B6F98DA3EA6BCF745" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_55D05FB491EFE64B6F98DA3EA6BCF745" xlink:to="us-gaap_LossContingenciesTable_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_636625070914104144" xlink:to="us-gaap_LitigationCaseAxis_636625070914104144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis_636625070914104144" xlink:to="us-gaap_LitigationCaseTypeDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MountSinaiMember" xlink:label="prpo_MountSinaiMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain_636625070914104144" xlink:to="prpo_MountSinaiMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_XIFINInc.Member" xlink:label="prpo_XIFINInc.Member_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain_636625070914104144" xlink:to="prpo_XIFINInc.Member_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CPAGlobalMember" xlink:label="prpo_CPAGlobalMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain_636625070914104144" xlink:to="prpo_CPAGlobalMember_636625070914104144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_BioRadLaboratoriesMember" xlink:label="prpo_BioRadLaboratoriesMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseTypeDomain_636625070914104144" xlink:to="prpo_BioRadLaboratoriesMember_636625070914104144" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_636625070914104144" xlink:to="us-gaap_SubsequentEventTypeAxis_636625070914104144" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_636625070914104144" xlink:to="us-gaap_SubsequentEventTypeDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_636625070914104144" xlink:to="us-gaap_SubsequentEventMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable_636625070914104144" xlink:to="us-gaap_LossContingenciesLineItems_636625070914104144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_636625070914104144" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_636625070914104144" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_636625070914104144" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_636625070914104144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914104144" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_636625070914104144" xlink:to="us-gaap_SecuredDebt_636625070914104144" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_636625070914104144" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_636625070914104144" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_636625070914104144" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_636625070914104144" order="7" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_636625070914104144" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914104144" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems_636625070914104144" xlink:to="prpo_ClassOfWarrantOrRightTerm_636625070914104144" order="9" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureIncomeTaxesNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - INCOME TAXES (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_304B6B40E3A1C98E6267BAF4C2974F6F" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_304B6B40E3A1C98E6267BAF4C2974F6F" xlink:to="us-gaap_IncomeTaxExpenseBenefit_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_304B6B40E3A1C98E6267BAF4C2974F6F" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails" xlink:type="extended" xlink:title="40801 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_7E4CEF7F84665B3EADFECA59C4DA2D84" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7E4CEF7F84665B3EADFECA59C4DA2D84" xlink:to="us-gaap_ScheduleOfStockByClassTable_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914104144" xlink:to="us-gaap_StatementClassOfStockAxis_636625070914104144" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636625070914104144" xlink:to="us-gaap_ClassOfStockDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914104144" xlink:to="us-gaap_CommonStockMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914104144" xlink:to="us-gaap_SeriesBPreferredStockMember_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914104144" xlink:to="us-gaap_SeriesCPreferredStockMember_636625070914104144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914104144" xlink:to="us-gaap_ShortTermDebtTypeAxis_636625070914104144" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_636625070914104144" xlink:to="us-gaap_ShortTermDebtTypeDomain_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_636625070914104144" xlink:to="us-gaap_BridgeLoanMember_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LevistonResourcesLlcMember" xlink:label="prpo_LevistonResourcesLlcMember_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_636625070914104144" xlink:to="prpo_LevistonResourcesLlcMember_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914104144" xlink:to="us-gaap_ClassOfStockLineItems_636625070914104144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="us-gaap_CommonStockSharesAuthorized_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="prpo_ConversionofStockPerShareConversionPrice_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="prpo_ConversionofStockPerShareConversionPrice_636625070914104144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_636625070914104144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636625070914104144" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_636625070914104144" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="us-gaap_ConversionOfStockSharesConverted1_636625070914104144" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_636625070914104144" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636625070914104144" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_StockNotIssuedShares" xlink:label="prpo_StockNotIssuedShares_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="prpo_StockNotIssuedShares_636625070914104144" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_636625070914104144" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_636625070914104144" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914104144" xlink:to="us-gaap_ProceedsFromWarrantExercises_636625070914104144" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesAndSeriesBPreferredStockDetails" xlink:type="extended" xlink:title="40802 - Disclosure - STOCKHOLDERS' EQUITY (Series A and Series B Preferred Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_DD2928BA7435E8664123C5F8F64ED31D" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_DD2928BA7435E8664123C5F8F64ED31D" xlink:to="us-gaap_PreferredStockSharesOutstanding_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockDetails" xlink:type="extended" xlink:title="40803 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4BA409ECABAC658C19DAC5F8F609EEB4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636625070914104144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4BA409ECABAC658C19DAC5F8F609EEB4" xlink:to="us-gaap_PreferredStockSharesAuthorized_636625070914104144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockInducedConversionsDetails" xlink:type="extended" xlink:title="40804 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Induced Conversions) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_370029D62D9E9BB6A0DBD9DB80D368FD" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_370029D62D9E9BB6A0DBD9DB80D368FD" xlink:to="us-gaap_ScheduleOfStockByClassTable_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914182259" xlink:to="us-gaap_StatementClassOfStockAxis_636625070914182259" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636625070914182259" xlink:to="us-gaap_ClassOfStockDomain_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914182259" xlink:to="us-gaap_PreferredStockMember_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914182259" xlink:to="us-gaap_CommonStockMember_636625070914182259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914182259" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636625070914182259" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636625070914182259" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914182259" xlink:to="prpo_InducementAgreement2018Member_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914182259" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis_636625070914182259" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis_636625070914182259" xlink:to="us-gaap_DebtConversionNameDomain_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAfterConversionPriceReductionMember" xlink:label="prpo_WarrantsAfterConversionPriceReductionMember_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionNameDomain_636625070914182259" xlink:to="prpo_WarrantsAfterConversionPriceReductionMember_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914182259" xlink:to="us-gaap_ClassOfStockLineItems_636625070914182259" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_PreferredStockSharesAuthorized_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_636625070914182259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="prpo_ConversionofStockPerShareConversionPrice_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="prpo_ConversionofStockPerShareConversionPrice_636625070914182259" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_636625070914182259" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_636625070914182259" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_ConversionOfStockAmountConverted1_636625070914182259" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_636625070914182259" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_StockNotIssuedShares" xlink:label="prpo_StockNotIssuedShares_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="prpo_StockNotIssuedShares_636625070914182259" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="prpo_DeemedDividend_636625070914182259" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_ConversionOfStockSharesConverted1_636625070914182259" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_636625070914182259" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914182259" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsExercised" xlink:label="prpo_WarrantsExercised_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="prpo_WarrantsExercised_636625070914182259" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_636625070914182259" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_PreferredStockSharesOutstanding_636625070914182259" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_PreferredStockSharesIssued_636625070914182259" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails" xlink:type="extended" xlink:title="40805 - Disclosure - STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_24C5566F3E21B9FD2E0BDA3EA69BC7D2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_24C5566F3E21B9FD2E0BDA3EA69BC7D2" xlink:to="us-gaap_ScheduleOfStockByClassTable_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914182259" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636625070914182259" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636625070914182259" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PublicStockOfferingMember" xlink:label="prpo_PublicStockOfferingMember_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914182259" xlink:to="prpo_PublicStockOfferingMember_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914182259" xlink:to="prpo_PurchaseAgreement2018Member_636625070914182259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914182259" xlink:to="prpo_InducementAgreement2018Member_636625070914182259" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914182259" xlink:to="us-gaap_StatementClassOfStockAxis_636625070914182259" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636625070914182259" xlink:to="us-gaap_ClassOfStockDomain_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredClassBMember" xlink:label="us-gaap_PreferredClassBMember_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914182259" xlink:to="us-gaap_PreferredClassBMember_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914182259" xlink:to="us-gaap_CommonStockMember_636625070914182259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914182259" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636625070914182259" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636625070914182259" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OfferingWarrantsMember" xlink:label="prpo_OfferingWarrantsMember_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914182259" xlink:to="prpo_OfferingWarrantsMember_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914182259" xlink:to="dei_LegalEntityAxis_636625070914182259" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_636625070914182259" xlink:to="dei_EntityDomain_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_AegisCapitalCorpMember" xlink:label="prpo_AegisCapitalCorpMember_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_636625070914182259" xlink:to="prpo_AegisCapitalCorpMember_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914182259" xlink:to="us-gaap_ClassOfStockLineItems_636625070914182259" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_636625070914182259" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_636625070914182259" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_636625070914182259" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="prpo_ConversionofStockPerShareConversionPrice_636625070914182259" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="prpo_ConversionofStockPerShareConversionPrice_636625070914182259" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_636625070914260374" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_SharePrice_636625070914260374" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_636625070914260374" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914260374" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" xlink:label="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights_636625070914260374" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_ConversionOfStockSharesConverted1_636625070914260374" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_636625070914260374" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_PreferredStockSharesAuthorized_636625070914260374" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_PreferredStockSharesOutstanding_636625070914260374" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_PreferredStockSharesIssued_636625070914260374" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_PreferredStockLiquidationPreference_636625070914260374" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914182259" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_636625070914260374" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCPreferredStockDetails" xlink:type="extended" xlink:title="40806 - Disclosure - STOCKHOLDERS' EQUITY (Series C Preferred Stock) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_636573540804554173" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_636573540804554173" xlink:to="us-gaap_ScheduleOfStockByClassTable_636625070914260374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914260374" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636625070914260374" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636625070914260374" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914260374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PublicStockOfferingMember" xlink:label="prpo_PublicStockOfferingMember_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914260374" xlink:to="prpo_PublicStockOfferingMember_636625070914260374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PlacementAgreementMember" xlink:label="prpo_PlacementAgreementMember_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914260374" xlink:to="prpo_PlacementAgreementMember_636625070914260374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914260374" xlink:to="prpo_PurchaseAgreement2018Member_636625070914260374" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914260374" xlink:to="us-gaap_StatementClassOfStockAxis_636625070914260374" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636625070914260374" xlink:to="us-gaap_ClassOfStockDomain_636625070914260374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914260374" xlink:to="us-gaap_CommonStockMember_636625070914260374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914260374" xlink:to="us-gaap_SeriesCPreferredStockMember_636625070914260374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914260374" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636625070914260374" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636625070914260374" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636625070914260374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OfferingWarrantsMember" xlink:label="prpo_OfferingWarrantsMember_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914260374" xlink:to="prpo_OfferingWarrantsMember_636625070914260374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636625070914260374" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914260374" xlink:to="us-gaap_ClassOfStockLineItems_636625070914260374" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_636625070914338489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConversionofStockPerShareConversionPrice" xlink:label="prpo_ConversionofStockPerShareConversionPrice_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="prpo_ConversionofStockPerShareConversionPrice_636625070914338489" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_SharePrice_636625070914338489" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_636625070914338489" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassofWarrantorRightUnitValueofWarrantsorRights" xlink:label="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="prpo_ClassofWarrantorRightUnitValueofWarrantsorRights_636625070914338489" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_ConversionOfStockSharesConverted1_636625070914338489" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_PreferredStockSharesAuthorized_636625070914338489" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_PreferredStockSharesOutstanding_636625070914338489" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_PreferredStockSharesIssued_636625070914338489" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_PreferredStockLiquidationPreference_636625070914338489" order="14" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_636625070914338489" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914260374" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock_636625070914338489" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails" xlink:type="extended" xlink:title="40807 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_D575294BCB2CE06CB738DA3EA6924079" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsExpiredInPeriod" xlink:label="prpo_WarrantsExpiredInPeriod_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_D575294BCB2CE06CB738DA3EA6924079" xlink:to="prpo_WarrantsExpiredInPeriod_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_D575294BCB2CE06CB738DA3EA6924079" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_D575294BCB2CE06CB738DA3EA6924079" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_D575294BCB2CE06CB738DA3EA6924079" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636625070914338489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_D575294BCB2CE06CB738DA3EA6924079" xlink:to="prpo_ClassOfWarrantOrRightTerm_636625070914338489" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_D575294BCB2CE06CB738DA3EA6924079" xlink:to="us-gaap_PreferredStockValue_636625070914338489" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityOfferingWarrantsDetails" xlink:type="extended" xlink:title="40810 - Disclosure - STOCKHOLDERS' EQUITY (Offering Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6D5F1B0FDF2DB77A29CFDA3EA6826680" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6D5F1B0FDF2DB77A29CFDA3EA6826680" xlink:to="us-gaap_ScheduleOfStockByClassTable_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OfferingWarrantsMember" xlink:label="prpo_OfferingWarrantsMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" xlink:to="prpo_OfferingWarrantsMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_StatementClassOfStockAxis_636625070914338489" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636625070914338489" xlink:to="us-gaap_ClassOfStockDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914338489" xlink:to="us-gaap_CommonStockMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_ClassOfStockLineItems_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights" xlink:label="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="prpo_ClassOfWarrantOrRightTerm_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="prpo_DeemedDividend_636625070914338489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsExercised" xlink:label="prpo_WarrantsExercised_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="prpo_WarrantsExercised_636625070914338489" order="5" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityNoteConversionWarrantsDetails" xlink:type="extended" xlink:title="40814 - Disclosure - STOCKHOLDERS' EQUITY (Note Conversion Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_57ACF23D76E544ABBC34DA3EA639EAB9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_57ACF23D76E544ABBC34DA3EA639EAB9" xlink:to="us-gaap_ScheduleOfStockByClassTable_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_ShortTermDebtTypeAxis_636625070914338489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_636625070914338489" xlink:to="us-gaap_ShortTermDebtTypeDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="us-gaap_BridgeLoanMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_636625070914338489" xlink:to="us-gaap_BridgeLoanMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_StatementClassOfStockAxis_636625070914338489" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636625070914338489" xlink:to="us-gaap_ClassOfStockDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914338489" xlink:to="us-gaap_CommonStockMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_DebtInstrumentAxis_636625070914338489" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636625070914338489" xlink:to="us-gaap_DebtInstrumentNameDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914338489" xlink:to="prpo_InducementAgreement2018Member_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914338489" xlink:to="prpo_PurchaseAgreement2018Member_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_ClassOfStockLineItems_636625070914338489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="prpo_ClassOfWarrantOrRightTerm_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="prpo_DeemedDividend_636625070914338489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityConvertiblePromissoryNoteWarrantsDetails" xlink:type="extended" xlink:title="40815 - Disclosure - STOCKHOLDERS' EQUITY (Convertible Promissory Note Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_636573549550326870" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_636573549550326870" xlink:to="us-gaap_ScheduleOfStockByClassTable_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_DebtInstrumentAxis_636625070914338489" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636625070914338489" xlink:to="us-gaap_DebtInstrumentNameDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914338489" xlink:to="prpo_InducementAgreement2018Member_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914338489" xlink:to="prpo_PurchaseAgreement2018Member_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ConvertiblePromissoryNoteWarrantsMember" xlink:label="prpo_ConvertiblePromissoryNoteWarrantsMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" xlink:to="prpo_ConvertiblePromissoryNoteWarrantsMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_ClassOfStockLineItems_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="prpo_ClassOfWarrantOrRightTerm_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="prpo_DeemedDividend_636625070914338489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCWarrantsDetails" xlink:type="extended" xlink:title="40816 - Disclosure - STOCKHOLDERS' EQUITY (Series C Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_636573553343551622" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_636573553343551622" xlink:to="us-gaap_ScheduleOfStockByClassTable_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_DebtInstrumentAxis_636625070914338489" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636625070914338489" xlink:to="us-gaap_DebtInstrumentNameDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_InducementAgreement2018Member" xlink:label="prpo_InducementAgreement2018Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914338489" xlink:to="prpo_InducementAgreement2018Member_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PurchaseAgreement2018Member" xlink:label="prpo_PurchaseAgreement2018Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914338489" xlink:to="prpo_PurchaseAgreement2018Member_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SeriesCWarrantsMember" xlink:label="prpo_SeriesCWarrantsMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" xlink:to="prpo_SeriesCWarrantsMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_ClassOfStockLineItems_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="prpo_ClassOfWarrantOrRightTerm_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914338489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DeemedDividend" xlink:label="prpo_DeemedDividend_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="prpo_DeemedDividend_636625070914338489" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityCreditorWarrantsDetails" xlink:type="extended" xlink:title="40817 - Disclosure - STOCKHOLDERS' EQUITY (Creditor Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable_636625070914338489" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CreditorWarrantsRelatingToSecuredDebtMember" xlink:label="prpo_CreditorWarrantsRelatingToSecuredDebtMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" xlink:to="prpo_CreditorWarrantsRelatingToSecuredDebtMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636625070914338489" xlink:to="us-gaap_StatementLineItems_636625070914338489" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914338489" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails" xlink:type="extended" xlink:title="40818 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_636573557923972077" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_636573557923972077" xlink:to="us-gaap_ScheduleOfStockByClassTable_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerMember" xlink:label="prpo_WarrantsAssumedInMergerMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" xlink:to="prpo_WarrantsAssumedInMergerMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringApril2020Member" xlink:label="prpo_WarrantsAssumedInMergerExpiringApril2020Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsAssumedInMergerExpiringApril2020Member_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringFebruary2020Member" xlink:label="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsAssumedInMergerExpiringFebruary2020Member_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringDecember2020Member" xlink:label="prpo_WarrantsAssumedInMergerExpiringDecember2020Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsAssumedInMergerExpiringDecember2020Member_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember" xlink:label="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember_636625070914338489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerMember" xlink:label="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914338489" xlink:to="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember_636625070914338489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember_636625070914338489" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember_636625070914338489" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member_636625070914338489" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringMay2023Member" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringMay2023Member_636625070914338489" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember" xlink:label="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_WarrantsNotAssumedInMergerMember_636625070914338489" xlink:to="prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember_636625070914338489" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_636625070914338489" xlink:to="us-gaap_ClassOfStockLineItems_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - FAIR VALUE (Narratives) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8B8131BAA87DC3A576D2D9C4CC3F6E01" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8B8131BAA87DC3A576D2D9C4CC3F6E01" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636625070914338489" xlink:to="us-gaap_FairValueByLiabilityClassAxis_636625070914338489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_636625070914338489" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="prpo_A2016WarrantLiabilityMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070914338489" xlink:to="prpo_A2016WarrantLiabilityMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_636625070914338489" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636625070914338489" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease" xlink:label="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636625070914338489" xlink:to="us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsCanceledInSettlementAgreement" xlink:label="prpo_WarrantsCanceledInSettlementAgreement_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636625070914338489" xlink:to="prpo_WarrantsCanceledInSettlementAgreement_636625070914338489" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636625070914338489" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_636625070914338489" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636625070914338489" xlink:to="us-gaap_SharePrice_636625070914338489" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636625070914338489" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_636625070914338489" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636625070914338489" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_636625070914338489" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_636625070914338489" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_636625070914338489" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureFairValueScheduleOfChangesInFairValueOfLiabilityDetails" xlink:type="extended" xlink:title="40902 - Disclosure - FAIR VALUE (Schedule of Changes in Fair Value of Liability) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3AAAFB03374E9A44CD279CCA02F5EDD7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3AAAFB03374E9A44CD279CCA02F5EDD7" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_636625070914338489" xlink:to="us-gaap_FairValueByLiabilityClassAxis_636625070914338489" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis_636625070914338489" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_A2016WarrantLiabilityMember" xlink:label="prpo_A2016WarrantLiabilityMember_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_636625070914338489" xlink:to="prpo_A2016WarrantLiabilityMember_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_636625070914338489" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_636625070914338489" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636625070914338489" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_TotalGainsOrLossesAbstract" xlink:label="prpo_TotalGainsOrLossesAbstract_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636625070914338489" xlink:to="prpo_TotalGainsOrLossesAbstract_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_TotalGainsOrLossesAbstract_636625070914338489" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_636625070914338489" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_636625070914338489" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_TotalGainsOrLossesAbstract_636625070914338489" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_636625070914338489" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6366250709143384891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_636625070914338489" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6366250709143384891" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - EQUITY INCENTIVE PLAN (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B94C38EFA06B2B8897CA9CCA02C09FEB" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_B94C38EFA06B2B8897CA9CCA02C09FEB" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636625070914416604" xlink:to="us-gaap_RangeAxis_636625070914416604" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis_636625070914416604" xlink:to="us-gaap_RangeMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636625070914416604" xlink:to="us-gaap_MinimumMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember_636625070914416604" xlink:to="us-gaap_MaximumMember_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636625070914416604" xlink:to="us-gaap_PlanNameAxis_636625070914416604" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_636625070914416604" xlink:to="us-gaap_PlanNameDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityIncentivePlan2017Member" xlink:label="prpo_EquityIncentivePlan2017Member_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_636625070914416604" xlink:to="prpo_EquityIncentivePlan2017Member_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636625070914416604" xlink:to="us-gaap_AwardTypeAxis_636625070914416604" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636625070914416604" xlink:to="us-gaap_EmployeeStockOptionMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636625070914416604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" xlink:label="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized_636625070914416604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_636625070914416604" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_636625070914416604" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_636625070914416604" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_636625070914416604" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_636625070914416604" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_636625070914416604" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_636625070914416604" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_636625070914416604" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_636625070914416604" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_636625070914416604" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_636625070914416604" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_636625070914416604" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_636625070914416604" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="41001 - Disclosure - EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E4FAD32CE1327705A53FCA59C3FDFBD9" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E4FAD32CE1327705A53FCA59C3FDFBD9" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636625070914416604" xlink:to="us-gaap_AwardTypeAxis_636625070914416604" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_636625070914416604" xlink:to="us-gaap_EmployeeStockOptionMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6366250709144166041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6366250709144166041" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6366250709144166041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6366250709144166041" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_636625070914416604" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_636625070914416604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Narrative) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636583686611251286" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636583686611251286" xlink:to="us-gaap_DeferredRevenueCurrent_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfNetRevenuesDetails" xlink:type="extended" xlink:title="41103 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable_636625070914416604" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_636625070914416604" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" order="1" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_MedicaidMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_MedicareMember_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="us-gaap_SelfPayMember_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="us-gaap_ThirdPartyPayorMember_636625070914416604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ContractDiagnosticServicesMember" xlink:label="prpo_ContractDiagnosticServicesMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_ContractDiagnosticServicesMember_636625070914416604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_636625070914416604" xlink:to="us-gaap_ProductOrServiceAxis_636625070914416604" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis_636625070914416604" xlink:to="us-gaap_ProductsAndServicesDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_DiagnosticTestingMember" xlink:label="prpo_DiagnosticTestingMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain_636625070914416604" xlink:to="prpo_DiagnosticTestingMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_BiomarkerTestingAndClinicalProjectServicesMember" xlink:label="prpo_BiomarkerTestingAndClinicalProjectServicesMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain_636625070914416604" xlink:to="prpo_BiomarkerTestingAndClinicalProjectServicesMember_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_636625070914416604" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="us-gaap_SalesRevenueServicesNet_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails" xlink:type="extended" xlink:title="41104 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636625014632937089" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636625014632937089" xlink:to="us-gaap_DisaggregationOfRevenueTable_636625070914416604" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_636625070914416604" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_MedicaidMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_MedicareMember_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="us-gaap_SelfPayMember_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="us-gaap_ThirdPartyPayorMember_636625070914416604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ContractDiagnosticServicesMember" xlink:label="prpo_ContractDiagnosticServicesMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_ContractDiagnosticServicesMember_636625070914416604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherPartyMember" xlink:label="prpo_OtherPartyMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_OtherPartyMember_636625070914416604" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_636625070914416604" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueGoodsGross" xlink:label="us-gaap_SalesRevenueGoodsGross_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="us-gaap_SalesRevenueGoodsGross_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherSalesRevenueGross" xlink:label="prpo_OtherSalesRevenueGross_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="prpo_OtherSalesRevenueGross_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_GrossRevenueIncludingOtherAdjustments" xlink:label="prpo_GrossRevenueIncludingOtherAdjustments_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="prpo_GrossRevenueIncludingOtherAdjustments_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesDiscountsReturnsAndAllowancesGoods" xlink:label="us-gaap_SalesDiscountsReturnsAndAllowancesGoods_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="us-gaap_SalesDiscountsReturnsAndAllowancesGoods_636625070914416604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueServicesNet" xlink:label="us-gaap_SalesRevenueServicesNet_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="us-gaap_SalesRevenueServicesNet_636625070914416604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSalesRevenueNet" xlink:label="us-gaap_OtherSalesRevenueNet_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="us-gaap_OtherSalesRevenueNet_636625070914416604" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_RevenueNetOfAllowanceAndAdjustments" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="prpo_RevenueNetOfAllowanceAndAdjustments_636625070914416604" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails" xlink:type="extended" xlink:title="41105 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636622461969554984" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636622461969554984" xlink:to="us-gaap_DisaggregationOfRevenueTable_636625070914416604" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_636625070914416604" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_MedicaidMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_MedicareMember_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="us-gaap_SelfPayMember_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="us-gaap_ThirdPartyPayorMember_636625070914416604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ContractDiagnosticServicesMember" xlink:label="prpo_ContractDiagnosticServicesMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_ContractDiagnosticServicesMember_636625070914416604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ServicesRevenueNetMember" xlink:label="prpo_ServicesRevenueNetMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_ServicesRevenueNetMember_636625070914416604" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_OtherPartyMember" xlink:label="prpo_OtherPartyMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_OtherPartyMember_636625070914416604" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_636625070914416604" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_RevenueNetOfAllowanceAndAdjustments" xlink:label="prpo_RevenueNetOfAllowanceAndAdjustments_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="prpo_RevenueNetOfAllowanceAndAdjustments_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="us-gaap_SalesAllowancesServices_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="us-gaap_SalesAllowancesServices_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_636625070914416604" xlink:to="us-gaap_Revenues_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails" xlink:type="extended" xlink:title="41106 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636590571094092724" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract_636590571094092724" xlink:to="us-gaap_StatementTable_636625070914416604" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636625070914416604" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_MedicaidMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_MedicareMember_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="us-gaap_SelfPayMember_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="us-gaap_ThirdPartyPayorMember_636625070914416604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ContractDiagnosticServicesMember" xlink:label="prpo_ContractDiagnosticServicesMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_ContractDiagnosticServicesMember_636625070914416604" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636625070914416604" xlink:to="us-gaap_StatementLineItems_636625070914416604" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914416604" xlink:to="us-gaap_AccountsReceivableGross_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914416604" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914416604" xlink:to="us-gaap_AccountsReceivableNet_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails" xlink:type="extended" xlink:title="41107 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:label="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract" xlink:to="us-gaap_StatementTable_636625070914416604" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesAxis" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636625070914416604" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_HealthCareOrganizationRevenueSourcesDomain" xlink:label="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesAxis_636625070914416604" xlink:to="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicaidMember" xlink:label="prpo_MedicaidMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_MedicaidMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MedicareMember" xlink:label="prpo_MedicareMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="prpo_MedicareMember_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelfPayMember" xlink:label="us-gaap_SelfPayMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="us-gaap_SelfPayMember_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ThirdPartyPayorMember" xlink:label="us-gaap_ThirdPartyPayorMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HealthCareOrganizationRevenueSourcesDomain_636625070914416604" xlink:to="us-gaap_ThirdPartyPayorMember_636625070914416604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_636625070914416604" xlink:to="us-gaap_StatementLineItems_636625070914416604" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914416604" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesAllowancesServices" xlink:label="us-gaap_SalesAllowancesServices_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914416604" xlink:to="us-gaap_SalesAllowancesServices_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914416604" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries_636625070914416604" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914416604" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_636625070914416604" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_6366250709144166041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_636625070914416604" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_6366250709144166041" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.precipiodx.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_71AAAAB21A39AC575939DA3EA608B163" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_71AAAAB21A39AC575939DA3EA608B163" xlink:to="us-gaap_SubsequentEventTable_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636625070914416604" xlink:to="us-gaap_LongtermDebtTypeAxis_636625070914416604" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_636625070914416604" xlink:to="us-gaap_LongtermDebtTypeDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_636625070914416604" xlink:to="us-gaap_ConvertibleDebtMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SeniorSecuredConvertiblePromissoryNotesMember" xlink:label="prpo_SeniorSecuredConvertiblePromissoryNotesMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConvertibleDebtMember_636625070914416604" xlink:to="prpo_SeniorSecuredConvertiblePromissoryNotesMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636625070914416604" xlink:to="us-gaap_DebtInstrumentAxis_636625070914416604" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_636625070914416604" xlink:to="us-gaap_DebtInstrumentNameDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_SecuritiesPurchaseAgreementMember" xlink:label="prpo_SecuritiesPurchaseAgreementMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_636625070914416604" xlink:to="prpo_SecuritiesPurchaseAgreementMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636625070914416604" xlink:to="us-gaap_SubsequentEventTypeAxis_636625070914416604" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_636625070914416604" xlink:to="us-gaap_SubsequentEventTypeDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_636625070914416604" xlink:to="us-gaap_SubsequentEventMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636625070914416604" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_636625070914416604" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_636625070914416604" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PreferredStockInducedConversionsSecondInvestorMember" xlink:label="prpo_PreferredStockInducedConversionsSecondInvestorMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914416604" xlink:to="prpo_PreferredStockInducedConversionsSecondInvestorMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PreferredStockInducedConversionsFirstInvestorMember" xlink:label="prpo_PreferredStockInducedConversionsFirstInvestorMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_636625070914416604" xlink:to="prpo_PreferredStockInducedConversionsFirstInvestorMember_636625070914416604" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636625070914416604" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_636625070914416604" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_636625070914416604" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_LevistonResourcesLlcMember" xlink:label="prpo_LevistonResourcesLlcMember_636625070914416604" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_636625070914416604" xlink:to="prpo_LevistonResourcesLlcMember_636625070914416604" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636625070914416604" xlink:to="us-gaap_StatementClassOfStockAxis_636625070914494719" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_636625070914494719" xlink:to="us-gaap_ClassOfStockDomain_636625070914494719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914494719" xlink:to="us-gaap_ConvertiblePreferredStockMember_636625070914494719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_636625070914494719" xlink:to="us-gaap_CommonStockMember_636625070914494719" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636625070914416604" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_636625070914494719" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_636625070914494719" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_636625070914494719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain_636625070914494719" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_636625070914494719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_636625070914416604" xlink:to="us-gaap_SubsequentEventLineItems_636625070914494719" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_DebtInstrumentFaceAmount_636625070914494719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_636625070914494719" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_636625070914494719" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_636625070914494719" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_DebtInstrumentTerm_636625070914494719" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue" xlink:label="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue_636625070914494719" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightTerm" xlink:label="prpo_ClassOfWarrantOrRightTerm_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_ClassOfWarrantOrRightTerm_636625070914494719" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_SecuredDebt_636625070914494719" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_636625070914494719" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_636625070914494719" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized" xlink:label="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized_636625070914494719" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_636625070914494719" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_636625070914494719" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreement" xlink:label="prpo_EquityPurchaseAgreement_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_EquityPurchaseAgreement_636625070914494719" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementCommitmentFeePercentage" xlink:label="prpo_EquityPurchaseAgreementCommitmentFeePercentage_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_EquityPurchaseAgreementCommitmentFeePercentage_636625070914494719" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage" xlink:label="prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage_636625070914494719" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementFee" xlink:label="prpo_EquityPurchaseAgreementFee_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_EquityPurchaseAgreementFee_636625070914494719" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_EquityPurchaseAgreementFeeContingentDiscount" xlink:label="prpo_EquityPurchaseAgreementFeeContingentDiscount_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_EquityPurchaseAgreementFeeContingentDiscount_636625070914494719" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_636625070914494719" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_SharePrice_636625070914494719" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_636625070914494719" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_636625070914494719" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_636625070914494719" order="23" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CompanyStockPercentageOfMarketRate" xlink:label="prpo_CompanyStockPercentageOfMarketRate_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_CompanyStockPercentageOfMarketRate_636625070914494719" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement" xlink:label="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement_636625070914494719" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_636625070914494719" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised" xlink:label="prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised_636625070914494719" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock" xlink:label="prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock_636625070914494719" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="prpo-20180331.xsd#prpo_CommonStockPurchaseFee" xlink:label="prpo_CommonStockPurchaseFee_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="prpo_CommonStockPurchaseFee_636625070914494719" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_636625070914494719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_636625070914494719" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_636625070914494719" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816204992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DOCUMENT AND ENTITY INFORMATION - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>May 18, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Precipio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001043961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,668,572<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816834736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">209<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">4,391<span></span>
</td>
<td class="nump">4,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangibles, net</a></td>
<td class="nump">20,138<span></span>
</td>
<td class="nump">20,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">26,093<span></span>
</td>
<td class="nump">27,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities of long-term debt</a></td>
<td class="nump">676<span></span>
</td>
<td class="nump">587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,956<span></span>
</td>
<td class="nump">5,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Current maturities of capital leases</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,529<span></span>
</td>
<td class="nump">1,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">2,982<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,751<span></span>
</td>
<td class="nump">10,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, less current maturities and discounts</a></td>
<td class="nump">2,894<span></span>
</td>
<td class="nump">2,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Common stock warrant liability</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Capital leases, less current maturities</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred tax liability</a></td>
<td class="nump">349<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,685<span></span>
</td>
<td class="nump">14,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.01 par value, 15,000,000 shares authorized at March 31, 2018 and December 31, 2017, respectively, 47 and 4,935 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 150,000,000 and 150,000,000 shares authorized at March 31, 2018 and December 31, 2017, respectively, 19,668,572 and 10,196,620 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">47,192<span></span>
</td>
<td class="nump">44,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(33,981)<span></span>
</td>
<td class="num">(31,542)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">13,408<span></span>
</td>
<td class="nump">13,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Liabilities and stockholders' equity</a></td>
<td class="nump">$ 26,093<span></span>
</td>
<td class="nump">$ 27,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=82849420&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68049868&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802833296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">19,668,572<span></span>
</td>
<td class="nump">10,196,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">19,668,572<span></span>
</td>
<td class="nump">10,196,620<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816730912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Service revenue, net</a></td>
<td class="nump">$ 791<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">less allowance for doubtful accounts</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">688<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Operating expenses</a></td>
<td class="nump">2,178<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">2,472<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(2,448)<span></span>
</td>
<td class="num">(596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_InterestIncomeAndExpenseNet', window );">Interest expense, net</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_GainLossOnStockWarrantsRevaluation', window );">Warrant revaluation</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain on settlement liability, net</a></td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnNonRecourseDebt', window );">Loss on settlement of equity instrument</a></td>
<td class="num">(385)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_OtherIncomeExpense', window );">Other expense</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE INCOME TAXES</a></td>
<td class="num">(2,439)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">INCOME TAX EXPENSE</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">(2,439)<span></span>
</td>
<td class="num">(758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPreferredStockDividendsAndAdjustments', window );">DEEMED DIVIDENDS ON ISSUANCE OR EXCHANGE OF PREFERRED UNITS</a></td>
<td class="num">(3,514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">TOTAL DIVIDENDS</a></td>
<td class="num">(3,514)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS AVAILABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (5,953)<span></span>
</td>
<td class="num">$ (758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE)</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES)</a></td>
<td class="nump">12,576,037<span></span>
</td>
<td class="nump">449,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_GainLossOnStockWarrantsRevaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_GainLossOnStockWarrantsRevaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_InterestIncomeAndExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income and (expense), net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_InterestIncomeAndExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_OtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_OtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_RevenueNetOfAllowanceAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue net of allowance and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_RevenueNetOfAllowanceAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnNonRecourseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the difference between the cash acquisition price of the debt and the net carrying amount of the debt at the time of its extinguishment (or deconsolidation of in-substance real estate when an entity defaults on its debt obligations).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnNonRecourseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPreferredStockDividendsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of preferred stock dividends and adjustments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SAB Topic 5.Q)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187283-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPreferredStockDividendsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAllowancesServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate selling price reductions recognized during an accounting period due to the rendering of deficient or nonconforming services. Allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAllowancesServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816449856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS USED IN OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net loss</a></td>
<td class="num">$ (2,439)<span></span>
</td>
<td class="num">$ (758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing costs and debt discount</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain on settlement of liability</a></td>
<td class="num">(141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfEquityInvestments', window );">Loss on settlement of equity instrument</a></td>
<td class="nump">385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation and change in liability of stock appreciation rights</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for losses on doubtful accounts</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant revaluation</a></td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">94<span></span>
</td>
<td class="num">(47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,145)<span></span>
</td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS PROVIDED BY INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments on capital lease obligations</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible bridge notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on long-term debt</a></td>
<td class="num">(116)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">1,015<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET CHANGE IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">286<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NON-CASH INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of equipment financed through accounts payable</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred debt issuance cost financed through accounts payable</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Other current liabilities canceled in exchange for common shares</a></td>
<td class="nump">1,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Warrant liability canceled due to settlement of equity instruments</a></td>
<td class="nump">$ 456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of equity securities, not separately or otherwise categorized as trading or available-for-sale. This element includes investments in which the entity holds a small ownership stake (generally, less than 20% of the shares outstanding) and cannot exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4613673-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130534-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807476352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS DESCRIPTION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BUSINESS DESCRIPTION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">BUSINESS DESCRIPTION</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">1. BUSINESS DESCRIPTION</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Business Description.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Precipio, Inc., and Subsidiary, (&#x201C;we&#x201D;, &#x201C;us&#x201D;, &#x201C;our&#x201D;, the &#x201C;Company&#x201D; or &#x201C;Precipio&#x201D;) is a cancer diagnostics company providing diagnostic products and services to the oncology market. We have built and continue to develop a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide. We operate a cancer diagnostic laboratory located in New Haven, Connecticut and have partnered with the Yale School of Medicine to capture the expertise, experience and technologies developed within academia so that we can provide a better standard of cancer diagnostics and solve the growing problem of cancer misdiagnosis. We also operate a research and development facility in Omaha, Nebraska which will focus on further development of ICE-COLD-PCR (&#x201C;ICP&#x201D;), the patented technology which was exclusively licensed by us from Dana-Farber Cancer Institute, Inc. (&#x201C;Dana-Farber&#x201D;) at Harvard University (&#x201C;Harvard&#x201D;). The research and development center will focus on the development of this technology, which we believe will enable us to commercialize other technologies developed by our current and future academic partners. Our platform connects patients, physicians and diagnostic experts residing within academic institutions. Launched in 2017, the platform facilitates the following relationships:</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Patients: patients may search for physicians in their area and consult directly with academic experts that are on the platform. Patients may also have access to new academic discoveries as they become commercially available.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Physicians: physicians can connect with academic experts to seek consultations on behalf of their patients and may also provide consultations for patients in their area seeking medical expertise in that physician&#x2019;s relevant specialty. Physicians will also have access to new diagnostic solutions to help improve diagnostic accuracy.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Academic Experts: academic experts on the platform can make themselves available for patients or physicians seeking access to their expertise. Additionally, these experts have a platform available to commercialize their research discoveries.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We intend to continue updating our platform to allow for patient-to-patient communications and allow individuals to share stories and provide support for one another, to allow physicians to consult with their peers to discuss and share challenges and solutions, and to allow academic experts to interact with others in academia on the platform to discuss their research and cross-collaborate.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">ICP was developed at Harvard and is licensed exclusively by us from Dana-Farber. The technology enables the detection of genetic mutations in liquid biopsies, such as blood samples. The field of liquid biopsies is a rapidly growing market, aimed at solving the challenge of obtaining genetic information on disease progression and changes from sources other than a tumor biopsy.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Gene sequencing is performed on tissue biopsies taken surgically from the tumor site in order to identify potential therapies that will be more effective in treating the patient. There are several limitations to this process. First, surgical procedures have several limitations, including:</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Cost: surgical procedures are usually performed in a costly hospital environment. For example, according to a recent study the mean cost of lung biopsies is greater than </font><font style="display: inline;">$14,000</font><font style="display: inline;">; surgery also involves hospitalization and recovery time.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Surgical access: various tumor sites are not always accessible (e.g. brain tumors), in which cases no biopsy is available for diagnosis.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Risk: patient health may not permit undergoing an invasive surgery; therefore a biopsy cannot be obtained at all.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Time: the process of scheduling and coordinating a surgical procedure often takes time, delaying the start of patient treatment.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Second, there are several tumor-related limitations that provide a challenge to obtaining such genetic information from</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">a tumor:</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Tumors are heterogeneous by nature: a tissue sample from one area of the tumor may not properly represent the tumor&#x2019;s entire genetic composition; thus, the diagnostic results from a tumor may be incomplete and non-representative.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Metastases: in order to accurately test a patient with metastatic disease, ideally an individual biopsy sample should be taken from each site (if those sites are even known). These biopsies are very difficult to obtain; therefore physicians often rely on biopsies taken from the primary tumor site.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The advent of technologies enabling liquid biopsies as an alternative to tumor biopsy and analysis is based on the fact that tumors (both primary and metastatic) shed cells and fragments of DNA into the blood stream. These blood samples are called &#x201C;liquid biopsies&#x201D; that contain circulating tumor DNA, or ctDNA, which hold the same genetic information found in the tumor(s). That tumor DNA is the target of genetic analysis. However, since the quantity of tumor DNA is very small in proportion to the &#x201C;normal&#x201D; (or &#x201C;healthy&#x201D;) DNA within the blood stream, there is a need to identify and separate the tumor DNA from the normal DNA.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">ICP is an enrichment technology that enables the laboratory to focus its analysis on the tumor DNA by enriching, and thereby &#x201C;multiplying&#x201D; the presence of, tumor DNA, while maintaining the normal DNA at its same level. Once the enrichment process has been completed, the laboratory genetic testing equipment is able to identify genetic abnormalities presented in the ctDNA, and an analysis can be conducted at a higher level of sensitivity, to enable the detection of such genetic abnormalities. The technology is encapsulated into a chemical that is provided in the form of a kit and sold to other laboratories who wish to conduct these tests in-house. The chemical within the kit is added to the specimen preparation process, enriching the sample for the tumor DNA so that the analysis will detect those genetic abnormalities.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Merger Transaction</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On </font><font style="display: inline;">June&nbsp;29, 2017</font><font style="display: inline;">, the Company (then known as &#x201C;Transgenomic, Inc.&#x201D;, or &#x201C;Transgenomic&#x201D;), completed a reverse merger (the &#x201C;Merger&#x201D;) with </font><font style="display: inline;">Precipio Diagnostics, LLC, a privately held Delaware limited liability company</font><font style="display: inline;"> (&#x201C;Precipio Diagnostics&#x201D;) in accordance with the terms of the Agreement and Plan of Merger (the &#x201C;Merger Agreement&#x201D;), dated </font><font style="display: inline;">October&nbsp;12, 2016</font><font style="display: inline;">, as amended on February&nbsp;2, 2017 and June&nbsp;29, 2017, by and among Transgenomic, Precipio Diagnostics and New Haven Labs Inc. (&#x201C;Merger Sub&#x201D;) a wholly-owned subsidiary of Transgenomic. Pursuant to the Merger Agreement, Merger Sub merged with and into Precipio Diagnostics, with Precipio Diagnostics surviving the Merger as a wholly-owned subsidiary of the combined company. Upon the consummation of the Merger, the historical financial statements of Precipio Diagnostics become the Company's historical financial statements. Accordingly, the historical financial statements of Precipio Diagnostics are included in the comparative prior periods.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">As a result of the Merger, historical preferred stock, common stock, restricted units, warrants and additional paid-in capital, including share and per share amounts, have been retroactively adjusted to reflect the equity structure of the combined company, including the effect of the Merger exchange ratio. Pursuant to the Merger Agreement, each outstanding unit of Precipio Diagnostics was exchanged for </font><font style="display: inline;">10.2502</font><font style="display: inline;"> pre-reverse stock split shares of Company Common Stock.</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Going Concern.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The </font><font style="display: inline;">condensed </font><font style="display: inline;">consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (&#x201C;GAAP&#x201D;) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the past </font><font style="display: inline;">few</font><font style="display: inline;"> years. As of </font><font style="display: inline;">March</font><font style="display: inline;"> 31, 201</font><font style="display: inline;">8</font><font style="display: inline;">, the Company had a net loss of </font><font style="display: inline;">$2.4</font><font style="display: inline;"> million, negative working capital of </font><font style="display: inline;">$7.5</font><font style="display: inline;"> million and net cash used in operating activities of </font><font style="display: inline;">$</font><font style="display: inline;">1.1</font><font style="display: inline;"> million. The Company&#x2019;s ability to continue as a going concern </font><font style="display: inline;">over the next twelve months from the date of issuance of this Form 10-Q </font><font style="display: inline;">is dependent upon a combination of achieving its business plan, including generating additional revenue, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due.&nbsp; </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">To meet its current and future obligations the Company has taken the following steps to capitalize the business and successfully achieve its business plan:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-bottom:1pt none #D9D9D9;font-size:11pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 11pt;margin:0pt;">
			<font style="display: inline;color:#000000;">On April 13, 2018, the Company filed a Form S-1 General Registration Statement to register and offer for future sale shares of our common stock,&nbsp;pursuant to entering into an </font><font style="display: inline;color:#000000;">Equity Purchase Agreement with Leviston Resources LLC (the &#x201C;Investor&#x201D;) on February 8, 2018. &nbsp;See Note 8 &#x2013; Stockholders&#x2019; Equity for further details.</font><font style="display: inline;font-size:11pt;color:#000000;">&nbsp;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;"><p style="width:18pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;border-top:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">On April 20, 2018, the Company&nbsp;entered into a securities purchase agreement (the &#x201C;Agreement&#x201D;) with certain investors, pursuant to which the Company will issue up to approximately </font><font style="display: inline;color:#000000;">$3,296,703.30</font><font style="display: inline;color:#000000;"> in </font><font style="display: inline;color:#000000;">8%</font><font style="display: inline;color:#000000;"> Senior Secured Convertible Promissory Notes with </font><font style="display: inline;color:#000000;">100%</font><font style="display: inline;color:#000000;"> common stock warrant coverage. </font><font style="display: inline;color:#000000;">See Note 12 &#x2013; Subsequent Events for further details.</font></p></td></tr></table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
			<font style="display: inline;font-size:11pt;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company&#x2019;s ability to continue as a going concern</font><font style="display: inline;color:#000000;"> over the next twelve months from the date of issuance of the Form 10-Q</font><font style="display: inline;color:#000000;">. There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern</font><font style="display: inline;color:#000000;"> over the next twelve months from the date of issuance of the Form 10-Q</font><font style="display: inline;color:#000000;">. The accompanying financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments that might result should the Company be unable to continue as a going concern as a result of the outcome of this uncertainty.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;color:#000000;">Nasdaq Delisting Notice </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">On March 26, 2018, Precipio, Inc. received written notice (the &#x201C;Notice&#x201D;) from The Nasdaq Stock Market LLC (&#x201C;Nasdaq&#x201D;) indicating that, based on the closing bid price of the Company&#x2019;s common stock for the preceding 30 consecutive business days</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market (the &#x201C;Minimum Bid Price Requirement&#x201D;). The Notice has no immediate effect on the listing of Precipio&#x2019;s common stock, and its common stock will continue to trade on the Nasdaq Capital Market under the symbol &#x201C;PRPO&#x201D; at this time.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">In accordance with Nasdaq Listing Rule 5810(c)(3)(A), Precipio has a period of 180 calendar days, or until September 24, 2018 to regain compliance with the Minimum Bid Price Requirement.</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">The Company intends to monitor the closing bid price of its common stock and consider its available options to resolve its noncompliance with the Minimum Bid Price Requirement. </font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800045184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">2.&nbsp;&nbsp;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Basis of Presentation.</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. We have evaluated events occurring subsequent to March 31, 2018 for potential recognition or disclosure in the condensed consolidated financial statements and concluded that, other than what is disclosed within the notes to unaudited condensed consolidated financial statements and in Note 12 - Subsequent Events, there were no other subsequent events that required recognition or disclosure.</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The condensed consolidated balance sheet as of December&nbsp;31, 2017 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2017. The accompanying condensed consolidated financial statements as of and for the three months ended March&nbsp;31, 2018 and 2017 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December&nbsp;31, 2017 contained in our Annual Report Form 10-K, filed with the Securities and Exchange Commission (the &#x201C;SEC&#x201D;) on April 13, 2018. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2018.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Recent Accounting Pronouncements. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2014-09, Revenue from Contracts with Customers and has subsequently issued supplemental and/or clarifying ASUs (collectively &#x201C;ASC 606&#x201D;). ASC 606 outlines a five-step framework that intends to clarify the principles for recognizing revenue and eliminate industry-specific guidance. In addition, ASC 606 revises current disclosure requirements in an effort to help financial statement users better understand the nature, amount, timing, and uncertainty of revenue that is recognized. ASC 606 may be applied either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We adopted this new standard as of January 1, 2018, by using the modified-retrospective method. An adjustment was not required and a change to the prior revenue recognition process and policy to adopt the new standard was not necessary. See Note 11 &#x2013; Sales Service Revenue, Net And Accounts Receivable for further details.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="display: inline;font-style:italic;">Leases</font><font style="display: inline;">. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In January 2017, FASB issued ASU No.&nbsp;2017-01, </font><font style="display: inline;font-style:italic;">Business Combinations</font><font style="display: inline;"> (Topic 805): Clarifying the Definition of a Business.&nbsp;&nbsp;ASU No. 2017-01 adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. The adoption of ASU No. 2017-01 did not have a material effect on the Company&#x2019;s financial position and results of operations.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In May 2017, the FASB issued ASU 2017-09 &#x201C;</font><font style="display: inline;font-style:italic;">Compensation &#x2013; Stock Compensation (Topic 718): Scope of Modification Accounting&#x201D;, </font><font style="display: inline;">which provides clarity and reduces both diversity in practice and cost and complexity when applying guidance in Topic 718. This amendment provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. &nbsp;The amendments are effective for all entities for annual periods, and interim periods within those periods, beginning after December 15, 2017. The adoption of ASU No. 2017-09 did not have a material effect on the Company&#x2019;s financial position and results of operations.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Property and Equipment, net.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Depreciation expense was less than </font><font style="display: inline;">$0.1</font><font style="display: inline;"> million for both the three months March&nbsp;31, 2018 and 2017. Depreciation expense during each year includes depreciation related to equipment acquired under capital leases.</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Goodwill and Intangible Assets.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As a result of the Merger, the Company recorded goodwill and intangible assets as part of its allocation of the purchase consideration.</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">Goodwill</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets of the business acquired. Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may indicate that the assets might be impaired. During the three months ended March 31, 2018, the Company experienced a decline in its share price and a reduction in its market capitalization, as such the Company determined that an assessment of goodwill should be performed using the qualitative approach. Based on the qualitative assessment, the Company concluded that it was more likely than not that the fair value of the Company was less than its carry value. As part of its analysis, the Company considered triggering events and compared its fair value with its carrying value. The analysis of the fair value of the Company involved using the discounted cash flow model. Based on the analysis, the Company concluded that its carrying value exceeded its fair value and goodwill impairment in the amount of </font><font style="display: inline;">$0.3</font><font style="display: inline;"> million was recorded for the three months ended March 31, 2018.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">Intangibles</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Amortization expense for intangible assets was </font><font style="display: inline;">$0.3</font><font style="display: inline;"> million and zero during the three months ended March&nbsp;31, 2018 and 2017, respectively. Amortization expense for intangible assets is expected to be </font><font style="display: inline;">$1.2</font><font style="display: inline;"> million, </font><font style="display: inline;">$1.0</font><font style="display: inline;"> million, </font><font style="display: inline;">$1.0</font><font style="display: inline;"> million, </font><font style="display: inline;">$0.9</font><font style="display: inline;"> million and </font><font style="display: inline;">$0.9</font><font style="display: inline;"> million for each of the years ending December 31, 2018, 2019, 2020, 2021 and 2022, respectively.</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Revenue Recognition.</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Revenue recognition occurs when a customer obtains control of the promised goods and service. Revenue assigned to the goods and services reflects the consideration which the Company expects to receive in exchange for those goods and services.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company derives its revenues from Diagnostic Testing - histology, flow cytometry, cytology and molecular testing; Clinical Research from bio-pharma customers, state and federal grant programs; and from Biomarker Testing from bio-pharma customers. All sources of revenue are recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. Due to differences in the substance of these revenue types, the transactions require, and the Company utilizes, different revenue recognition policies for each. See more detailed information on revenue in Note 11 &#x2013; Sales Service Revenue, Net And Accounts Receivable.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company recognizes revenue utilizing the five-step framework of ASC 606. Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for diagnostic testing at a point in time based on the delivery method (web-portal access or fax) for a patient&#x2019;s laboratory report. Diagnostic testing service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payors. Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions for third-party payor settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined. For clinical research and biomarker services, the Company utilizes an &#x201C;effort based&#x201D; method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results per the contract.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. Deferred net sales included in the balance sheet as deferred revenue was </font><font style="display: inline;">$0.2 million and less than $0.1 million</font><font style="display: inline;"> as of March 31, 2018 and December 31, 2017, respectively.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Loss Per Share.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.&nbsp;&nbsp;Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to </font><font style="display: inline;">9,506,515</font><font style="display: inline;"> and </font><font style="display: inline;">2,753,814</font><font style="display: inline;"> shares of our common stock have been excluded from the computation of diluted loss per share at March 31, 2018 and 2017, respectively, because the effect is anti-dilutive due to the net loss.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;font-family:Calibri;font-size:11pt;">
			<tr>
				<td valign="top" style="width:81.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:61.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:124.35pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">March 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">2018</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Stock options</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,520,059&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,651&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Warrants</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,923,789&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,971,058&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Preferred stock</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">62,667&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">780,105&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Total</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,506,515&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,753,814&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807373232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVERSE MERGER<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>REVERSE MERGER [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">REVERSE MERGER</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">3.&nbsp;&nbsp;REVERSE MERGER</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Unaudited pro forma information</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The operating results of Transgenomic </font><font style="display: inline;">have b</font><font style="display: inline;">een included in the Company's consolidated financial statements for </font><font style="display: inline;">all </font><font style="display: inline;">period</font><font style="display: inline;">s</font><font style="display: inline;"> after </font><font style="display: inline;">June 29, 2017</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2017 and combines Transgenomic&#x2019;s unaudited condensed consolidated statement of operations for the three months ended March&nbsp;31, 2017 with Precipio&#x2019;s unaudited condensed statement of operations for the three months ended March&nbsp;31, 2017:</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:405.00pt;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:195.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Dollars in thousands, except per share amounts</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="7" valign="bottom" style="width:210.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">For the Three Months Ended March 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:10.00pt;border-top:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Net sales</font></p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">712
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">907
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Net loss available to common stockholders</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5,953
				</td>
				<td valign="bottom" style="width:03.85pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:10.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,778
				</td>
				<td valign="bottom" style="width:03.85pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Loss per common share</font></p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.47
				</td>
				<td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:10.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.42
				</td>
				<td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;background-color: #auto;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800043216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>LONG-TERM DEBT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">LONG-TERM DEBT</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">4</font><font style="display: inline;font-weight:bold;">. LONG-TERM DEBT</font><font style="display: inline;font-weight:bold;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Long-term debt consists of the following:</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:510.00pt;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:302.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="7" valign="bottom" style="width:204.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Dollars&nbsp;in&nbsp;Thousands</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">March 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:13.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">December 31, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Department of Economic and Community Development (DECD)</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">293
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">DECD debt issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(30
				</td>
				<td valign="bottom" style="width:03.85pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;background-color: #auto;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Secured debt obligations</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;background-color: #auto;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,233
				</td>
				<td valign="top" style="width:03.85pt;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;background-color: #auto;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,233
				</td>
				<td valign="top" style="width:03.85pt;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Financed insurance loan</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">74
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">183
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Total long-term debt</font></p>
				</td>
				<td valign="top" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;border-top:1pt solid #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,570
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;border-top:1pt solid #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,416
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Current portion of long-term debt</font></p>
				</td>
				<td valign="top" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(676
				</td>
				<td valign="bottom" style="width:03.85pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(587
				</td>
				<td valign="bottom" style="width:03.85pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Long-term debt, net of current maturities</font></p>
				</td>
				<td valign="top" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-bottom:2pt double #000000 ;height:16.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,894
				</td>
				<td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-bottom:2pt double #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,829
				</td>
				<td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Department of Economic and Community Development.</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On January 8, 2018, the Company received gross proceeds of </font><font style="display: inline;">$400,000</font><font style="display: inline;"> when it entered into an agreement with the </font><font style="display: inline;">Department of Economic and Community Development (&#x201C;DECD&#x201D;)</font><font style="display: inline;"> by which the Company received a grant of </font><font style="display: inline;">$100,000</font><font style="display: inline;"> and a loan of </font><font style="display: inline;">$300,000</font><font style="display: inline;"> secured by substantially all of the Company&#x2019;s assets (the &#x201C;DECD 2018 Loan&#x201D;.) The grant is included in deferred revenue in the accompanying condensed consolidated balance sheet. </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Debt issuance costs associated with the DECD 2018 Loan were approximately </font><font style="display: inline;">$31,000</font><font style="display: inline;">. Amortization of the debt issuance cost was approximately </font><font style="display: inline;">$1,000</font><font style="display: inline;"> for the three months ended March 31, 2018.&nbsp;&nbsp;Net debt issuance costs were </font><font style="display: inline;">$30,000</font><font style="display: inline;"> at March 31, 2018 and are presented as a reduction of the related debt in the accompanying condensed consolidated balance sheet.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Secured Debt Obligations</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In 2017, the Company entered into Debt Settlement Agreements (the &#x201C;Settlement Agreements&#x201D;) with certain of its accounts payable and accrued liability vendors (the </font><font style="display: inline;">&#x201C;Creditors&#x201D;) pursuant to which the Creditors</font><font style="display: inline;">, who were owed </font><font style="display: inline;">$6.3</font><font style="display: inline;"> million (the &#x201C;Debt Obligations&#x201D;)</font><font style="display: inline;"> by the Company, agreed to reduce and exchange the Debt Obligations for a secured obligation in the amount of </font><font style="display: inline;">$3.2</font><font style="display: inline;"> million, </font><font style="display: inline;">$1.9</font><font style="display: inline;"> million in shares of the Company&#x2019;s common stock and </font><font style="display: inline;">108,112</font><font style="display: inline;"> warrants to purchase shares of the Company&#x2019;s common stock. </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Debt Obligations were restructured as follows:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:40pt;"><p style="width:40pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">The Company entered into a scheduled long-term debt repayment agreement of approximately </font><font style="display: inline;color:#000000;">$3.2</font><font style="display: inline;color:#000000;"> million, which includes interest of approximately </font><font style="display: inline;color:#000000;">$0.6</font><font style="display: inline;color:#000000;"> million, to be paid in </font><font style="display: inline;color:#000000;">forty-eight</font><font style="display: inline;color:#000000;"> equal monthly installments beginning in </font><font style="display: inline;color:#000000;">July 2018</font><font style="display: inline;color:#000000;"> (the &#x201C;Secured Debt Obligations&#x201D;).</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:40pt;"><p style="width:40pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Debt </font><font style="display: inline;color:#000000;">Obligations of </font><font style="display: inline;color:#000000;">$1.9</font><font style="display: inline;color:#000000;"> million</font><font style="display: inline;color:#000000;"> were canceled in exchange for </font><font style="display: inline;color:#000000;">1,814,754</font><font style="display: inline;color:#000000;"> shares of the Company&#x2019;s common stock with a weighted average price per </font><font style="display: inline;color:#000000;">share of </font><font style="display: inline;color:#000000;">$1.04</font><font style="display: inline;color:#000000;"> (the &#x201C;Settlement</font><font style="display: inline;color:#000000;"> Common Shares&#x201D;). The stock was issued in February 2018.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:40pt;"><p style="width:40pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">Warrants to </font><font style="display: inline;color:#000000;">purchase </font><font style="display: inline;color:#000000;">108,112</font><font style="display: inline;color:#000000;"> shares of the Company&#x2019;s common stock at an exercise price of </font><font style="display: inline;color:#000000;">$7.50</font><font style="display: inline;color:#000000;"> per share (the &#x201C;Creditor Warrants&#x201D;) were issued to certain Creditors. The Creditor Warrants were issued in February 2018</font><font style="display: inline;color:#000000;">. &nbsp;</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Financed Insurance Loan</font><font style="display: inline;font-style:italic;color:#000000;">.</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2017, t</font><font style="display: inline;color:#000000;">he Company financed</font><font style="display: inline;color:#000000;"> certain of its insurance premiums </font><font style="display: inline;color:#000000;">(the &#x201C;</font><font style="display: inline;color:#000000;">Financed Insurance Loan</font><font style="display: inline;color:#000000;">&#x201D;)</font><font style="display: inline;color:#000000;">. The original amount financed in July 2017 was </font><font style="display: inline;color:#000000;">$0.4</font><font style="display: inline;color:#000000;"> million with a </font><font style="display: inline;color:#000000;">4.99</font><font style="display: inline;color:#000000;"> % interest rate. The Company will make monthly payments through May 2018. As of </font><font style="display: inline;color:#000000;">March 31, 2018</font><font style="display: inline;color:#000000;"> and December 31, 2017, the Financed Insurance Loan outstanding balance of </font><font style="display: inline;color:#000000;">$0.1</font><font style="display: inline;color:#000000;"> million and </font><font style="display: inline;color:#000000;">$0.2</font><font style="display: inline;color:#000000;"> million, respectively, is included in current maturities of long-term debt in the Company&#x2019;s condensed consolidated balance sheet. A corresponding prepaid asset is included in other current assets.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807373232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">5</font><font style="display: inline;font-weight:bold;">.</font><font style="display: inline;font-weight:bold;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="display: inline;font-weight:bold;">OTHER CURRENT LIABILITIES</font><font style="display: inline;font-weight:bold;">.</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Other current liabilities are as follows:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:387.00pt;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:206.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font><font style="display: inline;font-size:1pt;">0</font></p>
				</td>
				<td valign="bottom" style="width:11.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:72.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:69.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:206.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">(dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:82.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:27.20pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">March 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:79.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:27.20pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 31, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:206.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Obligation to issue common shares</font></p>
				</td>
				<td valign="bottom" style="width:11.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:72.65pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:69.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,897&nbsp;
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:206.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Liability for settlement of equity instrument</font></p>
				</td>
				<td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:78.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,350&nbsp;
				</td>
				<td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:75.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,085&nbsp;
				</td>
				<td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:206.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:72.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,350&nbsp;
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:69.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,982&nbsp;
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As of December 31, 2017, t</font><font style="display: inline;">he Company </font><font style="display: inline;">had recorded a liability related to its obligation to issue shares of its common stock in the future.&nbsp;&nbsp;On February 12, 2018, the Company issued </font><font style="display: inline;">1,814,754</font><font style="display: inline;"> Settlement Common Shares with a fair value of approximately </font><font style="display: inline;">$1.9</font><font style="display: inline;"> million.</font>
		</p>
		<p style="margin:5pt 0pt 0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On February 20, 2018, Crede Capital Group LLC (&#x201C;Crede&#x201D;) filed a lawsuit against the Company in the Supreme Court of the State of New York for Summary Judgment in Lieu of Complaint requiring the Company to pay cash owed to Crede. Crede claimed that Precipio had breached a Securities Purchase Agreement and Warrant that Crede entered into in connection with an investment in Transgenomic and that pursuant to those agreements, Precipio owed Crede approximately </font><font style="display: inline;font-size:10pt;">$2.2</font><font style="display: inline;font-size:10pt;"> million. On March&nbsp;12, 2018, Precipio entered into a settlement agreement (the &#x201C;Crede Agreement&#x201D;) with Crede pursuant to which Precipio agreed to pay Crede a total sum of </font><font style="display: inline;font-size:10pt;">$1.925</font><font style="display: inline;font-size:10pt;"> million over a period of </font><font style="display: inline;font-size:10pt;">16</font><font style="display: inline;font-size:10pt;"> months payable in cash, or at the Company&#x2019;s discretion, in stock, in accordance with terms contained in the Crede Agreement. </font><font style="display: inline;font-size:10pt;">In accordance with the terms of the agreement and in addition to the agreement to pay, we have also executed and delivered to Crede an affidavit of confession of judgment.</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">As of December 31, 2017, the Compan</font><font style="display: inline;font-size:10pt;">y had recorded liabilities relating to Crede of </font><font style="display: inline;font-size:10pt;">$1.1</font><font style="display: inline;font-size:10pt;"> million included in other current liabilities on the accompanying condensed consolidated balance sheets and </font><font style="display: inline;font-size:10pt;">$0.6</font><font style="display: inline;font-size:10pt;"> million included in common stock warrant liability on the accompanying condensed consolidated balance sheets related to warrants classified as liabilities that Crede is the holder of. </font>
		</p>
		<p style="margin:5pt 0pt 0pt;text-indent:24.5pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">As of the date of the Crede Agreement, the fair value of the common stock warrant liability related to Crede was</font><font style="display: inline;font-size:10pt;"> revalued to</font><font style="display: inline;font-size:10pt;"> approximately </font><font style="display: inline;font-size:10pt;">$0.4</font><font style="display: inline;font-size:10pt;"> million</font><font style="display: inline;font-size:10pt;">, resulting in </font><font style="display: inline;font-size:10pt;">a gain of </font><font style="display: inline;font-size:10pt;">$0.2</font><font style="display: inline;font-size:10pt;"> million </font><font style="display: inline;font-size:10pt;">included in w</font><font style="display: inline;font-size:10pt;">arrant revaluation</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">in the unaudited condensed consolidated statement of operations</font><font style="display: inline;font-size:10pt;"> during the three months ended March 31, 2018. See Note 9 &#x2013; Fair Value for further discussion. During the three months ended March 31, 2018, at the time of the Crede Agreement, the Company paid approximately </font><font style="display: inline;font-size:10pt;">$0.2</font><font style="display: inline;font-size:10pt;"> million to Crede and recorded </font><font style="display: inline;font-size:10pt;">$1.3</font><font style="display: inline;font-size:10pt;"> million in other current liabilities and </font><font style="display: inline;font-size:10pt;">$0.4</font><font style="display: inline;font-size:10pt;"> million in </font><font style="display: inline;font-size:10pt;">other long-term liabilities, thus replacing its </font><font style="display: inline;font-size:10pt;">$1.1</font><font style="display: inline;font-size:10pt;"> million liability for settlement of equity instrument and </font><font style="display: inline;font-size:10pt;">$0.4</font><font style="display: inline;font-size:10pt;"> million common stock warrant liability. This resulted in the Company recording a</font><font style="display: inline;font-size:10pt;">n additional</font><font style="display: inline;font-size:10pt;"> loss</font><font style="display: inline;font-size:10pt;"> of</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">$0.4</font><font style="display: inline;font-size:10pt;"> million</font><font style="display: inline;font-size:10pt;">, which is</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">included in loss </font><font style="display: inline;font-size:10pt;">on settlement of equity instruments </font><font style="display: inline;font-size:10pt;">in the unaudited condensed consolidated statement of operations</font><font style="display: inline;font-size:10pt;">. The remaining amount due to Crede will be paid per the Crede Agreement payment schedule with the final installment</font><font style="display: inline;font-size:10pt;"> due in </font><font style="display: inline;font-size:10pt;">May 2019</font><font style="display: inline;font-size:10pt;">. &nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6653522512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENCIES</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">6</font><font style="display: inline;font-weight:bold;">.&nbsp;&nbsp;CONTINGENCIES</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company is involved in legal proceedings related to matters, which are incidental to its business. The Company has also assumed a number of claims as a result of the Merger. See below for a discussion on these matters.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The healthcare industry is subject to numerous laws and regulations of federal, state and local governments.&nbsp;&nbsp;These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed.&nbsp;&nbsp;Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations.&nbsp;&nbsp;While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The outcome of legal proceedings and claims brought against us are subject to significant uncertainty.&nbsp;&nbsp;Therefore, although management considers the likelihood of such an outcome to be remote, if one or more of these legal matters were resolved against us in the same reporting period for amounts in excess of management&#x2019;s expectations, our financial statements for such reporting period could be materially adversely affected. In general, the resolution of a legal matter could prevent us from offering our services or products to others, could be material to our financial condition or cash flows, or both, or could otherwise adversely affect our operating results.</font>
		</p>
		<p style="margin:18pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">L</font><font style="display: inline;font-style:italic;">ITIGATIONS</font><font style="display: inline;font-style:italic;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On June 23, 2016, the Icahn School of Medicine at Mount Sinai (&#x201C;Mount Sinai&#x201D;) filed a lawsuit against Transgenomic in the Supreme Court of the State of New York, County of New York, </font><font style="display: inline;">alleging, among other things, breach of contract and, alternatively, unjust enrichment and quantum merit, and seeking recovery of $0.7 million owed by us to Mount Sinai for services rendered. We and Mount Sinai entered into a settlement agreement dated October 27, 2016, which included, among other things, a mutual general release of claims, and our agreement to pay approximately </font><font style="display: inline;">$0.7</font><font style="display: inline;"> million to Mount Sinai in installments over a period of time.&nbsp;&nbsp;Effective as of October 31, 2017, we and Mount Sinai agreed to enter into a new settlement agreement to restructure these liabilities into a secured, long-term debt obligation of </font><font style="display: inline;">$0.5</font><font style="display: inline;"> million which includes accrued interest at </font><font style="display: inline;">10%</font><font style="display: inline;"> with monthly principal and interest payments of </font><font style="display: inline;">$9,472</font><font style="display: inline;"> beginning in July 2018 and con</font><font style="display: inline;">tinuing over 48 months and we issued warrants in the amount </font><font style="display: inline;">of </font><font style="display: inline;">24,900</font><font style="display: inline;"> shares, that are exercisable for shares of our common stock, on a 1-for-1 basis, with an exercise price of </font><font style="display: inline;">$7.50</font><font style="display: inline;"> per share, exercisable</font><font style="display: inline;"> on the date of issuance with a term of </font><font style="display: inline;">5</font><font style="display: inline;"> years. We do not plan to apply to list the warrants on the NASDAQ Capital Market, any other national securities exchange or any other nationally recognized trading system.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">A &nbsp;</font><font style="display: inline;">$0.5</font><font style="display: inline;"> million liability has been recorded and is reflected in long-term debt</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">within the accompanying condensed consolidated balance sheet at March 31, 2018 and December 31, 2017.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On February 21, 2017, XIFIN, Inc. (&#x201C;XIFIN&#x201D;) filed a lawsuit against us in the District Court for the Southern District of California alleging breach of written contract and seeking recovery of </font><font style="display: inline;">approximately </font><font style="display: inline;">$0.27</font><font style="display: inline;"> million owed by us to XIFIN for damages arising from a breach of our obligations pursuant to a Systems Services Agreement between us and XIFIN, dated as of February 22, 2013, as amended and restated on September 1, 2014. On April 5, 2017, the court clerk entered default against the Company. On May 5, 2017, XIFIN filed an application for entry of default judgment against us.</font><font style="display: inline;"> &nbsp; &nbsp;</font><font style="display: inline;">A liability of </font><font style="display: inline;">$0.1</font><font style="display: inline;"> million and </font><font style="display: inline;">$0.2</font><font style="display: inline;"> million is reflected in accounts payable within the accompanying condensed consolidated bal</font><font style="display: inline;">ance sheet at </font><font style="display: inline;">March 31, 2018 and </font><font style="display: inline;">December 31,</font><font style="display: inline;"> 2017, respectively.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owe approximately </font><font style="display: inline;">$0.2</font><font style="display: inline;"> million for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. </font><font style="display: inline;">A</font><font style="display: inline;"> liability of approximately less than </font><font style="display: inline;">$0.1</font><font style="display: inline;"> million has been recorded and is reflected in accounts payable within the accompanying </font><font style="display: inline;">condensed </font><font style="display: inline;">consolidated balance sheet at </font><font style="display: inline;">March 31, 2018 and </font><font style="display: inline;">December</font><font style="display: inline;"> 31, 2017.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On February 17, 2017, Jesse Campbell (&#x201C;Campbell&#x201D;) filed a lawsuit individually and on behalf of others similarly situated against us in the District Court for the District of Nebraska alleging we had a materially incomplete and misleading proxy relating to a potential merger and that the merger agreement&#x2019;s deal protection provisions deter superior offers.&nbsp; As a result, Campbell alleges that we have violated Sections 14(a) and 20(a) of the Exchange Act and Rule 14a-9 promulgated thereafter.&nbsp;</font><font style="display: inline;">The Company filed a motion to dismiss all claims, which motion was fully briefed on November 27, 2017.&nbsp;The Court granted the Company&#x2019;s motion in full on May 3, 2018 and dismissed the lawsuit</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On March 21, 2018, Bio-Rad Laboratories filed a lawsuit against</font><font style="display: inline;"> us in the Superior Court Judicial Branch of the State of Connecticut for Summary Judgment in Lieu of Complaint requiring us to pay cash owed to Bio-Rad in the </font><font style="display: inline;">amount of </font><font style="display: inline;">$39,000</font><font style="display: inline;">. We are currently in discussions with Bio-Rad to reach payment conditions. A liability of less than </font><font style="display: inline;">$0.1</font><font style="display: inline;"> million has been</font><font style="display: inline;"> recorded in accounts payable </font><font style="display: inline;">within the accompanying condensed consolidated balance sheet </font><font style="display: inline;">at </font><font style="display: inline;">March 31, 2018 and </font><font style="display: inline;">December 31, 2017.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6752424768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">7</font><font style="display: inline;font-weight:bold;">.&nbsp;&nbsp;INCOME TAXES </font>
		</p>
		<p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Income tax expense for the three months ended March 31, 2018 and 2017 was </font><font style="display: inline;">zero</font><font style="display: inline;"> as a result of recording a full valuation allowance against the deferred tax asset generated during the periods, which are predominantly net operating losses. </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We had </font><font style="display: inline;">no</font><font style="display: inline;"> material interest or penalties during fiscal 2018 or fiscal 2017, and we do not anticipate any such items during the next twelve months. Our policy is to record interest and penalties directly related to uncertain tax positions as income tax expense in the condensed consolidated statements of operations.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6645852320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 27pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">8</font><font style="display: inline;font-weight:bold;">.&nbsp;&nbsp;STOCKHOLDERS&#x2019; EQUITY</font>
		</p>
		<p style="margin:0pt 0pt 0pt 27pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 27pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Common Stock.</font>
		</p>
		<p style="margin:0pt 0pt 0pt 27pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have </font><font style="display: inline;">150,000,000</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">shares of common stock authorized for issuance.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On February 8, 2018 the Company entered into an equity purchase agreement (the &#x201C;</font><font style="display: inline;">2018 </font><font style="display: inline;">Purchase </font><font style="display: inline;">A</font><font style="display: inline;">greement&#x201D;) with Leviston Resources LLC (&#x201C;Leviston&#x201D;) for the purchase of up to </font><font style="display: inline;">$8,000,000</font><font style="display: inline;"> (the &#x201C;Aggregate Amount&#x201D;) of shares (the </font><font style="display: inline;color:#000000;">&#x201C;</font><font style="display: inline;">Shares&#x201D;) of the Company&#x2019;s common stock from time to time, at the Company&#x2019;s option. </font><font style="display: inline;color:#000000;">Shares offered and sold prior to February 13, 2018 were issued pursuant to the Company&#x2019;s shelf registration statement on Form S-3 (and the related prospectus) that the Company filed with the Securities and Exchange Commission (the &#x201C;SEC&#x201D;) and which was declared effective by the SEC on February 13, 2015 (the &#x201C;Shelf Registration Statement&#x201D;). </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Sales of the Company&#x2019;s common stock, if any, may be made in sales deemed to be &#x201C;at-the-market&#x201D; equity offerings as defined in Rule 415 promulgated under the Securities Act of 1933, as amended (the &#x201C;Securities Act&#x201D;), at a purchase price equal to </font><font style="display: inline;color:#000000;font-size:10pt;">97.25%</font><font style="display: inline;color:#000000;font-size:10pt;"> of the volume weighted average sales price of the common stock reported on the date that Leviston receives a capital call from the Company.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Leviston purchased </font><font style="display: inline;color:#000000;font-size:10pt;">721,153</font><font style="display: inline;color:#000000;font-size:10pt;"> shares (the &#x201C;Investor Shares&#x201D;) of the Company&#x2019;s common stock following the close of business on February 9, 2018, subject to customary closing conditions, at a price per share of </font><font style="display: inline;color:#000000;font-size:10pt;">$1.04</font><font style="display: inline;color:#000000;font-size:10pt;">. The shares were sold pursuant to the Shelf Registration Statement. The net proceeds to the Company from this sale were approximately </font><font style="display: inline;color:#000000;font-size:10pt;">$744,000</font><font style="display: inline;color:#000000;font-size:10pt;">. In addition to the </font><font style="display: inline;color:#000000;font-size:10pt;">$6,000</font><font style="display: inline;color:#000000;font-size:10pt;"> fee (</font><font style="display: inline;color:#000000;font-size:10pt;">0.75%</font><font style="display: inline;color:#000000;font-size:10pt;"> fee discussed below), the Company incurred approximately </font><font style="display: inline;color:#000000;font-size:10pt;">$136,000</font><font style="display: inline;color:#000000;font-size:10pt;"> of additional costs, both of which have been treated as issuance costs within additional paid-in capital in the accompanying unaudited condensed consolidated balance sheet</font><font style="display: inline;color:#000000;font-size:10pt;">.</font><font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">In consideration of Leviston&#x2019;s agreement to enter into the </font><font style="display: inline;color:#000000;font-size:10pt;">2018 </font><font style="display: inline;color:#000000;font-size:10pt;">Purchase Agreement, the Company agreed to pay to Leviston a commitment fee in shares of the Company&#x2019;s common stock equal in value to </font><font style="display: inline;color:#000000;font-size:10pt;">5.25%</font><font style="display: inline;color:#000000;font-size:10pt;"> of the total Aggregate Amount (the &#x201C;Commitment Shares&#x201D;), payable as follows: </font><font style="display: inline;color:#000000;font-size:10pt;">1.75%</font><font style="display: inline;color:#000000;font-size:10pt;"> on or before February 12, 2018. This amount, of </font><font style="display: inline;color:#000000;font-size:10pt;">$140,000</font><font style="display: inline;color:#000000;font-size:10pt;">, was paid to Leviston through the issuance of </font><font style="display: inline;color:#000000;font-size:10pt;">170,711</font><font style="display: inline;color:#000000;font-size:10pt;"> shares of the Company&#x2019;s common stock on February 12, 2018; 1.75% on the third calendar day after the date on which the registration statement on Form S-1 file</font><font style="display: inline;color:#000000;font-size:10pt;">d</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">on April 16, 2018 </font><font style="display: inline;color:#000000;font-size:10pt;">is declared effective by the SEC; and 1.75% on the thirtieth calendar day after the date on which such registration statement on Form S-1 is declared effective by the SEC.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Company agreed to pay to Leviston, on each day that Leviston receives a capital call from the Company, all expenses associated with depositing, clearing, selling and mailing of the stock certificates, a fee of </font><font style="display: inline;color:#000000;font-size:10pt;">0.75%</font><font style="display: inline;color:#000000;font-size:10pt;"> of any amount purchased by Leviston. Also, the Company paid </font><font style="display: inline;color:#000000;font-size:10pt;">$35,000</font><font style="display: inline;color:#000000;font-size:10pt;"> to Leviston for a documentation fee for preparing the </font><font style="display: inline;color:#000000;font-size:10pt;">2018 </font><font style="display: inline;color:#000000;font-size:10pt;">Purchase Agreement.</font><font style="display: inline;color:#000000;font-size:10pt;"> This was recorded in additional paid-in-capital as an off-set to the proceeds received. </font><font style="display: inline;color:#000000;font-size:10pt;">Leviston will refund the Company </font><font style="display: inline;color:#000000;font-size:10pt;">$15,000</font><font style="display: inline;color:#000000;font-size:10pt;"> if certain future conditions are met</font><font style="display: inline;color:#000000;font-size:10pt;">. Such conditions have not been met as of the date of issuance of this Form 10-Q</font><font style="display: inline;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">Because the Company&#x2019;s existing registration statement on Form S-3 expired on February 13, 2018 and, due to the timing of the filing of the Company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2017, the Company will not be eligible to file a new Form S-3 registration statement until September 1, 2018, the Company agreed to prepare and file with the SEC a registration statement on Form S-1 the (&#x201C;S-1 Registration Statement&#x201D;), by April 15, 2018 and to use reasonable best efforts to cause the S-1 Registration Statement to be declared effective by the SEC within ninety days thereafter.</font><font style="display: inline;color:#000000;font-size:10pt;"> The Company filed the S-1 Registration Statement with the SEC on April 16, 2018, which is yet to become effective and which was in a timely manner since the SEC was not open for filings on April 15, 2018. </font><font style="display: inline;color:#000000;font-size:10pt;">The Company is also required to pay liquidated damages of </font><font style="display: inline;color:#000000;font-size:10pt;">$100,000</font><font style="display: inline;color:#000000;font-size:10pt;"> on each event of default under the </font><font style="display: inline;color:#000000;font-size:10pt;">2018 </font><font style="display: inline;color:#000000;font-size:10pt;">Purchase Agreement. The Company has provided Leviston with customary indemnification rights under the </font><font style="display: inline;color:#000000;font-size:10pt;">2018 </font><font style="display: inline;color:#000000;font-size:10pt;">Purchase Agreement.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During the three months ended March 31, 2018, the Company issued </font><font style="display: inline;">3,120,000</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shares of its common stock in connection with conversions of its Series B Preferred Stock</font><font style="display: inline;"> and </font><font style="display: inline;">3,345,334</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shares of its common stock in connection with conversions of its Series </font><font style="display: inline;">C</font><font style="display: inline;"> Preferred Stock</font><font style="display: inline;">. Aside from </font><font style="display: inline;">60,000</font><font style="display: inline;"> shares of common stock issued in connection</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">with conversions of its Series </font><font style="display: inline;">C</font><font style="display: inline;"> Preferred Stock</font><font style="display: inline;">, all of the </font><font style="display: inline;">shares of common stock </font><font style="display: inline;">issued in the three months ended March 31, 2018 </font><font style="display: inline;">in connection with conversions of its Series B Preferred Stock</font><font style="display: inline;"> and Series C Preferred Stock </font><font style="display: inline;">(together the &#x201C;Preferred Stock&#x201D;)</font><font style="display: inline;"> were issued after the Company induced the holders </font><font style="display: inline;">of </font><font style="display: inline;">its </font><font style="display: inline;">Preferred Stock </font><font style="display: inline;">to convert their shares of Preferred Stock to shares of the company&#x2019;s common stock (see below - Preferred Stock induced conversions). </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During the three months ended March 31, 2018, the Company issued </font><font style="display: inline;">300,000</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shares of its common stock </font><font style="display: inline;">in connection with the exercise of </font><font style="display: inline;">300,000</font><font style="display: inline;"> warrants. The warrant exercise resulted in </font><font style="display: inline;">net cash proceeds to the Company</font><font style="display: inline;"> of approximately </font><font style="display: inline;">$0.2</font><font style="display: inline;"> million.</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Preferred Stock.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company&#x2019;s Board of Directors is authorized to issue up to </font><font style="display: inline;">15,000,000</font><font style="display: inline;"> shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. </font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Series B Preferred Stock.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On August&nbsp;25, 2017, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series&nbsp;B Convertible Preferred Stock (&#x201C;Series B Preferred Stock&#x201D;) with the State of Delaware which designates </font><font style="display: inline;">6,900</font><font style="display: inline;"> shares of our preferred stock as Series&nbsp;B Preferred Stock. The Series&nbsp;B Preferred Stock has a stated value of&#x2009;</font><font style="display: inline;">$1,000</font><font style="display: inline;"> per share and a par value of&#x2009;</font><font style="display: inline;">$0.01</font><font style="display: inline;"> per share. The Series B Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock).</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On August&nbsp;28, 2017, the Company completed the August 2017 Offering of </font><font style="display: inline;">6,000</font><font style="display: inline;"> units consisting of one share of the Company&#x2019;s Series B Preferred Stock, which </font><font style="display: inline;">was initially</font><font style="display: inline;"> convertible into </font><font style="display: inline;">400</font><font style="display: inline;"> shares of common stock, par value $0.01 per share, at a conversion price of </font><font style="display: inline;">$2.50</font><font style="display: inline;"> per share, and one warrant to purchase up to 400 shares of common stock (the &#x201C;August 2017 Offering Warrants&#x201D;) at a combined public offering price of </font><font style="display: inline;">$1,000</font><font style="display: inline;"> per unit. The August 2017 Offering included the sale of </font><font style="display: inline;">280,000</font><font style="display: inline;"> August 2017 Offering Warrants pursuant to the over-allotment option exercised by Aegis Capital Corp. (&#x201C;Aegis&#x201D;) for </font><font style="display: inline;">$0.01</font><font style="display: inline;"> per share or </font><font style="display: inline;">$2,800</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In November 2017, the down round feature of the Series B Preferred Stock was triggered at the time of the Company&#x2019;s issuance of its Series C Preferred Stock and, as a result, the conversion price of the Series B Preferred Stock was reduced from </font><font style="display: inline;">$2.50</font><font style="display: inline;"> per share to </font><font style="display: inline;">$1.40</font><font style="display: inline;"> per share. </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">T</font><font style="display: inline;color:#000000;">he </font><font style="display: inline;color:#000000;">2018 Purchase Agreement</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">triggered </font><font style="display: inline;">the down round feature of the Series B Preferred Stock</font><font style="display: inline;"> and</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> as a result,</font><font style="display: inline;color:#000000;"> the conversion price of the Company&#x2019;s Series B Convertible Preferred Stock was automatically adjusted from </font><font style="display: inline;color:#000000;">$1.40</font><font style="display: inline;color:#000000;"> per share to </font><font style="display: inline;color:#000000;">$1.04</font><font style="display: inline;color:#000000;"> per </font><font style="display: inline;color:#000000;">share.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximatel</font><font style="display: inline;">y &nbsp;</font><font style="display: inline;">$1.4</font><font style="display: inline;"> million</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">which was recognized as a deemed dividend at time of the down round adjustment</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">T</font><font style="display: inline;color:#000000;">he </font><font style="display: inline;color:#000000;">2018 Inducement Agreement, discussed below, </font><font style="display: inline;">triggered </font><font style="display: inline;">the down round feature of the Series B Preferred Stock</font><font style="display: inline;"> and</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> as a result,</font><font style="display: inline;color:#000000;"> the conversion price of the Company&#x2019;s Series B Convertible Preferred Stock was automatically adjusted from </font><font style="display: inline;color:#000000;">$1.04</font><font style="display: inline;color:#000000;"> per share to </font><font style="display: inline;color:#000000;">$0.75</font><font style="display: inline;color:#000000;"> per </font><font style="display: inline;color:#000000;">share.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximatel</font><font style="display: inline;">y &nbsp;</font><font style="display: inline;">$40,000</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">which was recognized as a deemed dividend at time of the down round adjustment</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During the three months ended March 31, 2018, </font><font style="display: inline;">2,340</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shares of Series B Preferred Stock </font><font style="display: inline;">that were outstanding at December 31, 2017 </font><font style="display: inline;">were converted</font><font style="display: inline;"> into </font><font style="display: inline;">3,120,000</font><font style="display: inline;"> shares of our common stock.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">At </font><font style="display: inline;">March 31</font><font style="display: inline;">, 201</font><font style="display: inline;">8</font><font style="display: inline;">, the Company had </font><font style="display: inline;">6,900</font><font style="display: inline;"> shares of Series B designated and </font><font style="display: inline;">47</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shares of Series B</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">issued</font><font style="display: inline;"> and outstanding</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Series C Preferred Stock</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On November 6, 2017, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series&nbsp;C Convertible Preferred Stock (&#x201C;Series C Preferred Stock&#x201D;) with the State of Delaware which designates </font><font style="display: inline;">2,748</font><font style="display: inline;"> shares of our preferred stock as Series&nbsp;C Preferred Stock. The Series&nbsp;C Preferred Stock has a stated value </font><font style="display: inline;">of&#x2009;</font><font style="display: inline;">$1,000</font><font style="display: inline;"> per share and a par value </font><font style="display: inline;">of&#x2009;</font><font style="display: inline;">$0.01</font><font style="display: inline;"> per share.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On November 2, 2017, the Company entered into a Placement Agency Agreement (the &#x201C;Placement Agreement&#x201D;) with Aegis Capital Corp. for the sale on a reasonable best efforts basis of </font><font style="display: inline;">2,748</font><font style="display: inline;"> units, each consisting of one share of the Company&#x2019;s Series C Preferred Stock, convertible into a number of shares of the Company&#x2019;s common stock equal to </font><font style="display: inline;">$1,000</font><font style="display: inline;"> divided by $1.40 and warrants to purchase up to </font><font style="display: inline;">1,962,857</font><font style="display: inline;"> shares of common stock with an exercise price of </font><font style="display: inline;">$1.63</font><font style="display: inline;"> per share (the &#x201C;Series C Warrants&#x201D;) at a combined offering price of </font><font style="display: inline;">$1,000</font><font style="display: inline;"> per unit, in a registered direct offering (the &#x201C;Series C Preferred Offering&#x201D;). The Series C Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock). The securities comprising the units are immediately separable and were issued separately.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The conversion price of the Series C Preferred Stock contains a down round feature. T</font><font style="display: inline;color:#000000;">he </font><font style="display: inline;color:#000000;">2018 Purchase Agreement</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">triggered </font><font style="display: inline;">the down round feature of the Series </font><font style="display: inline;">C</font><font style="display: inline;"> Preferred Stock</font><font style="display: inline;"> and</font><font style="display: inline;color:#000000;">,</font><font style="display: inline;color:#000000;"> as a result,</font><font style="display: inline;color:#000000;"> the conversion price of the Company&#x2019;s Series B Convertible Preferred Stock was automatically adjusted from </font><font style="display: inline;color:#000000;">$1.40</font><font style="display: inline;color:#000000;"> per share to </font><font style="display: inline;color:#000000;">$1.04</font><font style="display: inline;color:#000000;"> per </font><font style="display: inline;color:#000000;">share.</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">In connection with the down round adjustment, the Company calculated an incremental beneficial conversion feature of approximatel</font><font style="display: inline;">y &nbsp;</font><font style="display: inline;">$0.8</font><font style="display: inline;"> million</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">which was recognized as a deemed dividend at time of the down round adjustment</font><font style="display: inline;">.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During the three months ended March 31, 2018, </font><font style="display: inline;">2,548</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shares of Series </font><font style="display: inline;">C</font><font style="display: inline;"> Preferred Stock </font><font style="display: inline;">that </font><font style="display: inline;">were</font><font style="display: inline;"> outstanding at December 31, 2017 were</font><font style="display: inline;"> converted</font><font style="display: inline;"> into </font><font style="display: inline;">3,345,334</font><font style="display: inline;"> shares of our common stock.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">At </font><font style="display: inline;">March </font><font style="display: inline;">31, 201</font><font style="display: inline;">8</font><font style="display: inline;">, the Company had </font><font style="display: inline;">2,748</font><font style="display: inline;">&nbsp;</font><font style="display: inline;">shares of Series C</font><font style="display: inline;"> designated </font><font style="display: inline;">and </font><font style="display: inline;">zero</font><font style="display: inline;"> shares of Series C </font><font style="display: inline;">issued</font><font style="display: inline;"> and outstanding.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Preferred Stock induced conversions </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On March 21, 2018, the Company entered into a Letter Agreement (the &#x201C;</font><font style="display: inline;">2018 Inducement </font><font style="display: inline;">Agreement&#x201D;) with certain holders (the &#x201C;Investors&#x201D;) of shares of the Company&#x2019;s Series B Preferred Stock and Series C </font><font style="display: inline;">Preferred Stock (together the &#x201C;Preferred Stock&#x201D;), and warrants (the &#x201C;Warrants&#x201D;) to purchase shares of the Company&#x2019;s common stock, par value $0.01 per share (&#x201C;Common Stock&#x201D;), issued in the Company&#x2019;s public offering in August 2017 and registered direct offering in November 2017. Pursuant to the </font><font style="display: inline;">2018 Inducement </font><font style="display: inline;">Agreement, the Company and the Investors agreed that, as a result of the issuance of shares of Common Stock pursuant to that Purchase Agreement, dated February 8, 2018, by and between the Company and the investor named therein, and effective as of the time of execution of the </font><font style="display: inline;">2018 Inducement </font><font style="display: inline;">Agreement, the exercise price of the Warrants was reduced to $0.75 per share (the &#x201C;Exercise Price Reduction&#x201D;) and the conversion price of the Preferred Stock was reduced to </font><font style="display: inline;">$0.75</font><font style="display: inline;"> (the &#x201C;Conversion Price Reduction&#x201D;). As consideration for the Company&#x2019;s agreement to the Exercise Price Reduction and the Conversion Price Reduction, (i) each Investor agreed to convert the shares of Preferred Stock held by such Investor into shares of Common Stock in increments of up to </font><font style="display: inline;">4.99%</font><font style="display: inline;"> of the shares of Common Stock outstanding as of the date of the </font><font style="display: inline;">2018 Inducement </font><font style="display: inline;">Agreement </font><font style="display: inline;">and (ii) one Investor agreed to exercise </font><font style="display: inline;">666,666</font><font style="display: inline;"> Warrants and another Investor agreed to exercise </font><font style="display: inline;">500,000</font><font style="display: inline;"> Warrants in increments of</font><font style="display: inline;"> up to 4.99% of the shares of Common Stock outstanding as of the date of the </font><font style="display: inline;">2018 Inducement </font><font style="display: inline;">Agreement, in each case in accordance with the beneficial ownership limitations set forth in the Company&#x2019;s Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, the Company&#x2019;s Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible </font><font style="display: inline;">Preferred Stock and the Warrants. </font><font style="display: inline;">As discussed above, as of March 31, 2018, all shares of Preferred Stock, except </font><font style="display: inline;">47</font><font style="display: inline;"> shares of Series B Preferred Stock, have been converted to shares of our common stock and </font><font style="display: inline;">300,000</font><font style="display: inline;"> Warrants had been exercised.</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The 2018 Inducement Agreement represented an inducement by the Company to convert shares of the Preferred Stock. The conversion price of the Preferred Stock was reduced from </font><font style="display: inline;">$1.04</font><font style="display: inline;"> per share to </font><font style="display: inline;">$0.75</font><font style="display: inline;"> per share and the exercise price of the Warrants was reduced from </font><font style="display: inline;">$1.04</font><font style="display: inline;"> per share to </font><font style="display: inline;">$0.75</font><font style="display: inline;"> per share. The Company calculated the fair value of the additional securities and consideration to be approximately </font><font style="display: inline;">$1.2</font><font style="display: inline;"> million. This amount was recorded as a charge to additional paid-in-capital and as a deemed dividend resulting in </font><font style="display: inline;">a reduction of income available to common shareholders in our basic earnings per share calculation.</font><font style="display: inline;"> The $1.2 million is comprised of two components: 1) </font><font style="display: inline;">$1.1</font><font style="display: inline;"> million related to the fair value of the additional common shares issued upon conversion of the Preferred Stock due to the reduced conversion price and 2) </font><font style="display: inline;">$0.1</font><font style="display: inline;"> million in incremental fair value of the Warrants resulting from the reduction of the exercise price.</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Common Stock Warrants.</font>
		</p>
		<p style="margin:9pt 0pt 7pt;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following represents a summary of the warrants outstanding as of March 31, 2018:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:318.00pt;margin-left:2.5pt;">
			<tr>
				<td valign="bottom" style="width:22.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:89.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Issue&nbsp;Year</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 0pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:89.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Expiration</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Underlying</font></p>
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Shares </font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font></p>
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Price</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="8" valign="bottom" style="width:318.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-style:italic;color:#000000;text-decoration:underline;">Warrants Assumed in Merger</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(1)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2014</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">April 2020</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12,487&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$120.00</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(2)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2015</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 2020</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23,826&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$67.20</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(3)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2015</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 2020</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,081&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$49.80</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(4)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2016</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">January 2021</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,952&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$36.30</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="8" valign="bottom" style="width:318.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-style:italic;color:#000000;text-decoration:underline;">Warrants</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(5)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">June 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">45,600&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$2.75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(6)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">June 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">91,429&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$7.00</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(7)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,380,000&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$0.75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(8)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">60,000&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$3.125</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(9)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">856,446&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$10.00</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(10)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">359,999&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$0.75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #auto;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(11)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">October 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #auto;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10,000&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$0.75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(12)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">May 2023</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,962,857&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$0.75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(13)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">October 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">108,112&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$7.50</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-top:1pt solid #000000 ;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,923,789&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (1)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with a private placement which was completed in October 2014.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (2)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with an offering which was completed in February 2015.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (3)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with an offering which was completed in July 2015.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (4)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with an offering which was completed in January 2016. Of the remaining outstanding warrants as of March 31, 2018, 5,368 warrants are recorded as a liability, See Note 9 &#x2013; Fair Value for further discussion, and 3,584 are treated as equity.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (5)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the Merger and are the 2017 New Bridge Warrants.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (6)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the Merger and are considered Side Warrants.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (7)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the August 2017 Offering and are the August 2017 Offering Warrants discussed below.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (8)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the August 2017 Offering and are considered Representative Warrants.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (9)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the conversion of our Series A Senior stock, at the time of the closing of the August 2017 Offering, and are the Series A Conversion Warrants discussed above.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (10)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the conversion of convertible bridge notes, at the time of the closing of the August 2017 Offering, and are the Note Conversion Warrants discussed below.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (11)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the waiver of default the Company received in the fourth quarter of 2017 in connection with the Convertible Promissory Notes and are the Convertible Promissory Note Warrants discussed below.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (12)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the Series C Preferred Offering and are the Series C Warrants discussed below.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (13)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the Debt Obligation settlement agreements and are the Creditor Warrants discussed below.</font></p></td></tr></table></div>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">Warrants Assumed in Merger</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">At the time of the Merger, Transgenomic had a number of outstanding warrants related to various financing transactions that occurred between 2013-2016. Details related to year issued, expiration date, amount of underlying common shares and exercise price are included in the table </font><font style="display: inline;color:#000000;">above</font><font style="display: inline;color:#000000;">.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">During the three months ended March 31, 2018, </font><font style="display: inline;color:#000000;">23,055</font><font style="display: inline;color:#000000;"> of the warrants assumed in the Merger expired and are no longer outstanding. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">August 2017 Offering Warrants</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In connection with the August 2017 Offering, the Company issued </font><font style="display: inline;color:#000000;">2,680,000</font><font style="display: inline;color:#000000;"> warrants at an exercise price of </font><font style="display: inline;color:#000000;">$3.00</font><font style="display: inline;color:#000000;">, which contain a down round provision. As a result of the Series C Preferred Offering, the exercise price</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> of the August 2017 Offering Warrants was adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$1.40</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> per share.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">During the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the August 2017 Offering Warrants was adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$1.04</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">.</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$62,000</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> and recorded this as a deemed dividend.</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">In addition, as a result of the 2018 Inducement Agreement, the exercise price of the August 2017 Offering Warrants was further adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$0.75</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> as a result of the Exercise Price Reduction discussed above.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">During the three months ended March 31, 2018, </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">300,000</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> of the August 2017 Offering Warrants were exercised for </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$0.75</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> per share.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">Note Conversion Warrants</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Upon the closing of the August 2017 Offering, the Company</font><font style="display: inline;color:#000000;"> issued</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">359,999</font><font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;color:#000000;">warrants to purchase the Company&#x2019;s common stock (the &#x201C;</font><font style="display: inline;color:#000000;">Note Conversion Warrants</font><font style="display: inline;color:#000000;">&#x201D;)</font><font style="display: inline;color:#000000;">. The Note Conversion Warrants have an exercise price of </font><font style="display: inline;color:#000000;">$3.00</font><font style="display: inline;color:#000000;"> per share and contain a down round provision. As a result of the Series C Preferred Offering, the exercise price</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> of the Note Conversion Warrants was adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$1.40</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> per share. </font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">During the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the Note Conversion Warrants was adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$1.04</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">.</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$8,000</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> and recorded this as a deemed dividend. In addition, as a result of the 2018 Inducement Agreement, the exercise price of the Note Conversion Warrants was further adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$0.75</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">.</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$5,000</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> and recorded this as a deemed dividend.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">Convertible Promissory Note Warrants</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">T</font><font style="display: inline;color:#000000;">he Convertible Promissory Note Warrants ha</font><font style="display: inline;color:#000000;">d &nbsp;</font><font style="display: inline;color:#000000;">an</font><font style="display: inline;color:#000000;"> original</font><font style="display: inline;color:#000000;"> exercise price of </font><font style="display: inline;color:#000000;">$3.00</font><font style="display: inline;color:#000000;"> per share</font><font style="display: inline;color:#000000;"> and</font><font style="display: inline;color:#000000;"> contain a down round provision</font><font style="display: inline;color:#000000;">. &nbsp;</font><font style="display: inline;color:#000000;">As a result of the Series C Preferred Offering, the exercise price</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> of the Convertible Promissory Note Warrants was adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$1.40</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> per share.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">During the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the Convertible Promissory Note Warrants was adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$1.04</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">.</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">less than </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$1,000</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> and recorded this as a deemed dividend. In addition, as a result of the 2018 Inducement Agreement, the exercise price of the Convertible Promissory Note Warrants was further adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$0.75</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">.</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">less than </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$1,000</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> and recorded this as a deemed dividend.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">Series C Warrants</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In connection with the Series C Preferred Offering, the Company issued </font><font style="display: inline;color:#000000;">1,962,857</font><font style="display: inline;color:#000000;"> warrants at an exercise price of </font><font style="display: inline;color:#000000;">$1.63</font><font style="display: inline;color:#000000;">, which contain a down round provision.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;background-color: #FFFFFF;">During the three months ended March 31, 2018, as a result of 2018 Purchase Agreement, the exercise price of the Series C Warrants was adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$1.04</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">.</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">At the time the exercise price was adjusted, the Company calculated the fair value of the down round provision on the warrants to be approximately</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">&nbsp;</font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$58,000</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> and recorded this as a deemed dividend. In addition, as a result of the 2018 Inducement Agreement, the exercise price of the Series C Warrants was further adjusted to </font><font style="display: inline;color:#000000;background-color: #FFFFFF;">$0.75</font><font style="display: inline;color:#000000;background-color: #FFFFFF;"> as a result of the Exercise Price Reduction discussed above.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">Creditor </font><font style="display: inline;color:#000000;text-decoration:underline;">Warrants</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In the fourth quarter of 2017, the Company entered into Settlement Agreements with certain of its accounts payable and accrued liability vendors (the &#x201C;Creditors&#x201D;) pursuant to which the Company agreed to issue, to certain of its Creditors, </font><font style="display: inline;color:#000000;">108,112</font><font style="display: inline;color:#000000;"> warrants to purchase </font><font style="display: inline;color:#000000;">108,112</font><font style="display: inline;color:#000000;"> shares of the Company&#x2019;s common stock at an exercise price of </font><font style="display: inline;color:#000000;">$7.50</font><font style="display: inline;color:#000000;"> per share. The warrants </font><font style="display: inline;color:#000000;">were issued in February 2018. See </font><font style="display: inline;color:#000000;">Note 4 &#x2013;</font><font style="display: inline;color:#000000;"> Long</font><font style="display: inline;color:#000000;">-Term Debt.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;line-height:120%;text-indent:36pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6757827504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">FAIR VALUE</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -18pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">9</font><font style="display: inline;font-weight:bold;">.&nbsp;&nbsp;FAIR VALUE</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our </font><font style="display: inline;">condensed </font><font style="display: inline;">consolidated financial statements.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows:</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Level&nbsp;1&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Level&nbsp;2&#x2014;Observable inputs other than those included in Level&nbsp;1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets;&nbsp;and</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Level&nbsp;3&#x2014;Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability.</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Common Stock Warrant Liabilities.</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability.</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">2016 Warrant Liability</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company assumed the 2016 Warrant Liability in the Merger and it represents the fair value of Transgenomic warrants issued in January 2016, of which, </font><font style="display: inline;">5,368</font><font style="display: inline;"> warrants remain outstanding as of </font><font style="display: inline;">March </font><font style="display: inline;">31, 201</font><font style="display: inline;">8</font><font style="display: inline;">. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our </font><font style="display: inline;">condensed </font><font style="display: inline;">consolidated </font><font style="display: inline;">s</font><font style="display: inline;">tatement of </font><font style="display: inline;">o</font><font style="display: inline;">perations.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During the three months ended March 31, 2018, a portion of the 2016 Warrant Liability was part of a settlement agreement pursuant to a lawsuit that was filed against the Company by one of the warrant holders. As such, approximately </font><font style="display: inline;">$0.4</font><font style="display: inline;"> million of the warrant liability, representing </font><font style="display: inline;">20,216</font><font style="display: inline;"> warrants, was canceled on the date of the settlement agreement and replaced by and amounts now recorded as other current liabilities or other long-term liabilities. For further detail, see discussion of the Crede </font><font style="display: inline;">Agreement in Note </font><font style="display: inline;">5</font><font style="display: inline;"> &#x2013; </font><font style="display: inline;">Other Current Liabilities.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The 2016 Warrant Liability is considered a Level 3 financial instrument and was valued using the Monte Carlo methodology. </font><font style="display: inline;"> As of March 31, 2018, a</font><font style="display: inline;">ssumptions and inputs used in the valuation of the common stock warrants include: remaining life to maturity of </font><font style="display: inline;">2.75</font><font style="display: inline;"> years; annual volatility of </font><font style="display: inline;">167%</font><font style="display: inline;">; and a risk-free interest rate of </font><font style="display: inline;">2.39%</font><font style="display: inline;">. &nbsp;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;"> &nbsp; </font><font style="display: inline;">During the three months ended March 31, 2018, the change in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:&nbsp; </font><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;line-height:7pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:374.00pt;margin-left:2.5pt;">
			<tr>
				<td valign="bottom" style="width:269.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:86.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:08.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:18.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Dollars in Thousands</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 0pt;height:18.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:101.00pt;padding:0pt 0pt 0pt 3.6pt;height:18.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:101.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">For the Three Months Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:101.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">March 31, 2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Beginning balance at January 1</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:91.00pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">841
				</td>
				<td valign="top" style="width:04.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 25.2pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Total gains:</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:101.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 46.8pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Recognized in earnings</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:96.50pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(261
				</td>
				<td valign="middle" style="width:04.50pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 46.8pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Deductions &#x2013; warrant liability settlement</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:96.50pt;border-bottom:1pt solid #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(456
				</td>
				<td valign="middle" style="width:04.50pt;border-bottom:1pt solid #000000 ;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Balance at March 31</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:91.00pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">124
				</td>
				<td valign="top" style="width:04.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597387952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY INCENTIVE PLAN [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">EQUITY INCENTIVE PLAN</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">10.&nbsp;&nbsp;EQUITY INCENTIVE PLAN</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 9pt">
			<font style="display: inline;font-size:9pt;">&#xFEFF;</font>
		</p><font style="display: inline;font-size:10pt;">The Company's 2006 Equity Incentive Plan (the "2006 Plan") was terminated as to future awards on July 12, 2016. The Company's 2017 Stock Option and Incentive Plan (the "2017 Plan") was adopted by the Company's stockholders on June 5, 2017 and</font><font style="display: inline;font-size:10pt;"> &nbsp;t</font><font style="display: inline;font-size:10pt;">here </font><font style="display: inline;font-size:10pt;">were</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">666,666</font><font style="display: inline;font-size:10pt;"> shares of common stock reserved for</font><font style="display: inline;font-size:10pt;"> issuance</font><font style="display: inline;font-size:10pt;"> under the 2017 Plan</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">The 2017 Plan </font><font style="display: inline;font-size:10pt;">will expire on </font><font style="display: inline;font-size:10pt;">June 5, 2027</font><font style="display: inline;font-size:10pt;">.</font>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Amendment of the 2017 Stock Option and Incentive Plan </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">On January 31, 2018, at a special meeting of the stockholders of the Company, the stockholders approved an amendment and restatement of the Company&#x2019;s 2017 Stock Option and Incentive Plan (the &#x201C;2017 Plan&#x201D;) to:</font>
		</p>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:40pt;"><p style="width:40pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">increase the aggregate number of shares authorized for issuance under the 2017 Plan by </font><font style="display: inline;color:#000000;">5,389,500</font><font style="display: inline;color:#000000;"> shares to </font><font style="display: inline;color:#000000;">6,056,166</font><font style="display: inline;color:#000000;"> shares and cumulatively increased on January 1, 2019 and on each January 1 thereafter by the lesser of the annual increase for such year or </font><font style="display: inline;color:#000000;">500,000</font><font style="display: inline;color:#000000;"> shares;</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:40pt;"><p style="width:40pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;border-bottom:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">increase the maximum number of shares that may be granted in the form of stock options or stock appreciation rights to any one individual in any one calendar year and the maximum number of shares underlying any award intended to qualify as performance-based compensation to any one individual in any performance cycle, in each case to </font><font style="display: inline;color:#000000;">1,000,000</font><font style="display: inline;color:#000000;"> shares of Common Stock; and</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:40pt;"><p style="width:40pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
				<font style="margin:0pt;font-family:Symbol;line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9;font-size:10pt;;"> &#xB7;</font>
			</p>
		</td><td style="width:0pt;"><p style="width:0pt;width:0pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="line-height:120%;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt;margin:0pt;">
			<font style="display: inline;color:#000000;">add an &#x201C;evergreen&#x201D; provision, pursuant to which the aggregate number of shares authorized for issuance under the 2017 Plan will be automatically increased each year beginning on January 1, 2019 by </font><font style="display: inline;color:#000000;">5%</font><font style="display: inline;color:#000000;"> of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares determined by the Company&#x2019;s Board of Directors or Compensation Committee.</font></p></td></tr></table></div>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Stock Options.</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the three months ended March 31, 2018, the Company granted stock options to employees and directors to purchase up to </font><font style="display: inline;color:#000000;">3,286,528</font><font style="display: inline;color:#000000;"> shares of common stock at a weighted average exercise price of </font><font style="display: inline;color:#000000;">$0.71</font><font style="display: inline;color:#000000;">. These awards have vesting periods of </font><font style="display: inline;color:#000000;">one</font><font style="display: inline;color:#000000;"> to </font><font style="display: inline;color:#000000;">four</font><font style="display: inline;color:#000000;"> years and had a weighted average grant date fair value of </font><font style="display: inline;color:#000000;">$0.65</font><font style="display: inline;color:#000000;">. The fair value calculation of options granted during the three months ended March 31, 2018 used the follow assumptions: risk free interest rate of </font><font style="display: inline;color:#000000;">2.63%</font><font style="display: inline;color:#000000;"> based on the U.S. Treasury yield in effect at the time of grant; expected life of </font><font style="display: inline;color:#000000;">six</font><font style="display: inline;color:#000000;"> years; and volatility of </font><font style="display: inline;color:#000000;">135%</font><font style="display: inline;color:#000000;">. &nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 7pt;line-height:120%;text-indent:22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The following table summarizes stock option activity under our plans during the three months ended March 31, 2018:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:512.00pt;margin-left:2.5pt;">
			<tr>
				<td valign="bottom" style="width:368.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:61.15pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Number of</font></p>
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Options</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:00.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Weighted-Average</font></p>
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;color:#000000;">Exercise Price</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Outstanding at January&nbsp;1, 2018</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">236,484
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:65.65pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7.12
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;padding:0pt 2.4pt 0pt 25.2pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,286,528
				</td>
				<td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:71.15pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.71
				</td>
				<td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 25.2pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,953
				</td>
				<td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:71.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">110.23
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:17.85pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Outstanding at March 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:17.85pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,520,059
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:17.85pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:65.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:17.85pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.06
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:17.89pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Exercisable at March 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:17.89pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">42,249
				</td>
				<td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:17.89pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:65.65pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:17.89pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22.75
				</td>
				<td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:3pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;"></font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">As of </font><font style="display: inline;color:#000000;">March 31</font><font style="display: inline;color:#000000;">, 201</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">, there were </font><font style="display: inline;color:#000000;">2,650,694</font><font style="display: inline;color:#000000;"> options that were vested or expected to vest with an aggregate intrinsic value of </font><font style="display: inline;color:#000000;">zero</font><font style="display: inline;color:#000000;"> and a remaining weighted average contractual life of </font><font style="display: inline;color:#000000;">9.8</font><font style="display: inline;color:#000000;"> years. </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">For the three months </font><font style="display: inline;color:#000000;">ended </font><font style="display: inline;color:#000000;">March 31</font><font style="display: inline;color:#000000;">, 201</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;"> and 201</font><font style="display: inline;color:#000000;">7</font><font style="display: inline;color:#000000;">, we recorded compensation expense for all stock awards of </font><font style="display: inline;color:#000000;">$0.1</font><font style="display: inline;color:#000000;"> million</font><font style="display: inline;color:#000000;"> and </font><font style="display: inline;color:#000000;">zero</font><font style="display: inline;color:#000000;">, respectively, </font><font style="display: inline;color:#000000;">within operating expense</font><font style="display: inline;color:#000000;"> in the accompanying statements of operations</font><font style="display: inline;color:#000000;">.&nbsp;&nbsp;As of </font><font style="display: inline;color:#000000;">March </font><font style="display: inline;color:#000000;">31, 201</font><font style="display: inline;color:#000000;">8</font><font style="display: inline;color:#000000;">, the unrecognized compensation expense related to unvested stock awards was </font><font style="display: inline;color:#000000;">$2.4</font><font style="display: inline;color:#000000;"> million, which is expected to be recognized over a weighted-average period of </font><font style="display: inline;color:#000000;">3.6</font><font style="display: inline;color:#000000;"> years.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807476352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract', window );"><strong>Net Sales Service Revenue and Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock', window );">Net Sales Service Revenue and Accounts Receivable</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">1</font><font style="display: inline;font-weight:bold;">1</font><font style="display: inline;font-weight:bold;">.&nbsp; </font><a name="_Hlk510532097"></a><font style="display: inline;font-weight:bold;">SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Adoption of ASC Topic 606, &#x201C;Revenue from contracts with customers&#x201D;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">On January 1, 2018, the Company adopted ASC 606 that amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services by using the modified-retrospective method applied to any contracts that were not completed as of January 1, 2018. The Company performed a comprehensive review of its existing revenue arrangements following the five-step model:</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:EYInterstate;color:#000000;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Step 1: Identification of the contract with the customer.&nbsp;&nbsp;Sub-steps include determining the customer in a contract; Initial contract identification and determine if multiple contracts should be combined and accounted for as a single transaction.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:EYInterstate;color:#000000;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Step 2: Identify the performance obligation in the contract.&nbsp;&nbsp;Sub-steps include identifying the promised goods and services in the contract and identifying which performance obligations within the contract are distinct.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:EYInterstate;color:#000000;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Step 3: Determine the transaction price.&nbsp;&nbsp;Sub-steps include variable consideration, constraining estimates of variable consideration, the existence of a significant financing component in the contract, noncash consideration and consideration payable to a customer.</font>
		</p>
		<p style="margin:0pt 0pt 6pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:EYInterstate;color:#000000;font-size: 10pt">
			<font style="display: inline;font-family:Times New Roman;color:#000000;font-size:10pt;">Step 4: Allocate transaction price.&nbsp;&nbsp;Sub-steps include assessing the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to the customer. </font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Step 5: Satisfaction of performance obligations.&nbsp;&nbsp;Sub-steps include ascertaining the point in time when an asset is transferred to the customer and the customer obtains control of the asset upon which time the Company recognizes revenue.</font><font style="display: inline;color:#000000;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;"> Based on the Company's analysis, there were no changes identified that impacted the amount or timing of revenues recognized under the new guidance as compared to the previous guidance (ASC 605). Additionally, the Company's analysis indicated that there were no changes to how costs to obtain and fulfill our customer contracts would be recognized under the new guidance as compared to the previous guidance. Accordingly, the initial application of the new revenue standard did not result in the recognition of a cumulative effect adjustment to the opening balance of accumulated deficit as of January 1, 2018.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Nature of Contracts and Customers</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">T</font><font style="display: inline;color:#000000;">he Company&#x2019;s contracts and related performance obligations are similar for its customers and the sales process for all customers start upon the receipt of requisition forms from the customers for patient diagnostic testing and the execution of contracts for biomarker testing and clinical research.&nbsp; </font><font style="display: inline;">Payment terms for the services provided are 30 days, unless separately negotiated.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Diagnostic testing</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for laboratory testing services at a point in time based on the delivery method (web-portal access or fax) for the patient&#x2019;s laboratory report, per the contract. </font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Clinical research grants</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Control of the clinical research services are transferred to the customer over time.&nbsp;&nbsp;The Company will recognize revenue utilizing the &#x201C;effort based&#x201D; method, measuring its progress toward complete satisfaction of the performance obligation.&nbsp;&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Biomarker testing and clinical project services</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Control of the biomarker testing and clinical project services are transferred to the customer over time.&nbsp;&nbsp;The Company utilizes an &#x201C;effort based&#x201D; method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company generates revenue from the provision of diagnostic testing provided to patients, biomarker testing provided to bio-pharma customers and clinical research grants funded by both bio-pharma customers and government health programs.&nbsp; </font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Disaggregation of Revenues by Transaction Type</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">We operate in one business segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. </font><font style="display: inline;">Revenues, net of contractual allowances and adjustments for the three months ended March&nbsp;31, 2018 and 2017 were as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption):</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:521.35pt;margin-left:5.4pt;">
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:112.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Diagnostic Testing</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:94.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Biomarker Testing</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:94.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="top" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicaid</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicare</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">134&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">158&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">134&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">158&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Self-pay</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Third party payers</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">131&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">113&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">131&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">113&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Contract diagnostics</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Revenues, net of contractual allowances</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">791&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Revenue from the Medicare and Medicaid programs account for a portion of the Company&#x2019;s patient diagnostic service revenue. Laws and regulations governing those programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Revenue Recognition</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. </font><font style="display: inline;">The Company does not typically enter arrangements where multiple contracts can be combined as the terms regarding services are generally found within a single agreement/requisition form. </font><font style="display: inline;color:#000000;">The Company derives its revenues from three types of transactions: diagnostic testing, clinical research grants from state and federal research programs, and other revenues from the Company&#x2019;s ICP technology and bio-pharma projects encompassing genetic diagnostics.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;"> Deferred revenue</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;"> Deferred revenue, or&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;text-decoration:none;">unearned revenue</font><font style="display: inline;color:#000000;font-size:10pt;">, refers to advance payments for products or services that are to be delivered in the future. The Company records such prepayment of unearned revenue as a liability, as revenue that has not yet been earned, but represents products or services that are owed to a customer.&nbsp;&nbsp;As the product or service is delivered over time, the Company recognizes</font><font style="display: inline;color:#000000;font-size:10pt;"> the</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">appropriate amount of</font><font style="display: inline;color:#000000;font-size:10pt;">&nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;text-decoration:none;">revenue</font><font style="display: inline;color:#000000;font-size:10pt;text-decoration:none;"> from deferred revenue</font><font style="display: inline;color:#000000;font-size:10pt;">. For the period ended March 31, 2018 and December 31, 2017, the deferred revenue was </font><font style="display: inline;color:#000000;font-size:10pt;">$189,000</font><font style="display: inline;color:#000000;font-size:10pt;"> and </font><font style="display: inline;color:#000000;font-size:10pt;">$66,000</font><font style="display: inline;color:#000000;font-size:10pt;">, respectively</font><font style="display: inline;color:#000000;font-size:10pt;">.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;font-size:10pt;">Contractual Allowances and Adjustments</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">We are reimbursed by payors for services we provide. Payments for services covered by payors average less than billed charges. We monitor revenue and receivables from payors and record an estimated contractual allowance for certain revenue and receivable balances as of the revenue recognition date to properly account for anticipated differences between amounts estimated in our billing system and amounts ultimately reimbursed by payors. Accordingly, the total revenue and receivables reported in our financial statements are recorded at the amounts expected to be received from these payors. For service revenue, the contractual allowance is estimated based on several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payor/product mix. The billing functions for the remaining portion of our revenue are contracted and fixed fees for specific services and are recorded without an allowance for contractual discounts</font><font style="display: inline;color:#000000;font-size:10pt;">. &nbsp;</font><font style="display: inline;color:#000000;font-size:10pt;">The following table presents our revenues initially recognized for each associated payor class during the three months ended March 31, 2018 and 2017.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:521.40pt;margin-left:5.4pt;">
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:114.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Gross Revenues</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:137.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Contractual Allowances and adjustments</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:128.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Revenues, net of Contractual Allowances and adjustments</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="top" style="width:23.20pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicaid</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">15&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">24&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3)
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(12)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicare</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">137&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">166&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3)
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">134&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">158&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Self-pay</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Third party payers</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">317&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">295&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(186)
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(182)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">131&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">113&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Contract diagnostics</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">983&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">505&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(192)
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(202)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">791&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">988&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">505&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(192)
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(202)
				</td>
				<td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">796&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:23.20pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">Allowance for Doubtful Accounts</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:36pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The Company provides for a general allowance for collectability of services when recording </font><font style="display: inline;color:#000000;font-size:10pt;">n</font><font style="display: inline;color:#000000;font-size:10pt;">et </font><font style="display: inline;color:#000000;font-size:10pt;">sales.</font><font style="display: inline;color:#000000;font-size:10pt;"> &nbsp;The Company has adopted the policy of recognizing net </font><font style="display: inline;color:#000000;font-size:10pt;">sales</font><font style="display: inline;color:#000000;font-size:10pt;"> to the extent it expects to collect that amount.&nbsp;&nbsp;Reference FASB 954-605-45-5 and ASU 2011-07, Health Care Entities: Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debt, and the Allowance for Doubtful Accounts.&nbsp;&nbsp;The change in the allowance for doubtful accounts is directly related to the increase in </font><font style="display: inline;color:#000000;font-size:10pt;">p</font><font style="display: inline;color:#000000;font-size:10pt;">atient service revenues.&nbsp; </font><font style="display: inline;color:#000000;font-size:10pt;">The following table presents our reported revenues net of the collection allowance and adjustments for the three months ended March 31, 2018 and 2017.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:527.40pt;margin-left:5.4pt;">
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:112.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Revenues, net of </font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Contractual Allowances and adjustments</font></p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:144.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Allowances for doubtful accounts</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:128.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="top" style="width:23.75pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicaid</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(11)
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicare</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">134&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">158&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(20)
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(30)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">114&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">128&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Self-pay</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Third party payers</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">131&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">113&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(53)
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(19)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">78&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">94&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Contract diagnostics</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">791&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(84)
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(55)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">707&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">248&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">796&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(84)
				</td>
				<td valign="bottom" style="width:16.15pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(55)
				</td>
				<td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">712&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">248&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:23.75pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Costs to Obtain or Fulfill a Customer Contract</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in operating expenses in the condensed consolidated statements of operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Shipping and handling costs are comprised of inbound and outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in cost of sales in the condensed consolidated statements of operations.</font>
		</p>
		<p style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">Accounts Receivable</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The Company has provided an allowance for potential credit losses, which has been determined based on management&#x2019;s industry experience. The Company grants credit without collateral to its patients, most of who are insured under third party payer agreements.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following summarizes the mix of receivables: </font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 76.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:67.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.82%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.28%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:00.86%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.32%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.86%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:00.86%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Medicaid</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">33
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">37
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Medicare</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">611
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">256
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Self-pay</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">102
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">53
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Third party payers</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">768
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,066
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Contract diagnostic services</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.28%;background-color: #CCECFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">246
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.32%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCECFF;height:11.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">445
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Other</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.28%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.32%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.86%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,760
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.86%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,857
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.82%;background-color: #auto;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Less allowance for doubtful accounts </font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #auto;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.28%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,208
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #auto;height:11.50pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">)</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #auto;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.32%;background-color: #auto;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.86%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,127
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Accounts receivable, net</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">552
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.32%;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">730
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 1pt">
			<font style="display: inline;font-size:1pt;background-color:lime;">&#xFEFF;</font>
		</p>
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following table presents the roll-forward of the allowance for doubtful accounts for the three months ended March 31, 2018.</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 60.00%;margin-left:0pt;font-family:Calibri;font-size:11pt;">
			<tr>
				<td valign="top" style="width:114.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:24.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:110.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:14.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(dollars in thousands)</font></p>
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;">
						&nbsp;</p>
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;border-bottom:1pt solid #000000 ;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Allowance for Doubtful Accounts</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Balance, January 1, 2018</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:110.90pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,127
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.85pt;background-color: #CCEEFF;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Collection Allowance:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Medicaid</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(11
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Medicare</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(20
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Third party payers</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(53
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Service revenue, net</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;border-top:1pt solid #000000 ;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(84
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Bad debt expense</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Total charges</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;border-top:1pt solid #000000 ;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;border-bottom:1pt solid #000000 ;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(81
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Balance, March 31, 2018</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:110.90pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:28.80pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,208
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:28.80pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:110.90pt;border-top:2pt double #000000 ;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt 0pt 0pt 22.5pt;line-height:120%;text-indent: -22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Sales Service Revenue and Accounts Receivable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Sales Service Revenue and Accounts Receivable [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_NetSalesServiceRevenueAndAccountsReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807461088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">1</font><font style="display: inline;font-weight:bold;">2</font><font style="display: inline;font-weight:bold;">.&nbsp;&nbsp;SUBSEQUENT EVENTS</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;font-style:italic;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Issuance of Convertible Notes</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-indent:36pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-size:10pt;">On April 20</font><font style="display: inline;font-size:10pt;">, 2018, the Company entered into a securities purchase agreement with certain investors, pursuant to which the Company will issue up to approximately </font><font style="display: inline;font-size:10pt;">$3,296,703</font><font style="display: inline;font-size:10pt;"> in </font><font style="display: inline;font-size:10pt;">8%</font><font style="display: inline;font-size:10pt;"> Senior Secured Convertible Promissory Notes with </font><font style="display: inline;font-size:10pt;">25%</font><font style="display: inline;font-size:10pt;"> common stock warrant</font><font style="display: inline;font-size:10pt;"> coverage</font><font style="display: inline;font-size:10pt;">. The initial closing provided the Company with </font><font style="display: inline;font-size:10pt;">$1,660,000</font><font style="display: inline;font-size:10pt;"> of gross proceeds for the issuance of Notes with an aggregate principal of </font><font style="display: inline;font-size:10pt;">$1,809,400</font><font style="display: inline;font-size:10pt;">.</font><font style="display: inline;font-size:10pt;">&nbsp;</font><font style="display: inline;font-size:10pt;">The Note is payable by the Company on the earlier of (i) the </font><font style="display: inline;font-size:10pt;">one</font><font style="display: inline;font-size:10pt;"> year anniversary after the initial closing date or (ii) upon the closing of a qualified offering, namely the Company raising gross proceeds of at least </font><font style="display: inline;font-size:10pt;">$7,000,000</font><font style="display: inline;font-size:10pt;">. &nbsp;</font><font style="display: inline;font-size:10pt;">The obligations under the Note are secured, subject to certain exceptions and other permitted payments by a perfected security interest on the assets of the Company.</font>
		</p>
		<p style="margin:0pt;background-color: #FFFFFF;text-indent:36pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816544288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Basis of Presentation.</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The accompanying condensed consolidated financial statements are presented in conformity with GAAP. We have evaluated events occurring subsequent to March 31, 2018 for potential recognition or disclosure in the condensed consolidated financial statements and concluded that, other than what is disclosed within the notes to unaudited condensed consolidated financial statements and in Note 12 - Subsequent Events, there were no other subsequent events that required recognition or disclosure.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The condensed consolidated balance sheet as of December&nbsp;31, 2017 was derived from our audited balance sheet as of that date. There has been no change in the balance sheet from December 31, 2017. The accompanying condensed consolidated financial statements as of and for the three months ended March&nbsp;31, 2018 and 2017 are unaudited and reflect all adjustments (consisting of only normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the financial position and operating results for the interim periods. These unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December&nbsp;31, 2017 contained in our Annual Report Form 10-K, filed with the Securities and Exchange Commission (the &#x201C;SEC&#x201D;) on April 13, 2018. The results of operations for the interim periods presented are not necessarily indicative of the results for fiscal year 2018.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:12pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Recent Accounting Pronouncements. </font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">In May 2014, the Financial Accounting Standards Board (&#x201C;FASB&#x201D;) issued Accounting Standards Update (&#x201C;ASU&#x201D;) 2014-09, Revenue from Contracts with Customers and has subsequently issued supplemental and/or clarifying ASUs (collectively &#x201C;ASC 606&#x201D;). ASC 606 outlines a five-step framework that intends to clarify the principles for recognizing revenue and eliminate industry-specific guidance. In addition, ASC 606 revises current disclosure requirements in an effort to help financial statement users better understand the nature, amount, timing, and uncertainty of revenue that is recognized. ASC 606 may be applied either retrospectively to each prior reporting period presented or use the modified retrospective transition method with the cumulative effect of initial adoption recognized at the date of initial application. We adopted this new standard as of January 1, 2018, by using the modified-retrospective method. An adjustment was not required and a change to the prior revenue recognition process and policy to adopt the new standard was not necessary. See Note 11 &#x2013; Sales Service Revenue, Net And Accounts Receivable for further details.</font>
		</p>
		<p style="margin:12pt 0pt 0pt;line-height:120%;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&nbsp;</font><font style="display: inline;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="display: inline;font-style:italic;">Leases</font><font style="display: inline;">. The new standard amends the recognition of lease assets and lease liabilities by lessees for those leases currently classified as operating leases and amends disclosure requirements associated with leasing arrangements. The new standard is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2018. Early adoption is permitted. The new standard must be adopted using a modified retrospective transition, and provides for certain practical expedients. Transition will require application of the new guidance at the beginning of the earliest comparative period presented. We are currently assessing the impact that the adoption of this ASU will have on our consolidated financial statements.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In January 2017, FASB issued ASU No.&nbsp;2017-01, </font><font style="display: inline;font-style:italic;">Business Combinations</font><font style="display: inline;"> (Topic 805): Clarifying the Definition of a Business.&nbsp;&nbsp;ASU No. 2017-01 adds guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new guidance is effective for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. The adoption of ASU No. 2017-01 did not have a material effect on the Company&#x2019;s financial position and results of operations.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">In May 2017, the FASB issued ASU 2017-09 &#x201C;</font><font style="display: inline;font-style:italic;">Compensation &#x2013; Stock Compensation (Topic 718): Scope of Modification Accounting&#x201D;, </font><font style="display: inline;">which provides clarity and reduces both diversity in practice and cost and complexity when applying guidance in Topic 718. This amendment provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. &nbsp;The amendments are effective for all entities for annual periods, and interim periods within those periods, beginning after December 15, 2017. The adoption of ASU No. 2017-09 did not have a material effect on the Company&#x2019;s financial position and results of operations.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Property and Equipment, net.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Depreciation expense was less than </font><font style="display: inline;">$0.1</font><font style="display: inline;"> million for both the three months March&nbsp;31, 2018 and 2017. Depreciation expense during each year includes depreciation related to equipment acquired under capital leases.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Goodwill and Intangible Assets.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">As a result of the Merger, the Company recorded goodwill and intangible assets as part of its allocation of the purchase consideration.</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">Goodwill</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets of the business acquired. Goodwill is tested for impairment annually. We perform this impairment analysis during the fourth quarter of each year or when a significant event occurs that may indicate that the assets might be impaired. During the three months ended March 31, 2018, the Company experienced a decline in its share price and a reduction in its market capitalization, as such the Company determined that an assessment of goodwill should be performed using the qualitative approach. Based on the qualitative assessment, the Company concluded that it was more likely than not that the fair value of the Company was less than its carry value. As part of its analysis, the Company considered triggering events and compared its fair value with its carrying value. The analysis of the fair value of the Company involved using the discounted cash flow model. Based on the analysis, the Company concluded that its carrying value exceeded its fair value and goodwill impairment in the amount of </font><font style="display: inline;">$0.3</font><font style="display: inline;"> million was recorded for the three months ended March 31, 2018.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">Intangibles</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Amortization expense for intangible assets was </font><font style="display: inline;">$0.3</font><font style="display: inline;"> million and zero during the three months ended March&nbsp;31, 2018 and 2017, respectively. Amortization expense for intangible assets is expected to be </font><font style="display: inline;">$1.2</font><font style="display: inline;"> million, </font><font style="display: inline;">$1.0</font><font style="display: inline;"> million, </font><font style="display: inline;">$1.0</font><font style="display: inline;"> million, </font><font style="display: inline;">$0.9</font><font style="display: inline;"> million and </font><font style="display: inline;">$0.9</font><font style="display: inline;"> million for each of the years ending December 31, 2018, 2019, 2020, 2021 and 2022, respectively.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Revenue Recognition.</font>
		</p>
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-indent:22.3pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">Revenue recognition occurs when a customer obtains control of the promised goods and service. Revenue assigned to the goods and services reflects the consideration which the Company expects to receive in exchange for those goods and services.&nbsp; </font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company derives its revenues from Diagnostic Testing - histology, flow cytometry, cytology and molecular testing; Clinical Research from bio-pharma customers, state and federal grant programs; and from Biomarker Testing from bio-pharma customers. All sources of revenue are recorded net of accruals for estimated chargebacks, rebates, cash discounts, other allowances, and returns. Due to differences in the substance of these revenue types, the transactions require, and the Company utilizes, different revenue recognition policies for each. See more detailed information on revenue in Note 11 &#x2013; Sales Service Revenue, Net And Accounts Receivable.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;">The Company recognizes revenue utilizing the five-step framework of ASC 606. Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for diagnostic testing at a point in time based on the delivery method (web-portal access or fax) for a patient&#x2019;s laboratory report. Diagnostic testing service revenue is reported at the estimated net realizable amounts from patients, third-party payors and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payors. Revenue under third-party payor agreements is subject to audit and retroactive adjustment. Provisions for third-party payor settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined. For clinical research and biomarker services, the Company utilizes an &#x201C;effort based&#x201D; method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results per the contract.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt">
			<font style="display: inline;font-size:8pt;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. Deferred net sales included in the balance sheet as deferred revenue was </font><font style="display: inline;">$0.2 million and less than $0.1 million</font><font style="display: inline;"> as of March 31, 2018 and December 31, 2017, respectively.</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the income statement.</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:14pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-style:italic;">Loss Per Share.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period.&nbsp;&nbsp;Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to </font><font style="display: inline;">9,506,515</font><font style="display: inline;"> and </font><font style="display: inline;">2,753,814</font><font style="display: inline;"> shares of our common stock have been excluded from the computation of diluted loss per share at March 31, 2018 and 2017, respectively, because the effect is anti-dilutive due to the net loss.</font>
		</p>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;font-family:Calibri;font-size:11pt;">
			<tr>
				<td valign="top" style="width:81.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:61.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:124.35pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">March 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">2018</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Stock options</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,520,059&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,651&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Warrants</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,923,789&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,971,058&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Preferred stock</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">62,667&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">780,105&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Total</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,506,515&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,753,814&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807424176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Outstanding Securities not Included in the Computation of Diluted Net Loss</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following table summarizes the outstanding securities not included in the computation of diluted net loss per share:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;margin-left:0pt;font-family:Calibri;font-size:11pt;">
			<tr>
				<td valign="top" style="width:81.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:11.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:61.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="5" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:124.35pt;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">March 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">2018</font></p>
				</td>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;border-top:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Stock options</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,520,059&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,651&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Warrants</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,923,789&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,971,058&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Preferred stock</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:56.85pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">62,667&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">780,105&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:81.65pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Total</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:11.80pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:56.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">9,506,515&nbsp;
				</td>
				<td colspan="2" valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:13.50pt;background-color: #CCEEFF;padding:0pt 6.5pt">
					<p style="margin:9pt 0pt 0pt;line-height:120%;text-align:right;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:54.00pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,753,814&nbsp;
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786260496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVERSE MERGER (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>REVERSE MERGER [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-indent:21.6pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following unaudited pro forma information presents the Company's financial results as if the acquisition of Transgenomic had occurred on January 1, 2017 and combines Transgenomic&#x2019;s unaudited condensed consolidated statement of operations for the three months ended March&nbsp;31, 2017 with Precipio&#x2019;s unaudited condensed statement of operations for the three months ended March&nbsp;31, 2017:</font>
		</p>
		<p style="margin:0pt;line-height:120%;text-align:center;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;font-weight:bold;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:405.00pt;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:195.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Dollars in thousands, except per share amounts</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="7" valign="bottom" style="width:210.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">For the Three Months Ended March 31,</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:10.00pt;border-top:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Net sales</font></p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">712
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">907
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Net loss available to common stockholders</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(5,953
				</td>
				<td valign="bottom" style="width:03.85pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:10.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,778
				</td>
				<td valign="bottom" style="width:03.85pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:195.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Loss per common share</font></p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.47
				</td>
				<td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:10.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(0.42
				</td>
				<td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807424176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>LONG-TERM DEBT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of debt</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Long-term debt consists of the following:</font>
		</p>
		<p style="margin:0pt;line-height:120%;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:510.00pt;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:302.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="7" valign="bottom" style="width:204.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">Dollars&nbsp;in&nbsp;Thousands</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">March 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:13.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:100.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:13.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-weight:bold;color:#000000;">December 31, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Department of Economic and Community Development (DECD)</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">293
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">DECD debt issuance costs</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(30
				</td>
				<td valign="bottom" style="width:03.85pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;background-color: #auto;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Secured debt obligations</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;background-color: #auto;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,233
				</td>
				<td valign="top" style="width:03.85pt;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;background-color: #auto;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,233
				</td>
				<td valign="top" style="width:03.85pt;background-color: #auto;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Financed insurance loan</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">74
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">183
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Total long-term debt</font></p>
				</td>
				<td valign="top" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;border-top:1pt solid #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,570
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;border-top:1pt solid #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,416
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Current portion of long-term debt</font></p>
				</td>
				<td valign="top" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(676
				</td>
				<td valign="bottom" style="width:03.85pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:96.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(587
				</td>
				<td valign="bottom" style="width:03.85pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:302.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Long-term debt, net of current maturities</font></p>
				</td>
				<td valign="top" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-bottom:2pt double #000000 ;height:16.00pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,894
				</td>
				<td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:90.65pt;border-bottom:2pt double #000000 ;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,829
				</td>
				<td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807382064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other current liabilities</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;line-height:120%;text-indent:22.5pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Other current liabilities are as follows:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width:387.00pt;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:206.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font><font style="display: inline;font-size:1pt;">0</font></p>
				</td>
				<td valign="bottom" style="width:11.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:72.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:69.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:206.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">(dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:82.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:27.20pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">March 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:27.20pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:79.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:27.20pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 31, 2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:206.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Obligation to issue common shares</font></p>
				</td>
				<td valign="bottom" style="width:11.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:72.65pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:69.65pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,897&nbsp;
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:206.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Liability for settlement of equity instrument</font></p>
				</td>
				<td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:78.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,350&nbsp;
				</td>
				<td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:75.15pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,085&nbsp;
				</td>
				<td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:206.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:11.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:72.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,350&nbsp;
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:09.00pt;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:69.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,982&nbsp;
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807415056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of stockholders' equity, including warrants and rights</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:9pt 0pt 7pt;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following represents a summary of the warrants outstanding as of March 31, 2018:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:318.00pt;margin-left:2.5pt;">
			<tr>
				<td valign="bottom" style="width:22.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:89.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 3.6pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Issue&nbsp;Year</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 0pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:89.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Expiration</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Underlying</font></p>
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Shares </font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Exercise</font></p>
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Price</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="8" valign="bottom" style="width:318.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-style:italic;color:#000000;text-decoration:underline;">Warrants Assumed in Merger</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(1)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2014</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">April 2020</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12,487&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$120.00</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(2)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2015</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">February 2020</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">23,826&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$67.20</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(3)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2015</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">December 2020</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">4,081&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$49.80</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(4)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2016</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">January 2021</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">8,952&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$36.30</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td colspan="8" valign="bottom" style="width:318.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-style:italic;color:#000000;text-decoration:underline;">Warrants</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(5)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">June 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">45,600&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$2.75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(6)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">June 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">91,429&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$7.00</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(7)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">2,380,000&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$0.75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(8)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">60,000&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$3.125</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(9)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">856,446&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$10.00</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(10)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">August 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">359,999&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$0.75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #auto;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(11)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">October 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #auto;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10,000&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #auto;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$0.75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(12)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">May 2023</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,962,857&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$0.75</font></p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:22.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&#xFEFF;</font><font style="display: inline;color:#000000;font-size:8pt;">(13)</font></p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">October 2022</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">108,112&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$7.50</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:22.00pt;padding:0pt 0pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:89.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.00pt;border-top:1pt solid #000000 ;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5,923,789&nbsp;
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:65.00pt;padding:0pt 3.6pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (1)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with a private placement which was completed in October 2014.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (2)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with an offering which was completed in February 2015.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (3)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with an offering which was completed in July 2015.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (4)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with an offering which was completed in January 2016. Of the remaining outstanding warrants as of March 31, 2018, 5,368 warrants are recorded as a liability, See Note 9 &#x2013; Fair Value for further discussion, and 3,584 are treated as equity.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (5)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the Merger and are the 2017 New Bridge Warrants.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;font-family:Times New Roman;font-size:8pt;;"> (6)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the Merger and are considered Side Warrants.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (7)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the August 2017 Offering and are the August 2017 Offering Warrants discussed below.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (8)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the August 2017 Offering and are considered Representative Warrants.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (9)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the conversion of our Series A Senior stock, at the time of the closing of the August 2017 Offering, and are the Series A Conversion Warrants discussed above.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (10)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the conversion of convertible bridge notes, at the time of the closing of the August 2017 Offering, and are the Note Conversion Warrants discussed below.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (11)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the waiver of default the Company received in the fourth quarter of 2017 in connection with the Convertible Promissory Notes and are the Convertible Promissory Note Warrants discussed below.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (12)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the Series C Preferred Offering and are the Series C Warrants discussed below.</font></p></td></tr></table></div>
		<div style="width:100%"><table style="width:100%; table-layout: fixed;" cellpadding="0" cellspacing="0"><tr><td style="width:0pt;"><p style="width:0pt;font-size:0pt;"></p></td><td valign="top" align="left" style="width: 18.00pt;">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
				<font style="margin:6pt 0pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size:8pt;;"> (13)</font>
			</p>
		</td><td style="width:18pt;"><p style="width:18pt;width:18pt;font-size:0pt;"></p></td><td align="left" valign="top">
			<p style="text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 8pt;margin:6pt 0pt 0pt;">
			<font style="display: inline;font-size:8pt;color:#000000;">These warrants were issued in connection with the Debt Obligation settlement agreements and are the Creditor Warrants discussed below.</font></p></td></tr></table></div>
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;text-decoration:underline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6795604144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of Liability</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:9pt 0pt 0pt;line-height:120%;text-indent:24pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">During the three months ended March 31, 2018, the change in the fair value of the liability measured using significant unobservable inputs (Level 3) were comprised of the following:&nbsp; </font><font style="display: inline;"></font>
		</p>
		<p style="margin:0pt;line-height:7pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:374.00pt;margin-left:2.5pt;">
			<tr>
				<td valign="bottom" style="width:269.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:86.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:08.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:18.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">Dollars in Thousands</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 0pt;height:18.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:101.00pt;padding:0pt 0pt 0pt 3.6pt;height:18.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:101.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:21.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">For the Three Months Ended</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:101.00pt;border-top:1pt solid #000000 ;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;color:#000000;font-size:8pt;">March 31, 2018</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Beginning balance at January 1</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:91.00pt;background-color: #CCEEFF;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">841
				</td>
				<td valign="top" style="width:04.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 25.2pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Total gains:</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="4" valign="bottom" style="width:101.00pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 3.6pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 46.8pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Recognized in earnings</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:96.50pt;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(261
				</td>
				<td valign="middle" style="width:04.50pt;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;padding:0pt 2.4pt 0pt 46.8pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Deductions &#x2013; warrant liability settlement</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:15.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:96.50pt;border-bottom:1pt solid #000000 ;height:15.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(456
				</td>
				<td valign="middle" style="width:04.50pt;border-bottom:1pt solid #000000 ;height:15.00pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:269.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Balance at March 31</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:91.00pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:16.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">124
				</td>
				<td valign="top" style="width:04.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:16.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800041920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>EQUITY INCENTIVE PLAN [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt 0pt 7pt;line-height:120%;text-indent:22.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following table summarizes stock option activity under our plans during the three months ended March 31, 2018:</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:512.00pt;margin-left:2.5pt;">
			<tr>
				<td valign="bottom" style="width:368.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:65.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:61.15pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Number of</font></p>
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Options</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 0pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:00.00pt;border-bottom:1pt solid #000000 ;padding:0pt 3.6pt 0pt 3.6pt;height:20.00pt">
					<p style="margin:2pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Weighted-Average</font></p>
					<p style="margin:0pt 0pt 2pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">Exercise Price</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Outstanding at January&nbsp;1, 2018</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">236,484
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:65.65pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">7.12
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;padding:0pt 2.4pt 0pt 25.2pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Granted</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,286,528
				</td>
				<td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:71.15pt;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">0.71
				</td>
				<td valign="top" style="width:03.85pt;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 25.2pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Forfeited</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2,953
				</td>
				<td valign="bottom" style="width:03.85pt;background-color: #CCEEFF;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">)</font></p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:14.00pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="width:71.15pt;background-color: #CCEEFF;height:14.00pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">110.23
				</td>
				<td valign="top" style="width:03.85pt;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:14.00pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;padding:0pt 2.4pt 0pt 3.6pt;height:17.85pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Outstanding at March 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:17.85pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3,520,059
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;padding:0pt 3.6pt 0pt 0pt;height:17.85pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:65.65pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;height:17.85pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1.06
				</td>
				<td valign="top" style="width:03.85pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;padding:0pt 0pt 0pt 0pt;height:17.85pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:368.00pt;background-color: #CCEEFF;padding:0pt 2.4pt 0pt 3.6pt;height:17.89pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;color:#000000;">Exercisable at March 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:61.15pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:17.89pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">42,249
				</td>
				<td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:04.00pt;background-color: #CCEEFF;padding:0pt 3.6pt 0pt 0pt;height:17.89pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:05.50pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt">
					<p style="margin:2pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:65.65pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:17.89pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">22.75
				</td>
				<td valign="top" style="width:03.85pt;border-bottom:2pt double #000000 ;background-color: #CCEEFF;padding:0pt 0pt 0pt 0pt;height:17.89pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of a stock option or other award plan under which equity-based compensation is awarded to employees, typically comprised of the amount of unearned compensation (deferred compensation cost), compensation expense, and changes in the quantity and fair value of the shares (or other type of equity) granted, exercised, forfeited, and issued and outstanding pertaining to that plan.  Disclosure may also include nature and general terms of such arrangements that existed during the period and potential effects of those arrangements on shareholders, effect of compensation cost arising from equity-based payment arrangements on the income statement, method of estimating the fair value of the goods or services received, or the fair value of the equity instruments granted, during the period, cash flow effects resulting from equity-based payment arrangements and, for registrants that accelerate vesting of out of the money share options, reasons for the decision to accelerate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816211568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract', window );"><strong>Net Sales Service Revenue and Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Revenues</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">Revenues, net of contractual allowances and adjustments for the three months ended March&nbsp;31, 2018 and 2017 were as follows (prior-period amounts are not adjusted under the modified-retrospective method of adoption):</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:521.35pt;margin-left:5.4pt;">
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:112.40pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Diagnostic Testing</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:94.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Biomarker Testing</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:94.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="top" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicaid</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicare</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">134&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">158&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">134&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">158&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Self-pay</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Third party payers</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">131&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">113&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">131&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">113&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Contract diagnostics</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Revenues, net of contractual allowances</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">791&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:171.60pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:30.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock', window );">Schedule of Gross to Net Sales Adjustments</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The following table presents our revenues initially recognized for each associated payor class during the three months ended March 31, 2018 and 2017.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:521.40pt;margin-left:5.4pt;">
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:114.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Gross Revenues</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:137.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Contractual Allowances and adjustments</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:128.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Revenues, net of Contractual Allowances and adjustments</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="top" style="width:23.20pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicaid</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">15&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">24&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3)
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(12)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicare</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">137&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">166&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(3)
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(8)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">134&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">158&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Self-pay</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Third party payers</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">317&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">295&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(186)
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(182)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">131&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">113&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Contract diagnostics</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">983&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">505&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(192)
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(202)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">791&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">988&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">505&nbsp;
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(192)
				</td>
				<td valign="bottom" style="width:15.80pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(202)
				</td>
				<td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">796&nbsp;
				</td>
				<td valign="bottom" style="width:23.20pt;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:47.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:92.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.30pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:50.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:47.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:80.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.10pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:23.20pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:47.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok', window );">Schedule of Reported Revenues Net of Collection Allowance</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">The following table presents our reported revenues net of the collection allowance and adjustments for the three months ended March 31, 2018 and 2017.</font>
		</p>
		<p style="margin:0pt;text-indent:22.3pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;color:#000000;font-size:10pt;">&#xFEFF;</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:527.40pt;margin-left:5.4pt;">
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">(dollars in thousands)</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:112.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Revenues, net of </font></p>
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Contractual Allowances and adjustments</font></p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:144.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Allowances for doubtful accounts</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="3" valign="bottom" style="width:128.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">Total</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2018</font></p>
				</td>
				<td valign="top" style="width:23.75pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;height:15.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">2017</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicaid</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">12&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(11)
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(2)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">10&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Medicare</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">134&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">158&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(20)
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(30)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">114&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">128&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Self-pay</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">20&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(4)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">26&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">16&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Third party payers</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">131&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">113&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(53)
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(19)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">78&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">94&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Contract diagnostics</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">488&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:15.95pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">791&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(84)
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(55)
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">707&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">248&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font><font style="display: inline;color:#000000;">Other</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">5&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">796&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">303&nbsp;
				</td>
				<td valign="bottom" style="width:15.85pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(84)
				</td>
				<td valign="bottom" style="width:16.15pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(55)
				</td>
				<td valign="bottom" style="width:15.95pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">712&nbsp;
				</td>
				<td valign="bottom" style="width:23.75pt;border-left:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:16.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">$</font></p>
				</td>
				<td valign="bottom" style="width:46.65pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;height:16.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">248&nbsp;
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:93.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;color:#000000;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:15.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:48.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.85pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:43.45pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:16.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:83.35pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:15.95pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:58.55pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:23.75pt;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:46.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;height:6.50pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Receivables</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following summarizes the mix of receivables: </font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 76.00%;margin-left:0pt;">
			<tr>
				<td valign="middle" style="width:67.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 1pt">
						<font style="display: inline;font-size:1pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.32%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:00.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="middle" style="width:67.82%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 11pt">
						<font style="display: inline;font-size:11pt;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:01.28%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.28%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:00.86%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:02.32%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:10.86%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
				<td valign="middle" style="width:00.86%;padding:0pt;">
					<p style="margin:0pt 0pt 10pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:11.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">March 31, 2018</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-size:8pt;">&nbsp;&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:13.18%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;font-weight:bold;font-size:8pt;">December 31, 2017</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 8pt">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Medicaid</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">33
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">37
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Medicare</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">611
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">256
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Self-pay</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">102
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">53
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Third party payers</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">768
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,066
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Contract diagnostic services</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.28%;background-color: #CCECFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">246
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.32%;background-color: #CCECFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.86%;background-color: #CCECFF;height:11.50pt;color:#000000;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">445
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:67.82%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt 0pt 0pt 12pt;text-indent: -12pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Other</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.28%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.32%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.86%;border-bottom:1pt solid #000000 ;height:11.50pt;padding:0pt;">
					<p style="margin:2pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;color:#000000;">&#x2014;</font></p>
				</td>
				<td valign="bottom" style="width:00.86%;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,760
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.32%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.86%;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">1,857
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						<font style="display: inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.82%;background-color: #auto;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Less allowance for doubtful accounts </font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #auto;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.28%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,208
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #auto;height:11.50pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">)</font></p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #auto;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.32%;background-color: #auto;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:10.86%;border-bottom:1pt solid #000000 ;background-color: #auto;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,127
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:67.82%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;line-height:115%;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font><font style="display: inline;">Accounts receivable, net</font></p>
				</td>
				<td valign="bottom" style="width:03.62%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:01.28%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.28%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">552
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.08%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="width:02.32%;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;">$</font></p>
				</td>
				<td valign="bottom" style="width:10.86%;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:11.50pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">730
				</td>
				<td valign="bottom" style="width:00.86%;background-color: #CCEEFF;height:11.50pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock', window );">Schedule of Allowance for Doubtful Accounts</a></td>
<td class="text"><div> <div style="margin-left:0pt;margin-right:0pt;">
		<p style="margin:12pt 0pt 0pt;text-indent:24.5pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">The following table presents the roll-forward of the allowance for doubtful accounts for the three months ended March 31, 2018.</font>
		</p>
		<div style="width:100%"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 60.00%;margin-left:0pt;font-family:Calibri;font-size:11pt;">
			<tr>
				<td valign="top" style="width:114.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font></p>
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden">
						&nbsp;</p>
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:15.80pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:24.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:14.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:19.65pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="width:110.90pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="width:14.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt">
					<p style="margin:0pt;font-family:Times New Roman;height:1.00pt;overflow:hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">(dollars in thousands)</font></p>
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;">
						&nbsp;</p>
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:center;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;border-bottom:1pt solid #000000 ;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:center;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Allowance for Doubtful Accounts</font></p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:36.00pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Balance, January 1, 2018</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:110.90pt;border-top:1pt solid #000000 ;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,127
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:11.85pt;background-color: #CCEEFF;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">Collection Allowance:</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Medicaid</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(11
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Medicare</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(20
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Third party payers</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(53
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Service revenue, net</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;border-top:1pt solid #000000 ;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(84
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Bad debt expense</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;border-bottom:1pt solid #000000 ;background-color: #CCEEFF;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">3
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Total charges</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;border-top:1pt solid #000000 ;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:110.90pt;border-bottom:1pt solid #000000 ;height:7.20pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(81
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:114.90pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">&#xFEFF;</font><font style="display: inline;font-family:Times New Roman;font-size:10pt;">Balance, March 31, 2018</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:15.80pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:24.15pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:19.65pt;background-color: #CCEEFF;height:28.80pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;text-align:right;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">$</font></p>
				</td>
				<td valign="bottom" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:110.90pt;border-top:1pt solid #000000 ;border-bottom:2pt double #000000 ;background-color: #CCEEFF;height:28.80pt;font-family:Times New Roman;font-size:10pt;text-align:right;" nowrap="nowrap">(1,208
				</td>
				<td colspan="2" valign="bottom" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:14.15pt;background-color: #CCEEFF;height:28.80pt;">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;font-size: 10pt">
						<font style="display: inline;font-family:Times New Roman;font-size:10pt;">)</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:114.90pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;font-size: 10pt">
						<font style="display: inline;">&#xFEFF;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:15.80pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:24.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:19.65pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:110.90pt;border-top:2pt double #000000 ;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
				<td colspan="2" valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:14.15pt;height:7.20pt;padding:0pt 6.5pt">
					<p style="margin:12pt 0pt 0pt;font-family:Times New Roman;height:7.20pt;overflow: hidden;font-size:0pt;">
						&nbsp;</p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman;font-size: 10pt">
			<font style="display: inline;">&#xFEFF;</font>
		</p>
		<p><font size="1"> </font></p>
	</div> </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Sales Service Revenue and Accounts Receivable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Allowance for Doubtful Accounts [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ScheduleOfAllowanceForDoubtfulAccountsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Gross to Net Sales Adjustments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ScheduleOfGrossToNetSalesAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Reported Revenues Net of Collection Allowance [Table Text Blcok]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ScheduleOfReportedRevenuesNetOfCollectionAllowanceTableTextBlcok</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82913847&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816446048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS DESCRIPTION (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 09, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 29, 2017</div></th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_AccumulatedNetIncomeLoss', window );">Accumulated Net Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_WorkingCapitalDeficiency', window );">Working deficiency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,145,000)<span></span>
</td>
<td class="num">$ (326,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 618,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prpo_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Subsequent Events | Senior Secured Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 3,296,703.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Common stock warrant coverage</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember', window );">Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Merger transaction, effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 29,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1', window );">Merger transaction, agrement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 12,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity', window );">Merger transaction, name of acquired entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Precipio Diagnostics, LLC, a privately held Delaware limited liability company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_BusinessCombinationStockExchangeRatio', window );">Merger transaction, pre-reverse stock split exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.2502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_LevistonResourcesLlcMember', window );">Leviston Resources LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_EquityPurchaseAgreement', window );">Equity purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_CompanyStockPercentageOfMarketRate', window );">Company stock percentage of market rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_AccumulatedNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated Net Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_AccumulatedNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_BusinessCombinationStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination stock exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_BusinessCombinationStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_CompanyStockPercentageOfMarketRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company stock percentage of market rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_CompanyStockPercentageOfMarketRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_EquityPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_EquityPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_WorkingCapitalDeficiency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working Capital (Deficiency)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_WorkingCapitalDeficiency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the business acquisition agreement was executed, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e845-128460<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e848-128460<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionNameOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the acquired entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionNameOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=prpo_SeniorSecuredConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=prpo_SeniorSecuredConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_LevistonResourcesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prpo_LevistonResourcesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817442368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">$ 294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for intangible assets</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization expense, next twelve months</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization expense, 2019</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization expense, 2020</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization expense, 2021</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Amortization expense, 2022</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817801344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities not Included in the Computation of Diluted Net Loss) (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities not included in the computation of diluted net loss per share</a></td>
<td class="nump">9,506,515<span></span>
</td>
<td class="nump">2,753,814<span></span>
</td>
<td class="nump">2,753,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities not included in the computation of diluted net loss per share</a></td>
<td class="nump">3,520,059<span></span>
</td>
<td class="nump">2,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities not included in the computation of diluted net loss per share</a></td>
<td class="nump">5,923,789<span></span>
</td>
<td class="nump">1,971,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities not included in the computation of diluted net loss per share</a></td>
<td class="nump">62,667<span></span>
</td>
<td class="nump">780,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803074944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVERSE MERGER (Pro-forma Disclosures) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net sales</a></td>
<td class="nump">$ 712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (5,953)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember', window );">Transgenomics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net sales</a></td>
<td class="nump">$ 712<span></span>
</td>
<td class="nump">$ 907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (5,953)<span></span>
</td>
<td class="num">$ (2,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic', window );">Loss per common share (in dollars per share)</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=prpo_TransgenomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817467376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM DEBT (Schedule of Debt) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 3,570<span></span>
</td>
<td class="nump">$ 3,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="num">(676)<span></span>
</td>
<td class="num">(587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current maturities</a></td>
<td class="nump">2,894<span></span>
</td>
<td class="nump">2,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prpo_DepartmentofEconomicandCommunityDevelopmentMember', window );">Department of Economic and Community Development (DECD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Debt issuance cost</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prpo_FinancedInsuranceLoanMember', window );">Financed Insurance Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 3,233<span></span>
</td>
<td class="nump">$ 3,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_DepartmentofEconomicandCommunityDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_DepartmentofEconomicandCommunityDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_FinancedInsuranceLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_FinancedInsuranceLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817568960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT (Department of Economic and Community Development) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,416,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prpo_DepartmentofEconomicandCommunityDevelopmentMember', window );">Department of Economic and Community Development (DECD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_GrossProceedsFromGrantReceivedAndLoan', window );">Gross proceeds from grant received and loan</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Proceeds from grant</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember', window );">Term loan | Department of Economic and Community Development (DECD)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_GrossProceedsFromGrantReceivedAndLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from grant received and loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_GrossProceedsFromGrantReceivedAndLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3098-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3095-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_DepartmentofEconomicandCommunityDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_DepartmentofEconomicandCommunityDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=prpo_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6809888096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT (Secured Debt Obligations) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,570<span></span>
</td>
<td class="nump">$ 3,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant, number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,923,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_CreditorWarrantsRelatingToSecuredDebtMember', window );">Creditor Warrants Relating to Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant, number of securities called by warrants</a></td>
<td class="nump">108,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=prpo_SettlementAgreementsMember', window );">Settlement Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=prpo_SettlementAgreementsMember', window );">Settlement Agreements [Member] | Creditor Warrants Relating to Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant, number of securities called by warrants</a></td>
<td class="nump">108,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,233<span></span>
</td>
<td class="nump">3,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DebtRestructured', window );">Debt Restructured</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt [Member] | Settlement Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Date of first required payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">New shares issued (in shares)</a></td>
<td class="nump">1,814,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_DebtRestructured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Restructured</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_DebtRestructured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDateOfFirstRequiredPayment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_CreditorWarrantsRelatingToSecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_CreditorWarrantsRelatingToSecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=prpo_SettlementAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=prpo_SettlementAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817580320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT (Financed Insurance Loan ) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 3,570,000<span></span>
</td>
<td class="nump">$ 3,416,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prpo_FinancedInsuranceLoanMember', window );">Financed Insurance Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">Mar. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Total debt</a></td>
<td class="nump">$ 74,000<span></span>
</td>
<td class="nump">$ 183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_FinancedInsuranceLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_FinancedInsuranceLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802901088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 12, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 12, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonrecurringIncome', window );">Gain in warrant revaluation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (loss) on settlement of equity instrments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_CredeMember', window );">Crede [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_LiabilityForSettlementCommonSharesIssued', window );">Liability For Settlement Common Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,814,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_LiabilityForSettlementFairValueOfCommonSharesIssued', window );">Liability For Settlement Fair Value Of Common Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss Contingency, Damages Sought, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Settlement liablity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_LiabilityForSettlementOfCommonStockWarrantLiability', window );">Liability For Settlement Of Common Stock Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (loss) on settlement of equity instrments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation [Member] | Crede [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation Settlement, Amount Awarded to Other Party</a></td>
<td class="nump">$ 1,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_LiabilityForSettlementPaymentPeriod', window );">Liability For Settlement Payment Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesPaidValue', window );">Damages paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Settlement payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember', window );">2016 Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">(Decrease) in warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_LiabilityForSettlementCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Settlement Common Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_LiabilityForSettlementCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_LiabilityForSettlementFairValueOfCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Settlement Fair Value Of Common Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_LiabilityForSettlementFairValueOfCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_LiabilityForSettlementOfCommonStockWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Settlement Of Common Stock Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_LiabilityForSettlementOfCommonStockWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_LiabilityForSettlementPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Settlement Payment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_LiabilityForSettlementPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesPaidValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages paid to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesPaidValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonrecurringIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other income that is infrequent in occurrence or unusual in nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64828382&amp;loc=d3e15138-107781<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonrecurringIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_CredeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_CredeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597569280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Other Current Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ObigationToIssueCommonShares', window );">Obigation To Issue Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_LiabilityForSettlementOfEquityInstrument', window );">Liability For Settlement Of Equity Instrument</a></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other Liabilities, Current, Total</a></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="nump">$ 2,982<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_LiabilityForSettlementOfEquityInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability For Settlement Of Equity Instrument</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_LiabilityForSettlementOfEquityInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ObigationToIssueCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obigation To Issue Common Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ObigationToIssueCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818169072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONTINGENCIES (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 21, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_MountSinaiMember', window );">Mount Sinai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt Instrument, Periodic Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassOfWarrantOrRightTerm', window );">Class of Warrant or Right, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_XIFINInc.Member', window );">XIFIN, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_CPAGlobalMember', window );">CPA Global</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationCaseAxis=prpo_BioRadLaboratoriesMember', window );">Bio-Rad Laboratories [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement in favor of other party, amount</a></td>
<td class="nump">$ 39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_MountSinaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_MountSinaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_XIFINInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_XIFINInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_CPAGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_CPAGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=prpo_BioRadLaboratoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=prpo_BioRadLaboratoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6803098896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax, interest and penalites</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805185584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Common Stock) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 09, 2018</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,897,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=prpo_LevistonResourcesLlcMember', window );">Leviston Resources LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted from debt instrument (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted from debt instrument (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Common stock issued on conversion of preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Common stock issued on conversion of preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,345,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_StockNotIssuedShares', window );">Stock Not Issued, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_StockNotIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Not Issued, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_StockNotIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=prpo_LevistonResourcesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=prpo_LevistonResourcesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6802785056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Series A and Series B Preferred Stock) (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6800019440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Preferred Stock) (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817211568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Preferred Stock Induced Conversions) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Other current liabilities canceled in exchange for common shares</a></td>
<td class="nump">$ 1,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_WarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_InducementAgreement2018Member', window );">Inducement Agreement 2018 [Member] | Warrants After Conversion Price Reduction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_StockNotIssuedShares', window );">Shares not converted</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Inducement Agreement 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Shares converted, value</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, fair value</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of shares converted from debt instrument (in shares)</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ConversionofStockPerShareConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Per Share Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ConversionofStockPerShareConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_StockNotIssuedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Not Issued, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_StockNotIssuedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_InducementAgreement2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prpo_InducementAgreement2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=prpo_WarrantsAfterConversionPriceReductionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=prpo_WarrantsAfterConversionPriceReductionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818611920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Aug. 25, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prpo_AegisCapitalCorpMember', window );">Aegis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Stock rights issued (in shares)</a></td>
<td class="nump">280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassofWarrantorRightUnitValueofWarrantsorRights', window );">Warrant unit value (per unit)</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_OfferingWarrantsMember', window );">Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Stock rights issued (in shares)</a></td>
<td class="nump">2,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember', window );">Preferred Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Shares callable by warrant (in shares)</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Common stock issued on conversion of preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred stock, liquidation preference per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_PublicStockOfferingMember', window );">Public Stock Offering | Preferred Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_PurchaseAgreement2018Member', window );">Purchase Agreement 2018 [Member] | Preferred Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_InducementAgreement2018Member', window );">Inducement Agreement 2018 [Member] | Preferred Class B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Issued Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassofWarrantorRightUnitValueofWarrantsorRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Unit Value of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassofWarrantorRightUnitValueofWarrantsorRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ConversionofStockPerShareConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Per Share Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ConversionofStockPerShareConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prpo_AegisCapitalCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prpo_AegisCapitalCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_PublicStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prpo_PublicStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_PurchaseAgreement2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prpo_PurchaseAgreement2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_InducementAgreement2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prpo_InducementAgreement2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817359680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Series C Preferred Stock) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 02, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Nov. 06, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">4,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_OfferingWarrantsMember', window );">Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Stock rights issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,962,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassofWarrantorRightUnitValueofWarrantsorRights', window );">Warrant unit value (per unit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Preferred Stock, Liquidation Preference Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock', window );">Common stock issued on conversion of preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,345,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_PlacementAgreementMember', window );">Placement Agreement [Member] | Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold in offering (in shares)</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_PurchaseAgreement2018Member', window );">Purchase Agreement 2018 [Member] | Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ConversionofStockPerShareConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Issued Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassofWarrantorRightUnitValueofWarrantsorRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Unit Value of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassofWarrantorRightUnitValueofWarrantsorRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ConversionofStockPerShareConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Per Share Conversion Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ConversionofStockPerShareConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_PlacementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prpo_PlacementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_PurchaseAgreement2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prpo_PurchaseAgreement2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6791031008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_WarrantsExpiredInPeriod', window );">Warrants expired in period</a></td>
<td class="nump">23,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock issued, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_WarrantsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants expired in period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_WarrantsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817826496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Offering Warrants) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_WarrantsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_OfferingWarrantsMember', window );">Offering Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights', window );">Stock rights issued (in shares)</a></td>
<td class="nump">2,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Number of Issued Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassOfWarrantOrRightNumberOfIssuedWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_WarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_WarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805229184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Note Conversion Warrants) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of debt into stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Inducement Agreement 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Purchase Agreement 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DeemedDividend', window );">Deemed dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Conversion of debt into stock (in shares)</a></td>
<td class="nump">359,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Common Stock | Inducement Agreement 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember', window );">Bridge Loan | Common Stock | Purchase Agreement 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_InducementAgreement2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_InducementAgreement2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_PurchaseAgreement2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_PurchaseAgreement2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816438032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Convertible Promissory Note Warrants) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_ConvertiblePromissoryNoteWarrantsMember', window );">Convertible Promissory Note Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prpo_InducementAgreement2018Member', window );">Inducement Agreement 2018 [Member] | Convertible Promissory Note Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DeemedDividend', window );">Deemed dividend</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prpo_PurchaseAgreement2018Member', window );">Purchase Agreement 2018 [Member] | Convertible Promissory Note Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DeemedDividend', window );">Deemed dividend</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_ConvertiblePromissoryNoteWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_ConvertiblePromissoryNoteWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_InducementAgreement2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_InducementAgreement2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_PurchaseAgreement2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_PurchaseAgreement2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817461392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Series C Warrants) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares)</a></td>
<td class="nump">5,923,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,962,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prpo_PurchaseAgreement2018Member', window );">Purchase Agreement 2018 [Member] | Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_DeemedDividend', window );">Deemed dividend</a></td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Dividend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_PurchaseAgreement2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_PurchaseAgreement2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816527952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Creditor Warrants) (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant, number of securities called by warrants</a></td>
<td class="nump">5,923,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_CreditorWarrantsRelatingToSecuredDebtMember', window );">Creditor Warrants Relating to Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of warrant, number of securities called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_CreditorWarrantsRelatingToSecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_CreditorWarrantsRelatingToSecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818690272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">5,923,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringApril2020Member', window );">Warrants Assumed in Merger, Expiring April 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">12,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 120.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringFebruary2020Member', window );">Warrants Assumed in Merger, Expiring February 2020[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">23,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 67.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringDecember2020Member', window );">Warrants Assumed in Merger, Expiring December 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">4,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 49.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember', window );">Warrants Assumed in Merger, Expiring January 2021, Group B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">8,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 36.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember', window );">Warrants Not Assumed in Merger, Expiring June 2022, Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">45,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember', window );">Warrants Not Assumed in Merger, Expiring June 2022, Group B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">91,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember', window );">Warrants Not Assumed in Merger, Expiring August 2022, Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">2,380,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember', window );">Warrants Not Assumed in Merger, Expiring August 2022, Group B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember', window );">Warrants Not Assumed in Merger, Expiring August 2022, Group C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">856,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember', window );">Warrants Not Assumed in Merger, Expiring August 2022, Group D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">359,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member', window );">Warrants Not Assumed in Merger, Expiring October 2022 Group A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringMay2023Member', window );">Warrants Not Assumed in Merger, Expiring May 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">1,962,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember', window );">Warrants Not Assumed in Merger, Expiring October 2022 Group B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Underlying shares (in shares) | shares</a></td>
<td class="nump">108,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringApril2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringApril2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringFebruary2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringFebruary2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringDecember2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringDecember2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsAssumedInMergerExpiringJanuary2021GroupBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringJune2022GroupBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringAugust2022GroupDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringOctober2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringMay2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringMay2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_WarrantsNotAssumedInMergerExpiringOctober2022GroupBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818170416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Narratives) (Details) - 2016 Warrant Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares) | shares</a></td>
<td class="nump">5,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease', window );">(Decrease) in warrant liability | $</a></td>
<td class="num">$ (400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_WarrantsCanceledInSettlementAgreement', window );">Warrants canceled in settlement agreement | shares</a></td>
<td class="nump">20,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Debt settlment | $</a></td>
<td class="nump">$ 456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">2 years 9 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">167.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">2.39%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_WarrantsCanceledInSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants canceled in settlement agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_WarrantsCanceledInSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760426128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Schedule of Changes in Fair Value of Liability) (Details) - 2016 Warrant Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_TotalGainsOrLossesAbstract', window );"><strong>Total (gains) or losses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Recognized in earnings</a></td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Deductions - warrant liability settlement</a></td>
<td class="num">(456)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at end of period</a></td>
<td class="nump">$ 124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_TotalGainsOrLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total gains or losses [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_TotalGainsOrLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=prpo_A2016WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805560576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">5,389,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">6,056,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized', window );">Number of additional annual shares authorized</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares per employee</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Award plan, percentage of outstanding stock maximum</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Unvested stock options, unrecognized compensation expense weighted average recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Stock options, expected to vest, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,650,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Stock options, expected to vest, outstanding, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Stock options, expected to vest remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prpo_EquityIncentivePlan2017Member', window );">Equity Incentive Plan 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Plan expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  05,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prpo_EquityIncentivePlan2017Member', window );">Equity Incentive Plan 2017 [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, unvested options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options, unvested options, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Annual Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prpo_EquityIncentivePlan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prpo_EquityIncentivePlan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817456464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">236,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,286,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(2,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">3,520,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">42,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">110.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">1.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.75<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6807399968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract', window );"><strong>Net Sales Service Revenue and Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 189<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Sales Service Revenue and Accounts Receivable [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_NetSalesServiceRevenueAndAccountsReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6816417424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">$ 791<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=prpo_DiagnosticTestingMember', window );">Diagnostic Testing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=prpo_BiomarkerTestingAndClinicalProjectServicesMember', window );">Biomarker Testing and Clinical Project Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">488<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember', window );">Medicaid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember', window );">Medicaid [Member] | Diagnostic Testing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember', window );">Medicaid [Member] | Biomarker Testing and Clinical Project Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember', window );">Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember', window );">Medicare [Member] | Diagnostic Testing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember', window );">Medicare [Member] | Biomarker Testing and Clinical Project Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Self-Pay [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Self-Pay [Member] | Diagnostic Testing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Self-Pay [Member] | Biomarker Testing and Clinical Project Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Third-Party Payor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Third-Party Payor [Member] | Diagnostic Testing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Third-Party Payor [Member] | Biomarker Testing and Clinical Project Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember', window );">Contract Diagnostic Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">488<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember', window );">Contract Diagnostic Services [Member] | Diagnostic Testing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember', window );">Contract Diagnostic Services [Member] | Biomarker Testing and Clinical Project Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Revenues, net of contractual allowances and adjustments</a></td>
<td class="nump">$ 488<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=prpo_DiagnosticTestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=prpo_DiagnosticTestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=prpo_BiomarkerTestingAndClinicalProjectServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=prpo_BiomarkerTestingAndClinicalProjectServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818673824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsGross', window );">Gross revenue</a></td>
<td class="nump">$ 983<span></span>
</td>
<td class="nump">$ 505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_OtherSalesRevenueGross', window );">Other, gross</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_GrossRevenueIncludingOtherAdjustments', window );">Gross revenue including other</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods', window );">Contractual allowance</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Service revenue, net</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSalesRevenueNet', window );">Other, net</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember', window );">Medicaid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsGross', window );">Gross revenue</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods', window );">Contractual allowance</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Service revenue, net</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember', window );">Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsGross', window );">Gross revenue</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods', window );">Contractual allowance</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Service revenue, net</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Self-Pay [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsGross', window );">Gross revenue</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Service revenue, net</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Third-Party Payor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsGross', window );">Gross revenue</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods', window );">Contractual allowance</a></td>
<td class="num">(186)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Service revenue, net</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember', window );">Contract Diagnostic Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsGross', window );">Gross revenue</a></td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueServicesNet', window );">Service revenue, net</a></td>
<td class="nump">488<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_OtherPartyMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_GrossRevenueIncludingOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross revenue including other adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_GrossRevenueIncludingOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_OtherSalesRevenueGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Sales Revenue, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_OtherSalesRevenueGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_RevenueNetOfAllowanceAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue net of allowance and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_RevenueNetOfAllowanceAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesDiscountsReturnsAndAllowancesGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 50<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68069731&amp;loc=d3e63676-111659<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 15<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68051624&amp;loc=d3e47468-111626<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesDiscountsReturnsAndAllowancesGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from sale of goods in the normal course of business, before deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueServicesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueServicesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_OtherPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_OtherPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6818555936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">$ 796<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">712<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember', window );">Medicaid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember', window );">Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">134<span></span>
</td>
<td class="nump">158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Self-Pay [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Third-Party Payor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember', window );">Contract Diagnostic Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ServicesRevenueNetMember', window );">Services Revenue, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">707<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_OtherPartyMember', window );">Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_RevenueNetOfAllowanceAndAdjustments', window );">Revenue, net of contractual allowances and adjustments</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_RevenueNetOfAllowanceAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue net of allowance and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_RevenueNetOfAllowanceAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAllowancesServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate selling price reductions recognized during an accounting period due to the rendering of deficient or nonconforming services. Allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAllowancesServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ServicesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ServicesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_OtherPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_OtherPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806409152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">$ 1,760<span></span>
</td>
<td class="nump">$ 1,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Less allowance for doubtful accounts</a></td>
<td class="num">(1,208)<span></span>
</td>
<td class="num">(1,127)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">552<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember', window );">Medicaid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember', window );">Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">611<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Self-Pay [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Third-Party Payor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">768<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember', window );">Contract Diagnostic Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For unclassified balance sheet, amounts due from customers or clients for goods or services that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_ContractDiagnosticServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817457040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts, Beginning balance</a></td>
<td class="num">$ (1,127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="num">(84)<span></span>
</td>
<td class="num">$ (55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries', window );">Bad debt expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease', window );">Total charges</a></td>
<td class="num">(81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts, Ending balance</a></td>
<td class="num">(1,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember', window );">Medicaid [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember', window );">Medicare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember', window );">Self-Pay [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember', window );">Third-Party Payor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAllowancesServices', window );">Allowances for dubtful accounts</a></td>
<td class="num">$ (53)<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recoveries of receivables doubtful of collection that were previously charged off.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAllowancesServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate selling price reductions recognized during an accounting period due to the rendering of deficient or nonconforming services. Allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAllowancesServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=prpo_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_SelfPayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationRevenueSourcesAxis=us-gaap_ThirdPartyPayorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819288064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 21, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 09, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,056,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,389,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Annual Shares Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock', window );">Warrants Issued During Period, Maximum Allowed Percentage of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_LevistonResourcesLlcMember', window );">Leviston Resources LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_EquityPurchaseAgreement', window );">Equity Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_EquityPurchaseAgreementCommitmentFeePercentage', window );">Equity Purchase Agreement, Commitment Fee Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage', window );">Equity Purchase Agreement, Commitment Fee Installment Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_EquityPurchaseAgreementFee', window );">Equity Purchase Agreement, Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_EquityPurchaseAgreementFeeContingentDiscount', window );">Equity Purchase Agreement, Fee, Contingent Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 721,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_CompanyStockPercentageOfMarketRate', window );">Company stock percentage of market rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement', window );">Potential liquidation damage amount to each occurrence of default related to the purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_CommonStockPurchaseFee', window );">Common stock purchase fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_PreferredStockInducedConversionsSecondInvestorMember', window );">Preferred Stock Induced Conversions, Second Investor [Member] | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants', window );">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_PreferredStockInducedConversionsFirstInvestorMember', window );">Preferred Stock Induced Conversions, First Investor [Member] | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised', window );">Class of Warrant or Right, Warrants or Rights Excercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_SeniorSecuredConvertiblePromissoryNotesMember', window );">Senior Secured Convertible Promissory Notes [Member] | Securities Purchase Agreement [Member] | Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">$ 3,296,703.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Common stock warrant coverage</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue', window );">Maximum proceeds raised before note payable becomes due</a></td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=prpo_SeniorSecuredConvertiblePromissoryNotesMember', window );">Senior Secured Convertible Promissory Notes [Member] | Securities Purchase Agreement [Member] | Subsequent Events | Debt Instrument, Redemption, Period Within 180 Days [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="nump">1,809,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="nump">$ 1,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants or Rights Excercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ClassOfWarrantOrRightWarrantsOrRightsExcercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_CommonStockPurchaseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock purchase fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_CommonStockPurchaseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_CompanyStockPercentageOfMarketRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company stock percentage of market rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_CompanyStockPercentageOfMarketRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_EquityPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_EquityPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Purchase Agreement, Commitment Fee Installment Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_EquityPurchaseAgreementCommitmentFeeInstallmentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_EquityPurchaseAgreementCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Purchase Agreement, Commitment Fee Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_EquityPurchaseAgreementCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_EquityPurchaseAgreementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Purchase Agreement, Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_EquityPurchaseAgreementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_EquityPurchaseAgreementFeeContingentDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Purchase Agreement, Fee, Contingent Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_EquityPurchaseAgreementFeeContingentDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum proceeds raised before note payable becomes due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_MaximumProceedsRaisedBeforeNotePayableBecomesDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential liquidation damage amount to each occurrence of default related to the purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_PotentialLiquidationDamageAmountToEachOccurrenceOfDefaultRelatedToPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Annual Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalAnnualSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued During Period, Maximum Allowed Percentage of Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prpo_WarrantsIssuedDuringPeriodMaximumAllowedPercentageOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prpo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of preferred stock and warrants for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=prpo_LevistonResourcesLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=prpo_LevistonResourcesLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_PreferredStockInducedConversionsSecondInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_PreferredStockInducedConversionsSecondInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prpo_PreferredStockInducedConversionsFirstInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prpo_PreferredStockInducedConversionsFirstInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=prpo_SeniorSecuredConvertiblePromissoryNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=prpo_SeniorSecuredConvertiblePromissoryNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prpo_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prpo_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    "  U>K5,,*$C3^X    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!:L,P#(9?9?B>*$Y)&2;U96.G%@8K;.QF;+4UBV-C:R1]^R5>
MFS*V!]C1TN]/GT"M#D+[B,_1!XQD,=V-KNN3T&'#3D1! "1]0J=2.27ZJ7GP
MT2F:GO$(0>D/=42HJVH-#DD910IF8!$6(I.MT4)'5.3C!6_T@@^?L<LPHP$[
M=-A3 EYR8'*>&,YCU\(-,,,(HTO?!30+,5?_Q.8.L$MR3'9)#<-0#JN<FW;@
M\+;;ON1U"]LG4KW&Z5>R@LX!-^PZ^77U\+A_8K*N^'U1-47-][P1?"V:^GUV
M_>%W$W;>V(/]Q\970=G"K[N07U!+ P04    "  U>K5,F5R<(Q &  "<)P
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MXF0QPI1J*=8HM*8Q;,C21LRW%-#&F>FQ1C0-?-$((XDLDR@V8BR5F,VP(*/
M6F&,+D;H4I_.-5MT38B<(ER&S(0#2X8QXYCL3J1 Q<&87PSX19J3;-DT";")
M,9O8LHE(?\T9P"D4!J.) 9I( EU@-+%%4S=[6BG@CDXG@T:ABA/#B4$11/I;
MR18]4PK4:HS9PZ#((0UD!O#AT/Q@LC"H8TC3EBTU1)>Q&3#B:4@,1@L#M!B8
MLJ7&8TW]N:C'U!! #=+4$$@--049LG(!9@AFAMBZB%@?$L061EWUKA$&K"0.
M+#S!^!& '];X$8 ?$J,&6874!,Y?@%*L*2664DY+SH!1$MCZ@E$FX##'^MQQ
M,_JT"W3-EP$C"3!1,!,%'.9"ARC!)!- ,M8D$T RG<S4G$PIL.T%LTYF()G0
M'L(8$X Q4S2*)52@VA#,)P%\TE7-6L"!++#0',:3 WABC2=GP4/I/)"/P^1Q
M@#QBKB?(S*]+].Q$#Y="I:_WP_U9,]I4;Z>VOW]Y:+W?T3US?ZFDVM?TE%UO
MVGYT<[WX^SVO]\=3,WJMVK8JAXNE756UOM,8?^F&X>#S[?VE\+NV?YQUS_7U
MPNWZTE;GVV5B=+_17/T'4$L#!!0    ( #5ZM4P,ROUNLP$  -(#   8
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL?5/;;IPP$/T5RQ\0+[!MHQ4@95-5
MC=1(JU1MG[TP@!5?B&V6Y.\[-H32EN3%]HSGG#DS'N>CL8^N _#D64GM"MIY
MWQ\8<U4'BKLKTX/&F\98Q3V:MF6NM\#K"%*2I;O=1Z:XT+3,H^]DR]P,7@H-
M)TO<H!2W+T>09BQH0E\=#Z+M?'"P,N]Y"]_!_^A/%BVVL-1"@7;":&*A*>A-
M<CCN0WP,^"E@=*LS"96<C7D,QEU=T%T0!!(J'Q@X;A>X!2D#$<IXFCGIDC(
MU^=7]B^Q=JSES!W<&OE+U+XKZ#4E-31\D/[!C%]AKN<#)7/QW^ "$L.#$LQ1
M&>GB2JK!>:-F%I2B^/.T"QWW<;K)TAFV#4AG0+H KF,>-B6*RC]SS\O<FI'8
MJ?<]#T^<'%+L316<L17Q#L4[]%[*)$MR=@E$<\QQBDG7,4L$0_8E1;J5XIC^
M!T^WX=FFPBS"L[\4OD&PWR381X+]NR5NQ63_)&&KGBJP;9PF1RHSZ#C)*^\R
ML#?Q$=F?\&G:[[EMA7;D;#R^;.Q_8XP'E+*[PA'J\(,MAH3&A^,G/-MIS";#
MFW[^06SYQN5O4$L#!!0    ( #5ZM4QRB8SXM $  -(#   8    >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL?5/;;MP@$/T5Q >$7=:;1"O;4C91U4JIM$J5
MY)FUQQ<%&!?P.OW[ G8<M[7Z LPPY\R984@'-&^V 7#D74EM,]HXUQT8LT4#
M2M@K[$#[FPJ-$LZ;IF:V,R#*"%*2\<WFFBG1:IJGT7<R>8J]DZV&DR&V5TJ8
M7T>0.&1T2S\<3VW=N.!@>=J)&GZ >^Y.QEML9BE;!=JVJ(F!*J-WV\,Q"?$Q
MX*6%P2[.)%1R1GP+QK<RHYL@""04+C (OUW@'J0,1%[&SXF3SBD#<'G^8/\2
M:_>UG(6%>Y2O;>F:C-Y24D(E>NF></@*4SU[2J;B'^$"TH<')3Y'@=+&E12]
M=:@F%B]%B?=Q;W7<A_%FGTRP=0"? 'P&W,8\;$P4E3\()_+4X$#,V/M.A"?>
M'KCO31&<L17QSHNWWGO)M[LD99= -,4<QQB^C)DCF&>?4_"U%$?^#YROPW>K
M"G<1OOM#X7Z=(%DE2")!\M\2UV*N_TK"%CU58.HX3984V.LXR0OO/+!W/+[)
M9_@X[=^%J5MMR1F=?]G8_PK1@9>RN?(CU/@/-AL2*A>.-_YLQC$;#8?=](/8
M_(WSWU!+ P04    "  U>K5,9J!Q2[0!  #2 P  &    'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;'U386_;(!#]*X@?4!*2M5ED6VHZ39NT25&G;9^)?;91
M@?, Q]V_'V#7\UIK7X [[KU[=QS9@/;)M0">/&ME7$Y;[[LC8ZYL00MW@QV8
M<%.CU<('TS;,=19$E4!:,;[9W#(MI*%%EGQG6V38>R4-G"UQO=;"_CZ!PB&G
M6_KB>)1-ZZ.#%5DG&O@&_GMWML%B,TLE-1@GT1 +=4[OM\?3/L:G@!\2!K<X
MDUC)!?$I&I^KG&ZB(%!0^L@@PG:%!U J$@49OR9..J>,P.7YA?UCJCW4<A$.
M'E#]E)5O<WJ@I():],H_XO )IGK>43(5_P6NH$)X5!)RE*A<6DG9.X]Z8@E2
MM'@>=VG2/HPW_':"K0/X!. SX)#RL#%14OY!>%%D%@=BQ]YW(C[Q]LA#;\KH
M3*U(=T&\"]YKL=W=9>P:B::8TQC#ES%S! OL<PJ^EN+$W\#Y.GRWJG"7X+M_
M%![6"?:K!/M$L/]OB6LQ[U\E88N>:K!-FB9'2NQ-FN2%=Q[8>Y[>Y&_X..U?
MA6VD<>2"/KQLZG^-Z"%(V=R$$6K#!YL-!;6/Q[MPMN.8C8;';OI!;/[&Q1]0
M2P,$%     @ -7JU3-F!;[&R 0  T@,  !@   !X;"]W;W)K<VAE971S+W-H
M965T.2YX;6Q]4V%OW" ,_2N('U!R7-95IR12KU/52IMTZK3U,Y<X"2K$*9!+
M]^\'),VR+=L7P,;O^=F8;$3S8EL 1]ZTZFQ.6^?Z V.V;$$+>X4]=/ZF1J.%
M\Z9IF.T-B"J"M&(\2:Z9%K*C119])U-D.#@E.S@98@>MA?EQ!(5C3G?TW?$D
MF]8%!RNR7C3P%=RW_F2\Q1:62FKHK,2.&*AS>KL['-,0'P.^2QCMZDQ")6?$
MEV \5CE-@B!04+K (/QV@3M0*A!Y&:\S)UU2!N#Z_,Y^'VOWM9R%A3M4S[)R
M;4YO**F@%H-R3S@^P%S/!TKFXC_#!90/#TI\CA*5C2LI!^M0SRQ>BA9OTRZ[
MN(_3#;^>8=L /@/X KB)>=B4*"K_))PH,H,C,5/O>Q&>>'?@OC=E<,96Q#LO
MWGKOI=BE2<8N@6B..4XQ?!VS1##/OJ3@6RF._"\XWX;O-Q7N(WS_F\)_Y$\W
M"=)(D/ZWQ*V8/U6R54\UF"9.DR4E#EV<Y)5W&=A;'M_D5_@T[5^$:61GR1F=
M?]G8_QK1@9>27/D1:OT'6PP%M0O'C_YLIC&;#(?]_(/8\HV+GU!+ P04
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M ?^].UFTV,Q22@VMDZ8E%JJ,WFT/QR3$QX ?$@:W.)-0R=F8UV!\*3.Z"8)
M0>$#@\#M O>@5"!"&6\3)YU3!N#R_,G^&&O'6L["P;U1/V7IFXSN*2FA$KWR
MSV9X@JF>:TJFXK_"!12&!R68HS#*Q944O?-&3RPH18OW<9=MW(?QAE]/L'4
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M@MJ%XR=_-M.838;#?OY!;/G&Q6]02P,$%     @ -7JU3%(K0 *T 0  T@,
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M=WAVXYB-1K#=](/8_(V+7U!+ P04    "  U>K5,<!1?7K8!  #2 P  &0
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MCJ<LQ,> 'P)&MSJ34,G%F.=@?*X+N@N"0$+E P/'[0H/(&4@0AF_9DZZI S
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M=V]R:W-H965T<R]S:&5E=#$W+GAM;'U3VV[;, S]%4$?4"5*FG:!;:#I,&S
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M 4[5@^BA,R>5D)QJ8\J:J%X"O;D@SDBXVQT(IVWG%YGS7621B4&SMH.+]-3
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M!UL,!;4/QT]XMM.8388W_?R#V/*-B[]02P,$%     @ -7JU3!C:W\>W 0
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M-AL2:A^.G_!LQS$;#6^ZZ0>Q^1L7?P%02P,$%     @ -7JU3"2=XWSM 0
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MV1!UF,<60T88.L9L($PXQCQ!&#;&?($PT1CS#&'B'A/H?/ND"9@TL01T1)#
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M>^TM=IZO #KC=TDZ/EE;JI0#I6]J\^VXM%WEB%0D%XH"R\N5;$E5*2;IX^]
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M^<"8I$JF_Z($YFJP]YN2'J1>1FK-V^G6;B1KNLGM]9\/B[]02P,$%     @
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M%1"A,L>6!+@$(?I$]7%Q 2*NT7(!XXW-O5P +D' ]K74)DK&=77RX#H%1*=
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MM1=U!Y^:.)Z_JS^9Y%4R!R)@R^C?\BB+M;MPG2.<R(7*9]9^@SZAR'7Z['_
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M :T+TWL_-^,=&PNG^_1\R/2&JW]02P,$%     @ -7JU3#C)V:NQ 0  V0,
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MJ+/G7#$M)UYH(4<]_8X/-=LK<YOK>]&/@/V#XMTPWD;CC+W^#U!+ P04
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MYA:ZN](*H<%DDMR85'KS>BP&A5;;[:W92S]#WM!B#,\#6MZHZA]02P,$%
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M!0^]DJ!DA +V :97R(6=@*?_/\E+#SHYRC3/>]MRF@KV#!Z:9G YW'M0_W;
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MMM/<S.70S8:%%MW8J8/I<U'^ U!+ P04    "  U>K5,UG'#\/D!  !&!0
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MKO1MLO]\Q;D";67SH'MM]%"; PJ5,MM$[\5XM<= \7Z:6F@>G?D_4$L#!!0
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M>5N)\MB(HM'?SN;42%'V650I9?;2'?-*'R]]_M<P'$!]  T!RON]@* /"(8
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MPDPC)+)!AE%F@--D AD2698!89@)P)Q$A@\461ZUA$$FP.CHE7^= C-*]''
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M0EN64U:0ED4:Q]1RC!-.<4(Z=M3,IR6RK0!1[/*"N<3Y[WMVU/S&"Q YO6#
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M&=?%7+>-7>VZWW2VC6Y]6484SX.7-M"@>>@U=*%A9T6@HY^'(#3$ UG=Z7J
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MQDT3<W;@:<*NLBH;>N".N-8UX?_VM&+=UD7N_>"EO!12'WAITI(+_4GEK_;
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M'<)S,6CA$4)P[R.@^6T_V0!ZD!HNT,"]CX#F1TLIX*Y%0-O.*Q\!+X? M@.
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MS>-9D_2JB>]TX.%G,>X],2B&N;#'P"AF+LK_HQH.)] *&1A.8-X8;@CLAH[
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M;H[+\VO"\TE='.TKT.CR'G;^'U!+ P04    "  U>K5,T^=!PYEZ  "F] $
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M) PN4;=?^&*_0<0?"V__,UP 6G*"NSQ9 M*GV;8*S7J([%_ITJ<A&WP32[C
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M$J?/;*P\BP?Q1M_%#TE*<4'1/1(#RV&[0\/;9E%.SDIY'AP"OD9[R+)F<VO
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M/_NEB0&-#M\)2KE?\%-F+7?DH^VY^#GTV#;^5Z=]XIW ^P.NQT&A]]8@2^?
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MT<2YLUJ;-:7$))W:E;!T]2F?K%:#:1SDL^#./&3&24BP5-NO=AT"$6.7FZ+
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M@T9^+B.K%SV( YK.8\_1O'P8'"5O6=*V(;(N[D-Y'_?X'A_CE300T;,0)6Q
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M/P+Z84^@?(5L&)C;,EME#\]TKW4QQ$&)*VA.+H3)=;4PCOF:KO3V^;U3$3=
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M/+5P0]">&N'!A&^7H[OT8-NCN(&((\$V(2%D:\)V#58Z,8_*=+'-%AB4:G0
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M![(J4"1:O'2/5O?\5+OQDFX ]"D: 5=<H#"<=$[" <RJJADGKMY;J86;A(:
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MO;7"FOMZ^):9%?4[10=-:S ,1[#W-UZ+K>!H5!EXT@T'\++?C/VCCF7@=/>
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MYFMS?9EMEW/-VL-A,X+KM>\-U[OM-C#7XG):9?L]=FT;Q^V!M_\!4$L#!!0
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MG,_&/SLMW@!02P$"% ,4    "  U>K5,'R// \     3 @  "P
M    @ $     7W)E;',O+G)E;'-02P$"% ,4    "  U>K5,9O,+8((   "Q
M    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( #5ZM4PPH2-/[@   "L"   1              "  9D!  !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( #5ZM4R97)PC$ 8  )PG   3
M      "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ -7JU
M3.J3MC-6 @  KP<  !@              ( !]P@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( #5ZM4Q^6AR-' 0  #44   8
M      "  8,+  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M"  U>K5,S'US\3X"  "X!P  &               @ '5#P  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ -7JU3'8\9A6C P  51   !@
M             ( !21(  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( #5ZM4S').0[0@0  -T4   8              "  2(6  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  U>K5,#,K];K,!  #2
M P  &               @ &:&@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ -7JU3'*)C/BT 0  T@,  !@              ( !@QP
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #5ZM4QFH'%+
MM $  -(#   8              "  6T>  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    "  U>K5,V8%OL;(!  #2 P  &
M@ %7(   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ -7JU
M3#_< X:T 0  T@,  !D              ( !/R(  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    "  U>K5,1PPBS;0!  #2 P  &0
M        @ $J)   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( #5ZM4R@,)3YM $  -(#   9              "  14F  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ -7JU3!>(7I&S 0  T@,
M !D              ( ! "@  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    "  U>K5,4BM  K0!  #2 P  &0              @ 'J*0
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #5ZM4QP%%]>
MM@$  -(#   9              "  =4K  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ -7JU3$XMUENV 0  T@,  !D
M ( !PBT  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  U
M>K5,"'=9\K4!  #2 P  &0              @ &O+P  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( #5ZM4R1%7&*^@$  ,L%   9
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M970R,BYX;6Q02P$"% ,4    "  U>K5,-21[.+8!  #2 P  &0
M    @ &#.P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M #5ZM4P8VM_'MP$  -(#   9              "  7 ]  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ -7JU3(0<,<6Y 0  T@,  !D
M             ( !7C\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    "  U>K5,))WC?.T!  !F!0  &0              @ %.00  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #5ZM4R9RG7-W0(
M +\+   9              "  7)#  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ -7JU3%;]*%Y\ @  F @  !D              ( !
MAD8  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  U>K5,
M"1'DO78"  !*"   &0              @ $Y20  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( #5ZM4R";3!C9P(  " (   9
M      "  >9+  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ -7JU3+3#G_!9 @  7 @  !D              ( !A$X  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  U>K5,K(0]@6X"  "V"
M&0              @ $440  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( #5ZM4Q;%_L-30,  )\.   9              "  ;E3  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ -7JU3(.LFK0^
M @  [08  !D              ( !/5<  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    "  U>K5,8%'8):L"  "J"@  &0
M@ &R60  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #5Z
MM4R06FMGV0$  ,,$   9              "  91<  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ -7JU3,N#8Y+B @  80P  !D
M         ( !I%X  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    "  U>K5,^&0ZG>,!  #-!   &0              @ &]80  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( #5ZM4S%[:*;MP(  /T*
M   9              "  ==C  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ -7JU3(9R('BO 0  SP,  !D              ( !Q68
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  U>K5,.,G9
MJ[$!  #9 P  &0              @ &K:   >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( #5ZM4S1%*B^W@(  &\+   9
M  "  9-J  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
M-7JU3$7J")0,!   *10  !D              ( !J&T  'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    "  U>K5,K/L5/74#  #8#P  &0
M            @ 'K<0  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( #5ZM4QV6CXGX $  *\$   9              "  9=U  !X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ -7JU3)H\CG%' @
M" <  !D              ( !KG<  'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    "  U>K5,<)OC$<H"   4"P  &0              @ $L
M>@  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( #5ZM4RA
M5QEX7@(  #((   9              "  2U]  !X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ -7JU3(W)E_!. @  / <  !D
M     ( !PG\  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #5ZM4RJV*,P4@,  -4.   9              "
M ?2,  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ -7JU
M3,6Z0CYJ @  S <  !D              ( !?9   'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    "  U>K5,U7"LF[ !  #. P  &0
M        @ $>DP  >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( #5ZM4QQ"Q%YZ@,  (46   9              "  065  !X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ -7JU3"VJS&,"!   8A0
M !D              ( !)ID  'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    "  U>K5,F)66B;$#  "\$@  &0              @ %?G0
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( #5ZM4R96)OY
M; (  *<(   9              "  4>A  !X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ -7JU3$_L35:  @  RP@  !D
M ( !ZJ,  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    "  U
M>K5,;>$2X$0$  "3%0  &0              @ &AI@  >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( #5ZM4S3YT'#F7H  *;T 0 4
M          "  1RK  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    (
M #5ZM4R 'R=43P(   <,   -              "  ><E 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ -7JU3!0B)F&V!   C2@   \              ( !
M82@! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #5ZM4P.[*\!'@(  '\E
M   :              "  40M 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<U!+ 0(4 Q0    ( #5ZM4SCV@RJ[ $  /0D   3              "  9HO
K 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !' $< 8Q,  +<Q 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>193</ContextCount>
  <ElementCount>259</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>69</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00050 - Document - DOCUMENT AND ENTITY INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>DOCUMENT AND ENTITY INFORMATION</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/StatementUnauditedCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - BUSINESS DESCRIPTION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureBusinessDescription</Role>
      <ShortName>BUSINESS DESCRIPTION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - REVERSE MERGER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureReverseMerger</Role>
      <ShortName>REVERSE MERGER</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - LONG-TERM DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureLongTermDebt</Role>
      <ShortName>LONG-TERM DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureContingencies</Role>
      <ShortName>CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureFairValue</Role>
      <ShortName>FAIR VALUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - EQUITY INCENTIVE PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureEquityIncentivePlan</Role>
      <ShortName>EQUITY INCENTIVE PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11101 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivable</Role>
      <ShortName>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11201 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicy</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30303 - Disclosure - REVERSE MERGER (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureReverseMergerTables</Role>
      <ShortName>REVERSE MERGER (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureReverseMerger</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30403 - Disclosure - LONG-TERM DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureLongTermDebtTables</Role>
      <ShortName>LONG-TERM DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureLongTermDebt</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30503 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30803 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30903 - Disclosure - FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureFairValueTables</Role>
      <ShortName>FAIR VALUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureFairValue</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>31003 - Disclosure - EQUITY INCENTIVE PLAN (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables</Role>
      <ShortName>EQUITY INCENTIVE PLAN (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureEquityIncentivePlan</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>31103 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableTables</Role>
      <ShortName>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivable</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40101 - Disclosure - BUSINESS DESCRIPTION (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureBusinessDescriptionNarrativeDetails</Role>
      <ShortName>BUSINESS DESCRIPTION (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureBusinessDescription</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities not Included in the Computation of Diluted Net Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOutstandingSecuritiesNotIncludedInComputationOfDilutedNetLossDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities not Included in the Computation of Diluted Net Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40306 - Disclosure - REVERSE MERGER (Pro-forma Disclosures) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureReverseMergerProFormaDisclosuresDetails</Role>
      <ShortName>REVERSE MERGER (Pro-forma Disclosures) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureReverseMergerTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40401 - Disclosure - LONG-TERM DEBT (Schedule of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureLongTermDebtScheduleOfDebtDetails</Role>
      <ShortName>LONG-TERM DEBT (Schedule of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureLongTermDebtTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40404 - Disclosure - LONG-TERM DEBT (Department of Economic and Community Development) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureLongTermDebtDepartmentOfEconomicAndCommunityDevelopmentDetails</Role>
      <ShortName>LONG-TERM DEBT (Department of Economic and Community Development) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureLongTermDebtTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40406 - Disclosure - LONG-TERM DEBT (Secured Debt Obligations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureLongTermDebtSecuredDebtObligationsDetails</Role>
      <ShortName>LONG-TERM DEBT (Secured Debt Obligations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureLongTermDebtTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40408 - Disclosure - LONG-TERM DEBT (Financed Insurance Loan ) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureLongTermDebtFinancedInsuranceLoanDetails</Role>
      <ShortName>LONG-TERM DEBT (Financed Insurance Loan ) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureLongTermDebtTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40501 - Disclosure - OTHER CURRENT LIABILITIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesNarrativeDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40503 - Disclosure - OTHER CURRENT LIABILITIES (Other Current Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesOtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Other Current Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureOtherCurrentLiabilitiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40601 - Disclosure - CONTINGENCIES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureContingenciesNarrativeDetails</Role>
      <ShortName>CONTINGENCIES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureContingencies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40701 - Disclosure - INCOME TAXES (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureIncomeTaxesNarrativeDetails</Role>
      <ShortName>INCOME TAXES (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40801 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Common Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40802 - Disclosure - STOCKHOLDERS' EQUITY (Series A and Series B Preferred Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesAndSeriesBPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Series A and Series B Preferred Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40803 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Preferred Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40804 - Disclosure - STOCKHOLDERS' EQUITY (Preferred Stock Induced Conversions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquityPreferredStockInducedConversionsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Preferred Stock Induced Conversions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40805 - Disclosure - STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesBPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40806 - Disclosure - STOCKHOLDERS' EQUITY (Series C Preferred Stock) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Series C Preferred Stock) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40807 - Disclosure - STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquityCommonStockWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Common Stock Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40810 - Disclosure - STOCKHOLDERS' EQUITY (Offering Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquityOfferingWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Offering Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40814 - Disclosure - STOCKHOLDERS' EQUITY (Note Conversion Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquityNoteConversionWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Note Conversion Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40815 - Disclosure - STOCKHOLDERS' EQUITY (Convertible Promissory Note Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquityConvertiblePromissoryNoteWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Convertible Promissory Note Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40816 - Disclosure - STOCKHOLDERS' EQUITY (Series C Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquitySeriesCWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Series C Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40817 - Disclosure - STOCKHOLDERS' EQUITY (Creditor Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquityCreditorWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Creditor Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40818 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureStockholdersEquityScheduleOfWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureStockholdersEquityTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40901 - Disclosure - FAIR VALUE (Narratives) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureFairValueNarrativesDetails</Role>
      <ShortName>FAIR VALUE (Narratives) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureFairValueTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40902 - Disclosure - FAIR VALUE (Schedule of Changes in Fair Value of Liability) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureFairValueScheduleOfChangesInFairValueOfLiabilityDetails</Role>
      <ShortName>FAIR VALUE (Schedule of Changes in Fair Value of Liability) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureFairValueTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41001 - Disclosure - EQUITY INCENTIVE PLAN (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureEquityIncentivePlanNarrativeDetails</Role>
      <ShortName>EQUITY INCENTIVE PLAN (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41001 - Disclosure - EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureEquityIncentivePlanSummaryOfStockOptionActivityDetails</Role>
      <ShortName>EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureEquityIncentivePlanTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41101 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableNarrativeDetails</Role>
      <ShortName>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41103 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfNetRevenuesDetails</Role>
      <ShortName>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41104 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfGrossToNetSalesAdjustmentsDetails</Role>
      <ShortName>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41105 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfSalesNetOfCollectionAllowanceDetails</Role>
      <ShortName>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41106 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfReceivablesDetails</Role>
      <ShortName>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41107 - Disclosure - NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableScheduleOfAllowanceForDoubtfulAccountsDetails</Role>
      <ShortName>NET SALES SERVICE REVENUE AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureNetSalesServiceRevenueAndAccountsReceivableTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="prpo-20180331.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41201 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.precipiodx.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.precipiodx.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>62</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>prpo-20180331.xml</File>
    <File>prpo-20180331.xsd</File>
    <File>prpo-20180331_cal.xml</File>
    <File>prpo-20180331_def.xml</File>
    <File>prpo-20180331_lab.xml</File>
    <File>prpo-20180331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001144204-18-030045-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-18-030045-xbrl.zip
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MA@'F+_+B^ ?QAOZ2#)QFJ1&>;KW]?Y\_/=HC,L9G,TG O@C](M1[S>5/W\@
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M+R2/$9^W$)^?1I0Y7\'IIU_Q=&5"Z"OS11W  WLD[)7:*0C<43ST?!Y0^XG
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M#=HI\PR3=1HN&,G6;D@6EW6.1O)E"LB7*X%N.Y!G-I)7O-\3PN$+Z"_:D&L
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M(B]%#K'I&)S@UY./7SZ O%<7%Y>]?F>A+1M>MMRP#]0E[!9T/_39?GIXA%;
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M48 N"-!)-S_=QC(;7\Y>9+MS$/77Q!Y>6HT>2MT7=(O$O4HE+F"SWBWR7JJ
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MH:XHWA%'!HJCTY+^P_>B>J)HWC^#@#CL4*@-<Y0B#EY:Y_U>PA+LVKBM\GS
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M2-S!V02OGH.C 7NC$&?=:%Y'%3*ZH\M0V@!;#2I(&6"W#; U G;U[%%Q=NC
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MK^E?<RL@VL8L;2:/9HV=;&N<9!FI!QH+KCN=5G>1>/P]Y $=3*.OX@_7U L
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MR]$:RHGL.RSZ?HA)SB=)<GZ.2,[[.<DI2HCVTJP!X_%@W#EV[7146RH)6[I
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MX,I9M+$C)^(S#SU==N"42T8NPH4ZHJBX*7*TT"<<>O8H\EM1P1CC(7EUC$>
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MKTK+'E*8,-+]9JRQ6.T7@=9O+A@A@['<>3?[^5WOYW<W/X>":1=D?O#82-P
M>=S!I$*&/3R(#2@\'(-M=#APK\#<PAX5W3X7'<*?K6PARYWD4B,<AN-I>!%<
MNK$#ZM(<(3,2Q<X&%7HU^S4D+ KY\6M#F2N_T!\8>]0!!1\P3",[YE*I\R@N
M2N](E[Z[7+0[G>!!+)8-<A[O/.Q[$;[TT75 8/R+.8^*IF;I24?AG_0@1GK)
MW2M)Q50E1;=_N;KN7?TZ@IT.5I 6@D2XOV!V_$-P!WPK;HC#T-[8WQ_FW^6N
M@&^T%[Y!)PG +5,5!"L]U@9RV5!]-8U9&?B2Y5X:T(+IBD.7'FUR)]5N;@?.
M7@!#X3]XK_6*LMBQ;YQ;Q;+P^/L/17?9+O0-LV]LBAG+ ;*7>HM[\1T^&(P9
MZ+#?/3HF]]-C=SRL!LA',AI =%I(VG>,_[M3;H_"<GL_?J_!&MD/>C(<%:T@
MH^:YEGN#LI:@*S:HV'_RFX,'ZQL>-3_]P)8--B,;P?_1%K_:<@+EC#WT?Q<C
M?T\<^>:'9G]?62OS>^A^);A>P:L&;[;?R2B,XZ(?QD47.+H=P4.>U=0$(0\8
MM &<<K;K?UJ8EO/,K.4=FSK/ZQ6CM7N_?K0T]85],16#+SQXS7/'"LCHZ!]Y
ME6>XT/<GCC19_M[K'(!JY';_7!#P1.UC;K.N?]@[E?7OIW^!@D<OW2\#)]07
M$=UC*)3[KY_KS!R;./FB.<+T!]W/ F3\CIE,3YJA:&E7/6H/3F;5]=$DM:65
M[O?NF%N6:=D'! ?ZI;S!OS%>Q.O9%!$QB.MT2*DM*56)%'](I,>'^0V^\$+4
M%M95CJ/S[[Q@KY0*J[8H[7WORE&4IN&RD*3.J+-(5G7:HT%-L;'E"!??S_JO
MH&H#M-,_C_5[@]Y0OBZ<MGE=@4\_5AJBA0)'NYUN)R5>NIVZGDW*QLP=FQ%*
MTB.G/VF/+P,W7B)#>MP,1^WN9>#F[XHA4"/_9IGNZF/*,_^PW3LS!,'A9IO4
M<5]<VP$4=5.CB!1KKRUWST0O94;2;4H)?7X".C6*[M*AZ'R,F\P8:A"T(:Y=
M@V421'3:N1P6B^ G'7JZ%T0^ORNHZ7L-7\41(XHL9F>MVCH2JD31I=%/2F>X
M/QSZL>X-++P7]5C=8YGGJ,<*P6C0F0^=7N9[#F2>C\<D\<:N05U^/JSAO<@)
ML7X.@JLAP@]#XU]=A 4 ]E/;;ZE5S,?U)V6VB#Z;+B9D+R;\&P)Z8HN5L^'(
MZ.\]0&192B',Q/%\N*B'S9OMR; ['HQR8R:^E*KQ<LA+S#"R.NCF&<MRM\%4
MZ3>;IXWGK1=\&[PVF'1[H_'D]%9VF(NO.!ET^^/3D4N'OPJ+H:L/7'.QV-I_
M.1;#5K<W[@XO%ETI[\MB.!M/!B<HE0]]@Q9#VC"6HW/I6-MRI18GM<&PW[\
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M?&]C:9UVIS^9;%O9+IA+7*O<W5CL%R!-'A=QBZ3I+_9W1/,3K%A+O\*MDOI
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MY>+0&#/=53$1F8^LV;9+9Q1W1:461" H5L((S1G.6K9;$L@IC(^PL=05, L
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MG\@NM+Y#@!S#T@_L'.]J]@)3ZQ_F=VSJW"R!59S]N?)RUTN6_RZ&^_[%-%Y
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MTP@G^BT#/L9.Q L-CN(JF\.[=NBQEL1L-$8U>P'?*]+<4I;LS;3^E.:F)<;
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M!.$N79W72@(DP?-4I0@T!6)'4<T5O16L0A+%D(C,PX_B8GA1/BJ:1:]2Z1]
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MO=TA=;[+WNE>2E@V_U5D!I3/L?W^X'RLHF-DZEVN)?/@+)AU]DZA:@R3?0E
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M6K\*P3Z:A?\Y&+Q%Z^5XU)/"J"I%;#$RV9T"=P#R=%E_QL.1L\OQJ!:IR\+
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M+XO@2;6>3_-?E/^>1<':PJLO($8\(;1[D,LR6TJ GM^-,9.0>\+Y(X!_OP/
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M6B;PU?;Y/[;J_3EN*=D(_6!/\O]3JN54KL5"?UJ\#?(&T2$@W2V/7X\N!J6
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MS  QIT@D#V\SRK8> X<:<#0F_L8W'?^"C]Y-+I%#/3%!FX L$<.)%%X/LC8
M;*AV![WNAA"+=[T1I%C3SD;ABS:_^R[2[-K-YV]D#@:P1OI'"("_>4'HQ[25
MOU\UA2"=QP[_<O8KTG&:IE,5$SF#/,?B<ZQ:G?CN,?:8*0"7QU=S^>E6V"%[
M\97/,@;>([2/0F(E?XQBNDO^&*V4"1]_NO_MT_W-/WZ[^?9 ;OX)_[XO(;B6
M"ZQ]RZ<%0/"1\.$+*X#5&>6$UF$!8'&_2-"ZPY71].4H*]=<*P B U!K]9JB
MM"S"9+OE!!$XR]TF"XK=&)U3WOG8#0)W>J&"0NBX#B5_NA[A/V2;,,$7U9B?
MWCGD$DP6&Q3WXMQG;JS(&[[4F-:)C\+?"M!#%AM^<0'-K%EM <;ZW&Y=;0._
M6K;-31$2SO"1C+.TF!V2MZUW'44;]95!N]AU3-Y0:"I5'F3XY^KK$+UXA"ZV
MNK [.Y7*4VJ]&I:=,;R%+5O'J+!Y_:E8M&/>2-S&MD 3LW0[3HMFOGU3W (D
M2%L'4-^I2K]?O Y"+A1 2@#S\GU<KT&IZ;-B!KAF*R5(4BBA.T"Z0+M/0&?H
M]G ,:P;;+NKZ6+*O87ND=&O85[';I[P12EZ*Y T5)QE;B9MP_)9!#''_0W60
M3=Q#^=[ZP/Y4>7:0,-71A%4FU1T'NTSXZ/'1)^A)#7(0'XN5$L"A]Q;L(,RI
M%J"C(]:V)A80AQO?^SOZ%/EVIFV%;K%WYA 4APB(374_J 'G!DA'M=!2Z2#N
M93CCQI6G?5[R-<EQPZ1OG[-QA?CA^#_4"-)>8/K3H#/^)CJD778--0/CW KP
M'@JPD+NT 0UU_/L$WH>_"T']1IBV!H(X0DS=]VDP[QXMXPDKIS$%[FQ7ZM(J
MXC]TDZ%17KQEGH6L R*ZPKITS!\(3?\N598Y[8.X]!_O)H^J)KP.@WK]2QD7
MRWGO[%=UU,XZ658M-']+0,A\ 2@0;ITKW7_^K%L><\LDWLR<379PFUG7&[!@
MSBE@%)IL$&^!Z(8[ZB[9T&;+K'V+PGD4;Q$]ATEF[Z<WV 1@SS7U#<]BG"[9
M=7P4**.2=]@==7Q%/>>%7..,2^(!8DS!U6V*+,T&[7T (ANW=&4#GT_O/7HB
M#M1C/^T4=%J=L&,,F9J77//_QFJ]PX+1"YPBUT^Z;QE Q]>6':)47.7J'*1=
MG8,U;NEN=S30^JF]E%K/UO<TY[Y=XVK7>H-^NS.H9U?_Y_S\YF= '9\9I5\L
MT$#N>?CH^7G\Q&?7#; ;8^:GO_[EY]BS?_W_4$L#!!0    ( #5ZM4R" (-%
MS1(   C<   1    <')P;RTR,#$X,#,S,2YX<V3M75MWV[@1?N\Y_0^H7YH]
MI[(D.\DF/IOMH23*JU:W2G(V?>J!2$C&AB*T(.C8_?4%P(LH7L"+Y(WI\B56
MB!E@9K[!<'#E3W]_W%G@ 5$'$_O31?>R<P&0;1 3V]M/%Z[3@HZ!\<7??_[S
MGW[Z2ZOUI;<8 Y,8[@[9#!@4089,L'X"?429>#3 CF$1QZ4(3* -MT@2OK_L
M?KCL7'9!J^57U(,.9R0VD#5>77;#DKY?*;%OP+OV5;=]U>E^ -V;MV]OWKT%
M\TE(..%";G NY:-CWCC&/=I! !FC>.TR-"1T-T ;Z%J,*VG_[D)+5L5UMZ3$
M1P218@;I%K$IW"%G#PWTZ>*>L?U-N_WMV[?+/44&WF-B/EX:9">%Z5Q?=R\
MM[#MW%C8_GI$_[BFUB6A6T[9N6Z+XC4W2D!N$]MV=^D,)J-M]K1';4[4XE2(
M8B/DRV<Z9A $6"$8MAT&;2,4[#&AR+=K2=W]^/%C6Y:&I(Z91LBK[;:_3,9+
MB4I4#I.%]%$AWK6]PH!T3_>DD.DY_@!(#\"[/:$,V GD-M!9RW:XKV\AW OF
M'UN=;DL@Y_G-F!B0R>X1E2V5L8TLY@1/6H>J+KD,%Z!=0!X5 !GB)%G$_UH!
M7TL\:G6O3A3CX*#EQ CXSB+&QS8E%G=AM!4QHI@H%J5'7$*0CT*0[OLS",)*
M"\%.%R ] !21(\HY]1C/*4XU44Z0(SU,%/30@$&T_*YDFPXR+K?DH6TB+'K^
MVR(A(\XC?K0.S D)H&T3)NN1SX*G^SVV-\1_Q!^*'G8CG&O%K0G$C[O%2!4?
MI2,N><WR7=<GMD,L;(J^T8.6"!G+>X28<P$PC]\%Z$)1 F%,M,$VEH+S6-_I
M@!8(J^&_^[/I<C8>#;25/@ ];:Q-^SI8_J+KJ^5/[7@%\;I=GCC,[)_E;ZZ7
MPZN4)AKS!SZW3Z+B-*!EN%8%QH-DV7S^TP"29T$J?.C,-K,]HE(5%609#&KL
MKM38+5?\ST2?KI9@-@2SN;[05B-.T*"H0/'.AJZ).2(<'1/9COR1"E,?.O=#
MBWR+PUJE!C7.;Q,XWTVUN\%(@,P1'^C3I?<K"_N^MOP%#,>S7QOL4[ _C(K&
MQ-ZND!A<K)G(?TW70K.-^-\ ,8@M'^HR#"IDWW)D^:@K.BQK@?%L>MM:Z8L)
M&.B]%7@35 O(!HB*?P!O_+I_:,!4@3EC]XCV74JYTF,,U]CBDB GXW$&P-4J
M48/^KG,=!WVV^D5?@/[=8L&[+!B/M-YH/%J-]"5X(YL"?EL@TECC" 4=88K8
M$EK(62+Z@ VT0 _(=I%FFYIA$)='X@4R$'Z :PL=^O M)8ZS(@&O9O[F.DS&
M[0Q/>:96E*[4[7;>QEUIJJ_ 4AMSUUGJB\\CGKLM],_Z]$X'VG0 M'Y_=B?>
M"@N]KX\^:[VQ?AQBI$2 $<!E E(H$)&J\;GG]+G#L[,Z64JU>5[U_LQ>%1&A
M<:'G="'-XOFD&/P-"1T0=\TVKA70G].GBK23YV0_GMG)0IG AE 02 4"L1K'
M.[_CG>!+2O?H<O=(9,:EW:.!607STMWM('V:;99X:^,--J#-?)BPO9WS :O!
ML\R5#-IQG$OQJH"^[EQUKN) +^\F$VWQ;S%R78YNIZ/AJ*_QM-A'>#2]!7,^
MT.W+]-AKH^G1Y^K1Z7B7KT ).N_=B2%0A>#?8%\ ^Y[K8!LY_*WL&!3OA113
M2,4$XP/*R B*L*B'N"G1NW>W'$WUY1(,]&5_,9J+J4CP)JRW>3N?-6SG05RQ
M%C7J5TG4RX3RQA>>QQ=F+A-KS6+3R!(9+I6S1U/"1K9AN28R1W:?[/:N9[;9
M9H MER&3A_PQ<;(&#7]@RWD^EWB3E/&YB(3@("*P"0.!D #;@-TC$!%5SL5Z
MPLIY$B%NX[0%G58D#]1!$T2WB,XI$;MYX*$XR^.*LJG=Y3HYM2'2C,52!Q-]
M<:LOP!M>=VLC*H^0->A664(9H#VD<N)PMM$-8I,=-GC.R#O2SN4"/@TXI!;9
M"X("ZRL5:LM;?$E,GL877PYMBBX?M IXP !ANR#2<.,F55;:1-Q%IO@Y6UMX
MZZU]%UEQ4S+F@9\(!(F5-Z]ZN>H&(@TT(%< >8AM,37'7_F\1/P:$V@7P%C)
MEP?QASR(@]I!6#T0]8,&XM,66?.&'T79\A92$^,-Q4)J,[PH"VZ?R&P>V45&
ME&IB-9#ODT#V9S)5UZ?-V+ :>'SX0G9H!1_SH5.1JH'[,0G<:-J?372PTKXT
MN%4:TS-B?+TGELE'._KO+D\P1:9);/D\:S1>A$>-Y(>4N9O5K/_/7V;C 1\>
M_17H_[H;K?X-WG@U UEU VIE4)>(\CC)QR_>C]Z<H@WB[T.S',[%JLF#/KD"
MDPJ]UP;0Y/C'_T\/A$TV/G&B3QR#-[)-UY";1_T#8)ES<94KRO.+Q/@XW2]B
M'@#\!D&DQ<8K3HP4IP6(BG'A7:FXT(2"<X/>/PGT#.X\T!/S(DK0^PWHSY'H
M_2KRYNP]6Z5X\P!/[,/*3_Q T$:#=F6T9QO>;?B(N33468PY.'<[Q7 .JF\P
M/AWC*6'HD 651EK-GH=WP>Q--!))U1K8SQ'(A3497EMH3LD..PZA$LP*8;U@
M37G.4#"5B[0'#@T"Z2.-8YPKK2OM!AE\>:"73>4:A$_O^CP1QHS0\CT]@S$/
MXZ+9FU]]@_$9>G%X#*)\1\YDS<,YL9:9T9<C!R(:J$M"/828?H:6B\)EBRQD
M%91J(#\FY]F'VF@!/FOC.SVR7M* 5AJT0]_JWT-[BYR1'9;--L$R\U,>HB6K
MR8,[,;<>A3O:6_W6Q'9#T1Z0#8J"L,G&)0JZA!=K1[;!E>9]:6[!W#WO15B4
M4'<[R9[M!^71M*]/5Z//.IB/M6;3^WD />Q %B_9F3REH!F\-+N+5ZSE7+#[
M;8DN[4VB><V!H+W&&\Y_G"FOVY]2E=HOSG& L0D5?]"Q:<[D$Y[UE'1*M7E.
M<XYS<=&L0AQ/"&1H?.@Y?4AR<$Z>-Q++0H9\E01'TL_I584:RO.SQ'S@B7XF
MA?J;=#>1RX:"'4[E-]Y7^%37VD&_NUQE_4%QX4P6F1KYU#-ZO25/6<2&68$X
M![D!2@64?\%R\)?W5IWGDR*QE,>&A# ^5D4H57!U.IUW<M4NN-.9_YSU[\2]
M;K)7BO12)IK#V6(B+_=K *MRE^8<BHWH]XAAKE?1BS6/F=0P>O&VX"V;X,U1
MU4TG+'N^O<!Y=O7M(T7/KS?(G'XZN=K)XAS\3CJ)WJ!:^/BN\I!N#D;728R.
MC^(V.!0]7*<Z0)>#0NX-I T*%<Z_%3SOEH--F?-M#4R%3[(I3Z[E0))W4JV!
MH>"9-,49M!P(<LZ<-0B4V\R0OV<A!X^")\<:7 HM8F<N2^>@H-Q7T-B^Y.)B
M@97#G/LKBRX+-M"4F0K-FP/- :7(Y&<#R.EC>ODW^68IPZL"\NK42T.]-IJ)
MM>(#_?1K0=-(5,!=\T%_8H$S?O]6<ZMGR=%_.C8I%&IHWB:AB5^7TT!3?4H@
M'24UL1JP<M\1:;"K-#S*N/\ZBTZ-V(>4RRI3=W$W8)49,Z5C%"]60_,Q"4UT
MHVX#2+6!5#HTV81*D/B@*@%2QE[+!J\SW$!2\;Z1HN?."\;"_^O[!<0_XON\
M"[0!\NO--Y :@E;]C>?VGI*].,>)G'90Q85?P3VWYZ<+\97F5O IYO]P#2\?
M=U9 DFC@^,O!THUB1O&%#&H0GX[]=.'@W5Y\)*3]?;3BYB^KU3%B+U$I"Z[+
M*L59D/52]>'=LJP^\9Y<2*V?VO'/\_I/CC_C*S_BZW]G'L"UPR@TV*<+1H.I
M62']?S0N_GO_>%UX/&>"=FNQ)"Z^2?SI0DV"+4N\H8**'9>WA)DKQ+BEQ-U_
MNI!??K_!#.TN@*>1]]'Y&Y/L(+9'O$#$"ZZT).0FYV%^)0E-E_J[T-IE=$);
M[/3A'C-H]0G=Q]3)*GV!FO3GVJU%UM Z5B'Y^/O)?I#5@HX3G@:=T07>WK.I
M*P2<;4:.XR(S.,;I%SJA/I58J^CL/7'N(>]X9U*9!'(33[0['G5EMAX6."1-
MWW)\U97=$9MG&?0IKN[:VP+(=45KS-*,@&WQ10&68X/PO@WB'3V:([H4]CT4
MS"DV4*A[<?I*3LT]>N_7J (XKEM"KP'B#\P!?L FLLU ^L33F(QJP^=HH'+#
M&&:&/ 3/'^\LVTE[C?%W3+?]93)>RN_$EXLZA[OB27@_/4R_G_XX+E5A?(%1
M5[7+6?.90I6+T9X0JYBXPNCT6'7+334F/,P>7ZVU0 \\YOC\GDJ%*)\Q'H6^
M75'3D<T0#^_,VX@A@'G<BZ^73U&(FIKDY>F6Z:H3L>:TQ#;$QSTQY?D+[&CQ
M^[^.=<@L?0')CISM]KS'=YU0ZK22&GG4W%U;V/ .$?L ',.B(GB!/B96CL27
M$(Z52#Q]B9+ST9PE@C%/>D4\1D[\Y:.D^&ZOG&R%>#=VMDBF!;&^GE[T CKZ
MKX1^Y<;PQXL#M!%+^[;8$N )KBA_:2E[)BY?1L/1E(>LRV-,DH__6#P26&@&
MS[7$3)W\LIH78X7;AR/[[/+G3=-#JY\I2T]H/DS[=LPQ6FJ25/TSH#EEE'*J
MHKFW!,8F0@J3U\8 L<O3%DC,3-O;%8E\(RIFA%(LM3%$VIR0>&TK)XU\ D5W
M#T1\&5H*:!9\($)=@PFH#B/IQ/.:S30D5 VGCH>$+A%C7OEL$RRA"F7%D\ $
M)>AK'MUG:_^#;"LB)SO]&[#E)&4XK%#3U-P"(H2A9%1#M8M:Z4X;!<N;SE8[
M>2J] N+X?/8) #^/ 2+7SI6U11YKS3T_7>DY?))_I"1J^\1):_/JRXKOR?O_
M0\J\5X.:M>:>$KLY^3A:9A76)6X&@FN\6^_$(,;;B7VL9!Y1S975'_=83+QH
M>XHM<3*@D/;97*_$'$.TIB[OFZ4MDLKX2HPR0(;4J+114AE?B5'^ 6T?[ZZ4
MK%?*,MG<=3//E+!"<51!5W^50UA=&W%,KZ1D1>V@9GZEQLGH+J6Y7X]Y-'?K
M.JRR]V2QOUH#E?:@3/Y7:Z+^B2;JOWX3#4XTT> 5FFAF,.)E;5=EK9/&^GH,
M,X$B8[LN:Y0X6UT,XM^K*^_,#>^C%;?LFK_Q+K#S;A;PC%",M.ZK"B7N'8[O
MGJC&JIJ&C>V;R#%7?#W^61VGA+(K],AZ%C&^5C!4E%?5IUA ]S*ZU81[HP&Q
M&=M$%W]:ERCA"4Y1FCJT?HLJXEHST5$&&&YMPL4P?$],[@;(HZN+RG(7X1S2
M^%F<E.=U44FNV_2@([[?OA,;([T]TN)-O96DO:<#B;^JH7V#U P.@FBF*<^S
M04OCRD'+6PC27'9/*/[O81WICVCH.1?CSFAS_U"K2XU[KJRVI0A%E]BSB^N>
M%HS1 W88L1?((5P]Y(PMX[@G*2GJTJ<R !3K8%BF>$.$YHB*T^EPBW)@S^9*
M-X=WTD90U<<88ML(M"Q_Q;2"7;(JJ+6)N%XY-O HOE-4"':[/I_VX<6I3!SC
M%SEMOCU2>>H>-\4;$]I/P<$\W[]GFPFD7Q%;0(8.R58!RGKTBCEAXOH.:(TQ
M1]N4U0[@CJNC[02N*Z)#XWYF&/)V(X,K.4 ;Z%I,[K1$YHIDOF&?I^J:]\/C
M2S9&MND:(E<+CG\Z0TS%T:P'Q-_/L:6K:JQU>9T'\U;>YJ:!*Z83O(T]$_B(
M=^Y.SN/PI#72WR)[7N+37]6KJ4>_3=T!'#\HKC\:7&;L',8'Y=EJDNWG=8XE
M,HAM5NM8&;QUZ5D]3!;0',,UX542L5?J6'U%>5U4C/3@X)T1R>LR2^O1U5/N
MV;KJ='\\!C&/J"Y(!E_YX9BML2UKE<#QF"2_K+P0CT+/+4BLB&%[-WI7PG>=
M(PHW<X;I3F*CHX*B+@!SSS2.=8@%X^SRNJ@H?7!*F)>#')]ER"BKR5MVB6PL
MMAW+HU69!] 2;EN.J2XP\_8<ARMA(&0Z0Z[,K<BBO/4@9&JV*4XA!D8H2ESS
MX4V02NJ/L<0SK: F3A_NG=PP1&,W]2P03Q9%.QG;+0NQU,7A$\-Q<?U;_(($
M%4E=%/6& $<OH:2J>41U4;;4+IIJ6]VR*ZB;D:1&0L'CXTG9Q36)<8?O4LL7
MU8H$^QXB.V96J1LD*G'6:'O$84%]Q8?_B1MALHOKXMI\^+\3\];45X#G(GT+
MV^*CM3Q?^0T9+'W'006^NIA$YJKR"O_$^RR>VN83UD5I?WXTR%$74&1I/;0A
M%(G\? Z?A!H])&X6<09N.+M2@>_[G$8\=X[;%]5:(MJG#,SC;X8\XIJ\)^0>
M'!G>_9UP,N@?[=!)*ZW[TJ#4P]=I9!N6:XJL1FB;LOFT*''=C1*$]\-FV\2Y
MW*SRNL3$0W(3[B(>$CH@[IIM7"O8 IJ7&)7BK5%J=-!P@?:$,F3Z4#MRXW6?
M6!:2(]W0 !%M#9)BJ<KUO%"K>9>3._+)S_\#4$L#!!0    ( #5ZM4PE]I8]
M%0X  %N[   5    <')P;RTR,#$X,#,S,5]C86PN>&ULY5U;<^(X%G[?JOT/
MWLS+S(.#S9U4]TP1<+JIHB$%I&?>4K(M$N\8BY'MA.RO7\G88,"R92Y!F)=<
MX$C6=[ZCHR/I2/[RQV)F2V\0NQ9ROMZHM\J-!!T#F9;S\O7&=V7@&I9U\\?O
M__[7E__(\E_WH[YD(L.?0<>3# R!!TU)_Y Z$'OTHZ[E&C9R?0RE'\ !+S 0
MK-^JS5OE5I5D.:SH'KBD('*DH,;RK;KZIA-6BIP[J58JJZ6RHC8E]:Y:O:M5
MI<<?*\$?I)%3*U/2MIR_[^@/G3Q26KC6G6N\PAGH(P-X >A7SYO?E4KO[^^W
M"QW;MPB_D*J42FE5BBE!_Y,C,9E^)*MEN:+>+ESS1B*J==S@V1P/B<07._+O
ME4!:;;5:I>#;E:AK)0F2:M727S_ZXP"G;#FN!QP#WA!M2-(7C&PX@E,IJ.G.
M^YC#KS>N-9O;M 7!9Z\83K_>S/$<R52C2F6)YY>Q1XBA?':0XR+;,BE/]\"F
ME8]?(?3<&XG6_C3J;31KCJ%AS2UD+FX--"M1D1)/70%(+LV53@)M]:$[G [G
M$ ?F<BA&5J7G /OD -^T2*-( TWHN,$?B2WM /?UP4;O^Z#?ZRF?J(ZUR^HC
MYV4"\:P+=8]V'M.WX7!*_^M"#UAV#O2Y*CT+V*'W"G''QYCHOF\!W;(MSX(N
MX^,#%+#G@\ZBE 'TQL"&[ACB-\L@U;U!QX=MQVP;!O*)D8Z@ :TWH-MPS>4W
MC%QW@J*R;?._ONL%)GV UD[5DLM1Z_JS3]=CTJ,O1W%MF_A0.I ^(-Q%ONY-
M?3N2_VQ-<K4EMVH-8!N^'0R=??)=J$[:WN,$'C'&X(+$M28T5Y]:'GT*";$4
M19*E577D[\YP,![V>]WV1.M*]^U^>]#1I/%W39N,<V ,$!*,-C(V&F+3>!7A
M3=L)JPNJF@)7#^HC4?L+ ',:#C=*T/;<Z!-J90U94<, ]9?PX^>VZ\9PVT"'
M=O"\YTV!9Z.NU!JZ:LKU>K,F-\O5%JFQILIUH]:85H!:!ZT51Y^+X!M"YKME
MVUL8MK]^KE?J]7)-:2@MM4(8K%6JL?;&K*J--YL.L!%53?[<,;1-*D.)DNO/
M9D%M,HE^9E'Y*4:S [0;M@IQ@D/8A)C,ZVXDWR5M1G/:'D#T] ZMEU<O^.8<
MA/4<,B=YL8BO6*(GSD5;&+9/YYT99/(4+231>P,/C: LFA$$(6"(!3G&,A9D
ML)XH6TB:^9&&O%9$X_41(S*S]3X>R:CJD0!!^\>WYG20)!;+H#>M2"%9S@TX
M)+LJ&ME+/712.^^&3"'IS$88\E<3C3^ZZ$+LC_ZB-OA&0GP2F[>]#L#X@XPL
M/X'M0P:O7&7%X9N?K%V"]X<J:@BV.VTCKB>C'Z<4*0;-N1&*&EOU'#(])W5_
ML,?<N$@QV,M$)&K$%(OYTGO@KF QF./$)6H0%%O )H/$V$/&WZ_()FUUZ6#A
M?:2LK605?59K+=/0%476U0:4U8:IRT0G35F'5?)5H]6JUEKG09V)DRTHCM6>
M@(M=\^94@*BAPB.I"Y)>N51)6D28("D.U3G92)JT\:$3E<<.FLV0DTGBMEB!
M&.2")FI,US9-:]F41V"9/:<#YI8'6.ND#.D"D9D'H:B1WXAN@CG0U !VR#32
M)1,0?T89@&873BW#8D6"V04+Q/2>8"\@7&2P&Y,0A\9/"96RD(OJG.-Y/IF[
M&<G"XC#-2T8"??S(A(V2EL-('P(7#G7;>EGFZ&62FEFN"/SN!U+43ML-X_D)
M6,14D<ET5K$B$+T71IXH:XXMA,D($9C#V1;;\M#-+E $HG.BNX"8*GT)=5>P
M""QRHA)U%S(>-F30MRLI-'_YUL%YT8D:.T7[9X_@@VZ>\6TG;@H7B,T< $6-
MD!CQ7CJQZ84*1/ >0$5=B"*VBGUH<@^C3/D"T9L/HZB1413)AQG[Z;0F"Q>(
MTQP 10V6MB-VCI2!0G?3/ A#3NNB<=J%V'HC&GJ#V8O#B;)"\\G=-WF!'9_&
MW6-8]),5B(\'A,?0\^S@M,]P&MM(_!-@#-:'&+>3(/:MYI()/2KFD.M&SD6E
M+Z6M8V*G.3O&/- =8X1YB*R<?HAL/"&_?FB#R5@:/DC#1VW4GO2(P(W0Q\D&
MT.LY1&FPCURW_08LFTY^)BC&>[A5= ]<R]CJ+O%-IIPU/5?,EE[5S;+<JC6@
M;)IZ36XTJZI<![5&V80-I5ZMG\>];R!AN/4-F<V>T&S6JRT!=OU.0\CN0)"M
M"E$70-;-?B#:(X["LQS?<E[6KN$>3A&&2[D)6$!76W@8$#R6 _!'C^@_6((E
M)0DUI'TO/<>#&+KL--Z3/5$<(^0WC%UC^FP%B6V:!)^VF--[..ZA Z?,_!*&
M=)%,@@]<YLJ<+$169M=ZLTP29=!TC&4V]?KV!ZYDS;0*Q&']'*/1@7KB,B Q
M=D792+.MB;\"<:SI2 PSEB3V5P;/$')^BUF.GW0T9$2V\<Z:(/W<:K:JL-DB
MW;!.?E25,I!;4Z4B*TVSKNB-2J.B-\^,+1P@F$:_+2>.;1]'^0FFS04YTX+/
M-6J.81#!?2,C/@9VT!=GEF.Y'@X6GD)0#+KY"HMC _DXV^7Z +RB1L'131F]
MV1Q8F+K@E"EYLG!Q^,V!3]0-ZN#.LT>,V#.9F(0XS)W*.V>!%97&<#N.U1&C
MK\4AD%?ANQ2E8LD7^1UKER-L$IE0Q:YL2XWZ>8N)1UBJ^K>V,/8%F(_%RIDB
M(7J;7X@PO-3/9=\6P) 6A]^#"$L(?7+@/7&G/>($/XZ*S762:&&)Y@;+,W2>
M?5*^O/@U4DAT62=K6&5(B\-U3J>]#Z[+6)[K()=8.HW7@_-V(: QLDT&M>P"
MXK&;/X;*B>X$:_B,2"KP)LLX/GDI@0;^#,EGW9B:NEIMR6 ZK<IZK=Z2#0!,
MN0:!.JW5ZI6J:1ZIG=$.UK(!] *Z91MV!X4L<7',Z7#5;H5_>5$??\V#P=XW
M8#ETFCC<2*.A QBP_4 ]221FERHPEWN"%W6^',$9P> 4_ 3U+2],/U_G6K$6
M1'C*%M,4#E>!J/G[:_L>(&<$#>1C%])C1!E&L"-_'<3SP>9)Z?_<U,/]WJ82
M8XF9BUC=R45\&K2?NCV:B-@9#KK:8+S\BY6?V&F/OTL/_>&?@N<G)E_E^0@)
MCR8Q,DP/\W3A\G?*AF:>:IY-LPQ;IEZ7567:DLU&$\@Z:!+#59OE>K-<K8'F
MF5:!Z/V6! *)ONGVM'G_\41LJN<\6 Z9.EG.2]OPK+>T;'3^"L3R+"?D<=?M
M'*@D43?31G ./D)_$QU=99R)8R[L<]<@COD<B=6DK8'#M"'LKCM1D0&A&61@
M]ES7I\LR&R<!F"EJ&>6NP"CVT\%%K%;&H84S,FT!L6&Q,V[2BER9,7#!%W6^
MDFS5\?L/<KF$>,$K,X,<2A#UB')\W!L@#T8W)G $#7'Q*R ^%_3, \PBA -D
M_OH&L4??:\39Z[=*7 'K>='S'(\]^^#/T!*]Q-_U#IAY)E0@CHF(,O/D59*H
MZ]^/H1><H+9!=(<A\X5*+(?"78$XQG,D3A/\RV'*X)IVBNIO5MF7^_J;A K$
M,1E1_ VODD2=KA0R;?Q KA)V5W+GDPNWI'E%&ZNG,X-#=U?%.VR;?8B<81/9
M!:_ (/94@JB#01<&>[1!R\G?-@S8<<SV#)&)V?^2$G#R%+T"@]A;#:*N8,4;
M/IRN9OHT3Y%F*'8M=WD5*,,L>(M?@6D<I I1K^P;OP(,[T&0KC&C&2QI/B)9
M^ JHSP%<U'O\ F6XI"T/"'>1KWM3WXZN 68O;3*+7 'IN>'SW =W#NH?R)0G
M>*G8^@S*<!KEF3*X3RUS!>3GQQ^RWQ2-_>T%E)ZS^RYA]A0AL^@5V,+>:@A-
MHB7BI'$+4?2&8O8B8VJ9J[2"+/S12I)R ?P'F<QKY00O/.8VA*3"5VD1W(J(
M3$.\A#BVLTM/?<@L=Y4&P:.#R!:$V\IDV/<6)KHXLO,Z@GRN@Z?&JS2?P[03
M&99PRY2Q(V_ AL/I\LV<RUWBM)O\,LM=@9'LIX/(%-C+DYL[X:LS'\<_,437
MR6SD^AC&LP+'QBLT?0J(_M>EK]6U^0X(596JHDJRM*Z7_-,?#K[)$VWT0^IJ
M]Q/IUZAZ"4TE^H#?I%_#9_PF]ID@VMA@:YSG[$)\3SV]X+-1K[34!FS*2D4U
MY8JB-F58;T(95O5&V:B;2O5<-QP>\8UKHN0W'(6+75? BU_4'>VCOYGXBOC.
M4 %_=MPI'7P0OH26&0M6&!_G<_HUI;+M](>3[]I(ZCR-1MI@(O5[[?M>OS?I
M:6/IU^"14OA,*?;0BQD(CO)NI1._>R:*15P/^PG9*+G*BM.S.1G(?+T,%\(3
M7[#,NAQ&#YW3!-%#&S \PT5WO1+OUTN3OUSB<J/:\RC;*5TNF6\$=TR%-P^%
MUU,MYXQ;2];KD#NXYFB"HK*QJ\IR^6155:K;/GF@3:1QNT]\\%@;_>QU-&FD
M_=0&3YK4'G2E=J<S?**G]$=:1^O];-_WM<U8/6B9Y"&)M$T*&B?%6O<)SIMU
MSPT.LL@"Y9)IN^V;-&DH_>T&>0H>[\JG^ 5RP<,3^W.BI#@].;_.UYV:']I%
M7&Z_ 85>,Y9$:KKPI?.Z![JB>.KU9[E=<_W(KCG6E(L)HG=5R[YKE"%[SI>7
MKYN2UND9TN+T>BXVDEY7SH/H(ISXZ@;0A-2BS*P,OL*73/?^ />],U4X1Y^F
M@[R>OW%DS[]JFS1%6(I:)T7-NYS1@,O.N.[?.DZ5XKHB>B'=&TS)#LI;C8#N
MZ0C6D-^+96@DYP'6<U[87[R[O8]M$4>]_)M_'/M26K(0>MK?_P]02P,$%
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M)0\*>8*P(^AL09TMV/Z>? ;9@GU)4ZN5)0@S38UYD12"(/P"PD8N!X>0#0#
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M)GRMXH.19Z.=)0Q/42P1%-[%@?6 #YV#38#H45^T;!5^!&&I*M*?W&I5R ^
MZ7 \F\7G7&[K#I8GGG5(<GGBL@(3%.$B)6@/9)4J4+,"8 "=?(^H$WOXV&TA
MK&*%&B9 !-#J-73-,)RO?S.#P/2B>;!P-@^BDY6@?0<K&,\F*KF""9B!"HUP
M%1-^ 60=*U2X0H#:/'?=X1]1@"]'R\BW_IAX=FSM+DJ$QQ ?27S/GN#_#B..
M.[Q&/Q#6-0FMRPYHU;ALO>A,$5DW3A!&]3%D=@/!#]LDA$PFH=D%R'KOV(X9
MO!"?Y7Q->2DXA'/:=[")\7P[)8[A'&8@0+.GB=STYNL5ULG0I/5^Q2=RB0^!
M;&F%ZG?L52_BJXU%<8J>'#R'O04*DWBGJ6OQUSY1:PB[E+Q:92N=B"5P"]K.
MKYLNY84+&K]]!PL:IX*=](+&9P8 -'FB9 [C!PVA+%A%ZL4X@Q_P 0&'O/<B
M?X:1=:6QOX*PN/%5C.-08[," J3MUO=D8#EI!^@@70C$"?$ 1']H95\@&VTI
M/4F8C[3OC/UA!YL*ITQG-5\:FROPJ)7PL_$^!;(#R6NG/(B -J>68?S]ZOW5
MU;N/%Y\N/E^^_W3Y_N/59Q7(HK49NU%WT#+9!H_VW&,GDI7^&L+1I(QBR\.;
M8Q( G$=;RK0HM8;;O,,$FP(61-["?B?;'"K:C6FAP98$.DM-OGQS".?/,C#R
M.8%FW#BD=((U*D!AM,!74GHOM?&:8.$?S WW!:T2'8!(MZD,HY@WV,#F[J=[
M?\*")%Y>2N$J_!Y$YDUE6(6L04/U+O MA.SP!C,_"<.8))+,UR3P=Y4&_G+@
ME/D01!)-"1QE>((&X*'N$3JEYE_2$,+3)]4G6L)#ZP[G6_/9V<;;G7(L3 >?
M@J[1V@\0B:>^,U_(H>H:6?X6A:/X>%^KV >$5U)DH*G(7NNH,=WDC.E1U%@I
M#IQG;Z5Q$/ !;=U*TQ0$.\Q!"Z4P?&[@WI4G'ISL'\P 79LAB079/B(O-!-Y
M8J79T+O?]<N^"9Z\-'+^NQG8LYC(:;ZFOX:#.'K ?/VU3\X\1K#Y<=2:22X:
M4(3F97!VZC2P;2=A0)5BB494JV)-V'C:E$;K&W6#U \\+R[4(56#JE6C&C8F
M50(YFV4K/>T>+M!W*!AO'UW_!7$S]]L;3ZVN-6 (:U$69Z-F>V/@?#V/HS R
M/=OQ-DDH0B*&IC5-:DBURM: >:Y=<;2^08[_C''W)TF2K&V-VU0M9C5,<6(V
MNI(U"0)RZ#N4-PAQ/1B5>E"+3 T;7"7N0 !&+(:FZY+_JH\=IS.U,-:UU]5@
MM"M$;T[.586MU6)2UW8GXJ1#H9,G=O">A_^#E-IB.-LK?*\6F!K6O J\@3M^
MTNAOSTYMPB'Q:R%[% >8\"0^YYOIQD=!QKGVO"-F[6[5AF T8<FKS3(XW2"G
MWKO L817UK2!6KR:,HNEQ$.3/-O3C(E],B-TYYH6ZXA?]F.UB#40Y23+&#0T
MD^S:D^4@,4XD?[\AA;G$-85+=J(6W29L/B49[ G*=-&O"3*O#[48-V%J*<=?
M^U$ _O;1]%XH67EKSJT9_(%HX!TS'$#B*[70U+6HR'#4?N4&/\+C.J8[=?"1
MVJ96N)&YQ80DP:PK?VQ:#W/+BO'QB2[]HR0I88%<$AVY\J6,8*T,HQ;NNF::
M5D0 ;3UF!KN,G[%V.V%R[LM^#--?0UYP:L6^U&I%#:M/33Z[B=8Z)F3\;"6$
M,EVZI;M0"UXKH5TB]EK'C'\/3GTCM#(].O"BY+)I61C6[E(MIG4M2[7957%^
MVHVVVQ$XAEA>2[4I&C7,/$(NP.U].3K-8!XDZ2.)_0D%]$K%V^EDOE0+6@.V
M'BFN*KUU\;>WB12=Y'6(__K_4$L#!!0    ( #5ZM4S>5X\/368  $0/!P 5
M    <')P;RTR,#$X,#,S,5]L86(N>&UL[;UMD^.XD2[Z_4:<_X#KO1';$Z&>
MF9[Q>CV.W3VA4JEZ=%9=JJU2]]@Q<<+!(J$JVA2I(:GJ+O_Z"X!OH 2 (/B"
MI-H?[*F6@,Q\4L@'B??_^-]?]@%ZP7'B1^%__N[=M]__#N'0C3P_?/K/WQV3
MMT[B^O[O_O=__:__YS_^W[=O_WQUOT9>Y![W.$R1&V,GQ1YZ?$4+'*?THVL_
M<8,H.<88?7!"YPFS@G_X]MT?O_W^VW?H[=M<T)63D(I1B)C$'[Y]5WZSR(5&
MX9_0OWWWP[OO?OC^W1_1NS_]_O=_^K??H[L/9<$/Q,B=WU@R\,.__XG^WR-1
MB;XD_I\2]QGOG77D.BD#_9RFAS]]]]WGSY^__?(8!]]&\1,1]?V/WY6UI"7H
MO]X6Q=[2C]Z^^^'MC^^^_9)XOT/$M6'"=&LH*8I_.2O_^4=6^MU//_WT'?NV
M+)KXHH)$[+OO_OQA_<!POO7#)'5"%_^.> .A_XBC -_C'6*2_I2^'O!__B[Q
M]X> 6L ^>X[Q3FQP$,??T?K?A?B)_D@4\4\4\;L_4,3_DG^\)<T)KYU''/P.
MT>(?[U=2!_Q4$\C79!BU'/?=:,B,0 '&LXU2)S#[I;B:$)'=X=B/O&5H]I.=
MUH:+\"%UXK0#1KY^:Y09M]+*:_)7#HSJ4 AA)N0LQCD'?R']AX>]C*6H[,BM
M%0@H7T=QW7V'^!"]I;3__8\9Z?X+_>2OUWD/-0_);YCZZ>LJW$7QGO']_#%)
M8\=-"T',_$R2;KV6;J)@J))Y7$?DQ&YA!/FSP6UYB>_<B%#Y(7T;Y#\9J[Z+
MHWT[")D948M*?PT>#9I(@;T&/,9)=(S=,A1T6DR1=#";3'^[$@.I2?,;'+[]
M^- "U'\52I 3>BA3@S@]Z-="T__]C^^8<?TZH?:C3PB\3BCG!C#E"7:_?8I>
MOO.P3Y.ZW],_:)C__NWW[_+LZE_(1W_-C+C'3SY5'*:WSAZ?N$=1#&@8-P&C
M42LK8SE(1>VST533YIBWP$HJHF('B;N43TL!@1LVKA8DUF,G6)%N^<M_XU<I
M]/-RX"-+ JT>6B>%0,>6S-:.[2\7BYA<1 3;"B];^(:*L,4QCHGN&S]QG> O
MV(G)6..:9.4"!RB* HZS)H!%J,G* 8VV1G--&V0N&&62$15-<BP/4>'C!QT(
MF,/V;C=^@.,%4?L4Q?*^[;04X(A3P*KW:[4B0.-,96E'SF="42'55H=F =I0
M\52,"[=$K #OR=> (T@$I @=_CN@,2,TL?-@GTH;/TC&PS)T5)13R9+T3E9N
M G$BA'8:,+5"P"-';&OG9I>)M9C.V<4W=(156>H-^211X#\O.8$HD\ [C;.3
M8L C369MY[;(#RR8:'O19@_C.!&7A;U>S-7+3B;J!!#%<<<5G$3DB>SMJUWF
MW0&(Z+.%<Z@(G!,#/ 8O<)X$Z$^_!QQI0BA%=-6^!!I18AM-6U<I#5%QX\?-
MF&@&7K>*]OLH?$@C]^\/SPYQU.:8TBUP=$^C?(%!70EP'.F#/EG>4M0 &G$M
M#.^Z,,1T(*9DAC(UB--C;1T,(/:VT;QSDD>F_IB\?7*< PWI?_\.!VE2?$)C
M^]^YV,X__NM#2H:7E%4VNQL_=$+7)SU\E/B*?5TMJP*-<Q,'T&AO4P]@S!N9
M;]KZ2R4HVJ%2#2KT]+B]R3P YDF"TZ2AJ9\5 MZHQ:#XYELO ;BA2@PUSJ*8
MN*%W%4J[G:%0/3PLMP^V@RA?B=:*I?.RDP@I"<3SR#HI"#[ 9/9VB[,9*G8G
MP BXOE$N/M[?+V^W*(N_/]D+P(63/,]#C_YG^=O1?W$" C.9IPLGCE])@OG)
M"8ZG2V5MZP(/T%8NX -6JR+@ &YGOW%3)^+9-G7V!Z=HAIP4%;H04S9(B!].
M#Q!9],7\X6<TO[U&[(_E_WQ<?9JO"0\\H/D6+<GGFQMTM[Q?;:X']$3MF!%0
M7UPMWZ]N;U>W[P?V2"/]CQ<C%I,PUXV.!-4]=C%!^!C@6YSF/9ZL5U17 <[X
M.H!KF9FB/&!^US+;.$_+A:-*^@P1^67F9BE=&P5SS&$.\1G4\4)W%;X08%'\
M2E!*/')2!'AHB@#QH<A_#SCTA&::-KM2& LP.W$U"" ?)Y;C9Y,^X[@VQ)/@
M%Q8$'DMR<'Q$G9<"'%<*8TT;(Q.)3J8=[ 398.C<?#+%8;*!3/?I3+C #[+&
M^)I*:/7;[D:))_[>D^$AL6M6P(3271R1X7SZ>D?0L+L&R.CT0)?,Y)E@0Q7@
M@:8#F(\[57G 8:AEMFD3+H3/$!.?W1Y1*+"870X+^GYSM[S?_H5--M%YIKL/
MR]LM0;O<VNX);TFS;['V)2P./&R;@)YWE>=E 8=KH\E=.]!*-)"EL &P;K8_
M+^_MKX6]CR+OLQ_(X'-? X^Y4R!\C!7? 8ZI,Q--VU4AR$ZX# YCS&G&E)CN
M/P8XYP"<+K^XP9%N06R(&LVJP".JC0/JTY7-]0!'8BOSS6<#"R7E+ S1@]Z4
MFE"AZAM;<Y^C>@'0G&C5US?/6-7* @]G)43)Y&A5$'# JNWM9XJT$FQ]EK1W
MC+9G=3)8ROP;?G3509P/\ #'SXF!W09O-B<]!X(P7B2L?>?1#_S4Q\D\]-@!
MF.<H\ @YT,FA]+5APJ1%=>#1U-81?+SIU@4<D:TAF#9X3E$Y+YJ^6I]T&0__
M:GZU6J^VJ^4#FRE]V&X6__WS9GV]O'_X5S9ONOT+>G.]O%DM5MNS3-P*,>B=
M&U!6F$[P:YP@D)>>1H#WO<N>$PWG0,& >(M3!5PH6YQ.74?ATQ;'^VO\V+";
M5%P2>FC*X=5B\KP8Y&!46&L<A43F6Q(6>T2E5H'XP4F/,8N#?@-1\8S-6) +
MB(<H9N=5HQT*2B]X1)$EZAD0ZK[\-9O1CK^U_<YYI;MU]3:UGQ4&SD1JD**-
M[/62@/FHP>#.&[ESN4 VK0^%\I#)M7G*\.#3:0M,[-H\!OX3>Z6D82-@8R7@
M8:D'NGZ@4%4#<)AJ&FY^/(J)1TP^XA18CMNA80N[5C=W1D"UVIRJ=MWXB+WS
MX8R<Y*3E@4=R(]23/E9<&'#\-MO<H0^BDI%H*&ZMLQT8*_YRP*'5V+S&.TPP
M>??X!8?'AK176AAX5*I!\B$I+@DX'AL,-KXU,Q>+<KF6(W%HE'$FU_)."NT.
M4EX:>" VP#S;3S&IKK')XF[[#>!TB\/B++8P!Y4".ZOCX_^<,\0.#D%:,-->
MF8#//7JT,RG&&:!UCD<S3?$W +CZN3P%PU@).>TC/DUUIA.(>H=]E!6F$9X#
M'(6I12J@LS\#H][<OD?;Y?T'@$O7C7N@I86A1ZP2I&P->Q+;H!L,[FLENSJA
M,/2:MLD*[R# /08\P$E2]KC<]#3=-^?Y2;;L-(@'7G#\&('P08C9[=3G7K Y
M[1?[+T[JOV".KJ63+^*RP$E+";$^YR<H")BRU/::SX454LNQZ<C/K Z++W\?
M(:';8M%G)XX=;@A@].KJ(3Y$-+[^^/V/>7313\K\Y_4FBA]PF@;Y'?C<(Q"_
M9.K+DB>.Z" &:$QV=0P-5U,9EB/9R]^?8@N^/?W0O8T=7A%1BBJM:+.K/22"
M<LT#4X*([?[IFP:ZM.:@_IETT*U#C:,RG7I >;4U=(T]1),8MNG;/L!.(MO'
M6L<#G^T<DH[B[&];V#I?A/--#>O(BFK (UT7N&A3@ZP.X#C7-KWS%@"BH;XH
MQVZH'CC4->8HQO- 2CP H!L_77?5NUEBHN'<#%:U)V(2(:QA=(]+Z;;[YL'1
M5N=EH*U?-J\'P8_'AJG":4P0]CEMMI8WLM&W ?2T_@\B;EI?4S'EBRG:744Q
MR<LG!KQN@1?]K\5E$_,TC?W'8TI/:Z$T0G<.B,7_(=T@N&7"XL+_79SGS0RR
MZO$[<4G@(:N 5[\Z^ZP8X"!566M^478Q?LJ?WF9B9VB5)$?LV;HD>TB<V<3O
M6_3_??_M]^_0P8G12P;YW;_-OO_^>_H_E&3OCSO']#F*_7^06@[=\A"[S^C'
M=S-$5\W8%H!K[.+](TEK\T__?89(O0-VZ?)?\#I#O_]W5N[WLY]^_+="JL]<
MRSZ/J@?.S338&M:/\1-E?IIE/X_%>?EJ+4+Y1NAY,> <*0-6FV0_*0.8':6F
M=EPH@L.+0R%,,H0"0OR^9$3*1?R_>V/(=S_-_O"'/\[^[=]_R'1\/WOWTQ]F
M?_CA^S'H<L1#Q)[GTV4.)[AS?&\5YDL4DE]:7AHXIS3 K!T?%A<%S#!-%AL?
MIRWE(BH8^2'*15LZ.#P\S@,1_);@=,4XQXO+>YPZ?HB]I1.'A%:2N>L>]\>
M7JATC7>^Z\LF-+0J H]6??!\X#;7 AS#+8PW;>:%"E3H0&\X+2A78^F*]Q'P
M\V"]3":DB4KMJ1_X\2L'IYZ0!!R?"F-'F("TLT8P .9LJ2"I(<=,-(BU-N$%
MO\TK*+)JP,-4%WB;"ZT!A["VZ?U>8&U]?6\<L+!BNCX/2$AT$S^DM.=G$Q1W
M.'Z@@WBM241%9>#QW<X)\O4'64W L=X20&^K%$03HMO;F:YL;@X1;8BI@[!J
M,8(K\FF[<L(.O2$#:B\* B=.T($X@TV@6;S ONX1!C^9EQ.&6FX45)H4&<A
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MN",M$,'%[C?T)I<]4+[3-#H:#&D9B\4^.+OL-=AOF9+?TGIZ=XO3QBU^IV6
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M'*;<#=1:T:M;%W@8MW+!V;WK314!!W8[^[O=O9ZKJ=W!#B74Q_2#F_LAJ/1
MZ+'%%SO]XL2Q$Z;))K[WGYXU-F=WD ><)#J[2IP(M!0&F$RZ8^JC,Y7>HS9#
MA0$HBE%F A@"@N&[I.8[S+3/D,_F-NBDQ^?"@73Y-V:& +B1C2/L#]BAI_B]
M37A/YV=B8C3;3/LQC!X3'+,#6JOP<$SIFE;HDEI:TQT#J0).>$,Z6'AS7(]Z
M -/DH'"-[Z@B1B%FU:R6H!6&(7:71VX:8K;-$&\=8N:ANGU@Z!6DSWGF73P3
M&<3??HBJGX)^41C\"N,*H^H6%/Z>E#GM%IZR3<57KV<WI<Q)O^&UN=*H'RW
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M%' RT62Q^94']:>P$95L/046H%7O0U"4GUZK5>PZD!6>5LOM:X%=W';M[BL
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M1;LE:8_1WG>=D!X#W1]#/WV]QB\XB ZT@#"TC(4 C;MN3BF?:F\M ?K+[>:
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M-?)YDZ"IL;@VG@&XN]"-F'*N#$RZ'MQ5A<09PH5G#LPSTG?;K#+UX/Y8UKT
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MB$I!IRBUT<8)#).*%K;9YR+0-;R78QEB#PL.+)VC<YT?V#M><NYHJ@"90[3
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MIKIH,,DOY&VJ #1Z],&6ZQ'*TM"7)/2,-S[=RJ2C4CQB;90J*/.E;\==F;"
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MC=R_KT+OZ-+S:2'):Q)ZZ.R!Y#@A(907G!"1'[#@EN<N<H#&8V?7E-M73(1
MW\W2"9-I+)1*$=.*<K6(TSM#F694J$:_9LJ'X03IAA>H_AG7/>I]>U!]I-^&
M!B3=&S].TNZ<*Q8S9<I5.$:;<04RIDZX*DB#Q@I3#)UN+7EG5.=T(UOH[6?4
M,]K$NM2G0^F:TX0LK%\+*.FVA'UR9%M5!?!H5-?R#CON"OGH- KLD   Y& F
MC=8-1WL5Q8$'<1-0Q032>@)'>!M-[F^692T_L6ME-LD2U@XCG _.%W]_W-_%
MD8NQE]P[?H*]*[R+8GP;I?C.>:4365=DJ+7'R?7Q=!;75 ;0".WDDG)@TU8
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M?#V-.#^SMELS(IV)S3B?&!J=.!\/TH@G4W&PNW->E1MQ3LL Y04EI-K)4;X
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MT;7S*IYY^X_O*A1K\A?YL/@HU_5?_S]02P,$%     @ -7JU3+IJ1QAE60
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M ZJ^@N*"1L37\,A/L21P28E\!7[,2YRV('21"AS,A KE6\J/B;F-XK-0AA3
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MD"7N%$'^0+>7:$/2AG'=6EJ$Y*&[J#5L$@'#!CMTA%M7'GD4+@\<())?2X\
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M3U1TG>\1/]1\X&O>% I(B?9]-#YR[5UQOWN$#PT+)'F4"K-V+CB W*&;C1M
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M;"]Z?>#1,+?7[Y=A6@F##AZ"3(NMRZ:VA)HME=_L$\ZA]RG@7X^^:GN;<KE
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M'\;Y'W[3H0<081#A(,4L>RKXL'*@E/JWE3\&D,*8*WX<O"8,^"(,<B?X8N4
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MY#N"T%,IXW-RYZ]\1UR ][J0#QA@D+I(A@YF4LM]L>W RQN6K#@F>I[H2=:
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M%"%4QFIUX9E;V6S< #G&CK&I667$,_O) Y5\I/*J7B<46BY63<@4PU*A>OV
M/XKJYX2'_[F]<5%,MP:B/^G4#?UX\J"++PMXU=(3"G7A H3+S4TBOR KG#T.
M4YC6\B"&A4!2Y;S:XN&S8=IHV83/C"'#49IM"8,.JK[R8"4_N9+6VI,Y4R\W
M2O(EZ:46O>,*C4K2LC _9DW2ZC$D:86?;,7?;)U\M$G:8D_:PMA9EL^QWEL[
MH8ORU&>99E AM1=NY;.E9^6CCZ^;OU3;F?Y' ']XU&@L!K/+OC+(NA"M?+WV
ME=T?J!TTF-8UQT$>ZG@59W!0AO?MTJV/M^G\2=;#ZR1K=;E8SQ>?]85:T\1J
MI.%-'ZUS].+/&9>82G$RC?-M,-#:@]FT/^GH,WW8GPYGD[&F]'1E.%5GH_Y
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MTN'ZHIB#Y4P5R0V5)CF$;K' OSGO$,U8I+ .(P^$N%!>PGFS)LB*=.3<WKC
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MPC.C!WG_\_\#4$L! A0#%     @ -7JU3 GR@6I** $ AJP2 !$
M     ( !     '!R<&\M,C Q.# S,S$N>&UL4$L! A0#%     @ -7JU3((
M@T7-$@  "-P  !$              ( !>2@! '!R<&\M,C Q.# S,S$N>'-D
M4$L! A0#%     @ -7JU3"7VECT5#@  6[L  !4              ( !=3L!
M '!R<&\M,C Q.# S,S%?8V%L+GAM;%!+ 0(4 Q0    ( #5ZM4RY6"U <C<
M #-?!  5              "  ;U) 0!P<G!O+3(P,3@P,S,Q7V1E9BYX;6Q0
M2P$"% ,4    "  U>K5,WE>/#TUF  !$#P< %0              @ %B@0$
M<')P;RTR,#$X,#,S,5]L86(N>&UL4$L! A0#%     @ -7JU3+IJ1QAE60
M3Q(' !4              ( !XN<! '!R<&\M,C Q.# S,S%?<')E+GAM;%!+
4!08     !@ & (H!  !Z00(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
